Covid 19 Trials

TrialID Last Refre Public title Scientific tiAcronym Primary sp Date registDate regist Export dat Source Reg
ChiCTR200 17-Feb-20 Constructi Construction and Analysis

Zhongnan
of H ### 20200217 4/15/2020 ChiCTR
ChiCTR200 17-Feb-20 A Single-a A Single-arm Clinical Trial

HwaMei Hos ### 20200216 4/15/2020 ChiCTR
NCT04246 3-Feb-20 A Randomize

A Randomized Multicen
Xiangya Hos ### 20200127 4/15/2020 ClinicalTria
ChiCTR200 17-Feb-20 A Medical A Medical Records Based

Emergency
S ### 20200216 4/15/2020 ChiCTR
ChiCTR200 17-Feb-20 Study on c Effecacy and safty of conv

The First A ### 20200215 4/15/2020 ChiCTR
ChiCTR200 17-Feb-20 Clinical T Clinical Trial for Integrat
Children's ### 20200214 4/15/2020 ChiCTR
ChiCTR200 17-Feb-20 A RandomizA Randomized Controlled

Longhua
Tr Hos ### 20200216 4/15/2020 ChiCTR
ChiCTR200 17-Feb-20 Evaluate t Evaluate the effectiveness

Affiliated
o ### 20200216 4/15/2020 ChiCTR
ChiCTR200 17-Feb-20 Clinical S Clinical Study for Anti-agi

Guangzhou ### 20200214 4/15/2020 ChiCTR
ChiCTR200 17-Feb-20 Clinical st Development and applicatio

Shenzhen S ### 20200214 4/15/2020 ChiCTR
NCT04252 17-Feb-20 The Efficac A Randomize

ELACOI Guangzhou ### 20200130 4/15/2020 ClinicalTria
NCT04255 17-Feb-20 2019-nCoVImpact of a Novel Cor Qilu Hospit 2/3/2020 20200203 4/15/2020 ClinicalTria
NCT04260 17-Feb-20 A Survey o A Survey of Psycholog Huazhong U2/3/2020 20200203 4/15/2020 ClinicalTria
ChiCTR200 17-Feb-20 A comparatA comparative study on

Tongji
the Hosp ### 20200216 4/15/2020 ChiCTR
ChiCTR200 17-Feb-20 Analysis of Optimization of treatment

Wuhan
andJiny
di ### 20200214 4/15/2020 ChiCTR
ChiCTR200 17-Feb-20 RandomizedRandomized controlledThe tri First A ### 20200213 4/15/2020 ChiCTR
ChiCTR200 17-Feb-20 Study for Study for the key issues
Wuxi
of Peopl ### 20200213 4/15/2020 ChiCTR
ChiCTR200 17-Feb-20 Clinical S Clinical Study for Traditio

Shanghai U ### 20200213 4/15/2020 ChiCTR
ChiCTR200 17-Feb-20 A multicentA multicenter, randomiz

Huangshi H ### 20200215 4/15/2020 ChiCTR
ChiCTR200 17-Feb-20 The efficac The efficacy and safetyBeijing

of You ### 20200215 4/15/2020 ChiCTR
ChiCTR200 17-Feb-20 A multicentA multicenter, randomize

Huangshi H ### 20200213 4/15/2020 ChiCTR
ChiCTR200 17-Feb-20 A randomize

A randomized, open-label,
NCT04251 17-Feb-20 Treatment Effects of Traditiona Beijing 302 ### 20200128 4/15/2020 ClinicalTria
NCT04260 17-Feb-20 Clinical S Randomized, Open, Mul
Jieming QU 2/6/2020 20200206 4/15/2020 ClinicalTria
NCT04261 17-Feb-20 The Effica A Randomized, Open-la

Peking Uni 2/6/2020 20200206 4/15/2020 ClinicalTria
NCT04261 17-Feb-20 Evaluating A Randomized, Open-la

First Affil 2/6/2020 20200206 4/15/2020 ClinicalTria
ChiCTR200 17-Feb-20 Clinical st Clinical study for the Zhejiang Pr ### 20200213 4/15/2020 ChiCTR
ChiCTR200 17-Feb-20 Imaging Fe Imaging Features and Mechanis

West China ### 20200213 4/15/2020 ChiCTR
ChiCTR200 17-Feb-20 A randomizA randomized controlled

Longhua
tria Hos ### 20200216 4/15/2020 ChiCTR
ChiCTR200 17-Feb-20 A Single-b A Single-blind, Randomized

HwaMei Hos ### 20200216 4/15/2020 ChiCTR
ChiCTR200 17-Feb-20 Applicatio Application of Regulating
TheInt
First A ### 20200215 4/15/2020 ChiCTR
ChiCTR200 17-Feb-20 A randomize A randomized controlled

Nanjing
tria Se ### 20200214 4/15/2020 ChiCTR
ChiCTR200 17-Feb-20 Study for c Study for constructionWest
and aChina ### 20200216 4/15/2020 ChiCTR
ChiCTR200 17-Feb-20 A medical Co-infection of novel corona

Zhongnan H ### 20200216 4/15/2020 ChiCTR
ChiCTR200 17-Feb-20 Early Dete Early Detection of Novel

Shenzhen T ### 20200210 4/15/2020 ChiCTR

A randomized, open-label
Wuhan
s Pul 2/9/2020 20200209 4/15/2020 ChiCTR
ChiCTR200 17-Feb-20 PsychologicPsychological survey ofGuangdong

fro ### 20200214 4/15/2020 ChiCTR
ChiCTR200 17-Feb-20 Clinical T Clinical Trial for Tanreqing
Shanghai
C Pu ### 20200214 4/15/2020 ChiCTR

A randomized, parallelTongji
con Hos ### 20200211 4/15/2020 ChiCTR
ChiCTR200 17-Feb-20 Efficacy of Efficacy of ChloroquineThe

a Fifth A ### 20200211 4/15/2020 ChiCTR
ChiCTR200 17-Feb-20 Evaluation Evaluation of Rapid Diagnostic
Jiangsu Ins ### 20200215 4/15/2020 ChiCTR

A randomized, open and
Thecont
First A ### 20200215 4/15/2020 ChiCTR
ChiCTR200 17-Feb-20 Immunomodu

Optimization of treatment
Wuhan
andJiny
di ### 20200214 4/15/2020 ChiCTR
ChiCTR200 17-Feb-20 Clinical st Clinical study for the inte

Shanghai P ### 20200213 4/15/2020 ChiCTR
ChiCTR200 17-Feb-20 Immune Rep

Immune Repertoire (TCR
The&First
B A 2/7/2020 20200207 4/15/2020 ChiCTR
ChiCTR200 17-Feb-20 A real wor A real world study for tradit

Shanghai Pu2/7/2020 20200207 4/15/2020 ChiCTR
ChiCTR200 17-Feb-20 Traditiona Traditional Chinese medicin

Dongzhimen ### 20200213 4/15/2020 ChiCTR
ChiCTR200 17-Feb-20 A multicentA multicenter, randomized

The First
c A ### 20200213 4/15/2020 ChiCTR
ChiCTR200 17-Feb-20 An observaAn observational studyGuangdong

for Xi 2/8/2020 20200208 4/15/2020 ChiCTR
ChiCTR200 17-Feb-20 Efficacy an Efficacy and safety of aeros

Union Hosp 2/8/2020 20200208 4/15/2020 ChiCTR

People's
co H ### 20200215 4/15/2020 ChiCTR
ChiCTR200 17-Feb-20 An observaAn observational studyNingbo

on th Firs ### 20200215 4/15/2020 ChiCTR
ChiCTR200 17-Feb-20 The efficac Study on Prevention and

China
TreaAcad ### 20200212 4/15/2020 ChiCTR
ChiCTR200 17-Feb-20 Cohort StudCohort Study of Novel Department
Coronavir ### 20200212 4/15/2020 ChiCTR
ChiCTR200 17-Feb-20 CommunityCommunity based prevention

Hubei Prov 2/6/2020 20200206 4/15/2020 ChiCTR
ChiCTR200 17-Feb-20 Safety and Safety and efficacy of uXiangyang 12/4/2020 20200204 4/15/2020 ChiCTR
ChiCTR200 17-Feb-20 An open, prAn open, prospective, Beijing

mult hos 2/5/2020 20200205 4/15/2020 ChiCTR
ChiCTR200 17-Feb-20 Chinese meChinese medicine prevention
Zhejianga C 2/5/2020 20200205 4/15/2020 ChiCTR
ChiCTR200 17-Feb-20 Based on DBased on Delphi Method

Deyang Int ### 20200214 4/15/2020 ChiCTR
ChiCTR200 17-Feb-20 Ba-Bao-DanStudy for the pharmacodyn

Sir Run Run ### 20200214 4/15/2020 ChiCTR
ChiCTR200 17-Feb-20 Study for t A prospective cohort study

Sun Yat sen 2/3/2020 20200203 4/15/2020 ChiCTR

Tongji
s Hosp2/3/2020 20200203 4/15/2020 ChiCTR
ChiCTR200 17-Feb-20 Chinese meA prospective randomized

Zhejiang C 2/3/2020 20200203 4/15/2020 ChiCTR
ChiCTR200 17-Feb-20 Chinese meChinese medicine prevention

Zhejianga C 2/3/2020 20200203 4/15/2020 ChiCTR
ChiCTR200 17-Feb-20 Clinical Ap Optimization of treatment

WuhanandJiny
di ### 20200214 4/15/2020 ChiCTR
ChiCTR200 17-Feb-20 Babaodan CBabaodan Capsule used Enze
for Hospi
the ### 20200213 4/15/2020 ChiCTR
ChiCTR200 17-Feb-20 Clinical st Clinical study of nebulized

Renmin
X Hos ### 20200212 4/15/2020 ChiCTR
ChiCTR200 17-Feb-20 Effect eva Effect evaluation and prognos
ChiCTR200 17-Feb-20 Traditiona Traditional Chinese Medic

1. Xinhua A 2/2/2020 20200202 4/15/2020 ChiCTR
ChiCTR200 17-Feb-20 Traditiona Traditional Chinese Medi

1. Xinhua a 2/2/2020 20200202 4/15/2020 ChiCTR

A randomized, open, cZhongnan H ### 20200213 4/15/2020 ChiCTR
ChiCTR200 17-Feb-20 Study for Effect of Novel Coronavirus

West Pn
China ### 20200212 4/15/2020 ChiCTR
ChiCTR200 17-Feb-20 Study for c Study for clinical characteri

The First A 2/2/2020 20200202 4/15/2020 ChiCTR
Beijing
tri hos 2/1/2020 20200201 4/15/2020 ChiCTR
ChiCTR200 17-Feb-20 A Real WorA Real World Study ForThe

theFirst A 2/1/2020 20200201 4/15/2020 ChiCTR
ChiCTR200 17-Feb-20 Clinical s Clinical study of type I Affiliated

macr 2/1/2020 20200201 4/15/2020 ChiCTR
ChiCTR200 17-Feb-20 Clinical S Clinical Study for Tradition

ChiCTR200 17-Feb-20 Risks of D Risks of Death and Severe

Tongji
case
Hosp ### 20200210 4/15/2020 ChiCTR
ChiCTR200 17-Feb-20 A MulticenA Multicenter, Randomized

ChiCTR200 17-Feb-20 Impact of Impact of vitamin D deficiency

ChiCTR200 17-Feb-20 A single a The evaluation of integrate

The First H 2/1/2020 20200201 4/15/2020 ChiCTR
ChiCTR200 17-Feb-20 Chinese HeChinese Herbal medicine

Dongzhimen
for S ### 20200130 4/15/2020 ChiCTR
ChiCTR200 17-Feb-20 Study for MMental health and psycho

The Fifth A 2/8/2020 20200208 4/15/2020 ChiCTR
ChiCTR200 17-Feb-20 A clinical Observational study ofGuangdong
Xin-G 2/7/2020 20200207 4/15/2020 ChiCTR
ChiCTR200 17-Feb-20 EpidemiologEpidemiological investigation
The First P ### 20200210 4/15/2020 ChiCTR
ChiCTR200 17-Feb-20 Clinical st Multicenter, randomized,

Ruijin Hosp 2/7/2020 20200207 4/15/2020 ChiCTR
ChiCTR200 17-Feb-20 Constructi Construction of Early Warnin

ChiCTR200 17-Feb-20 Clinical s Clinical study for communi

Hubei Prov 2/6/2020 20200206 4/15/2020 ChiCTR
ChiCTR200 17-Feb-20 A prospectiA prospective, open-label,

The Fifth A 2/6/2020 20200206 4/15/2020 ChiCTR
ChiCTR200 17-Feb-20 Clinical S Clinical Study for Human

TheMe
First A 2/7/2020 20200207 4/15/2020 ChiCTR
ChiCTR200 25-Feb-20 Key techni Key techniques of umbilica
Hunan yuan ### 20200224 4/15/2020 ChiCTR
ChiCTR200 25-Feb-20 Randomized

Randomized, parallel contr
The 5th Me ### 20200224 4/15/2020 ChiCTR
ChiCTR200 17-Feb-20 Clinical st Clinical study on safetyThe

andThird 2/6/2020 20200206 4/15/2020 ChiCTR
ChiCTR200 17-Feb-20 Safety and Safety and efficacy of um

Xiangyang F2/5/2020 20200205 4/15/2020 ChiCTR

Tongji Hosp2/7/2020 20200207 4/15/2020 ChiCTR
ChiCTR200 17-Feb-20 A RandomizA Randomized, Open-LabeThe First A 2/6/2020 20200206 4/15/2020 ChiCTR
ChiCTR200 17-Feb-20 TherapeutiTherapeutic effect of hydroxyc
Renmin Hos2/4/2020 20200204 4/15/2020 ChiCTR

A randomized controlled
ChiCTR200 17-Feb-20 RecommendaRecommendations of Integr
Hospital of 2/4/2020 20200204 4/15/2020 ChiCTR
ChiCTR200 17-Feb-20 Randomized,

Randomized, open-label,
ChiCTR200 17-Feb-20 A randomise

A randomised, open, contr
Zhongnan H2/3/2020 20200203 4/15/2020 ChiCTR
ChiCTR200 17-Feb-20 Clinical St Clinical Study for Gu-Biao

Wuhan
Ji Hosp2/2/2020 20200202 4/15/2020 ChiCTR
ChiCTR200 25-Feb-20 A clinical A clinical study for ''Huo-She

Shenzhen na ### 20200223 4/15/2020 ChiCTR
ChiCTR200 25-Feb-20 Safety and Safety and effectiveness

ChiCTR200 17-Feb-20 A real-worlThe early use of lopinav

Institute 2/2/2020 20200202 4/15/2020 ChiCTR
ChiCTR200 17-Feb-20 A single a A single arm study for Hubei
comb Provi 2/1/2020 20200201 4/15/2020 ChiCTR
ChiCTR200 17-Feb-20 A RandomizA Randomized Controlled

1. Xinhua
T a 2/2/2020 20200202 4/15/2020 ChiCTR
ChiCTR200 17-Feb-20 The effect The effect of shadowboxing

1. Xinhua a 2/2/2020 20200202 4/15/2020 ChiCTR
ChiCTR200 17-Feb-20 The effect Pulmonary rehabilitation
1.Xinhua
t af 2/2/2020 20200202 4/15/2020 ChiCTR
ChiCTR200 17-Feb-20 CombinatioCombination of traditional

Beijing Hos 2/1/2020 20200201 4/15/2020 ChiCTR
ChiCTR200 17-Feb-20 Randomized Randomized controlledWuhan

trial 1st 2/1/2020 20200201 4/15/2020 ChiCTR
ChiCTR200 17-Feb-20 Study for An epidemiology studyHubeifor TCM
Inte 2/1/2020 20200201 4/15/2020 ChiCTR
ChiCTR200 25-Feb-20 Study for a Study for application oThe Second ### 20200223 4/15/2020 ChiCTR
ChiCTR200 25-Feb-20 A multicen A multicenter study forThe First H ### 20200222 4/15/2020 ChiCTR
ChiCTR200 25-Feb-20 Shen-Fu injShen-Fu injection in the

Peking
tr Univ ### 20200221 4/15/2020 ChiCTR
ChiCTR200 25-Feb-20 A single-ar A single-arm, single-center

NCT04259 24-Feb-20 Viral Excre Viral Excre Cov-CONT Institut N 2/5/2020 20200205 4/15/2020 ClinicalTria
NCT04268 24-Feb-20 Immunoregu

Immunoregulatory TheSoutheast U2/8/2020 20200208 4/15/2020 ClinicalTria
ChiCTR200 25-Feb-20 ExperimentExperimental study of The

novel
First A ### 20200224 4/15/2020 ChiCTR
ChiCTR200 17-Feb-20 Clinical Co Study for Traditional Chines

China Acad ### 20200129 4/15/2020 ChiCTR
NCT04244 24-Feb-20 GlucocorticGlucocorticSteroids-S Peking Uni ### 20200123 4/15/2020 ClinicalTria
ChiCTR200 25-Feb-20 A cross-se A cross-sectional studyWuhan
of noveJin ### 20200224 4/15/2020 ChiCTR
ChiCTR200 25-Feb-20 Randomized

Clinical study for safetyThe
a Third ### 20200223 4/15/2020 ChiCTR
ChiCTR200 25-Feb-20 Traditiona Traditional Chinese Medicin

Tongde Hos ### 20200221 4/15/2020 ChiCTR
ChiCTR200 25-Feb-20 Study on ulStudy on ultrasonographic

Xi'anmChest ### 20200221 4/15/2020 ChiCTR
ChiCTR200 17-Feb-20 A prospect A prospective comparative

The First
st A ### 20200127 4/15/2020 ChiCTR
NCT04269 24-Feb-20 Umbilical Clinical Research Reg ZhiYong Pe 2/7/2020 20200207 4/15/2020 ClinicalTria
ChiCTR200 25-Feb-20 The Value oThe Value of Critical Care
ChiCTR200 25-Feb-20 Clinical T Clinical Trial for Recombina

Renmin Hos ### 20200224 4/15/2020 ChiCTR
ChiCTR200 25-Feb-20 Study for eStudy for establishment

Peking
of Univ ### 20200223 4/15/2020 ChiCTR
ChiCTR200 25-Feb-20 Effects of Effects of novel coronaviru

Chengdu Un ### 20200223 4/15/2020 ChiCTR
ChiCTR200 25-Feb-20 Clinical s Clinical study for ozonated

Tianjin
a Uni ### 20200224 4/15/2020 ChiCTR
ChiCTR200 25-Feb-20 A multicentA multicenter, randomize

Shanghai Pu ### 20200223 4/15/2020 ChiCTR
ChiCTR200 25-Feb-20 A clinical A clinical research for Tongji Hosp ### 20200223 4/15/2020 ChiCTR
ChiCTR200 25-Feb-20 AssessmentAssessment of cardiac Department
funct ### 20200223 4/15/2020 ChiCTR
ChiCTR200 25-Feb-20 Clinical S Clinical Study on Syndrome

Guangdong
D ### 20200224 4/15/2020 ChiCTR
ChiCTR200 25-Feb-20 Study for s Study for safety and effic
ChiCTR200 25-Feb-20 A single ar A single arm trial to eva

First Peopl ### 20200221 4/15/2020 ChiCTR
ChiCTR200 25-Feb-20 A medical The risk factor and prognosis
Tongji Hosp ### 20200220 4/15/2020 ChiCTR
ChiCTR200 25-Feb-20 A multi-ce A multi-center study on

The
theFirst A ### 20200221 4/15/2020 ChiCTR
ChiCTR200 25-Feb-20 Traditiona Traditional Chinese medic

Dongzhimen ### 20200220 4/15/2020 ChiCTR
ChiCTR200 25-Feb-20 A Prospect A Prospective Randomized
ChiCTR200 25-Feb-20 A multicentA multicenter, randomized,

ChiCTR200 25-Feb-20 Clinical T Clinical Trial for HumanChinese

Mes PL ### 20200224 4/15/2020 ChiCTR
ChiCTR200 25-Feb-20 HumanisticThe Effect of Humanistic TheCaSecond ### 20200224 4/15/2020 ChiCTR
ChiCTR200 25-Feb-20 Basic and cEfficacy evaluation of iGuangxi me ### 20200219 4/15/2020 ChiCTR
ChiCTR200 25-Feb-20 MulticenteMulticenter randomized

Thecontr
First A ### 20200219 4/15/2020 ChiCTR
ChiCTR200 25-Feb-20 Study for Study for the effect of Union

earl Hosp ### 20200222 4/15/2020 ChiCTR
ChiCTR200 25-Feb-20 A study fo A study for the interventi

ChiCTR200 25-Feb-20 HumanisticThe Therapeutic Efficacy

theoSecond ### 20200224 4/15/2020 ChiCTR
ChiCTR200 25-Feb-20 A multicen A multicenter randomized

Tianjin
co Hu ### 20200223 4/15/2020 ChiCTR
ChiCTR200 25-Feb-20 Feature of Feature of Multiple Organs
Department ### 20200220 4/15/2020 ChiCTR
ChiCTR200 25-Feb-20 Study for Study for the correlation

Tongji
b Hosp ### 20200220 4/15/2020 ChiCTR
ChiCTR200 25-Feb-20 Developmen

Development of 2019-nCoV
The First
therape
P ### 20200219 4/15/2020 ChiCTR

A randomized, double-bli
Wuhan Jiny ### 20200219 4/15/2020 ChiCTR
ChiCTR200 25-Feb-20 A clinical A randomized, open-label,
Shanghai C ### 20200222 4/15/2020 ChiCTR
ChiCTR200 25-Feb-20 Umbilical Umbilical cord Wharton's
TheJeSixth ### 20200222 4/15/2020 ChiCTR
ChiCTR200 25-Feb-20 Correalati Correalation between The

anxieFifth A ### 20200219 4/15/2020 ChiCTR

Union
tri Hosp ### 20200219 4/15/2020 ChiCTR
ChiCTR200 25-Feb-20 An open, coAn open, controlled clin

Nanchang N ### 20200219 4/15/2020 ChiCTR
ChiCTR200 25-Feb-20 Chinese MeChinese Medicine Promotes
Hospital
Reof ### 20200217 4/15/2020 ChiCTR
ChiCTR200 25-Feb-20 Clinical st Clinical study for the diagno

Union Hosp ### 20200222 4/15/2020 ChiCTR
ChiCTR200 25-Feb-20 Study for t Study for the effects onUnion Hosp ### 20200222 4/15/2020 ChiCTR
ChiCTR200 25-Feb-20 A prospect An open randomized contro

Zhongshan H ### 20200222 4/15/2020 ChiCTR
ChiCTR200 25-Feb-20 Clinical st Clinical study for infusing

Affiliated
c ### 20200221 4/15/2020 ChiCTR

Beijing Cha ### 20200220 4/15/2020 ChiCTR
ChiCTR200 25-Feb-20 Study on anStudy on anxiety of different

Shanghai Ge ### 20200219 4/15/2020 ChiCTR
ChiCTR200 25-Feb-20 The efficac The efficacy and safetyHealth

of com ### 20200219 4/15/2020 ChiCTR
ChiCTR200 25-Feb-20 A clinical A clinical study for probio

Shanghai 1 ### 20200219 4/15/2020 ChiCTR
ChiCTR200 25-Feb-20 A medical A medical records based Department
ana ### 20200220 4/15/2020 ChiCTR
ChiCTR200 25-Feb-20 The clinica The clinical applicationSecond

and Hos ### 20200220 4/15/2020 ChiCTR
ChiCTR200 25-Feb-20 The COVID-1

The COVID-19 Mobile Health
Zhongshan
St ### 20200220 4/15/2020 ChiCTR
ChiCTR200 25-Feb-20 Effect of Effect of New Coronavirus
WestPneu
China ### 20200219 4/15/2020 ChiCTR
ChiCTR200 25-Feb-20 Optimizati Optimization Protocal Hospital
of In of ### 20200219 4/15/2020 ChiCTR
ChiCTR200 25-Feb-20 Clinical s Clinical study for novelThe

NLRP
First A ### 20200219 4/15/2020 ChiCTR
ChiCTR200 25-Feb-20 Liu-Zi-Jue Liu-Zi-Jue Qigong and Acu

Shanghai U ### 20200218 4/15/2020 ChiCTR

Yueyang
tria Ho ### 20200218 4/15/2020 ChiCTR
ChiCTR200 25-Feb-20 A prospect An open randomized contro

Zhongshan H ### 20200218 4/15/2020 ChiCTR
ChiCTR200 25-Feb-20 Clinical t Clinical trials of mesenchyma

Institute o ### 20200218 4/15/2020 ChiCTR

Chinese
T PL ### 20200218 4/15/2020 ChiCTR
ChiCTR200 25-Feb-20 Clinical S Clinical Study of Chloroquine

ChiCTR200 25-Feb-20 ComparativComparative study forThe inteFirst A ### 20200217 4/15/2020 ChiCTR
ChiCTR200 25-Feb-20 Clinical ob Clinical observation of West

the nov
China ### 20200217 4/15/2020 ChiCTR

Union Hospi ### 20200213 4/15/2020 ChiCTR
ChiCTR200 25-Feb-20 Efficacy of Efficacy of therapeuticThe

ef First H ### 20200211 4/15/2020 ChiCTR
ChiCTR200 25-Feb-20 Study for Study on mental healthSichuan

stat Ac ### 20200218 4/15/2020 ChiCTR

Tongji
tri Hos ### 20200217 4/15/2020 ChiCTR
ChiCTR200 25-Feb-20 Early warn Early warning prediction

Enze
of Hospi
p ### 20200215 4/15/2020 ChiCTR
ChiCTR200 25-Feb-20 DescriptiveClinical characteristics Union

and Hospi ### 20200215 4/15/2020 ChiCTR
ChiCTR200 25-Feb-20 Study for nStudy for nucleic acid detect

ChiCTR200 25-Feb-20 A prospectiA prospective, multicent
Qingdao Ea ### 20200218 4/15/2020 ChiCTR
ChiCTR200 25-Feb-20 A prospectiA prospective, randomize

ChiCTR200 25-Feb-20 A multicentA multicenter, randomized,

Union Hospi ### 20200213 4/15/2020 ChiCTR

Zhongshan ### 20200215 4/15/2020 ChiCTR
NCT04252 2-Mar-20 Mild/ModeA Phase 3 Randomized,Capital Med ### 20200131 4/15/2020 ClinicalTria
ChiCTR200 25-Feb-20 Efficacy an Efficacy and safety of hon

Hubei Hospi ### 20200217 4/15/2020 ChiCTR
NCT04279 2-Mar-20 The Invest A Multicenter ObservaChildren's ### 20200218 4/15/2020 ClinicalTria
NCT04256 2-Mar-20 Efficacy of Registry St COVID-19 Beijing Ts 2/1/2020 20200201 4/15/2020 ClinicalTria
NCT04273 2-Mar-20 The Effica The Efficacy and Safe First Affil ### 20200214 4/15/2020 ClinicalTria
NCT04273 2-Mar-20 The Effica The Efficacy and Safe First Affil ### 20200214 4/15/2020 ClinicalTria
ChiCTR200 2-Mar-20 Applicatio The Application of Rehabil
ChiCTR200 2-Mar-20 ApplicationApplication of rehabilitatio

NCT04270 2-Mar-20 Clinical Ch A Multicenter ObservatBeijing Chi ### 20200211 4/15/2020 ClinicalTria
NCT04273 2-Mar-20 Study of H Clinical Study of Hum Wuhan Unio ### 20200214 4/15/2020 ClinicalTria
NCT04275 2-Mar-20 The COVID-The COVID-CMHS Chinese Al ### 20200217 4/15/2020 ClinicalTria
ChiCTR200 2-Mar-20 A Clinical A Clinical Trial Study foInstitute o 3/1/2020 20200301 4/15/2020 ChiCTR
NCT04257 2-Mar-20 Severe 201A Phase 3 Randomized,Capital Med ### 20200131 4/15/2020 ClinicalTria
NCT04275 2-Mar-20 Clinical S Single Center, Single Tang-Du Ho2/6/2020 20200206 4/15/2020 ClinicalTria
NCT04275 2-Mar-20 Xiyanping A Prospective, Randomi
Jiangxi Qin ### 20200217 4/15/2020 ClinicalTria
NCT04279 2-Mar-20 Treatment A Randomized, PlaceboShuGuang H ### 20200215 4/15/2020 ClinicalTria
ChiCTR200 2-Mar-20 Study for Study for moxibustion Hu'nan

in the puni ### 20200218 4/15/2020 ChiCTR
ChiCTR200 2-Mar-20 Constructi Construction and applica
Hubei Prov ### 20200217 4/15/2020 ChiCTR
ChiCTR200 2-Mar-20 Research a Research and Development

Key Labora
o 3/1/2020 20200301 4/15/2020 ChiCTR
ChiCTR200 2-Mar-20 Novel CoroNovel Coronavirus Infected

TongjiDHosp ### 20200229 4/15/2020 ChiCTR
ChiCTR200 2-Mar-20 Identifica Identification and Clinical

Xinyang
Tr Cen ### 20200228 4/15/2020 ChiCTR
ChiCTR200 2-Mar-20 Traditiona Traditional Chinese medici

Xiangyang C ### 20200228 4/15/2020 ChiCTR
NCT04280 2-Mar-20 FingolimodEfficacy of Fingolimo First Affil ### 20200220 4/15/2020 ClinicalTria
ChiCTR200 2-Mar-20 ApplicationApplication of rehabilitat

ChiCTR200 2-Mar-20 A randomize

Wuhan Jiny 3/1/2020 20200301 4/15/2020 ChiCTR
ChiCTR200 2-Mar-20 A Comparati

A Comparative Study for
Hubei
th Prov 3/1/2020 20200301 4/15/2020 ChiCTR
NCT04279 2-Mar-20 Clinical Fe Investigation on Clini Third Affil ### 20200215 4/15/2020 ClinicalTria
NCT04279 2-Mar-20 Detection oStudy on Detection of Third Affil ### 20200219 4/15/2020 ClinicalTria
NCT04280 2-Mar-20 NK Cells T Clinical Investigation Xinxiang me ### 20200213 4/15/2020 ClinicalTria
ChiCTR200 2-Mar-20 CombinatioThe therapeutic efficacy

theofSecond 3/2/2020 20200302 4/15/2020 ChiCTR
ChiCTR200 2-Mar-20 microRNA as

microRNA as a markerNanjing
for earlySe ### 20200228 4/15/2020 ChiCTR

Tongji
s Hos ### 20200228 4/15/2020 ChiCTR
ChiCTR200 2-Mar-20 MultiomicsMultiomics study and eme
Li Caixia ### 20200228 4/15/2020 ChiCTR
ChiCTR200 2-Mar-20 Clinical st Clinical study for combina

ChiCTR200 2-Mar-20 A single-ce A single-center, single-arm

Henanc Provi3/1/2020 20200301 4/15/2020 ChiCTR
ChiCTR200 2-Mar-20 A medical rA medical records based

Lishui
analy
Cent 3/1/2020 20200301 4/15/2020 ChiCTR
ChiCTR200 2-Mar-20 Clinical ob Clinical observation and

Tongji
res Hosp3/1/2020 20200301 4/15/2020 ChiCTR
ChiCTR200 2-Mar-20 Investigati Investigation and analysis
Beijing
o Ger ### 20200226 4/15/2020 ChiCTR
ChiCTR200 2-Mar-20 Clinical st A prospective randomized

ChiCTR200 2-Mar-20 Clinical S Clinical Study for Tradition

Affiliated ### 20200228 4/15/2020 ChiCTR
ChiCTR200 2-Mar-20 Analysis of Analysis of clinical characteri
The Second ### 20200228 4/15/2020 ChiCTR
ChiCTR200 2-Mar-20 A survey ofA survey of mental health

ChiCTR200 2-Mar-20 Umbilical Umbilical cord mesenchyma

Nanjing Se ### 20200228 4/15/2020 ChiCTR
ChiCTR200 2-Mar-20 Correlatio Correlation between imaging

Xianningc Ce ### 20200227 4/15/2020 ChiCTR
ChiCTR200 2-Mar-20 Traditiona Traditional Chinese Medicine
ChiCTR200 2-Mar-20 Clinical o Clinical observation and

Shanghai
resea Pu ### 20200227 4/15/2020 ChiCTR
ChiCTR200 2-Mar-20 Study for Clinical research program

ChiCTR200 2-Mar-20 ICU health ICU healthcare personnel
Department
bur ### 20200226 4/15/2020 ChiCTR
ChiCTR200 2-Mar-20 Health relaHealth related quality Xiamen
of Uni ### 20200227 4/15/2020 ChiCTR
ChiCTR200 2-Mar-20 Evaluation Evaluation Danorevir sodiu

ChiCTR200 2-Mar-20 A multicentA multicenter, randomized,

The Fourth ### 20200226 4/15/2020 ChiCTR
ChiCTR200 2-Mar-20 The coagul The coagulation function
Puren
of nov
Hosp ### 20200226 4/15/2020 ChiCTR
ChiCTR200 2-Mar-20 Clinical st Clinical study on novelGanzi

co Hospi ### 20200226 4/15/2020 ChiCTR
ChiCTR200 2-Mar-20 Efficacy a Efficacy and Safety of Jing-

Shanghai Un ### 20200226 4/15/2020 ChiCTR
ChiCTR200 2-Mar-20 A study fo A study for the key techno

Wuxi Fifth ### 20200226 4/15/2020 ChiCTR
ChiCTR200 2-Mar-20 Cancelled du

Study for the Impact ofThe
Novel
Thirte ### 20200225 4/15/2020 ChiCTR
ChiCTR200 2-Mar-20 Exploratio Exploration and Research
GanziforHospi ### 20200226 4/15/2020 ChiCTR
ChiCTR200 2-Mar-20 Study for Study for evaluation ofFirst

int Teach ### 20200225 4/15/2020 ChiCTR
ChiCTR200 2-Mar-20 The treatme
The treatment status and
The Fourth ### 20200226 4/15/2020 ChiCTR
ChiCTR200 2-Mar-20 Clinical R Clinical Reseach of Acupunctur

Yueyang Ho ### 20200226 4/15/2020 ChiCTR
ChiCTR200 2-Mar-20 Study for Study for the efficacy of

TheKaFirst A ### 20200225 4/15/2020 ChiCTR
ChiCTR200 2-Mar-20 A multicentA multicenter, single arm

Central So ### 20200225 4/15/2020 ChiCTR
ChiCTR200 2-Mar-20 Quality of Quality of life among Chines
NA ### 20200226 4/15/2020 ChiCTR
ChiCTR200 2-Mar-20 Cancelled bCancelled Cancelled ### 20200224 4/15/2020 ChiCTR
ChiCTR200 2-Mar-20 A prospect A prospective randomized

A Medical Records Based
Chongqing
Stu L ### 20200221 4/15/2020 ChiCTR
ChiCTR200 2-Mar-20 A parallel, A parallel, randomizedFirst Affil ### 20200220 4/15/2020 ChiCTR
ChiCTR200 2-Mar-20 A prospectiA study on the efficacyChinese
a PL ### 20200219 4/15/2020 ChiCTR
ChiCTR200 2-Mar-20 Evaluation Evaluation the Efficac Peking Univ ### 20200216 4/15/2020 ChiCTR
ChiCTR200 2-Mar-20 Evaluation Evaluation the EfficacyPeking Univ ### 20200216 4/15/2020 ChiCTR
ChiCTR200 2-Mar-20 Single arm Single arm study for explor

The First Ho ### 20200218 4/15/2020 ChiCTR
ChiCTR200 2-Mar-20 Cancelled due

ChiCTR200 2-Mar-20 Study of P Study of Pinavir / Ritonavi

Fifth Peopl ### 20200225 4/15/2020 ChiCTR
ChiCTR200 2-Mar-20 Cancelled dEpidemiological and clinical
Chongqing ### 20200217 4/15/2020 ChiCTR


A randomized, open, parall
ChiCTR200 2-Mar-20 A RetrospeA Retrospective Study Tongji

for P Hosp ### 20200210 4/15/2020 ChiCTR
ChiCTR200 2-Mar-20 Comparative

Comparative effectivene
ChiCTR200 2-Mar-20 Research f Research for Risks Associa

ChiCTR200 2-Mar-20 Cancelled dMulticenter, randomized,

ChiCTR200 2-Mar-20 Retracted dA multicenter, randomiz

ChiCTR200 2-Mar-20 EffectiveneA study on treatment strategies


Thestu
Second ### 20200212 4/15/2020 ChiCTR
NCT04286 9-Mar-20 The Clinic The Efficacy and Safe Beijing Yo ### 20200225 4/15/2020 ClinicalTria
ChiCTR200 2-Mar-20 Cancelled dMedical records basedChongqing
study ### 20200215 4/15/2020 ChiCTR
ChiCTR200 9-Mar-20 Critical ul Critical ultrasound in eval

NCT04276 9-Mar-20 Lopinavir/ An Open-label Randomi

The Univer ### 20200211 4/15/2020 ClinicalTria
NCT04281 9-Mar-20 A New ScreIdentification of a Ne Affiliated ### 20200220 4/15/2020 ClinicalTria
NCT04282 9-Mar-20 A Study to A Randomized, Open-lab

Huilan Zha ### 20200210 4/15/2020 ClinicalTria
NCT04252 9-Mar-20 Mesenchyma

Safety and Efficiency Beijing 302 ### 20200127 4/15/2020 ClinicalTria
NCT04276 9-Mar-20 A Pilot Cl A Pilot Clinical Stud Ruijin Hosp ### 20200216 4/15/2020 ClinicalTria
ChiCTR200 9-Mar-20 Novel coronNovel coronavirus pneumonia

ChiCTR200 9-Mar-20 A medical rRetrospective study toThe

asseFirst A 3/7/2020 20200307 4/15/2020 ChiCTR
ChiCTR200 9-Mar-20 A retrospe A retrospective study on

Thev Third A 3/7/2020 20200307 4/15/2020 ChiCTR
ChiCTR200 9-Mar-20 Multi-Cent Multi-Center Clinical Study
Wuhan Red 3/6/2020 20200306 4/15/2020 ChiCTR
ChiCTR200 9-Mar-20 Efficacy a Efficacy and safety of Ma-Xin

Affiliated 3/6/2020 20200306 4/15/2020 ChiCTR
NCT04284 9-Mar-20 CT Scores CT Scores Predict MorShanghai G ### 20200222 4/15/2020 ClinicalTria
NCT04285 9-Mar-20 The Effect A Clinical Study to In Tasly Pharm ### 20200219 4/15/2020 ClinicalTria
ChiCTR200 9-Mar-20 Study for uStudy on the application
TheofFirst
con A 3/8/2020 20200308 4/15/2020 ChiCTR
ChiCTR200 9-Mar-20 The immediThe immediate psychologica
West China 3/8/2020 20200308 4/15/2020 ChiCTR
ChiCTR200 9-Mar-20 Research onResearch on peripheralUnion

immuHosp 3/7/2020 20200307 4/15/2020 ChiCTR
ChiCTR200 9-Mar-20 Risk Facto Risk Factors for Outcomes

Shandong
of No P3/8/2020 20200308 4/15/2020 ChiCTR
ChiCTR200 9-Mar-20 Clinical P Clinical Prediction and Shandong

Int P3/8/2020 20200308 4/15/2020 ChiCTR
ChiCTR200 9-Mar-20 ExtracorporEffecacy and safty of extr

ChiCTR200 9-Mar-20 A single-ce A single-center, single-arm

The First
c A 3/4/2020 20200304 4/15/2020 ChiCTR
ChiCTR200 9-Mar-20 Psychologi Psychological Intervention

Tongji
ofHosp3/7/2020
C 20200307 4/15/2020 ChiCTR
ChiCTR200 9-Mar-20 Study for t Study for the risk factors

Tongji
of Hos 3/6/2020 20200306 4/15/2020 ChiCTR
ChiCTR200 9-Mar-20 Study for t Study for timing of mechan

ChiCTR200 9-Mar-20 An open andAn open and controlled

Shenyang
cl S 3/3/2020 20200303 4/15/2020 ChiCTR
ChiCTR200 9-Mar-20 Detection Detection of coronavirus
Central
i The 3/6/2020 20200306 4/15/2020 ChiCTR
ChiCTR200 9-Mar-20 Novel coro Novel coronavirus pneumonia
Xiamen Med3/6/2020 20200306 4/15/2020 ChiCTR
ChiCTR200 9-Mar-20 Clinical s Clinical study of nano-nose
AnhuiaCanc 3/7/2020 20200307 4/15/2020 ChiCTR
ChiCTR200 9-Mar-20 A clinical A clinical study about tWest China 3/6/2020 20200306 4/15/2020 ChiCTR
ChiCTR200 9-Mar-20 Survey for Survey for sleep, anxiety

Renmin
a Hos3/4/2020 20200304 4/15/2020 ChiCTR
ChiCTR200 9-Mar-20 Randomized

Randomized, open, blank
Department3/3/2020 20200303 4/15/2020 ChiCTR
ChiCTR200 9-Mar-20 Research f Research for the mechanis

ChiCTR200 9-Mar-20 RetrospectRetrospective studyforThe
int First A 3/4/2020 20200304 4/15/2020 ChiCTR
ChiCTR200 9-Mar-20 Efficacy an Efficacy and safety of lipo

Maoming Pe3/2/2020 20200302 4/15/2020 ChiCTR
ChiCTR200 9-Mar-20 A randomizA randomized parallel Shanghai

contro U 3/2/2020 20200302 4/15/2020 ChiCTR
ChiCTR200 9-Mar-20 Zedoary TurZedoary Turmeric Oil for

TheInSecond 3/5/2020 20200305 4/15/2020 ChiCTR
ChiCTR200 9-Mar-20 A medical Comparative Study forWest
Clini China 3/4/2020 20200304 4/15/2020 ChiCTR
ChiCTR200 9-Mar-20 Study for t Study for the Effectiveness

ChiCTR200 9-Mar-20 oXiris Memb

The Effect and Safety of
ChiCTR200 9-Mar-20 To evaluat To evaluate the efficacy

Huo-Shen-S3/4/2020 20200304 4/15/2020 ChiCTR
ChiCTR200 9-Mar-20 The clinica The clinical value of cort

Zhongnan H3/3/2020 20200303 4/15/2020 ChiCTR
ChiCTR200 9-Mar-20 Study for t Study for the route of ocula

ChiCTR200 9-Mar-20 HUMSCs and HUMSCs and Exosomes Hubei
Treating
Shiy 3/3/2020 20200303 4/15/2020 ChiCTR
ChiCTR200 9-Mar-20 Study for Key techniques of combinati

ChiCTR200 9-Mar-20 Clinical st Clinical study for the effect
ChiCTR200 9-Mar-20 A MulticenSARS-CoV-2 Infection on

Peking
MyocUniv3/3/2020 20200303 4/15/2020 ChiCTR
ChiCTR200 9-Mar-20 Cytosorb inThe Effect and Safety of

ChiCTR200 9-Mar-20 A RandomizA Randomized Controlled

Dalian Medi3/2/2020 20200302 4/15/2020 ChiCTR
ChiCTR200 9-Mar-20 Cancelled bInfluence of nasal high-fo

ChiCTR200 9-Mar-20 ApplicationApplication of flash gluc

Shanghai Si 3/1/2020 20200301 4/15/2020 ChiCTR
ChiCTR200 9-Mar-20 A medical rA medical records based

ChiCTR200 9-Mar-20 Cancelled, dA single-center, open-la

First peopl ### 20200228 4/15/2020 ChiCTR
ChiCTR200 9-Mar-20 Protective Protective factors of mental

The Third A ### 20200228 4/15/2020 ChiCTR
ChiCTR200 9-Mar-20 Study for t Study for the clinical characte
The Third X 3/2/2020 20200302 4/15/2020 ChiCTR
ChiCTR200 9-Mar-20 A Medical The Real World Study to Yueyang
E Hos ### 20200224 4/15/2020 ChiCTR
ChiCTR200 9-Mar-20 Cancelled duEffect of early pulmonary
Wuhan
tr Four ### 20200220 4/15/2020 ChiCTR
ChiCTR200 9-Mar-20 Severe noveSevere novel coronavirus

ChiCTR200 9-Mar-20 A pilot st A multicenter, randomiz

ChiCTR200 9-Mar-20 A MulticenA Multicenter, Randomized

West China 2/8/2020 20200208 4/15/2020 ChiCTR
ChiCTR200 9-Mar-20 Recommenda

Recommendations forHospital
Diag of 2/4/2020 20200204 4/15/2020 ChiCTR
ChiCTR200 9-Mar-20 Recommenda
Recommendations of Integrate
Hospital of 2/4/2020 20200204 4/15/2020 ChiCTR
ChiCTR200 9-Mar-20 The investi The investigation of cytokine

ChiCTR200 9-Mar-20 A randomizA randomized, open-label,

Hebei Yili 2/1/2020 20200201 4/15/2020 ChiCTR
ChiCTR200 9-Mar-20 Convalescen

Convalescent plasma for
China-Japan
the ### 20200212 4/15/2020 ChiCTR
NCT04292 ### Anti-SARS- The Efficacy and Safe Shanghai Pu ### 20200225 4/15/2020 ClinicalTria
ChiCTR200 9-Mar-20 A randomizA randomized, open-label,

Hebei Yilin 2/1/2020 20200201 4/15/2020 ChiCTR
NCT04292 ### Clinical Pr Clinical Pr 2019-nCoVFujian Prov ### 20200223 4/15/2020 ClinicalTria
ChiCTR200 9-Mar-20 Research f Research for Traditional

Hospital
C of 2/2/2020 20200202 4/15/2020 ChiCTR
ChiCTR200 ### Clinical Ap Clinical Application andZhengzhou

Th ### 20200316 4/15/2020 ChiCTR
ChiCTR200 ### RetrospectRetrospective and Prospecti

ChiCTR200 ### Favipiravi Favipiravir Combined With

Peking Univ ### 20200316 4/15/2020 ChiCTR
NCT04293 ### Efficacy an Randomized, Open, BlaTongji Hosp ### 20200215 4/15/2020 ClinicalTria
ChiCTR200 ### Analysis fo Analysis for the mentalJingzhou

h M ### 20200316 4/15/2020 ChiCTR
ChiCTR200 ### Study for eStudy of effects of crisis
Zhengzhou
inte ### 20200316 4/15/2020 ChiCTR
ChiCTR200 ### Clinical a Clinical and CT imagingJinling

Char Hos ### 20200316 4/15/2020 ChiCTR
NCT04295 ### MulticenterMulticenter Clinical S Jiangxi Qin 3/3/2020 20200303 4/15/2020 ClinicalTria
NCT04296 ### Medical MaMedical Masks Versus McMaster U3/3/2020 20200303 4/15/2020 ClinicalTria
NCT04299 ### Mental HeaMental Health and Its University 3/4/2020 20200304 4/15/2020 ClinicalTria
ChiCTR200 ### Evaluation Evaluation of the effectHwaMei Hos ### 20200316 4/15/2020 ChiCTR
ChiCTR200 ### CorrelationCorrelation analysis ofTongji

bloo Hosp ### 20200316 4/15/2020 ChiCTR
ChiCTR200 ### Developmen Development and application

ChiCTR200 ### RetrospectRetrospective analysis The
of eChines ### 20200316 4/15/2020 ChiCTR
ChiCTR200 ### A clinical A clinical multicenter study
Li Lanjuan
o ### 20200316 4/15/2020 ChiCTR
ChiCTR200 ### Evaluation Evaluation of the protective

ChiCTR200 ### Factors as Factors associated withBeijing

deathAn ### 20200316 4/15/2020 ChiCTR
ChiCTR200 ### Efficacy a Efficacy and Safety of Pi
State Key L ### 20200316 4/15/2020 ChiCTR
ChiCTR200 ### Clinical r Clinical research and pre

ChiCTR200 ### A medical rInvestigation of dynamic
Tongji
profile
Hosp ### 20200316 4/15/2020 ChiCTR
ChiCTR200 ### Study for Study for the virus molec

Shanghai N ### 20200315 4/15/2020 ChiCTR
ChiCTR200 ### EstablishmeEstablishment of an early

Tongji
warHosp ### 20200316 4/15/2020 ChiCTR
ChiCTR200 ### Clinical ch Clinical characteristic Hubei Canc ### 20200316 4/15/2020 ChiCTR
ChiCTR200 ### Clinical o Clinical observation anHubei 672 ### 20200315 4/15/2020 ChiCTR
ChiCTR200 ### A medical Clinical outcomes and Tongji

follow-up
Hosp
s ### 20200315 4/15/2020 ChiCTR
ChiCTR200 ### Development

Development of warning
Zhongnan
sys H ### 20200315 4/15/2020 ChiCTR
ChiCTR200 ### Novel coro Novel covid-19 pneumonia

Longhua
c Hos ### 20200315 4/15/2020 ChiCTR
ChiCTR200 ### An artifici An artificial intelligenceTongji

as Hosp ### 20200316 4/15/2020 ChiCTR
ChiCTR200 ### Investigati Investigation on psychologic

Zhengzhou ### 20200315 4/15/2020 ChiCTR

A randomized, controlled
Wuhan
op Jiny ### 20200123 4/15/2020 ChiCTR
EUCTR2015 ### Adaptive t Randomized, Embedded,
University
Multi ### 20150713 4/15/2020 EU Clinical
ChiCTR200 ### Clinical s Clinical study on the effic

the First A ### 20200315 4/15/2020 ChiCTR
ChiCTR200 ### Epidemiolog Epidemiological Characterist

ChiCTR200 ### Clinical va Clinical validation and Tongji
appli Hosp ### 20200315 4/15/2020 ChiCTR
ChiCTR200 ### The analysiThe analysis of relatedTongji Hosp ### 20200315 4/15/2020 ChiCTR
ChiCTR200 ### RetrospectRetrospective analysis Wuhan
of di Thir ### 20200315 4/15/2020 ChiCTR
ChiCTR200 ### A medical The value of Lymphocyte Department
subsets ### 20200315 4/15/2020 ChiCTR
ChiCTR200 ### Nutritional Nutritional risk assessment

Tongjiand
Hosp ### 20200315 4/15/2020 ChiCTR
ChiCTR200 ### A medical Ocular dectection of SARS-Co

Tongji hosp ### 20200315 4/15/2020 ChiCTR
ChiCTR200 ### A multicen A multicenter retrospective

Tongjistud
Hosp ### 20200315 4/15/2020 ChiCTR
ChiCTR200 ### A medical rEpidemiologic and Clinical
Ningbo
featur
Firs ### 20200314 4/15/2020 ChiCTR
ChiCTR200 ### Clinical ch Screening and Identification

ChiCTR200 ### QuantitativQuantitative CT characteristic
Tongji Hosp
e ### 20200315 4/15/2020 ChiCTR
ChiCTR200 ### Collection Clinical characteristics Union
of seveHospi ### 20200315 4/15/2020 ChiCTR
ChiCTR200 ### A retrospecA retrospective study of

Tongji
clinica
Hosp ### 20200315 4/15/2020 ChiCTR
ChiCTR200 ### A medical rClinical characteristics Wuhan

of COVID-1
3rd ### 20200315 4/15/2020 ChiCTR
ChiCTR200 ### Clinical c Clinical characteristics The
and Second
treat ### 20200315 4/15/2020 ChiCTR
ChiCTR200 ### Analysis of Analysis of risk factorsThe

af Third ### 20200315 4/15/2020 ChiCTR
ChiCTR200 ### Cancelled bStudy on levels of inflamma
NCT04298 ### Safety Rel Analysis of Safety Re Tongji Hosp ### 20200226 4/15/2020 ClinicalTria
ChiCTR200 ### Evaluation Evaluation on the effect

Theof affilia
C ### 20200316 4/15/2020 ChiCTR
ChiCTR200 ### Study for Study for the therapeutic

TheeFirst A ### 20200313 4/15/2020 ChiCTR
ChiCTR200 ### A medical rSedation and AnalgesiaTongji

UsageHosp
i ### 20200313 4/15/2020 ChiCTR
ChiCTR200 ### The value The value of CD4 / CD8Cangzhou
cells, C P ### 20200314 4/15/2020 ChiCTR
ChiCTR200 ### Applicatio Application of blood purificat

Huashan Ho ### 20200314 4/15/2020 ChiCTR
ChiCTR200 ### A study forA study for clinical characte

The People ### 20200314 4/15/2020 ChiCTR
ChiCTR200 ### Study for Risk Factors for AnxietyZhongnan
of H ### 20200314 4/15/2020 ChiCTR
ChiCTR200 ### Open-labelOpen-label, observational

The sFirst H ### 20200316 4/15/2020 ChiCTR
ChiCTR200 ### Traditiona Clinical study for TCM Xiangyang

Decocti 1 ### 20200316 4/15/2020 ChiCTR
ChiCTR200 ### Impact of NImpact of Novel Coronavir

Clinical R ### 20200313 4/15/2020 ChiCTR
ChiCTR200 ### Detection Detection of SARS-CoV-2
Shenzhen
in EP H ### 20200313 4/15/2020 ChiCTR
ChiCTR200 ### Research f Research for the influence

Xiyuan Hos ### 20200313 4/15/2020 ChiCTR
ChiCTR200 ### Diagnosis Diagnosis and treatment TheofSecond ### 20200313 4/15/2020 ChiCTR
ChiCTR200 ### A medical bAnalysis of influencingWuhan

factors Thir ### 20200316 4/15/2020 ChiCTR
ChiCTR200 ### Clinical st Clinical study for bronchos

ChiCTR200 ### A medical rClinical characteristics Zhejiang
of 20 Ho ### 20200313 4/15/2020 ChiCTR
ChiCTR200 ### A medical Characteristics, prognosis
Tongji Hos ### 20200313 4/15/2020 ChiCTR
ChiCTR200 ### Clinical R Clinical Research for Tradit

ChiCTR200 ### Randomized

Clinical Study of Chloroquine
Zhongnan
P H ### 20200311 4/15/2020 ChiCTR
ChiCTR200 ### Study for t Study for the effect of Department

ext ### 20200316 4/15/2020 ChiCTR
ChiCTR200 ### Study for Study for the physical and

The men
First A ### 20200315 4/15/2020 ChiCTR
ChiCTR200 ### A medical Analysis of the Incidence

Shandong
a P ### 20200313 4/15/2020 ChiCTR
ChiCTR200 ### Clinical A Clinical Application of EShandong P ### 20200313 4/15/2020 ChiCTR
ChiCTR200 ### CharacterisCharacteristics, prognosis

ChiCTR200 ### ObservatioObservational Study for

Shandong
Pr P ### 20200313 4/15/2020 ChiCTR
ChiCTR200 ### A medical rRisk assessment and treatmen

ChiCTR200 ### Shedding oShedding of SARS-CoV-2 Tongji
in hum
Med ### 20200311 4/15/2020 ChiCTR
ChiCTR200 ### Analysis of Analysis of the incidence

Shandong
and P ### 20200313 4/15/2020 ChiCTR
ChiCTR200 ### Cross sect Cross sectional study of

West
dial China ### 20200311 4/15/2020 ChiCTR
ChiCTR200 ### ExplorationExploration of the Clinica
Shandong P ### 20200313 4/15/2020 ChiCTR
ChiCTR200 ### A comparatA comparative study for

Affiliated
t ### 20200312 4/15/2020 ChiCTR
ChiCTR200 ### Explorator Treatment of Acute Severe

UnionCOVI
hosp ### 20200315 4/15/2020 ChiCTR
ChiCTR200 ### Preliminar Preliminary screening of
Tongren
Cor Ho ### 20200315 4/15/2020 ChiCTR
ChiCTR200 ### RetrospectRetrospective study onGanzi
novelHospi
c ### 20200311 4/15/2020 ChiCTR
ChiCTR200 ### Cancelled bApplication of cas13a-mediated

ChiCTR200 ### A retrospe A retrospective cohortWuhan

st Hosp ### 20200311 4/15/2020 ChiCTR
ChiCTR200 ### A randomize
A randomized, blinded,Xiangya
c Hos ### 20200310 4/15/2020 ChiCTR
ChiCTR200 ### Study for Study on the pathogenesis

Tongji
a Hosp ### 20200315 4/15/2020 ChiCTR
ChiCTR200 ### DevelopmenDevelopment and application
Hwa Meio Ho ### 20200315 4/15/2020 ChiCTR
ChiCTR200 ### RetrospectiRetrospective study forWuhan

th Thir ### 20200315 4/15/2020 ChiCTR
ChiCTR200 ### ExocarpiumExocarpium Citri Grandis

Maoming
Re Pe ### 20200315 4/15/2020 ChiCTR
ChiCTR200 ### Establishm Establishment and validation

ChiCTR200 ### clinical s clinical study for hemodynamic

Shanghai Fi ### 20200315 4/15/2020 ChiCTR
ChiCTR200 ### Novel coro COVID-19 infection associated

Department3/9/2020
kid 20200309 4/15/2020 ChiCTR
ChiCTR200 ### Efficacy an Efficacy and safety of hon

Hubei Hospi3/6/2020 20200306 4/15/2020 ChiCTR
ChiCTR200 ### Study for Study on immune cell subsets

The Third
in A ### 20200310 4/15/2020 ChiCTR
ChiCTR200 ### Efficacy a Tozumab combined with

Shanghai
ad G 3/8/2020 20200308 4/15/2020 ChiCTR

A randomized, parallelThe
c Third ### 20200310 4/15/2020 ChiCTR
ChiCTR200 ### Study for An evaluative clinical sUnion Hospi ### 20200310 4/15/2020 ChiCTR
ChiCTR200 ### A clinical A randomized, open-label,

ChiCTR200 ### A Medical Analysis of Risk FactorsShandong

fo P ### 20200313 4/15/2020 ChiCTR
ChiCTR200 ### Cancelled dInvestigation on MentalYongchuan
Hea 3/2/2020 20200302 4/15/2020 ChiCTR
ChiCTR200 ### Efficacy an Efficacy and safety of Xue-B

Jingzhou Fi 3/1/2020 20200301 4/15/2020 ChiCTR
ChiCTR200 ### ContinuousContinuous renal replace

Renji Hospi ### 20200313 4/15/2020 ChiCTR
ChiCTR200 ### Medical re Accuracy analysis of SARS-CoV-2
ChiCTR200 ### Cancelled bEpidemiological research Guangzhou 3/7/2020 20200307 4/15/2020 ChiCTR
ChiCTR200 ### Cancelled bClinical trial for umbilicThe Second ### 20200228 4/15/2020 ChiCTR
ChiCTR200 ### The predic The prediction value ofThe

proSixth A 3/9/2020 20200309 4/15/2020 ChiCTR
ChiCTR200 ### An anaesthAn anaesthesia procedurLiaocheng 3/9/2020 20200309 4/15/2020 ChiCTR
ChiCTR200 ### Lung ultra Lung ultrasound in thePeking
diagn Univ ### 20200223 4/15/2020 ChiCTR
ChiCTR200 ### Cancelled bRandomized controlledThe triaFirst A ### 20200222 4/15/2020 ChiCTR
ChiCTR200 ### Cancelled bNovel coronavirus pneumonia

Luohu hosp ### 20200228 4/15/2020 ChiCTR
ChiCTR200 ### Cancelled bStudy for sleep status of
Guangzhou
me ### 20200225 4/15/2020 ChiCTR
ChiCTR200 ### Cancelled bStudy on the effect of hum

ChiCTR200 ### Cancelled bAn observational studyThe

of hSecond ### 20200217 4/15/2020 ChiCTR
ChiCTR200 ### A medical Analysis of the characte

ChiCTR200 ### Cancelled bA multicentre, randomized,

The first a 3/3/2020 20200303 4/15/2020 ChiCTR
ChiCTR200 ### A medical rAnalysis of risk factorsShandong
for d P ### 20200313 4/15/2020 ChiCTR
ChiCTR200 ### A prospect A prospective cohort stud

Hubei Prov ### 20200313 4/15/2020 ChiCTR
ChiCTR200 ### Clinical st Efficacy and safety of Lopina

Jingzhou Fi ### 20200224 4/15/2020 ChiCTR
ChiCTR200 ### Cancelled bSingle arm study for the

Guangzhou
effi ### 20200216 4/15/2020 ChiCTR
ChiCTR200 ### Cancelled bPositively Controlled Clini

ChiCTR200 ### MulticenteMulticenter study for the

Thetre
First A ### 20200222 4/15/2020 ChiCTR
ChiCTR200 ### Auscultato Auscultatory characteristics

Shanghaiof Fi ### 20200312 4/15/2020 ChiCTR
ChiCTR200 ### Prognosis Prognosis InvestigationHubei
a Prov ### 20200311 4/15/2020 ChiCTR
ChiCTR200 ### Cancelled bClinical Study of Cord Blo

ChiCTR200 ### Cancelled bClinical Study for Umbilical

ChiCTR200 ### Cancelled bA randomized, double-bl

Jingzhou Ce ### 20200215 4/15/2020 ChiCTR

Jingzhou Ce ### 20200214 4/15/2020 ChiCTR

The Sixth A ### 20200221 4/15/2020 ChiCTR
ChiCTR200 ### Nucleic ac Nucleic acid analysis ofTongji

n Hosp ### 20200219 4/15/2020 ChiCTR
ChiCTR200 ### Plasma of tConvalescent plasma for

China-Japan
the t ### 20200310 4/15/2020 ChiCTR
ChiCTR200 ### A multi-cenA multi-center, open-lab

Ningbo Firs ### 20200310 4/15/2020 ChiCTR
ChiCTR200 ### The effect The effects of preventio

Peking Univ3/9/2020 20200309 4/15/2020 ChiCTR
ChiCTR200 ### Cohort studCohort study of Novel Wuhan

Coronavir
Chil 3/9/2020 20200309 4/15/2020 ChiCTR
ChiCTR200 ### Medical re Medical records basedXiyuan

stud Hos 3/8/2020 20200308 4/15/2020 ChiCTR
ChiCTR200 ### Medical re Study for the correlation

China
be Acad 3/8/2020 20200308 4/15/2020 ChiCTR
ChiCTR200 ### Applicatio Application of TCM Nursing
The Second
Sch 3/6/2020 20200306 4/15/2020 ChiCTR
ChiCTR200 ### Cancelled bClinical Study of NK Cells

TheinFirst H 3/5/2020 20200305 4/15/2020 ChiCTR
ChiCTR200 ### Cancelled by
A cox regression analysis
Wuhan
of prAsia ### 20200214 4/15/2020 ChiCTR
NCT04264 ### Vitamin C Vitamin C Infusion fo ZhiYong Pe 2/4/2020 20200204 4/15/2020 ClinicalTria
ChiCTR200 ### Clinical St Clinical Study of Arbidol

Union
H Hosp 2/5/2020 20200205 4/15/2020 ChiCTR
NCT04307 ### ComparisonRandomized ControlledAsan Medic ### 20200310 4/15/2020 ClinicalTria
ChiCTR200 ### Study for mStudy for meditation assists

Cancer Inst 3/3/2020 20200303 4/15/2020 ChiCTR
ChiCTR200 ### Cancelled bEfficacy and safety of chl

Harbin infe 3/1/2020 20200301 4/15/2020 ChiCTR
ChiCTR200 ### Cancelled bA randomized, open-labe

First peopl ### 20200229 4/15/2020 ChiCTR
ChiCTR200 ### Cancelled bA randomized controlled

ThetriSecond ### 20200224 4/15/2020 ChiCTR
ChiCTR200 ### Cancelled bStudy for the false positive

ChiCTR200 ### Cancelled bClinical Study for Umbilical

ChiCTR200 ### Cancelled bClinical Study of Cord Guangzhou

Bloo ### 20200214 4/15/2020 ChiCTR
ChiCTR200 ### Study for Study for epidemiology, Union
diagno
Hosp ### 20200213 4/15/2020 ChiCTR
NCT04302 ### Novel CoroClinical Study of Nov CAR-T (Shan ### 20200227 4/15/2020 ClinicalTria
ChiCTR200 ### The relati The correlation between
TheVita
People ### 20200323 4/15/2020 ChiCTR
NCT04308 ### Influence The COVISTCOVISTRESUniversity ### 20200312 4/15/2020 ClinicalTria
ChiCTR200 ### A medical A medical records based Zhengzhou
stu ### 20200322 4/15/2020 ChiCTR
ChiCTR200 ### Study for t Study on the impact onUnion
fetusHosp
an ### 20200322 4/15/2020 ChiCTR
ChiCTR200 ### ProspectiveProspective exploratory

The
cl third x ### 20200322 4/15/2020 ChiCTR
ChiCTR200 ### Study for Study for metagenomicsTheofFifth

pati A ### 20200322 4/15/2020 ChiCTR
ChiCTR200 ### A prognosi The Cohotr of COVID-19
Xiangyang 1 ### 20200322 4/15/2020 ChiCTR
ChiCTR200 ### A medical The Diagnosis and prognosis

Changzheng ### 20200320 4/15/2020 ChiCTR
ChiCTR200 ### Internet b Internet based SolutionBeijing

F Nor ### 20200320 4/15/2020 ChiCTR
ChiCTR200 ### Psychologi Psychological Support Ningbo

for DiagKan ### 20200322 4/15/2020 ChiCTR
ChiCTR200 ### Effect of A Effect of Auricular point

Xiyuan
pr Hos ### 20200320 4/15/2020 ChiCTR
ChiCTR200 ### Perioperat Perioperative immuneHu'nan

predi Can ### 20200321 4/15/2020 ChiCTR
ChiCTR200 ### A Study fo Detection of SARS-COV-2

HwaMei
RNA Hos ### 20200321 4/15/2020 ChiCTR
ChiCTR200 ### A medical A medical records based
Hu'nan
stu Prov ### 20200318 4/15/2020 ChiCTR
ChiCTR200 ### PreliminaryPreliminary evaluationPLA

of tGenera ### 20200318 4/15/2020 ChiCTR
ChiCTR200 ### A medical rClinical application of ex

ChiCTR200 ### Effects of Effects of different VTEThe

preFirst A ### 20200319 4/15/2020 ChiCTR
ChiCTR200 ### Correlationassociation of T lymphocytes
ChiCTR200 ### A Medical The Retrospective Study

Changzheng
abo ### 20200320 4/15/2020 ChiCTR
NCT04285 ### Critically Critically Ill Patient Chinese Un ### 20200224 4/15/2020 ClinicalTria
NCT04299 ### Safety and Safety and Immunity Ev

Shenzhen G3/5/2020 20200305 4/15/2020 ClinicalTria
NCT04302 ### Accurate C Accurate Classificati Renmin Hos3/7/2020 20200307 4/15/2020 ClinicalTria
ChiCTR200 ### ApplicationApplication of radiologyHwa in tMei Ho ### 20200323 4/15/2020 ChiCTR
ChiCTR200 ### EffectiveneEffectiveness of ''Liu-Zi-The First A ### 20200318 4/15/2020 ChiCTR
ChiCTR200 ### CorrelationCorrelation between virolog
Anqing Mun ### 20200318 4/15/2020 ChiCTR
ChiCTR200 ### MyocardialMyocardial injury and The

arrythmias
Fifth H ### 20200319 4/15/2020 ChiCTR
ChiCTR200 ### Study for Study for novel coronavirus
ChiCTR200 ### Safety and Safety and Effectiveness

Wuhan Jiny ### 20200322 4/15/2020 ChiCTR
ChiCTR200 ### A medical Clinical Research on Treatmen

ChiCTR200 ### ProspectiveProspective, open-label,

Foshan
con Firs ### 20200317 4/15/2020 ChiCTR
ChiCTR200 ### A phase I c A single-center, open and

Jiangsu Pro ### 20200317 4/15/2020 ChiCTR
ChiCTR200 ### Venous ThrVenous Thrombosis Risk

Shandong
of 2019 P ### 20200318 4/15/2020 ChiCTR
ChiCTR200 ### A Platform A Platform for Rapid Immuno-d

The Fifth A ### 20200318 4/15/2020 ChiCTR
ChiCTR200 ### A Medical Clinical Characteristic and
HuiZhou
Ou Mu ### 20200318 4/15/2020 ChiCTR
ChiCTR200 ### Screening aScreening and identification
ChiCTR200 ### A medical rUpper Respiratory Tract

Renmin
Viru Hos ### 20200320 4/15/2020 ChiCTR
ChiCTR200 ### A RandomizClinical Trial of Favipirav

ChiCTR200 ### Study for t Study for the clinical charac

Guangzhou 3/5/2020 20200305 4/15/2020 ChiCTR
ChiCTR200 ### the Efficac the Efficacy and SafetyZhongnan

of H ### 20200226 4/15/2020 ChiCTR
ChiCTR200 ### Cancelled bClinical guidance of diagnose
ChiCTR200 ### Nasal high-Nasal high-fow preoxygenat

Central The 2/9/2020 20200209 4/15/2020 ChiCTR
ChiCTR200 ### Psychologi Psychological Responses

Renmin
of M Hos ### 20200320 4/15/2020 ChiCTR
ChiCTR200 ### DevelopingDeveloping and evaluating

Tongji
o Hosp ### 20200319 4/15/2020 ChiCTR

ChiCTR200 ### Evaluation Evaluation of the effecHwaMei Hos ### 20200317 4/15/2020 ChiCTR
ChiCTR200 ### Cancelled bClinical study of mesenchymal

ChiCTR200 ### Cancelled bA prospective real world

ChiCTR200 ### Clinical s An open, multi-center,The

contSecond ### 20200318 4/15/2020 ChiCTR
ChiCTR200 ### Combined dCombined diagnostic value
Shanghai
of noK ### 20200318 4/15/2020 ChiCTR
ChiCTR200 ### Evaluation Evaluation of myocardial

Westinj China ### 20200217 4/15/2020 ChiCTR
ChiCTR200 ### A study forA study for the psycholog

The Fifth A ### 20200215 4/15/2020 ChiCTR
ChiCTR200 ### A multicentA multicenter, randomiz

A randomized, open labe
ChiCTR200 ### An observaAn observational studyXiangya

of Ho ### 20200317 4/15/2020 ChiCTR
ChiCTR200 ### Study for c Study for the effect of Guangzhou

3% 3/6/2020 20200306 4/15/2020 ChiCTR
ChiCTR200 ### A medical Optimization and evaluati The First A ### 20200223 4/15/2020 ChiCTR
ChiCTR200 ### HydroxychlHydroxychloroquine treating

Ruijin Hosp ### 20200215 4/15/2020 ChiCTR
EUCTR2020 ### HydroxychlTreatment of Coronavirus Fondation

SARS ### 20200310 4/15/2020 EU Clinical
DRKS00021 ### Identificat Identification of host cell
Klinik fÃ¼r ### 20200319 4/15/2020 German Clin
IRCT20100 ### Interferon Evaluating efficacy andTehran
safety Uni ### 20200316 4/15/2020 IRCT
IRCT20200 ### Effect of h Formulation of two natura
Iran Univer ### 20200317 4/15/2020 IRCT
IRCT20100 ### Interferon Evaluating efficacy andTehran
safety Uni ### 20200319 4/15/2020 IRCT
IRCT20160 ### The effect The effect of NOSCOVID Qazvin
on pul
Univ ### 20200322 4/15/2020 IRCT
IRCT20151 ### Evaluting t Evaluting the therapeutic
Shahid
a Behe ### 20200323 4/15/2020 IRCT
IRCT20100 ### ?Effect of Evaluating efficacy andTehran
safety Uni ### 20200319 4/15/2020 IRCT
IRCT20200 ### Study to EvA prospective randomized
Digestive D ### 20200314 4/15/2020 IRCT
NCT04263 ### The Effica An Open, Prospective/Tongji Hosp2/2/2020 20200202 4/15/2020 ClinicalTria
IRCT20100 ### CombinatioEvaluating efficacy andTehran
saf Uni ### 20200322 4/15/2020 IRCT
JPRN-jRCT ### Triple com A prospective multi-cente
Tokue Yuta ### 20200227 4/15/2020 JPRN
TCTR20200 ### ED ResponsResponse adjustment of

Study
emerg
Grou ### 20200320 4/15/2020 TCTR
NCT04251 ### Washed Mic Washed Microbiota Tra The Second ### 20200130 4/15/2020 ClinicalTria
JPRN-jRCT ### Favipiravir A prospective multi-center
TokueopYuta ### 20200227 4/15/2020 JPRN
JPRN-jRCT ### Favipiravir Multicenter, open-label,
Doir Yohei 3/2/2020 20200302 4/15/2020 JPRN
NCT04273 ### Evaluating Evaluating the Effica Second Aff ### 20200214 4/15/2020 ClinicalTria
NCT04283 ### Study for Study for Clinical Ep Wuhan Unio ### 20200213 4/15/2020 ClinicalTria
NCT04287 ### Recombinan

A Randomized, Open La
The First A ### 20200221 4/15/2020 ClinicalTria
NCT04254 ### A Prospect An Open, Prospective/Tongji Hosp2/2/2020 20200202 4/15/2020 ClinicalTria
NCT04255 ### A Prospect An Open, Prospective/Tongji Hosp2/2/2020 20200202 4/15/2020 ClinicalTria

NCT04261 ### A RandomizA Randomized,Open,Con
Tongji Hosp2/4/2020 20200204 4/15/2020 ClinicalTria
Critical
Care
Research
Group
The
Prince
Charles
JPRN-UMIN ### ExtraCorpoExtraCorporeal Membrane
Hospital
Oxyg 3/6/2020 20200306 4/15/2020 JPRN
NCT04276 ### Immunity aPhase I/II Multicenter Shenzhen G ### 20200217 4/15/2020 ClinicalTria
NCT04264 ### Treatment An Exploratory Clini Wuhan Unio2/8/2020 20200208 4/15/2020 ClinicalTria
NCT04278 ### Yinhu Qing Adaptive, Randomized,China Acad ### 20200219 4/15/2020 ClinicalTria
NCT04292 ### Prognostic Prognostic Factors of Chongqing 3/1/2020 20200301 4/15/2020 ClinicalTria
NCT04306 ### Clinical Tr Clinical Tr CTOROTSAJiangsu Fa 3/1/2020 20200301 4/15/2020 ClinicalTria

JPRN-UMIN ### COVID-19 RCOVID-19 Registry - COVID-19
NationalRegis
C ### 20200319 4/15/2020 JPRN
TCTR20200 ### Covid-19 p Preparedness and Responsive
Study Grou ### 20200321 4/15/2020 TCTR
NCT04291 ### The Efficac The Efficacy and Safet Tongji Hosp ### 20200227 4/15/2020 ClinicalTria
NCT04293 ### Therapy fo Human Umbilical CordPuren Hosp ### 20200224 4/15/2020 ClinicalTria
NCT04305 ### Social MedGetting it Right: Tow Jean Liu 3/8/2020 20200308 4/15/2020 ClinicalTria
NCT04310 ### Yinhu Qing An Adaptive, RandomizZhong Wan ### 20200315 4/15/2020 ClinicalTria
NCT04272 ### Prognositc Prognostic Characteri Chongqing ### 20200212 4/15/2020 ClinicalTria
NCT04304 ### A Pilot Stu A Pilot Study of Silde Tongji Hosp ### 20200214 4/15/2020 ClinicalTria
NCT04306 ### Tocilizuma A RetrospeTACOS Tongji Hosp3/8/2020 20200308 4/15/2020 ClinicalTria
NCT04314 ### Mechanisms

Changes in COVID ME University ### 20200317 4/15/2020 ClinicalTria
NCT04314 ### Adverse EvAdverse EvCovidTox Groupe Hosp ### 20200317 4/15/2020 ClinicalTria
NCT04308 ### Tetrandrin Clinical S TT-NPC Henan Provi3/4/2020 20200304 4/15/2020 ClinicalTria
NCT04312 ### MyocardialRetrospective Study Wuhan Unio3/4/2020 20200304 4/15/2020 ClinicalTria
NCT04313 ### Treatment Treatment of COVID-19

Stem Cells ### 20200315 4/15/2020 ClinicalTria
ChiCTR200 ### Causes of Causes of fever in outpatie

Chinese PL ### 20200329 4/15/2020 ChiCTR
NCT04312 ### Sequential Sequential SOTSPC Henan Provi ### 20200313 4/15/2020 ClinicalTria
NCT04318 ### HydroxychlChemoproph

PHYDRA National In ### 20200319 4/15/2020 ClinicalTria
NCT04318 ### ACE InhibitACE InhibitCODIV-ACENeuromed ### 20200319 4/15/2020 ClinicalTria
ChiCTR200 ### Study for t Altered brain structureUnion

and fun
Hosp ### 20200328 4/15/2020 ChiCTR
NCT04316 ### MechanismsUppsala In UMODCOVIUppsala Un ### 20200313 4/15/2020 ClinicalTria

ChiCTR200 ### RetrospectRetrospective analysis Hubei
o Mate ### 20200328 4/15/2020 ChiCTR
NCT04311 ### Developmen

Development and VerifHuashan Ho ### 20200314 4/15/2020 ClinicalTria
NCT04314 ### The ObservThe Observational StuXiangya Hos ### 20200316 4/15/2020 ClinicalTria
NCT04315 ### Clinical Ch Clinical Ch I-COVID Federico II ### 20200318 4/15/2020 ClinicalTria
NCT04315 ### HydroxychlHydroxychlHYDRA National In ### 20200318 4/15/2020 ClinicalTria

ChiCTR200 ### Analysis f Analysis for preventionShandong
an E ### 20200327 4/15/2020 ChiCTR
ChiCTR200 ### Influence oInfluence of COVID-19Guangdong

on dise ### 20200327 4/15/2020 ChiCTR
ChiCTR200 ### To explore Serum and urine proteins
WESTLAKE
and me ### 20200329 4/15/2020 ChiCTR
ChiCTR200 ### Safety and Safety and Efficacy Study

ChiCTR200 ### AI based p AI based prognostic evaluation

ChiCTR200 ### The investi The investigation on medica
Nanjing Uni ### 20200327 4/15/2020 ChiCTR
ChiCTR200 ### The protec The protective effect ofFirst

sl Teach ### 20200327 4/15/2020 ChiCTR
ChiCTR200 ### Clinical ch Clinical characteristics Tongji

and deaHosp ### 20200327 4/15/2020 ChiCTR
NCT04316 ### Clinical Pe Clinical Performance oCentro Stud ### 20200314 4/15/2020 ClinicalTria
ChiCTR200 ### The relati The relationship between
Shandong E ### 20200328 4/15/2020 ChiCTR
ChiCTR200 ### The effect The effectiveness of mindf
China Euro ### 20200326 4/15/2020 ChiCTR
ChiCTR200 ### Outcomes aOutcomes and infectivity

Chongqing
of pa ### 20200325 4/15/2020 ChiCTR
ChiCTR200 ### Metabolic Metabolic abnormalitiesTheandThird A ### 20200326 4/15/2020 ChiCTR

ChiCTR200 ### EpidemiologEpidemiologic and Clinical
RenminCh Hos ### 20200325 4/15/2020 ChiCTR
ChiCTR200 ### A retrospecA retrospective study of
China-Japan
cl ### 20200327 4/15/2020 ChiCTR
ChiCTR200 ### Study on t Study on the mental state
WestofChina ### 20200325 4/15/2020 ChiCTR
ChiCTR200 ### A medical rA medical records based
Yichang
stud Cen ### 20200327 4/15/2020 ChiCTR
ChiCTR200 ### Epidemiolog

Epidemiological study Tongji
of novel
Hosp ### 20200327 4/15/2020 ChiCTR
ChiCTR200 ### EpidemioloEpidemiological surveySchool

of closof ### 20200325 4/15/2020 ChiCTR
ChiCTR200 ### Shedding vShedding virus and functional

ChiCTR200 ### A multicentA multicenter, single-blin
Beijing you ### 20200324 4/15/2020 ChiCTR
ChiCTR200 ### A medical A medical records based

Wuhan
retrosThir ### 20200323 4/15/2020 ChiCTR
ChiCTR200 ### Study for Study for the effect of Zhengzhou

Mo ### 20200324 4/15/2020 ChiCTR
ChiCTR200 ### Study on h Study on home pharmaceutical
People's h ### 20200323 4/15/2020 ChiCTR
ChiCTR200 ### Clinical fe Clinical features and prRenmin Hos ### 20200325 4/15/2020 ChiCTR
ChiCTR200 ### Study for ' Study for ''Bai-Du DuanLonghua

Fan Hos ### 20200318 4/15/2020 ChiCTR
ChiCTR200 ### Clinical st Clinical study on the corre

Wuhan Thir ### 20200324 4/15/2020 ChiCTR
ChiCTR200 ### A medical rClinical characteristics Nothern
and ri Ji ### 20200323 4/15/2020 ChiCTR
ChiCTR200 ### Clinical ef Clinical efficacy of TCMHospital of ### 20200320 4/15/2020 ChiCTR
ChiCTR200 ### Clinical i Clinical investigation and

First
resea
Teach ### 20200318 4/15/2020 ChiCTR
ChiCTR200 ### A real-worlHospital of Chengdu Univer

Hospital of ### 20200318 4/15/2020 ChiCTR
ChiCTR200 ### The treatmThe treatment and diagnosis

ChiCTR200 ### A randomizGu-Shen Ding-Chuan-Wan

The First
use A ### 20200318 4/15/2020 ChiCTR
ChiCTR200 ### ObservatioObservation Of ClinicalThe

Eff First P ### 20200310 4/15/2020 ChiCTR
ChiCTR200 ### Efficacy an Clinical efficacy of novel

Diagnosis,
co ### 20200323 4/15/2020 ChiCTR
ChiCTR200 ### A RCT for Efficacy and safety of CGuangdong ### 20200320 4/15/2020 ChiCTR
ChiCTR200 ### MulticenterMulticenter clinical study
ChiCTR200 ### Prediction Prediction of prognosisUnion Hosp ### 20200218 4/15/2020 ChiCTR
ChiCTR200 ### Cancelled bthe effects of 6-minuteThe

w First A ### 20200228 4/15/2020 ChiCTR
ChiCTR200 ### Efficacy o Study on Prevention and

China
TreaAcad ### 20200227 4/15/2020 ChiCTR
ChiCTR200 ### EpidemiologEpidemiological and clinical
Daping Hos ### 20200226 4/15/2020 ChiCTR
ChiCTR200 ### Clinical re Effect of pulmonary rehab

ChiCTR200 ### Clinical co Clinical comparative study

WestoChina ### 20200220 4/15/2020 ChiCTR
EUCTR2020 ### Covid-19: ACovid-19: A randomized,

UZLeuven
op ### 20200327 4/15/2020 EU Clinical
ChiCTR200 ### The effect Novel coronavirus pneumonia
Shanghai Un ### 20200218 4/15/2020 ChiCTR
EUCTR2020 ### Sarilumab An adaptive phase 2/3,Sanofi-ave
ran ### 20200320 4/15/2020 EU Clinical
EUCTR2020 ### Reducing hReducing health care wo
University ### 20200317 4/15/2020 EU Clinical
EUCTR2020 ### Systematic Randomized controlledUniversitÃ
tria ### 20200324 4/15/2020 EU Clinical
EUCTR2020 ### A clinical The NOR Solidarity multicen
Oslo Univer ### 20200324 4/15/2020 EU Clinical
EUCTR2020 ### a trial of A randomised double-bl
Synairgen ### 20200317 4/15/2020 EU Clinical
NCT04312 6-Apr-20 The Use of A Phase 2 Multiple DosPulmotect, ### 20200316 4/15/2020 ClinicalTria
NCT04315 6-Apr-20 Trial of Tr Multi-centrDisCoVeRy Institut N ### 20200313 4/15/2020 ClinicalTria
NCT04319 6-Apr-20 Clinical T Clinical Trial of Fav Beijing Cha ### 20200320 4/15/2020 ClinicalTria
NCT04061 6-Apr-20 Sero-epide Serum TestSTORY University ### 20190730 4/15/2020 ClinicalTria
NCT04288 6-Apr-20 EculizumabSoliris to SOLID-C19 Hudson Me ### 20200227 4/15/2020 ClinicalTria
NCT04290 6-Apr-20 Nitric Oxi Nitric Oxi NOSARSCOXijing Hosp ### 20200227 4/15/2020 ClinicalTria
NCT04303 6-Apr-20 ChloroquinChloroquinCOPCOV University 3/6/2020 20200306 4/15/2020 ClinicalTria
NCT04305 6-Apr-20 BevacizumaThe Efficac BEST-RCT Qilu Hospit 3/9/2020 20200309 4/15/2020 ClinicalTria
NCT04321 6-Apr-20 Personaliz Personaliz PROACTIVEUniversity ### 20200320 4/15/2020 ClinicalTria

NCT04322 6-Apr-20 The Use of The Use of AngiotensinUniversity ### 20200323 4/15/2020 ClinicalTria
NCT04323 6-Apr-20 Anti-infla Anti-infla ONSCOVID King Saud U ### 20200323 4/15/2020 ClinicalTria
NCT04313 6-Apr-20 The Use PUA Phase 2 Multiple DoPulmotect, ### 20200316 4/15/2020 ClinicalTria
NCT04316 6-Apr-20 Acute KidneAcute Kidney Injury i Zhenhua Z ### 20200317 4/15/2020 ClinicalTria
NCT04318 6-Apr-20 COVID-19: COVID-19: COVID19- University ### 20200317 4/15/2020 ClinicalTria
NCT04318 6-Apr-20 HydroxychlHydroxychloroquine PoColumbia U ### 20200320 4/15/2020 ClinicalTria

NCT04320 6-Apr-20 Joint Use Joint Use JOCOVID Groupe Hosp ### 20200320 4/15/2020 ClinicalTria
NCT04322 6-Apr-20 Colchicine COLCHICINE TO COUNLucio Mane ### 20200324 4/15/2020 ClinicalTria
NCT04323 6-Apr-20 Use of AscoUse of Ascorbic Acid University ### 20200318 4/15/2020 ClinicalTria
NCT04323 6-Apr-20 HydroxychlHydroxychloroquine foRambam He ### 20200325 4/15/2020 ClinicalTria
NCT04319 6-Apr-20 Effects of Investigati COVID-19 Istanbul U ### 20200320 4/15/2020 ClinicalTria
NCT04320 6-Apr-20 Closed-LooAutomated Oxygen TitrLaval Unive ### 20200319 4/15/2020 ClinicalTria
NCT04320 6-Apr-20 Baricitinib Baricitinib BARI-COVI Hospital of ### 20200320 4/15/2020 ClinicalTria
NCT04320 6-Apr-20 Non-contacNon-contact EndoscopChanghai H ### 20200321 4/15/2020 ClinicalTria
NCT04322 6-Apr-20 Escin in Pa Efficacy an add-on-CO University ### 20200323 4/15/2020 ClinicalTria
NCT04323 6-Apr-20 Outcomes oOutcomes oCovidSurg University ### 20200325 4/15/2020 ClinicalTria
ChiCTR200 6-Apr-20 Clinical st Clinical study for Celebrex

Guangzhou
in 4/5/2020 20200405 4/15/2020 ChiCTR
NCT04321 6-Apr-20 COVID-19 RCOVID-19 RCORIPREV- Darrell Tan ### 20200318 4/15/2020 ClinicalTria
NCT04321 6-Apr-20 Hyperimmun

Plasma FroCOV19-PL Foundation ### 20200323 4/15/2020 ClinicalTria
NCT04322 6-Apr-20 Simple, Sa Proposal foLUSCOVID1Catholic Un ### 20200323 4/15/2020 ClinicalTria
NCT04323 6-Apr-20 Traditiona A Retrospective CohorXiyuan Hos 3/8/2020 20200308 4/15/2020 ClinicalTria
ChiCTR200 6-Apr-20 Investigat What happens to non-health

RenmincHos4/5/2020 20200405 4/15/2020 ChiCTR
ChiCTR200 6-Apr-20 A paired cl A paired clinical study Tongji
of Hosp4/4/2020 20200404 4/15/2020 ChiCTR
NCT04324 6-Apr-20 A Phase I/ A Phase I/II Study of Chongqing ### 20200325 4/15/2020 ClinicalTria
NCT04325 6-Apr-20 Cardiac comCardiac comCAPACITY- UMC Utrec ### 20200325 4/15/2020 ClinicalTria
NCT04325 6-Apr-20 Efficacy of Efficacy of ENACOVID Assistance ### 20200326 4/15/2020 ClinicalTria
NCT04326 6-Apr-20 Audio DataAudio Data Collection HealthMode ### 20200326 4/15/2020 ClinicalTria
ChiCTR200 6-Apr-20 Study for Study for the Mechanism

N0.2ofPeople4/5/2020 20200405 4/15/2020 ChiCTR
ChiCTR200 6-Apr-20 Survey of Survey of psychologicalPeking

stat Uni 4/3/2020 20200403 4/15/2020 ChiCTR
NCT04325 6-Apr-20 CoronaviruComprehensive ClinicaChinese Un ### 20200324 4/15/2020 ClinicalTria
NCT04327 6-Apr-20 In-depth I In-depth C COntAGIouUniversita ### 20200326 4/15/2020 ClinicalTria
ChiCTR200 6-Apr-20 A Medical A Medical Records Based

Wuhan Wome
4/3/2020 20200403 4/15/2020 ChiCTR
ChiCTR200 6-Apr-20 Study for c Study for clinical effectAffiliated

of 4/3/2020 20200403 4/15/2020 ChiCTR
ChiCTR200 6-Apr-20 AssessmentAssessment of mental Ninth

healt Peopl4/3/2020 20200403 4/15/2020 ChiCTR
NCT04323 6-Apr-20 Efficacy o The Efficacy of Natura Misr Unive ### 20200323 4/15/2020 ClinicalTria
NCT04323 6-Apr-20 Efficacy o Prolonged MP-C19 University ### 20200319 4/15/2020 ClinicalTria
NCT04324 6-Apr-20 Anti-CoronAnti-CoronACT COVIDPopulation ### 20200325 4/15/2020 ClinicalTria
NCT04324 6-Apr-20 PrevalencePrevalence and Incide Universita ### 20200324 4/15/2020 ClinicalTria
ChiCTR200 6-Apr-20 A multi-ce A multi-center telephone

ChiCTR200 6-Apr-20 Sleep qualiSleep quality of patients
Shanghai
wi O 4/2/2020 20200402 4/15/2020 ChiCTR
ChiCTR200 6-Apr-20 Clinical st Clinical study for stem Huangshi

cells Ho4/2/2020 20200402 4/15/2020 ChiCTR
ChiCTR200 6-Apr-20 Novel coronNovel coronavirus (2019-nCOV)

The First P 4/2/2020 20200402 4/15/2020 ChiCTR
ChiCTR200 6-Apr-20 Efficacy an Efficacy and safety of Tongji Hos 4/1/2020 20200401 4/15/2020 ChiCTR
ChiCTR200 6-Apr-20 Analysis of Analysis of changes in Affiliated

high 4/1/2020 20200401 4/15/2020 ChiCTR
ChiCTR200 6-Apr-20 Clinical st Clinical study for preventio

Infection p 4/1/2020 20200401 4/15/2020 ChiCTR
ChiCTR200 6-Apr-20 A medical Clinical experience of 59

Tongji
n Hosp4/1/2020 20200401 4/15/2020 ChiCTR
NCT04327 6-Apr-20 CharacterizCharacterization of C University ### 20200326 4/15/2020 ClinicalTria
NCT04331 6-Apr-20 COVID-19 PCOVID-19 PC19REG RAD-AID In ### 20200330 4/15/2020 ClinicalTria
ISRCTN149 6-Apr-20 Does point-Evaluating the clinical University ### 20200318 4/15/2020 ISRCTN
ChiCTR200 6-Apr-20 The Effect The Effects of novel corTongji Hosp ### 20200331 4/15/2020 ChiCTR
ChiCTR200 6-Apr-20 Novel coronNovel coronavirus infection

The First
( P ### 20200331 4/15/2020 ChiCTR
ChiCTR200 6-Apr-20 A Medical A Medical Records BasedXiangya
Retr Ho ### 20200323 4/15/2020 ChiCTR
EUCTR2020 6-Apr-20 Multi-centrMulti-centre, adaptive,INSERM
rand 3/9/2020 20200309 4/15/2020 EU Clinical
ChiCTR200 6-Apr-20 Effects of Effects of a single sessio

Peking Univ4/5/2020 20200405 4/15/2020 ChiCTR
ChiCTR200 6-Apr-20 Applicatio Application of non-invasiv

Shanghai Si 4/3/2020 20200403 4/15/2020 ChiCTR
ChiCTR200 6-Apr-20 Clinical ap Clinical application value

Wuhan
of m Asia ### 20200331 4/15/2020 ChiCTR
ChiCTR200 6-Apr-20 A medical Safety and effectiveness

Peking
ana Univ ### 20200329 4/15/2020 ChiCTR
ChiCTR200 6-Apr-20 The efficac The efficacy of convalesce

Eastern th 4/2/2020 20200402 4/15/2020 ChiCTR
ChiCTR200 6-Apr-20 Impact of Impact of measuring distance
Dermatolog4/2/2020 20200402 4/15/2020 ChiCTR
ChiCTR200 6-Apr-20 A single ce A clinical study evaluating

Nanjing
th Uni ### 20200331 4/15/2020 ChiCTR
ChiCTR200 6-Apr-20 Clinical s Evaluation of the safety

TheanFifth M ### 20200331 4/15/2020 ChiCTR
EUCTR2020 6-Apr-20 SargramostiA prospective, randomiUniversity ### 20200324 4/15/2020 EU Clinical

EUCTR2020 6-Apr-20 CHROLOQUICHROLOQUINE PHOSPHATE
Uni-Pharma
AG ### 20200331 4/15/2020 EU Clinical
EUCTR2020 6-Apr-20 CounteringCOUNTER-COVID - OralAmsterda

ima ### 20200331 4/15/2020 EU Clinical
EUCTR2020 6-Apr-20 NORWEGIAN
NORWEGIAN CORONAVIRU
Akershus Un ### 20200316 4/15/2020 EU Clinical
EUCTR2020 6-Apr-20 Recombinan

Recombinant human angiotens
APEIRON Re ### 20200323 4/15/2020 EU Clinical
EUCTR2020 6-Apr-20 Efficacy of Uno studio randomizzato
Azienda
m UnitÃ
4/2/2020
Sanitaria
20200402
Locale-IRCCS
4/15/2020
di Reggio
EU Emilia
Clinical
NCT03331 14-Apr-20 Inhaled GasAn Open LaNONTM University ### 20171025 4/15/2020 ClinicalTria
NCT04261 14-Apr-20 Efficacy a Efficacy and Safety o Shanghai Pu2/6/2020 20200206 4/15/2020 ClinicalTria
NCT04273 14-Apr-20 Efficacy an Efficacy and Safety of Beijing Cha ### 20200215 4/15/2020 ClinicalTria
NCT04298 14-Apr-20 DAS181 forA Phase II STOP-Flu Ansun Biop ### 20200228 4/15/2020 ClinicalTria
EUCTR2020 6-Apr-20 HYCOVID - Hydroxychloroquine
HYCOVID - Hydroxychloroquine
versus
CHU Anger
placebo
versus
chez
placebo
###
les patients
20200324
chez les
ayant
4/15/2020
patients
une infection
ayant
EU Clinical
uneCOVID-19
infectionÃ
COVID-1
risque
EUCTR2020 6-Apr-20 Evaluation Evaluation of the concentrat

CHU de Sai ### 20200326 4/15/2020 EU Clinical
NCT04303 14-Apr-20 Various Com
A 6 Week PTHDMS-CORajavithi H ### 20200224 4/15/2020 ClinicalTria
NCT04305 14-Apr-20 Nitric Oxi Nitric Oxi NoCovid Massachuse3/9/2020 20200309 4/15/2020 ClinicalTria
NCT04312 14-Apr-20 NO PreventNitric Oxid NOpreventMassachuse ### 20200315 4/15/2020 ClinicalTria
ACTRN126 6-Apr-20 ExtraCorpoExtraCorporeal Membrane

The Prince
Oxyge ### 20200330 4/15/2020 ANZCTR
NCT03808 14-Apr-20 Phase III A Phase III RandomizeAnsun Biop ### 20190116 4/15/2020 ClinicalTria
ACTRN126 6-Apr-20 ChloroquinMulti-Site, Randomized,

Australian ### 20200330 4/15/2020 ANZCTR
NCT03680 14-Apr-20 Lessening Lessening LOVIT UniversitÃ ### 20180919 4/15/2020 ClinicalTria
NCT04316 14-Apr-20 Norwegian Norwegian NO COVID-University ### 20200313 4/15/2020 ClinicalTria

NCT04321 14-Apr-20 The ImpactThe ImpactCamoCO-1 University ### 20200323 4/15/2020 ClinicalTria
NCT04321 14-Apr-20 Outcomes aOutcomes aCOVIP Heinrich-He ### 20200319 4/15/2020 ClinicalTria
NCT04322 14-Apr-20 Proactive Proactive ProPAC-COChronic Ob ### 20200323 4/15/2020 ClinicalTria
EUCTR2020 6-Apr-20 Anti-il6 tr Effectiveness of InterleThe Parker ### 20200324 4/15/2020 EU Clinical
NCT04290 14-Apr-20 COVID-19 -MulticenteNOSO-CORHospices Ci ### 20200227 4/15/2020 ClinicalTria
NCT04245 14-Apr-20 Developmen

Development of a SimpBeijing Dit ### 20200126 4/15/2020 ClinicalTria
NCT04275 14-Apr-20 BevacizumaA Pilot St BEST-CP Qilu Hospit ### 20200214 4/15/2020 ClinicalTria
NCT04292 14-Apr-20 Study to E A Phase 3 RandomizedGilead Sci ### 20200228 4/15/2020 ClinicalTria
NCT04324 14-Apr-20 DAS181 forDAS181 for Severe CORenmin Hos ### 20200325 4/15/2020 ClinicalTria
NCT04324 14-Apr-20 Cytokine A Cytokine A CYCOV Dr. Alexan ### 20200325 4/15/2020 ClinicalTria
NCT04324 14-Apr-20 A Study of A Phase I/II Study to University ### 20200320 4/15/2020 ClinicalTria
NCT04328 14-Apr-20 EffectiveneEffectiveneCovid Prof. Dr. ### 20200325 4/15/2020 ClinicalTria
NCT04252 14-Apr-20 Efficacy an Efficacy an DC-COVID- Shanghai Pu ### 20200129 4/15/2020 ClinicalTria
NCT04274 14-Apr-20 Identifying Identifying Criticall Peking Univ ### 20200216 4/15/2020 ClinicalTria
NCT04280 14-Apr-20 Adaptive C A Multicenter, AdaptivNational In ### 20200220 4/15/2020 ClinicalTria
NCT04283 14-Apr-20 Safety and Phase I, Open-Label, National In ### 20200221 4/15/2020 ClinicalTria
NCT04310 14-Apr-20 Favipiravi Favipiravir Combined Peking Univ3/9/2020 20200309 4/15/2020 ClinicalTria
NCT04315 14-Apr-20 NestCellÂ®Explorator HOPE Azidus Bras ### 20200318 4/15/2020 ClinicalTria
NCT04318 14-Apr-20 HypertensiHypertensiHT-COVID1Zhenhua Z ### 20200320 4/15/2020 ClinicalTria
NCT04319 14-Apr-20 MindfulnesMindfulness During C Wake Fores ### 20200320 4/15/2020 ClinicalTria
NCT04292 14-Apr-20 Study to EvA Phase 3 RandomizedGilead Sci ### 20200228 4/15/2020 ClinicalTria
NCT04304 14-Apr-20 COVID-19 SCOVID-19 SSEROCOV Assistance 3/9/2020 20200309 4/15/2020 ClinicalTria
NCT04306 14-Apr-20 Blood DonoBlood Donor RecruitmGuangzhou 3/8/2020 20200308 4/15/2020 ClinicalTria
NCT04308 14-Apr-20 Post-exposPost-exposCOVID-19 University ### 20200311 4/15/2020 ClinicalTria
NCT04328 14-Apr-20 The ECLA PThe ECLA PCOLCOVID Estudios ClÃnicos ###
Latino
20200330
AmÃ©rica
4/15/2020 ClinicalTria
NCT04328 14-Apr-20 The Vietna A Multi Ce VICO Oxford Univ ### 20200327 4/15/2020 ClinicalTria
NCT04328 14-Apr-20 HydroxychlEfficacy of Hydroxych University ### 20200323 4/15/2020 ClinicalTria
NCT04329 14-Apr-20 ALBERTA HO

A Randomized, Double-b
Dr. Michael ### 20200329 4/15/2020 ClinicalTria
NCT04288 14-Apr-20 Treatment A Multicenter, RandomBeijing 302 ### 20200224 4/15/2020 ClinicalTria
NCT04291 14-Apr-20 Evaluation An Open Clinical Tria The Ninth ### 20200227 4/15/2020 ClinicalTria
NCT04302 14-Apr-20 Expanded AIntermediate-Size Pat U.S. Army 3/2/2020 20200302 4/15/2020 ClinicalTria
NCT04304 14-Apr-20 Treatment Treatment HCQ4COV1Fundacio Ll 3/5/2020 20200305 4/15/2020 ClinicalTria
NCT04320 14-Apr-20 Experimenta

An Clinic Trial of Re Shanghai J ### 20200321 4/15/2020 ClinicalTria
NCT04320 14-Apr-20 Acute Encep
Outcomes iNeuroCOVIIctal Group ### 20200322 4/15/2020 ClinicalTria
NCT04320 14-Apr-20 COVID-19 Pandemic Response NDuke Unive ### 20200323 4/15/2020 ClinicalTria
NCT04321 14-Apr-20 Safety and Evaluation of the Safe Hospital Is ### 20200323 4/15/2020 ClinicalTria
NCT04329 14-Apr-20 HydroxychlHydroxychlHAHPS Intermounta ### 20200330 4/15/2020 ClinicalTria
NCT04330 14-Apr-20 Clinical Ch Clinical C PERN-COVIUniversity ### 20200330 4/15/2020 ClinicalTria
NCT04330 14-Apr-20 Randomized,

Randomized, Controlled
Instituto ### 20200331 4/15/2020 ClinicalTria
NCT04311 14-Apr-20 Losartan foRandomized ControlledUniversity ### 20200313 4/15/2020 ClinicalTria
NCT04313 14-Apr-20 A Phase I CA Single-ceAPICTH CanSino Bio ### 20200315 4/15/2020 ClinicalTria
NCT04315 14-Apr-20 Evaluation An Adaptive Phase 2/3Regeneron ### 20200315 4/15/2020 ClinicalTria
NCT04315 14-Apr-20 Tocilizuma Tocilizumab (RoActemrUniversitÃ Politecnica

### 20200314
delle Marche
NCT04306 14-Apr-20 Nitric Oxi Nitric Oxi NOSARSCOMassachuse ### 20200310 4/15/2020 ClinicalTria
NCT04311 14-Apr-20 IntravenousIntravenousCOVID-AIV NeuroRx, I ### 20200314 4/15/2020 ClinicalTria
NCT04312 14-Apr-20 Losartan foRandomized ControlledUniversity ### 20200313 4/15/2020 ClinicalTria

NCT04313 14-Apr-20 Artificial The Benefi AI-COVID-XProfessor ### 20200317 4/15/2020 ClinicalTria
NCT04321 14-Apr-20 Impact of SImpact of Swab Site anDr. Deneen ### 20200323 4/15/2020 ClinicalTria
NCT04322 14-Apr-20 Safety and An Open-laCoalition-I Hospital d ### 20200324 4/15/2020 ClinicalTria
NCT04322 14-Apr-20 An ObservaAn ObservaSISCO A.O. Osped ### 20200324 4/15/2020 ClinicalTria
NCT04323 14-Apr-20 Viral Infec Viral Infec VIRUS Mayo Clini ### 20200324 4/15/2020 ClinicalTria
NCT04330 14-Apr-20 TreatmentsA Multi-cenCATCO Sunnybrook ### 20200323 4/15/2020 ClinicalTria

NCT04331 14-Apr-20 Survey of Online-bas CORA Charite Uni ### 20200327 4/15/2020 ClinicalTria
NCT04331 14-Apr-20 Bidirectio GO2 PEEP SGO2 PEEP Emory Univ ### 20200331 4/15/2020 ClinicalTria
NCT04331 14-Apr-20 Renin-AngiPhase IV O SARS-RAS Societa Ita ### 20200330 4/15/2020 ClinicalTria
NCT04317 14-Apr-20 CD24Fc as A Randomize

SAC-COVIDOncoImmun ### 20200319 4/15/2020 ClinicalTria
NCT04317 14-Apr-20 Tocilizuma MulticenteTOCIVID-1 National Ca ### 20200319 4/15/2020 ClinicalTria
NCT04318 14-Apr-20 COVID-19 PStudy to ChCOVID-Bio UniversitÃ Vita-Salute

### 20200319
San Raffaele
NCT04319 14-Apr-20 Clinical Ch Clinical Ch COVID-pre Federico II ### 20200320 4/15/2020 ClinicalTria
NCT04323 14-Apr-20 COVID-19 PPRIORITY ( PRIORITY University ### 20200324 4/15/2020 ClinicalTria
NCT04324 14-Apr-20 DIgital Onl Online Sup DISPOSE Gunther Me ### 20200326 4/15/2020 ClinicalTria
NCT04325 14-Apr-20 ConvalesceConvalescent Plasma tMayo Clini ### 20200326 4/15/2020 ClinicalTria
NCT04325 14-Apr-20 HydroxychlHydroxychlHYCOVID University ### 20200325 4/15/2020 ClinicalTria
NCT04331 14-Apr-20 TocilizumabEarly Insti COVIDOSE University 4/1/2020 20200401 4/15/2020 ClinicalTria
NCT04332 14-Apr-20 COVID-19 BBiological COLCOV19 University ### 20200330 4/15/2020 ClinicalTria
NCT04332 14-Apr-20 Angiotensi Angiotensi ATCO Erasme Uni ### 20200327 4/15/2020 ClinicalTria
NCT04333 14-Apr-20 ApplicationApplication of Iron Ch Kermanshah4/1/2020 20200401 4/15/2020 ClinicalTria
NCT04319 14-Apr-20 Social MedImpact of Social Med Assiut Univ ### 20200316 4/15/2020 ClinicalTria
NCT04320 14-Apr-20 Beaumont Q

COVID CT, Beaumont Qu
William Be ### 20200323 4/15/2020 ClinicalTria
NCT04320 14-Apr-20 Risk Facto Risk Factors for Com Oslo Univer ### 20200323 4/15/2020 ClinicalTria
NCT04322 14-Apr-20 BiomarkersBiomarkersB-DT-COV2University ### 20200323 4/15/2020 ClinicalTria

NCT04320 14-Apr-20 A Study to A RandomizCOVACTA Hoffmann- ### 20200323 4/15/2020 ClinicalTria
NCT04321 14-Apr-20 The Efficac The (Norwegian) NOR Oslo

So Univer ### 20200323 4/15/2020 ClinicalTria
NCT04321 14-Apr-20 Behavior, A PATIENT BEAT19 xCures ### 20200323 4/15/2020 ClinicalTria
NCT04321 14-Apr-20 Treatment Treatment of Moderate

Lisa Barret ### 20200324 4/15/2020 ClinicalTria
NCT04326 14-Apr-20 Evaluation Evaluation COVIDx CCTU- Can ### 20200326 4/15/2020 ClinicalTria
NCT04326 14-Apr-20 Treating C The Use of a Bidirect TMC Healt ### 20200325 4/15/2020 ClinicalTria
NCT04326 14-Apr-20 The GReek TShe GReek G
S RECCO-1 National an ### 20200326 4/15/2020 ClinicalTria
NCT04327 14-Apr-20 BCG VaccinBCG VaccinBRACE Murdoch Ch ### 20200325 4/15/2020 ClinicalTria
NCT04333 14-Apr-20 CROWN COR

A Phase 2, CROWN C Washington ### 20200331 4/15/2020 ClinicalTria
NCT04333 14-Apr-20 COVID-19 i Prospective Observati University ### 20200331 4/15/2020 ClinicalTria
NCT04334 14-Apr-20 HydroxychlHydroxychlHyAzOUT Intermounta4/2/2020 20200402 4/15/2020 ClinicalTria
NCT04334 14-Apr-20 LIBA Trial Lipid Ibup LIBA King's Col 4/2/2020 20200402 4/15/2020 ClinicalTria
NCT04322 14-Apr-20 Colchicine Colchicine COVID-19 Montreal He ### 20200323 4/15/2020 ClinicalTria
NCT04323 14-Apr-20 Efficacy a ConvalesceCSSC-001 Johns Hopk ### 20200324 4/15/2020 ClinicalTria
NCT04323 14-Apr-20 Early CPAP EC-COVID-PC

EC-COVID- Mario Negri ### 20200325 4/15/2020 ClinicalTria
NCT04324 14-Apr-20 Prognostic Time of Re NIKE_C19 Catholic Un ### 20200325 4/15/2020 ClinicalTria
NCT04322 14-Apr-20 Anti-il6 T Effectiven TOCIVID Marius Hen ### 20200324 4/15/2020 ClinicalTria
NCT04324 14-Apr-20 Efficacy a A Phase 2/3, RandomizSwedish Or ### 20200325 4/15/2020 ClinicalTria
NCT04324 14-Apr-20 Cohort MulCohort MulCORIMUNOAssistance ### 20200325 4/15/2020 ClinicalTria
NCT04327 14-Apr-20 Sarilumab An Adaptive Phase 2/3Sanofi ### 20200326 4/15/2020 ClinicalTria
NCT04327 14-Apr-20 Safety and Safety and COVID-19- Karolinska ### 20200325 4/15/2020 ClinicalTria
NCT04327 14-Apr-20 Evaluation Evaluation of Covid 1 Kanuni Sul ### 20200327 4/15/2020 ClinicalTria
NCT04328 14-Apr-20 Reducing HReducing HBCG-CORO UMC Utrec ### 20200327 4/15/2020 ClinicalTria
NCT04334 14-Apr-20 Use of a R Use of a R MultiCov Assistance 4/2/2020 20200402 4/15/2020 ClinicalTria
NCT04335 14-Apr-20 EPA-FFA toA Randomized ControllS.L.A. Pha 4/1/2020 20200401 4/15/2020 ClinicalTria
NCT04335 14-Apr-20 Tocilizuma CORON-ACTCORON-ACUniversity 4/2/2020 20200402 4/15/2020 ClinicalTria

NCT04325 14-Apr-20 Efficacy o Efficacy o DEXA-COVIDr. Negrin ### 20200325 4/15/2020 ClinicalTria
NCT04325 14-Apr-20 Sero-epidem

Sero-epidem
CORSER Institut Pa ### 20200326 4/15/2020 ClinicalTria
NCT04325 14-Apr-20 Early PP W Early Prone Position Rush Unive ### 20200326 4/15/2020 ClinicalTria
NCT04326 14-Apr-20 Use of cSV Use of cSV GARM-COVHealeon Me ### 20200326 4/15/2020 ClinicalTria
NCT04324 14-Apr-20 Cohort MulCohort MulCORIMUNOAssistance ### 20200325 4/15/2020 ClinicalTria
NCT04325 14-Apr-20 Integrated Integrated eCardioCovProfessor ### 20200321 4/15/2020 ClinicalTria
NCT04326 14-Apr-20 Early CPAP EC-COVID-RC

EC-COVID- Mario Negri ### 20200326 4/15/2020 ClinicalTria
NCT04326 14-Apr-20 EffectiveneEffectiveness and SafeUniversida ### 20200326 4/15/2020 ClinicalTria
NCT04328 14-Apr-20 Pre-exposuPre-exposure ProphylaUniversity ### 20200327 4/15/2020 ClinicalTria
NCT04329 14-Apr-20 Understan How Immune Responses

University ### 20200329 4/15/2020 ClinicalTria
NCT04329 14-Apr-20 Efficacy a Open, Multicentric, N Azidus Bras ### 20200329 4/15/2020 ClinicalTria
NCT04330 14-Apr-20 Impact of Impact of the CoronavStanford Un ### 20200330 4/15/2020 ClinicalTria
NCT04335 14-Apr-20 Evaluation A Partiall SPIN-CHAT Lady Davis 4/1/2020 20200401 4/15/2020 ClinicalTria
NCT04336 14-Apr-20 Outcomes oOutcomes oMexCOVIDInstituto N 4/2/2020 20200402 4/15/2020 ClinicalTria
NCT04336 14-Apr-20 Impact of Impact of COVID-CH University ### 20200330 4/15/2020 ClinicalTria
NCT04336 14-Apr-20 CAPTION AIUse of CaptCAPTION ADuke Unive 4/3/2020 20200403 4/15/2020 ClinicalTria
NCT04326 14-Apr-20 Proflaxis Proflaxis for Healthc Istinye Uni ### 20200326 4/15/2020 ClinicalTria
NCT04327 14-Apr-20 PREdiction PCR-COVID-1

PREDICT University H ### 20200325 4/15/2020 ClinicalTria
NCT04327 14-Apr-20 Investigati Investigating Effect o Mazandaran ### 20200324 4/15/2020 ClinicalTria
NCT04327 14-Apr-20 The Use of The Use of Focused LuUniversity ### 20200327 4/15/2020 ClinicalTria
NCT04330 14-Apr-20 Treatment A Prospect COV-AID University ### 20200331 4/15/2020 ClinicalTria
NCT04331 14-Apr-20 Protective Protective INHASCO Assistance ### 20200329 4/15/2020 ClinicalTria
NCT04331 14-Apr-20 EpidemioloEpidemioloCOVID CAL Weprom ### 20200330 4/15/2020 ClinicalTria
NCT04326 14-Apr-20 ODYSSEY: AODYSSEY: A Randomized,

Vanda Phar ### 20200326 4/15/2020 ClinicalTria
NCT04326 14-Apr-20 SargramostA Prospect SARPAC University ### 20200324 4/15/2020 ClinicalTria
NCT04327 14-Apr-20 COVID-19-aCOVID-19-aCODEX Luiz F. L. R ### 20200326 4/15/2020 ClinicalTria
NCT04336 14-Apr-20 Physical AcDetermination Of PhysIstanbul K 4/3/2020 20200403 4/15/2020 ClinicalTria
NCT04337 14-Apr-20 Renin Angi Renin Angi SRA-COV Assistance 4/3/2020 20200403 4/15/2020 ClinicalTria
NCT04337 14-Apr-20 MavrilimumMavrilimumab to Reduc

Virginia C 4/1/2020 20200401 4/15/2020 ClinicalTria
NCT04337 14-Apr-20 Remote Mon

REmote MOn
REMOTE-C Imperial C 4/1/2020 20200401 4/15/2020 ClinicalTria
NCT04328 14-Apr-20 COVID MEDComparisonCOVIDMEDBassett He ### 20200327 4/15/2020 ClinicalTria

NCT04328 14-Apr-20 Household Household EPI-COVID-Institut Pa ### 20200323 4/15/2020 ClinicalTria
NCT04328 14-Apr-20 Clinical Ch Clinical Characteristi Shanghai 1 ### 20200327 4/15/2020 ClinicalTria
NCT04329 14-Apr-20 Effects of Effects of a Mobile M University ### 20200326 4/15/2020 ClinicalTria
NCT04331 14-Apr-20 Safety and Safety and Efficacy S Chinese Ac 2/6/2020 20200206 4/15/2020 ClinicalTria
NCT04332 14-Apr-20 Convalescen

Convalescen
CP-COVID- Universida ### 20200331 4/15/2020 ClinicalTria
NCT04333 14-Apr-20 Study Test Evaluating ConvalesceBaylor Rese ### 20200327 4/15/2020 ClinicalTria
NCT04333 14-Apr-20 Outcomes oOutcomes oCovid-VAS Vascular In ### 20200331 4/15/2020 ClinicalTria
NCT04329 14-Apr-20 Non-invasi Non-invasive DetectioNHS Lothia ### 20200326 4/15/2020 ClinicalTria
NCT04329 14-Apr-20 The PATCH The PATCH PATCH Ravi Amara ### 20200330 4/15/2020 ClinicalTria
NCT04330 14-Apr-20 HydroxychlA Study of Hydroxychl Gangnam Se ### 20200330 4/15/2020 ClinicalTria
NCT04330 14-Apr-20 A Trial of A Trial of Ciclesonid Korea Univ ### 20200331 4/15/2020 ClinicalTria
NCT04337 14-Apr-20 Clinical a A Clinical and Radiolo Maastricht 4/6/2020 20200406 4/15/2020 ClinicalTria
NCT04337 14-Apr-20 Nitric Oxi Multi-CenteNOCOVID Sanotize R 4/6/2020 20200406 4/15/2020 ClinicalTria
NCT04338 14-Apr-20 CAP-1002 iCAP-1002 Treatment inCapricor In ### 20200331 4/15/2020 ClinicalTria
NCT04338 14-Apr-20 Expanded AExpanded Access to CoMayo Clini 4/3/2020 20200403 4/15/2020 ClinicalTria
NCT04334 14-Apr-20 Descriptiv Descriptive Study Reg Jessa Hospi 4/2/2020 20200402 4/15/2020 ClinicalTria
NCT04334 14-Apr-20 TelerehabilInvestigation Of The Kubra Koce 4/2/2020 20200402 4/15/2020 ClinicalTria
NCT04334 14-Apr-20 Safety and Phase 2, Randomized, Blade Ther 4/2/2020 20200402 4/15/2020 ClinicalTria
NCT04334 14-Apr-20 HydroxychlRandomized Study to EProvidence 4/2/2020 20200402 4/15/2020 ClinicalTria
NCT04329 14-Apr-20 COVID-19 i Clinical Characteristi Hepatopanc ### 20200329 4/15/2020 ClinicalTria
NCT04329 14-Apr-20 Efficacy an Phase 2, Randomized, Judit Pich MartÃn###

ez 20200331 4/15/2020 ClinicalTria
NCT04330 14-Apr-20 CoronaviruThe CORONA

CORONACI National Un ### 20200330 4/15/2020 ClinicalTria
NCT04331 14-Apr-20 COVID-19 COVID-19 Symptom TrKing's Col ### 20200331 4/15/2020 ClinicalTria
NCT04331 14-Apr-20 ChloroQUinMulticenterQUARANTI Wroclaw Me ### 20200330 4/15/2020 ClinicalTria
NCT04331 14-Apr-20 CORIMUNO-1

Cohort MulCORIMUNOAssistance ### 20200331 4/15/2020 ClinicalTria
NCT04331 14-Apr-20 Pre-ExposuPre-ExposuPrEP_COVI Barcelona I 4/1/2020 20200401 4/15/2020 ClinicalTria
NCT04330 14-Apr-20 Longitudin Longitudin COVIDENC Queen Mary ### 20200331 4/15/2020 ClinicalTria
NCT04331 14-Apr-20 Evaluation Evaluation of Efficac Fasa Univer ### 20200330 4/15/2020 ClinicalTria
NCT04331 14-Apr-20 Study of thA Single Arm Open-labe
University 4/1/2020 20200401 4/15/2020 ClinicalTria
NCT04331 14-Apr-20 An ObservaAn ObservaCOVID-19 Target Pha ### 20200331 4/15/2020 ClinicalTria
NCT04338 14-Apr-20 Screening Accuracy a SCOUT Hasselt Uni 4/4/2020 20200404 4/15/2020 ClinicalTria
NCT04338 14-Apr-20 Efficacy a Efficacy and Safety o Huilan Zha 4/1/2020 20200401 4/15/2020 ClinicalTria
NCT04339 14-Apr-20 AtovaquoneOpen-Label, Non-Rando

HonorHealt 4/7/2020 20200407 4/15/2020 ClinicalTria
NCT04339 14-Apr-20 Clinical R Clinical Research of Puren Hosp 4/2/2020 20200402 4/15/2020 ClinicalTria
NCT04335 14-Apr-20 Interest of Interest of eChoVid Assistance 4/2/2020 20200402 4/15/2020 ClinicalTria
NCT04335 14-Apr-20 A Study of An Open Lab
HELPCOVIDProgenaBi 4/2/2020 20200402 4/15/2020 ClinicalTria
NCT04335 14-Apr-20 Defibrotid Use of Def DEFI-VID19IRCCS San ### 20200331 4/15/2020 ClinicalTria
NCT04335 14-Apr-20 Video-Based

Effectiveness of Vide Biruni Univ 4/2/2020 20200402 4/15/2020 ClinicalTria
NCT04331 14-Apr-20 Mild COVIDA Phase 2 COVID-LamStanford Un ### 20200327 4/15/2020 ClinicalTria
NCT04332 14-Apr-20 Clinical T Pilot, Ran TOCOVID FundaciÃ³ I ### 20200331 4/15/2020 ClinicalTria
NCT04332 14-Apr-20 AzithromycAzithromycACTION University ### 20200330 4/15/2020 ClinicalTria
NCT04332 14-Apr-20 HyperbaricOpen Label Single-CenNYU Lango ### 20200330 4/15/2020 ClinicalTria
NCT04332 14-Apr-20 ConvalesceConvalesceCP-COVID- Universida ### 20200330 4/15/2020 ClinicalTria
NCT04332 14-Apr-20 Efficacy a Efficacy a TOSCA University ### 20200326 4/15/2020 ClinicalTria
NCT04333 14-Apr-20 Safety in Phase 1 Study to Eval Hospital S ### 20200331 4/15/2020 ClinicalTria
NCT04340 14-Apr-20 Low-dose HLow-dose HHCQINRLGIInstituto N 4/2/2020 20200402 4/15/2020 ClinicalTria
NCT04340 14-Apr-20 HydroxychlHydroxychlCOMIHY University 4/3/2020 20200403 4/15/2020 ClinicalTria
NCT04341 14-Apr-20 Clinical an Clinical and ImmunoloUniversity 4/3/2020 20200403 4/15/2020 ClinicalTria
NCT04341 14-Apr-20 A Phase II A RandomizCTII-nCoV Insitute of 4/7/2020 20200407 4/15/2020 ClinicalTria

NCT04336 14-Apr-20 Rutgers COCohort Study of SARS-Rutgers, Th 4/2/2020 20200402 4/15/2020 ClinicalTria
NCT04336 14-Apr-20 Randomized

Randomized Compariso
Rutgers, Th ### 20200331 4/15/2020 ClinicalTria
NCT04336 14-Apr-20 Corona-Lik COVID-19-Like Illnes Assiut Univ 4/3/2020 20200403 4/15/2020 ClinicalTria
NCT04336 14-Apr-20 Covid-19 P Covid-19 P PANDOR Centre Hos ### 20200330 4/15/2020 ClinicalTria
NCT04341 14-Apr-20 Impact of Randomized

SOS-COVIDFondation 4/7/2020 20200407 4/15/2020 ClinicalTria
NCT04341 14-Apr-20 ASC TherapAllogeneic ASC COVIDRigshospit 4/7/2020 20200407 4/15/2020 ClinicalTria
NCT04341 14-Apr-20 Study of I Efficacy o CORIMUNOAssistance 4/6/2020 20200406 4/15/2020 ClinicalTria

NCT04332 14-Apr-20 Outcomes ROutcomes RORCHID Massachuse ### 20200331 4/15/2020 ClinicalTria
NCT04333 14-Apr-20 HydroxychlA Prospective Clinical Baylor Rese 4/1/2020 20200401 4/15/2020 ClinicalTria
NCT04333 14-Apr-20 Preventing Preventing C-19-ACS Imperial C 4/1/2020 20200401 4/15/2020 ClinicalTria
NCT04337 14-Apr-20 AssessmentAssessment of DistressWefight 4/3/2020 20200403 4/15/2020 ClinicalTria
NCT04337 14-Apr-20 Impact of Impact of PCOVID-ARAUniversity 4/3/2020 20200403 4/15/2020 ClinicalTria
NCT04337 14-Apr-20 Reduction Reduction in COVID-19Rigshospit 4/2/2020 20200402 4/15/2020 ClinicalTria

NCT04337 14-Apr-20 Dynamic EvDynamic EvTRODVID-1Tourcoing 4/1/2020 20200401 4/15/2020 ClinicalTria
NCT04333 14-Apr-20 Piclidenos Piclidenoson for Trea Can-Fite B 4/1/2020 20200401 4/15/2020 ClinicalTria
NCT04333 14-Apr-20 Corona Vir The Mechanism, ClinicPeking Univ4/1/2020 20200401 4/15/2020 ClinicalTria
NCT04334 14-Apr-20 Vitamin D Effect of COVITD-19Universida ### 20200329 4/15/2020 ClinicalTria
NCT04334 14-Apr-20 HealthcareHealthcareHERO-HCQDuke Unive 4/2/2020 20200402 4/15/2020 ClinicalTria
NCT04342 14-Apr-20 The Role ofThe Role of Resistant Yale Univer 4/8/2020 20200408 4/15/2020 ClinicalTria
NCT04342 14-Apr-20 A Study on A Study on the ProspeSecond Aff 4/4/2020 20200404 4/15/2020 ClinicalTria
NCT04342 14-Apr-20 COVID-19 UCORONAVIRCOVIDAtoZThe Clevela 4/8/2020 20200408 4/15/2020 ClinicalTria
NCT04343 14-Apr-20 CORIMUNO1

Cohort MulCORIMUNOAssistance 4/9/2020 20200409 4/15/2020 ClinicalTria
NCT04338 14-Apr-20 Nitric Oxid Nitric Oxi NO COV-E Massachuse4/5/2020 20200405 4/15/2020 ClinicalTria
NCT04338 14-Apr-20 Impact of PImpact of Pandemic COV

Ospedale P 4/7/2020 20200407 4/15/2020 ClinicalTria
NCT04339 14-Apr-20 COVID-19 RiCOVID-19 Risk Stratifi Brigham an 4/6/2020 20200406 4/15/2020 ClinicalTria
NCT04339 14-Apr-20 Max COVIDA Prospective, Longit Max Healthc4/7/2020 20200407 4/15/2020 ClinicalTria
NCT04334 14-Apr-20 Evaluating A Phase 1, Randomized,

Symvivo Co ### 20200331 4/15/2020 ClinicalTria
NCT04335 14-Apr-20 Sensor BaseSensor BaseHSC19 Lars Wik 4/1/2020 20200401 4/15/2020 ClinicalTria
NCT04335 14-Apr-20 Study of O An Open Label Phase 1University ### 20200331 4/15/2020 ClinicalTria
NCT04335 14-Apr-20 COVID-19 RCOVID-19 Registry RhiIHF GmbH - ### 20200331 4/15/2020 ClinicalTria
NCT04343 14-Apr-20 National S National S COVID19P University 4/9/2020 20200409 4/15/2020 ClinicalTria
NCT04343 14-Apr-20 Using Biov Using BiovitalsÂ® Sen The Univer ### 20200220 4/15/2020 ClinicalTria
ACTRN126 14-Apr-20 Effect of Randomised ControlledUNSW

Tria Syd ### 20200414 4/15/2020 ANZCTR
NCT04333 14-Apr-20 Open-labelA PragmatiPANAMO InflaRx G 4/1/2020 20200401 4/15/2020 ClinicalTria
NCT04333 14-Apr-20 ChloroquinChloroquine for Mild HaEmek Med

4/1/2020 20200401 4/15/2020 ClinicalTria
NCT04333 14-Apr-20 HydroxychlA Phase 1b, RandomizeSanofi 4/1/2020 20200401 4/15/2020 ClinicalTria
NCT04333 14-Apr-20 Telephony Telephony TOVID-49 University 4/1/2020 20200401 4/15/2020 ClinicalTria
ACTRN126 14-Apr-20 Home rehab Home telerehabilitation
Flinders
for M 4/6/2020 20200406 4/15/2020 ANZCTR
ISRCTN100 14-Apr-20 ComparisonEVALUATION: Extravascular
Klinikum d 4/7/2020 20200407 4/15/2020 ISRCTN
NCT04339 14-Apr-20 Simulation Simulation of Risk of Tabula Ras 4/7/2020 20200407 4/15/2020 ClinicalTria
NCT04339 14-Apr-20 AzithromycAzithromycAZIQUINE- Frantisek 4/6/2020 20200406 4/15/2020 ClinicalTria
NCT04340 14-Apr-20 COVID-19 CPilot Study for Use o University 4/7/2020 20200407 4/15/2020 ClinicalTria
NCT04340 14-Apr-20 French MulFrench MulFRENCH C Centre Hosp4/7/2020 20200407 4/15/2020 ClinicalTria
NCT04335 14-Apr-20 CheckpointA Multicen COPERNIC MedSIR ### 20200331 4/15/2020 ClinicalTria
NCT04335 14-Apr-20 Cardiovasc Cardiovascular ManifeMemorial 4/2/2020 20200402 4/15/2020 ClinicalTria
NCT04335 14-Apr-20 COVID-19 ICOVID-19 Infection in Salome Kri 4/3/2020 20200403 4/15/2020 ClinicalTria
NCT04335 14-Apr-20 COVID-19 i COVID-19 in Hospitali University 4/3/2020 20200403 4/15/2020 ClinicalTria
ISRCTN152 14-Apr-20 A phase I/ A phase I/II study to det
University 4/6/2020 20200406 4/15/2020 ISRCTN
ISRCTN400 14-Apr-20 UKOSS: PanMaternal and perinatalUniversity
outcomes 4/1/2020 20200401 4/15/2020 ISRCTN
NCT04336 14-Apr-20 Safety, To Phase 1 Open-label St Inovio Pha 4/3/2020 20200403 4/15/2020 ClinicalTria
NCT04336 14-Apr-20 PrevalencePrevalenceINCOVPED University H4/3/2020 20200403 4/15/2020 ClinicalTria

NCT04337 14-Apr-20 Blood Tita Blood Titanium AnalysRoyal Nati 4/3/2020 20200403 4/15/2020 ClinicalTria
NCT04337 14-Apr-20 Evaluation Postnatal Outcomes oKanuni Sul 4/5/2020 20200405 4/15/2020 ClinicalTria
NCT04333 14-Apr-20 AssessmentAssessmentCovid-19 University 4/1/2020 20200401 4/15/2020 ClinicalTria
NCT04334 14-Apr-20 Treatment Treatment of Severe Grupo Cooperativo

4/1/2020de 20200401
HemopatÃ4/15/2020
as MalignasClinicalTria
NCT04334 14-Apr-20 Efficacy an Efficacy and Safety o Peking Univ4/1/2020 20200401 4/15/2020 ClinicalTria
NCT04334 14-Apr-20 InternationInternatio HOPE COVIIVAN J NUÃ 4/1/2020 20200401 4/15/2020 ClinicalTria
NCT04341 14-Apr-20 Study of T A Phase 1b/2, RandomiI-Mab Biop 4/4/2020 20200404 4/15/2020 ClinicalTria
NCT04341 14-Apr-20 AssessmentAssessmentCOVID-SERHospices Ci 4/8/2020 20200408 4/15/2020 ClinicalTria
NCT04341 14-Apr-20 Will Hydro Will Hydro WHIP COVIHenry Ford 4/7/2020 20200407 4/15/2020 ClinicalTria
NCT04341 14-Apr-20 HydroxychlTreatment With HydroxHugo Mend4/7/2020 20200407 4/15/2020 ClinicalTria

ChiCTR200 13-Apr-20 Impact of Impact of WeChat-based
Fujian
pa Prov 4/9/2020 20200409 4/15/2020 ChiCTR
ChiCTR200 13-Apr-20 ExperiencePublic health emergencies

Shanghai
of Ji 4/9/2020 20200409 4/15/2020 ChiCTR
NCT04337 14-Apr-20 Beat COVID-

A Virtual O JUPITER Beat COVID 4/6/2020 20200406 4/15/2020 ClinicalTria
NCT04337 14-Apr-20 Hemodynami

Hemodynami
PiCCOVID Bicetre Hos ### 20200330 4/15/2020 ClinicalTria
NCT04338 14-Apr-20 TXA and CoExplorator TCOutpatieUniversity 4/6/2020 20200406 4/15/2020 ClinicalTria
NCT04338 14-Apr-20 Point Of CaPoint Of C POCUSCO University ### 20200331 4/15/2020 ClinicalTria
NCT04334 14-Apr-20 A Study of A Phase II HAZDpaC ProgenaBi 4/2/2020 20200402 4/15/2020 ClinicalTria
NCT04334 14-Apr-20 Randomized

PreventionEPICOS Plan Nacion4/2/2020 20200402 4/15/2020 ClinicalTria
NCT04335 14-Apr-20 Recombinan

Recombinan
APN01-COVApeiron Bio 4/1/2020 20200401 4/15/2020 ClinicalTria
NCT04335 14-Apr-20 Cardiovasc Screening CovCardio Centre Hosp4/3/2020 20200403 4/15/2020 ClinicalTria
ChiCTR200 13-Apr-20 A medical rObservational study forthe

myoc
First A 4/9/2020 20200409 4/15/2020 ChiCTR
ChiCTR200 13-Apr-20 Novel coro Novel coronavirus pneumonia

Wuhan Four4/8/2020
( 20200408 4/15/2020 ChiCTR
NCT04341 14-Apr-20 CORIMUNO-

CORIMUNO-
CORIMUNOAssistance 4/7/2020 20200407 4/15/2020 ClinicalTria
NCT04341 14-Apr-20 Sirolimus Sirolimus SCOPE University 4/5/2020 20200405 4/15/2020 ClinicalTria
NCT04341 14-Apr-20 Evolution oProspective DescriptivCentre Hos 4/1/2020 20200401 4/15/2020 ClinicalTria
NCT04341 14-Apr-20 Predictive Predictive BIOCOVU University H4/7/2020 20200407 4/15/2020 ClinicalTria
NCT04338 14-Apr-20 COVID-19 COVID-19 and Deep VeJessa Hospi 4/7/2020 20200407 4/15/2020 ClinicalTria
NCT04338 14-Apr-20 Ruxolitini A Phase-II RuxCoFlamProf. Dr. 4/7/2020 20200407 4/15/2020 ClinicalTria
NCT04340 14-Apr-20 The Use of The Use of UltrasoundUniversity 4/6/2020 20200406 4/15/2020 ClinicalTria
NCT04340 14-Apr-20 The Role o The Role of Adaptive Barts & Th 4/3/2020 20200403 4/15/2020 ClinicalTria
ChiCTR200 13-Apr-20 Study for A cross-sectional observati
The Chines 4/7/2020 20200407 4/15/2020 ChiCTR
ChiCTR200 13-Apr-20 Study for Study for sleep qualityShanghai

of O 4/7/2020 20200407 4/15/2020 ChiCTR
NCT04335 14-Apr-20 Valsartan PRAETORIAN-COVID: ARadboud

D Un4/2/2020 20200402 4/15/2020 ClinicalTria
NCT04336 14-Apr-20 Safety and Safety and Efficacy S Renmin Hos ### 20200328 4/15/2020 ClinicalTria
NCT04336 14-Apr-20 Hydrogen-OA Multi-ce COVID-19 Shanghai A ### 20200325 4/15/2020 ClinicalTria
NCT04341 14-Apr-20 Breath AnaDevelopment of a BreaMayo Clini 4/7/2020 20200407 4/15/2020 ClinicalTria
NCT04341 14-Apr-20 The Safety The Safety of ChemothTongji Hosp4/7/2020 20200407 4/15/2020 ClinicalTria
NCT04341 14-Apr-20 A Clinical A Double BlCOVID-19 Aga Khan U 4/6/2020 20200406 4/15/2020 ClinicalTria
NCT04341 14-Apr-20 A Online-d Evaluation of a Brief Karolinska 4/7/2020 20200407 4/15/2020 ClinicalTria
ChiCTR200 13-Apr-20 Developmen
Development and applicatio
Beijing Uni 4/6/2020 20200406 4/15/2020 ChiCTR
ChiCTR200 13-Apr-20 A clinical A clinical study for effec

NCT04336 14-Apr-20 Clinical St A Multi-center, Random

Giuliano Ri 4/3/2020 20200403 4/15/2020 ClinicalTria
NCT04337 14-Apr-20 Evaluation Endometriosis PatientKanuni Sul 4/5/2020 20200405 4/15/2020 ClinicalTria
NCT04337 14-Apr-20 Ruxolitini Ruxolitinib Managed ANovartis P 4/3/2020 20200403 4/15/2020 ClinicalTria
NCT04337 14-Apr-20 GerontologGerontologCOVIDeHP University 4/3/2020 20200403 4/15/2020 ClinicalTria
NCT04342 14-Apr-20 NIV and CPA

NIV and CPAP Failure Hospital G 4/8/2020 20200408 4/15/2020 ClinicalTria
NCT04342 14-Apr-20 HydroxychlRandomized
COV-HCQ University 4/8/2020 20200408 4/15/2020 ClinicalTria
NCT04342 14-Apr-20 COVID-19 GastrointesCOVID-19 Al-Azhar Un4/7/2020 20200407 4/15/2020 ClinicalTria
NCT04342 14-Apr-20 A Double-blA Double-blSTOP COVI Washington4/8/2020 20200408 4/15/2020 ClinicalTria
NCT04342 14-Apr-20 Evaluate t Evaluate the Working Istanbul U 4/7/2020 20200407 4/15/2020 ClinicalTria
NCT04342 14-Apr-20 ChloroquinPhase IIb CloroCOVIDFundaÃ§Ã£o4/4/2020 20200404 4/15/2020 ClinicalTria
NCT04342 14-Apr-20 COVID-19 CA Multicenter, Prospe Wake Fores4/8/2020 20200408 4/15/2020 ClinicalTria
NCT04343 14-Apr-20 CoronavirusAspirin, Lo CRASH-19 London Sch 4/8/2020 20200408 4/15/2020 ClinicalTria
An open
label
randomiz
ed
controlle
An open d trial of
label chloroqui
randomiz ne,
ed hydroxyc
controlle hloroquin
d trial of e or only
chloroqui supportiv
ne, e care in
hydroxyc patients
hloroquin admitted
e or only with
supportiv moderate
e care in to severe
patients COVID-19
admitted
with
moderate
to severe
COVID-19
NL8490 14-Apr-20 UMC Utrec ### 20200331 4/15/2020 Netherlands
NL8501 14-Apr-20 Using eHealUsing eHealth to support
Interactive
COVID 4/1/2020 20200401 4/15/2020 Netherlands
NCT04338 14-Apr-20 EliminationThe Random

REPLACECOUniversity 4/1/2020 20200401 4/15/2020 ClinicalTria
NCT04338 14-Apr-20 The ImpactThe Impact of the Cor Sheba Medi4/4/2020 20200404 4/15/2020 ClinicalTria
NCT04338 14-Apr-20 HydroxychlPakistan R PROTECT Shehnoor 4/4/2020 20200404 4/15/2020 ClinicalTria
NCT04338 14-Apr-20 CombinatioEvaluation CLOCC Heinrich-He4/3/2020 20200403 4/15/2020 ClinicalTria
NCT04342 14-Apr-20 A Study of A Randomized, Double-

Eli Lilly a ### 20200410 4/15/2020 ClinicalTria
NCT04343 14-Apr-20 Evolution Evolution EPILOGUE University 4/8/2020 20200408 4/15/2020 ClinicalTria
NCT04343 14-Apr-20 PLACE OF STUDY ECMECMO-COVUniversity 4/8/2020 20200408 4/15/2020 ClinicalTria
NCT04343 14-Apr-20 Mental HeaMental HeaNew Tjhin Wigu 4/9/2020 20200409 4/15/2020 ClinicalTria
EUCTR202014-Apr-20 COVID-19 -COVID-19 - Epidemiology
GUSTAVE
o ### 20200324 4/15/2020 EU Clinical
EUCTR202014-Apr-20 Treatment A prospective, randomiUniversity 4/4/2020 20200404 4/15/2020 EU Clinical
NCT04343 14-Apr-20 ConvalescePhase IIa Study Explo Hackensack 4/8/2020 20200408 4/15/2020 ClinicalTria
ACTRN126 14-Apr-20 COVID-19 RISARIC/WHO Clinical Character

South Metr 4/6/2020 20200406 4/15/2020 ANZCTR
NCT04343 14-Apr-20 Ivermectin Adjuvant Use of IvermUniversity 4/5/2020 20200405 4/15/2020 ClinicalTria
NCT04343 14-Apr-20 HyperbaricHyperbaric Oxygen TheOchsner He 4/7/2020 20200407 4/15/2020 ClinicalTria
NCT04343 14-Apr-20 Study to E A Phase 2, RandomizedCytoDyn, In ### 20200331 4/15/2020 ClinicalTria
NCT04343 14-Apr-20 DeterminatiDetermination of the Genesis Fo 4/7/2020 20200407 4/15/2020 ClinicalTria
NCT04339 14-Apr-20 Characteri Characteri COVID-19 Assiut Univ 4/7/2020 20200407 4/15/2020 ClinicalTria
NCT04339 14-Apr-20 Mental HeaMental Health Impact National In 4/8/2020 20200408 4/15/2020 ClinicalTria
NCT04339 14-Apr-20 AssessmentAssessment of Exam FiUniversity 4/6/2020 20200406 4/15/2020 ClinicalTria
NCT04340 14-Apr-20 Oncology-pA Prospect ONCOVID University ### 20200331 4/15/2020 ClinicalTria
EUCTR202014-Apr-20 MANAGEME EFFICIENCY IN MANA HELLENIC I ### 20200331 4/15/2020 EU Clinical

ACTRN126 14-Apr-20 Use of therUse of therapeutic drug
Royal
moniBris 4/6/2020 20200406 4/15/2020 ANZCTR
ISRCTN501 14-Apr-20 A randomise
Randomized evaluation
University
of COVID-19
4/2/2020 20200402 4/15/2020 ISRCTN
NCT04343 14-Apr-20 An InvestigAn InvestigDIC Shahid Behe4/8/2020 20200408 4/15/2020 ClinicalTria
ACTRN126 14-Apr-20 Expressive Expressive Writing To Comba

Deakin Uni 4/6/2020 20200406 4/15/2020 ANZCTR
ISRCTN136 14-Apr-20 Distress anDistress And ResilienceUniversity
of heal 4/1/2020 20200401 4/15/2020 ISRCTN
ISRCTN512 14-Apr-20 Aspergillos Incidence and pathogenesis
St George'
o ### 20191206 4/15/2020 ISRCTN
NCT04340 14-Apr-20 Safety and Safety and Efficacy of University 4/3/2020 20200403 4/15/2020 ClinicalTria
NCT04340 14-Apr-20 Safety and Safety and Effective Peking Uni 3/3/2020 20200303 4/15/2020 ClinicalTria
NCT04341 14-Apr-20 AlloSure G AlloSure G Al-COVE CareDx ### 20200316 4/15/2020 ClinicalTria
NCT04341 14-Apr-20 Early Vers Early Vers ECMO-VID University ### 20200330 4/15/2020 ClinicalTria
To
compare
the
effectiven
ess of two
drugs
(hydroxyc
hloroquin
e and
lopinavir/
ritonavir
alone or
combined
in
treating
hospitaliz
ed
patients
with
confirme
d COVID-
19
compared
to
standard
of care
ACTRN126 14-Apr-20 Australasian COVID-19University 4/6/2020 20200406 4/15/2020 ANZCTR
ACTRN126 14-Apr-20 Virucidal p Virucidal pilot study ofFirebrick

N P ### 20200414 4/15/2020 ANZCTR
ISRCTN169 14-Apr-20 RECOVERY IRn adult patients with University 4/6/2020 20200406 4/15/2020 ISRCTN
An
internatio
nal
randomiz
ed trial of
additional
treatmen
ts for
COVID-19
in
hospitaliz
ed
patients
who are
all
receiving
the local
standard
of care
ISRCTN839 14-Apr-20 Public heal World Heal ### 20200325 4/15/2020 ISRCTN
NCT04341 14-Apr-20 Non-contacEvaluating Non-contacNorthwest 4/7/2020 20200407 4/15/2020 ClinicalTria
NCT04341 14-Apr-20 Psychologi "PsychologBURDENCOAssistance 4/7/2020 20200407 4/15/2020 ClinicalTria
NCT04341 14-Apr-20 Efficiency Efficiency and Satisf Pierre and 4/8/2020 20200408 4/15/2020 ClinicalTria
NCT04341 14-Apr-20 Effects of Effects of DPP4 Inhib University 4/6/2020 20200406 4/15/2020 ClinicalTria
ChiCTR200 13-Apr-20 Study for t Study for the exercise Beijing

reha Spo ### 20200412 4/15/2020 ChiCTR
ChiCTR200 13-Apr-20 A clinical A clinical study for theJiangsu

ef Pro ### 20200411 4/15/2020 ChiCTR
ChiCTR200 13-Apr-20 A medical rClinical features and outc
Huanggang ### 20200410 4/15/2020 ChiCTR
ChiCTR200 13-Apr-20 Investigat The impact of Information

N/A Sour ### 20200410 4/15/2020 ChiCTR
ChiCTR200 13-Apr-20 Clinical st Clinical study for natural

Huzhou Cen4/8/2020 20200408 4/15/2020 ChiCTR
ChiCTR200 13-Apr-20 A medical Retrospective analysis Women's
of Ho4/6/2020 20200406 4/15/2020 ChiCTR
NCT04342 14-Apr-20 Safety And Safety And SHARP COVTan Tock S 4/8/2020 20200408 4/15/2020 ClinicalTria
NCT04342 14-Apr-20 University Hydroxychloroquine f University 4/7/2020 20200407 4/15/2020 ClinicalTria
NCT04342 14-Apr-20 ConvalesceConvalesceConCoVid- Erasmus Me ### 20200331 4/15/2020 ClinicalTria

NCT04342 14-Apr-20 Acquiring Acquiring ConvalescenColumbia U 4/8/2020 20200408 4/15/2020 ClinicalTria
ChiCTR200 13-Apr-20 Evaluation Evaluation Danorevir sodi

Huoshensha4/8/2020 20200408 4/15/2020 ChiCTR
ChiCTR200 13-Apr-20 Study for eStudy for early biological

Shanghai
w Ji 4/7/2020 20200407 4/15/2020 ChiCTR
ChiCTR200 13-Apr-20 Cancelled bClinical application of inhal

The use
of ACE2
receptor
increasing
medicatio
n at
hospital
The use admission
of ACE2 and
receptor mortality
increasing rates in
medicatio COVID-19
n at patiÃ«nts
hospital
admission
and
mortality
rates in
COVID-19
patiÃ«nts
NL8512 14-Apr-20 nonen 4/2/2020 20200402 4/15/2020 Netherlands
NCT04342 14-Apr-20 HealthcareHealthcare Worker Ex Duke Unive 4/8/2020 20200408 4/15/2020 ClinicalTria
NCT04343 14-Apr-20 A Randomize

A Randomized, Double-B
Romark Lab4/8/2020 20200408 4/15/2020 ClinicalTria
NCT04343 14-Apr-20 CONVALESCCONVALESCENT PLASM
Saint Franc 4/8/2020 20200408 4/15/2020 ClinicalTria
NCT04343 14-Apr-20 Military C Military COVID-19 HydUnited Sta 4/9/2020 20200409 4/15/2020 ClinicalTria
ChiCTR200 13-Apr-20 Early risk Early risk stratification West

of China 3/5/2020 20200305 4/15/2020 ChiCTR
ChiCTR200 13-Apr-20 Constructi Construction of a Bio inform

the First A ### 20200228 4/15/2020 ChiCTR
NL8513 14-Apr-20 COVID-19 i COVID-19 in rheumaticReade
patients:
Resea 4/7/2020 20200407 4/15/2020 Netherlands
NL8498 14-Apr-20 Lung ultrasLung ultrasound (LUS) Radboudu
as a tool ### 20200331 4/15/2020 Netherlands
NL8460 14-Apr-20 BiomarkersBiomarkers for prognosisnone
in cri ### 20200316 4/15/2020 Netherlands
NL8483 14-Apr-20 A weapon aThe use of (social) media
Fred Found ### 20200326 4/15/2020 Netherlands
NCT04343 14-Apr-20 COPING WiEffectiveness of Cris Duke Unive 4/9/2020 20200409 4/15/2020 ClinicalTria
NCT04343 14-Apr-20 Study of thStudy of thSTOP-COVIBrigham an 4/9/2020 20200409 4/15/2020 ClinicalTria
ACTRN126 14-Apr-20 Utilizing l Utilizing lung ultrasound

Griffith
in Un 4/6/2020 20200406 4/15/2020 ANZCTR
EUCTR202014-Apr-20 COVID-19 -COVID-19 - ACE inhibitASSISTANC ### 20200329 4/15/2020 EU Clinical
ACTRN126 14-Apr-20 Maternal aProspective registry ofUniversity
mate 4/6/2020 20200406 4/15/2020 ANZCTR
A
Randomis
ed,
Double
Blind,
Placebo-
Controlle
d Trial of
the
Efficacy of
Hydroxyc
hloroquin
e for the
Communi
ty-Based
Treatmen
t of
Adults
With
Diagnose
d COVID-
19
ACTRN126 14-Apr-20 Hydroxychl Medical Re 4/8/2020 20200408 4/15/2020 ANZCTR

NL8491 14-Apr-20 CounteringCountering Lung Damage
Amsterda
in COVID- ### 20200331 4/15/2020 Netherlands
EUCTR202014-Apr-20 Clinical St A randomized, prospectiv
DRK-Blusp ### 20200331 4/15/2020 EU Clinical
Home Home
treatmen treatmen
t of t of
elderly elderly
patients patients
with with
symptom symptom
atic SARS- atic SARS-
CoV-2 CoV-2
infection infection
(COVID- (COVID-
19) : a 19) : a
multiarm, multiarm,
multi- multi-
stage stage
(MAMS) (MAMS)
randomiz randomiz
ed trial to ed trial to
assess the assess the
efficacy efficacy
and and
safety safety
of several of several
experime experime
ntal ntal
treatmen treatmen
ts to ts to
reduce reduce
the risk of the risk of
hospitaliz hospitaliz
ation or ation or
death death
EUCTR202014-Apr-20 (COVE (COVE CENTRE HO 4/1/2020 20200401 4/15/2020 EU Clinical
EUCTR202014-Apr-20 Dexamethas
Dexamethasone associated
Groupe Hosp4/2/2020 20200402 4/15/2020 EU Clinical
ACTRN126 14-Apr-20 Can intraveHigh-dose intravenousAustin
zinc ( Hea 4/8/2020 20200408 4/15/2020 ANZCTR
ISRCTN439 14-Apr-20 Testing an Testing an early onlineNorthumbri4/8/2020

inte 20200408 4/15/2020 ISRCTN
EUCTR202014-Apr-20 An internatAn international randomised

FIB-HCSC ### 20200326 4/15/2020 EU Clinical
EUCTR202014-Apr-20 DEFIBROTI A prospective, multiceFFIS 4/3/2020 20200403 4/15/2020 EU Clinical

ISRCTN773 14-Apr-20 Cohort studPredicting hospitalization
University 4/7/2020 20200407 4/15/2020 ISRCTN
ISRCTN865 14-Apr-20 A trial eva Platform Randomised trial

University
of I ### 20200322 4/15/2020 ISRCTN
EUCTR202014-Apr-20 Clinical tr Clinical trial randomizeSociedad E 4/7/2020 20200407 4/15/2020 EU Clinical
EUCTR202014-Apr-20 Randomized
Randomized clinical triInstituto I 4/7/2020 20200407 4/15/2020 EU Clinical
EUCTR202014-Apr-20 Interest in Interest in the administr

HÃ´pital F 4/1/2020 20200401 4/15/2020 EU Clinical
EUCTR202014-Apr-20 Pilot study Pilot study to evaluateFÃ©lix
t Gut 4/7/2020 20200407 4/15/2020 EU Clinical
ChiCTR200 13-Apr-20 A Medical Clinical CharacteristicsThe First A ### 20200411 4/15/2020 ChiCTR
ChiCTR200 13-Apr-20 A questionnA questionnaire investigat

The 2nd Xia ### 20200410 4/15/2020 ChiCTR
EUCTR202014-Apr-20 PreventionPRE-EXPOSURE PROPHYLA

ISGlobal 4/7/2020 20200407 4/15/2020 EU Clinical
ChiCTR200 13-Apr-20 A randomizA randomized, double-bli

Jiangsu Pro ### 20200410 4/15/2020 ChiCTR
ChiCTR200 13-Apr-20 Effect of Effect of novel coronavirus
Shandong
pn P ### 20200410 4/15/2020 ChiCTR
ChiCTR200 13-Apr-20 Developmen Development and clinical

Chinese
appl PL 4/7/2020 20200407 4/15/2020 ChiCTR
ChiCTR200 13-Apr-20 Study for Serum, faeces and sputum
Wenzhou
pro Ce4/7/2020 20200407 4/15/2020 ChiCTR
NL8473 14-Apr-20 Immunity aThird population-basedNational
immuneIn ### 20200323 4/15/2020 Netherlands
NL8485 14-Apr-20 COVID-19 dCOVID-19 during pregnancy:
MÃ¡ximaa pro ### 20200327 4/15/2020 Netherlands
NL8497 14-Apr-20 Lung ultra A prospective observational
Radboudu ### 20200331 4/15/2020 Netherlands
NL8504 14-Apr-20 Pre-emptivePre-emptive tocilizumab
UMCG,
in hypo
Roc 4/3/2020 20200403 4/15/2020 Netherlands
EUCTR202014-Apr-20 Efficacy of Efficacy of Addition of Assistance

Nap ### 20200326 4/15/2020 EU Clinical
EUCTR202014-Apr-20 An open labA pragmatic adaptive open

InflaRx G ### 20200327 4/15/2020 EU Clinical
EUCTR202014-Apr-20 Chemoproph
Chemoprophylaxis of SARS-C
CHU de Sai ### 20200324 4/15/2020 EU Clinical
IMMUNO
NCOVID-
20 : A
prospecti
ve,
controlle
d,
randomiz
ed,
multicent
er study
to
compare
the
efficacy
of a
chloroqui
ne analog
(GNS561),
anti PD-1
(nivoluma
b) and
anti-
interleuki
ne-6
receptor
(tocilizum
ab) versus
standard
of care in
advanced
or
metastati
EUCTR202014-Apr-20 Study compa
c can Centre LÃ ### 20200329 4/15/2020 EU Clinical
EUCTR202014-Apr-20 Dexamethas
Dexamethasone and oxygen
APHP supp 4/2/2020 20200402 4/15/2020 EU Clinical
EUCTR202014-Apr-20 CLINICAL PRAGMATIC, CONTROLLE
Dr. Xavier 4/3/2020 20200403 4/15/2020 EU Clinical
EUCTR202014-Apr-20 Clinical tr Pilot, randomized, multi

INSTITUT 4/3/2020 20200403 4/15/2020 EU Clinical
EUCTR202014-Apr-20 EPICOS - ExPrevention of SARS-CoV-
Plan Nacio 4/3/2020 20200403 4/15/2020 EU Clinical
EUCTR202014-Apr-20 Hydroxychlo
An adaptive Phase 2/3,sanofi-ave
ra ### 20200330 4/15/2020 EU Clinical
EUCTR202014-Apr-20 Efficacy an Efficacy and Safety of cort

FundaciÃ³n 4/8/2020 20200408 4/15/2020 EU Clinical
web addre Recruitmenother reco Inclusion Inclusion Inclusion Date enrol Target size Study type Study desi
http://wwwNot Recrui No Both 2/1/2020 survival gr ObservatioFactorial
http://wwwRecruiting No Both 2/6/2020 Case seriesInterventioSingle arm
https://cl Not recruitNo N/A N/A All 25-Jan-20 500 InterventioAllocation:
http://wwwNot Recrui No 18 Both ### Case seriesObservatioSequential
http://wwwRecruiting No 16 99 Male ### experimentInterventioNon random

http://wwwRecruiting No 0 18 Both ### control gr InterventioNon random
http://wwwNot Recrui No 18 75 Both 3/1/2020 experimentInterventioParallel
http://wwwRecruiting No Both ### Case seriesObservatioSequential
http://wwwNot Recrui No 18 Both ### ExperimentInterventioParallel
http://wwwRecruiting No 1 100 Both ### Target condDiagnostic Factorial
https://cl Recruiting No 18 Years 80 Years All 28-Jan-20 125 InterventioAllocation
https://cl Recruiting No N/A N/A All 20-Jan-20 12000 Observational

https://cl Recruiting No N/A N/A All 3-Feb-20 30000 Observational
http://wwwNot Recrui No 18 75 Both ### Target condDiagnostic Sequential
http://wwwRecruiting No Both ### case series ObservatioSequential
http://wwwRecruiting No 18 90 Both ### ExperimentInterventioParallel

http://wwwRecruiting No Both ### Target condDiagnostic Factorial
http://wwwRecruiting No 15 85 Both ### TCM Group:InterventioNon random
http://wwwNot Recrui No 18 80 Both ### experimentInterventioParallel
http://wwwRecruiting No 18 80 Both 2/5/2020 experimentInterventioParallel
http://wwwRecruiting No Both ### experimentInterventioParallel

https://cl Not recruitNo 18 Years 75 Years All 7-Feb-20 380 InterventioAllocation
https://cl Not recruitNo 18 Years N/A All 10-Feb-20 80 InterventioAllocation
http://wwwNot Recrui No 18 80 Both ### Case seriesObservatioSequential
http://wwwNot Recrui No Both ### case series ObservatioSequential
http://wwwRecruiting No Both ### ConventionInterventioParallel

http://wwwRecruiting No 18 75 Both 2/1/2020 ExperimentInterventioParallel

http://wwwRecruiting No Both ### Case seriesObservatioFactorial
http://wwwNot Recrui No 1 100 Both 3/1/2020 Target condDiagnostic Sequential
http://wwwNot Recrui No 18 Both ### control gr InterventioParallel
http://wwwRecruiting No 18 75 Both 2/1/2020 Case seriesObservatioSequential

http://wwwRecruiting No 18 70 Both ### General paInterventioParallel

http://wwwRecruiting No Both ### Target condDiagnostic Sequential
http://wwwRecruiting No 18 75 Both ### Chinese traInterventioParallel
http://wwwRecruiting No 18 Both ### Thymosin tInterventioParallel
http://wwwRecruiting No 18 80 Both ### Control gr InterventioParallel
http://wwwNot Recrui No 18 90 Both ### Normal groBasic ScienFactorial
http://wwwNot Recrui No Both 2/8/2020 Case seriesObservatioSequential
http://wwwNot Recrui No 18 80 Both 3/1/2020 Control groInterventioParallel
http://wwwRecruiting No 18 85 Both ### control gr InterventioParallel
http://wwwNot Recrui No Both 2/7/2020 ExperimentObservatioSequential
http://wwwRecruiting No 18 Both 2/9/2020 Case seriesInterventioSingle arm
http://wwwRecruiting No 18 Both ### ExperimentInterventioParallel
http://wwwRecruiting No 18 Both ### Case seriesObservatioSequential
http://wwwRecruiting No 18 75 Both ### experimentInterventioParallel

http://wwwRecruiting No Both 2/3/2020 Case seriesObservatioSequential
http://wwwRecruiting No 18 65 Both 2/1/2020 Control gr InterventioParallel

http://wwwNot Recrui No 18 Both 2/5/2020 control gr InterventioParallel
http://wwwRecruiting No Both 2/6/2020 control gr InterventioNon random

http://wwwRecruiting No Both 2/6/2020 Treatment InterventioSingle arm
http://wwwNot Recrui No 3 85 Both ### ObservatioPreventionNon random
http://wwwRecruiting No 18 90 Both ### ExperimentInterventioNon random
http://wwwRecruiting No 18 80 Both 2/3/2020 ExperimentInterventioNon random
http://wwwRecruiting No 18 Both 2/4/2020 experimentInterventioParallel
http://wwwRecruiting No 14 80 Both 2/4/2020 (ordinary) InterventioParallel
http://wwwRecruiting No 14 80 Both 2/4/2020 treament gInterventioParallel
http://wwwRecruiting No Both ### Case seriesPrognosis Cohort stu

http://wwwNot Recrui No 18 80 Both ### ExperimentInterventioParallel

http://wwwNot Recrui No 18 70 Both 2/3/2020 experimenta

InterventioParallel
http://wwwRecruiting No Both ### Epilepsy g ObservatioFactorial
http://wwwNot Recrui No 18 90 Both 2/1/2020 Case seriesObservatioSequential

http://wwwNot Recrui No Both 2/4/2020 control gr InterventioParallel
http://wwwNot Recrui No Both 2/1/2020 Case seriesInterventioSequential
http://wwwRecruiting No Both ### A:15;B:15; InterventioParallel
http://wwwRecruiting No Both 2/1/2020 Suspected ObservatioNon random
http://wwwRecruiting No Both ### non-severeObservatioFactorial
http://wwwNot Recrui No Both ### Vitamin D ObservatioFactorial
http://wwwNot Recrui No Both 2/1/2020 Group 1:50InterventioNon random
http://wwwRecruiting No 18 Both 2/3/2020 ExperimentInterventioParallel
http://wwwRecruiting No 14 ?? Both ### doctors gr InterventioFactorial

http://wwwNot Recrui No Both 2/7/2020 ExperimentObservatioNon random
http://wwwNot Recrui No 18 80 Both ### mild-moderInterventioNon random

http://wwwNot Recrui No 18 Both ### Control groInterventioParallel
http://wwwRecruiting No 16 75 Both ### Group A:30InterventioNon random
http://wwwRecruiting No 18 Both 2/5/2020 control gr InterventioParallel
http://wwwRecruiting No 18 Both 2/6/2020 Low dose gInterventioParallel

http://wwwNot Recrui No 18 75 Both 2/4/2020 ExperimentInterventioParallel

http://wwwRecruiting No Both ### single arm InterventioSingle arm
http://wwwNot Recrui No 18 75 Both 2/4/2020 A:10;B:10; InterventioParallel
http://wwwNot Recrui No 18 65 Both ### DRV/c grouInterventioParallel
http://wwwNot Recrui No Both ### ExperimentPreventionCase-Contr
http://wwwNot Recrui No Both ### ExperimentInterventioParallel
http://wwwRecruiting No 18 75 Both 2/1/2020 Two groupsInterventioDose comp
http://wwwNot Recrui No 18 80 Both 2/1/2020 experimentaInterventioNon random

http://wwwNot Recrui No Both 2/3/2020 Case seriesObservatioSingle arm

http://wwwNot Recrui No Both 2/2/2020 control gr InterventioParallel
http://wwwNot Recrui No 18 60 Both 2/1/2020 CommunityInterventioParallel

http://wwwNot Recrui No 18 65 Both 3/1/2020 1:30;2:30; InterventioNon random
http://wwwRecruiting No 18 75 Both ### Psychologi InterventioParallel
http://wwwNot Recrui No 18 Both ### Case seriesInterventioSingle arm
https://cl Not recruitNo 18 Years N/A All 10-Feb-20 120 InterventioAllocation:
http://wwwRecruiting No 18 Both ### Group A:20InterventioNon random

https://cl Recruiting No 18 Years N/A All 26-Jan-20 80 InterventioAllocation
http://wwwNot Recrui No Both ### Case seriesObservatioSequential
http://wwwRecruiting No 1 90 Both ### Case seriesObservatioSequential
http://wwwNot Recrui No 18 75 Both ### Group 1:20InterventioNon random
https://cl Recruiting No 18 Years 75 Years All 6-Feb-20 10 InterventioInterventi

http://wwwNot Recrui No 16 50 Female 3/1/2020 AdolescentObservatioFactorial
http://wwwRecruiting No 18 80 Both ### control groInterventioFactorial
http://wwwRecruiting No 18 70 Both ### CombinatioInterventioParallel
http://wwwNot Recrui No 18 Both ### Case seriesObservatioSingle arm

http://wwwRecruiting No Both ### Severe gro ObservatioFactorial

http://wwwRecruiting No 50 100 Both ### severe NCPInterventioFactorial
http://wwwRecruiting No 18 80 Both 2/7/2020 Case seriesInterventioSingle arm

http://wwwNot Recrui No 18 75 Both ### Case seriesInterventioSingle arm
http://wwwRecruiting No 18 Both ### Case seriesInterventioSingle arm

http://wwwNot Recrui No 15 35 Both ### Exercise p InterventioParallel
http://wwwNot Recrui No 16 75 Male ### ExperimentInterventioParallel

http://wwwNot Recrui No 15 60 Both ### Case seriesObservatioSingle arm
http://wwwRecruiting No 18 80 Both 2/4/2020 1:30;2:30; InterventioParallel
http://wwwNot Recrui No Both ### case series ObservatioSequential
http://wwwNot Recrui No 18 80 Both ### Interventi InterventioParallel
http://wwwNot Recrui No 0 90 Both ### HumanisticInterventioNon random

http://wwwRecruiting No Both ### Severe gro ObservatioFactorial
http://wwwRecruiting No Female ### Case seriesBasic ScienSequential
http://wwwNot Recrui No 18 60 Both ### Case seriesTreatment Sequential

http://wwwRecruiting No Both ### ExperimentInterventioParallel
http://wwwRecruiting No 18 75 Both ### Ganovo / r InterventioNon random

http://wwwRecruiting No Both ### Light grou ObservatioFactorial

http://wwwRecruiting No Both ### general aneObservatioFactorial
http://wwwNot Recrui No 18 75 Both ### HydroxychlInterventioParallel
http://wwwRecruiting No 18 Both ### Low-dose gInterventioParallel
http://wwwRecruiting No Male ### pneumoniaObservatioFactorial
http://wwwNot Recrui No 18 100 Both ### Mild GroupInterventioFactorial

http://wwwRecruiting No 18 70 Both 2/6/2020 Case seriesInterventioSequential
http://wwwNot Recrui No 18 90 Both ### Training:1 ObservatioFactorial

http://wwwNot Recrui No 16 30 Both ### college st ObservatioSequential
http://wwwNot Recrui No Both ### Group 1:12InterventioParallel
http://wwwNot Recrui No 18 80 Both ### Control gr InterventioParallel
http://wwwNot Recrui No 18 75 Both ### ChloroquinInterventioParallel
http://wwwNot Recrui No 60 Both ### experimentInterventioParallel

http://wwwNot Recrui No Both ### Control gr InterventioNon random
http://wwwRecruiting No 0 1 Both ### COVID-19 pObservatioFactorial
http://wwwRecruiting No 18 Both ### experimentInterventioParallel
http://wwwRecruiting No 16 99 Both ### hydroxychlInterventioParallel
http://wwwRecruiting No Both ### common gro

ObservatioFactorial
http://wwwRecruiting No 18 Female ### Target condDiagnostic Sequential

http://wwwNot Recrui No 18 60 Both ### A1:80;A2:8InterventioParallel
https://cl Recruiting No 18 Years N/A All 12-Feb-20 308 InterventioAllocation:
http://wwwRecruiting No Both ### Control gr InterventioParallel
https://cl Recruiting No N/A 28 Days All 1-Feb-20 100 Observational

http://wwwNot Recrui No Both 3/1/2020 one group:InterventioSingle arm
http://wwwRecruiting No 18 80 Male 3/1/2020 Group 1:40InterventioParallel
https://cl Not recruitNo N/A 18 Years All 15-Feb-20 500 Observational
https://cl Recruiting No 18 Years 90 Years All 14-Feb-20 450 Observational
http://wwwNot Recrui No Both 3/1/2020 Control gr InterventioParallel

https://cl Recruiting No 18 Years 65 Years All 15-Feb-20 136 InterventioAllocation:
http://wwwNot Recrui No 0 0 Both 3/1/2020 Case seriesInterventioSequential

http://wwwRecruiting No 18 65 Both 3/1/2020 Case seriesObservatioSingle arm
http://wwwRecruiting No Both 1/1/2020 Target condDiagnostic Sequential
http://wwwRecruiting No 0 18 Both ### Monitor caObservatioSequential
http://wwwRecruiting No 18 90 Both 2/1/2020 Light and ObservatioFactorial
https://cl Recruiting No 18 Years 80 Years All 22-Feb-20 30 InterventioAllocation
http://wwwNot Recrui No 20 45 Both 3/2/2020 Case seriesInterventioParallel
http://wwwRecruiting No 18 Both ### Exposure gObservatioNon random

http://wwwNot Recrui No 20 90 Male 3/5/2020 Case seriesInterventioNon random
http://wwwRecruiting No 18 Both 3/4/2020 Pirfenidon InterventioParallel

http://wwwNot Recrui No 18 90 Both 3/9/2020 Case seriesObservatioSingle arm
http://wwwRecruiting No 18 70 Both 2/1/2020 Group 2:10InterventioSequential
http://wwwNot Recrui No 18 Both 3/2/2020 Case seriesInterventioSingle arm
http://wwwRecruiting No Both 3/1/2020 Mild groupObservatioFactorial

http://wwwNot Recrui No Both ### Case seriesEpidemilogSequential
http://wwwNot Recrui No 18 79 Both 3/1/2020 The experi InterventioParallel
http://wwwRecruiting No 18 Both 1/1/2020 Case seriesObservatioSequential

http://wwwNot Recrui No Both ### Interventi ObservatioSequential
http://wwwRecruiting No 18 75 Both ### Case seriesInterventioNon random
http://wwwRecruiting No Both ### case series ObservatioSingle arm

http://wwwNot Recrui No Both ### Two groupsInterventioNon random
http://wwwNot Recrui No Both ### High infla InterventioParallel

http://wwwNot Recrui No 18 Both ### Burnout poObservatioSequential
http://wwwNot Recrui No 18 70 Both ### ExperimentTreatment Single arm

http://wwwNot Recrui No 18 75 Both 3/1/2020 Routine tr InterventioParallel
http://wwwNot Recrui No Both 3/1/2020 Exocrine g InterventioParallel
http://wwwNot Recrui No 60 Both ### the elderly ObservatioSequential

http://wwwNot Recrui No Both ### Target condDiagnostic Cross-secti
http://wwwRecruiting No 8 91 Both ### Case seriesInterventioSequential

http://wwwNot Recrui No Both ### Case seriesInterventioSingle arm

http://wwwRecruiting No 18 100 Both ### General poHealth servSequential
http://wwwNot Recrui No Both 3/1/2020 InterventioParallel

http://wwwNot Recrui No Both ### ExperimentInterventioNon random
http://wwwRecruiting No 18 Both ### hydroxychlInterventioParallel
http://wwwRecruiting No 18 75 Both ### hydroxychlInterventioParallel
http://wwwNot Recrui No 18 Both ### ExperimentInterventioSingle arm

http://wwwRecruiting No 18 75 Both ### Kesuting s InterventioParallel
http://wwwRecruiting No 18 65 Both ### arm A:36;aInterventioParallel
http://wwwRecruiting No 18 80 Both ### Low-dose gInterventioParallel
http://wwwNot Recrui No 18 80 Both ### control gr InterventioParallel

https://cl Recruiting No 18 Years N/A All 10-Feb-20 70 InterventioAllocation
https://cl Not recruitNo N/A N/A All Feb-20 230 InterventioInterventi
https://cl Not recruitNo 18 Years 75 Years All 15-Feb-20 30 InterventioInterventi
http://wwwNot Recrui No 18 100 Both ### Case seriesObservatioSingle arm
http://wwwRecruiting No 18 Both 3/7/2020 Case seriesObservatioSequential

https://cl Not recruitNo N/A N/A All 31-Jan-20 39 Observational

http://wwwRecruiting No Both 2/1/2020 ExperimentInterventioParallel
http://wwwRecruiting No 18 90 Both 3/8/2020 case series ObservatioSequential
http://wwwNot Recrui No Both 3/7/2020 ExperimentInterventioParallel
http://wwwRecruiting No 18 Both ### ExperimentInterventioNon random
http://wwwRecruiting No 18 Both 3/4/2020 Azvudine PInterventioSingle arm
http://wwwRecruiting No 0 18 Both ### monitor ca ObservatioSequential
http://wwwNot Recrui No 14 90 Both 3/3/2020 Group 2:50ObservatioFactorial

http://wwwNot Recrui No 16 30 Both 3/6/2020 Medical st ObservatioSequential
http://wwwNot Recrui No 18 - Both ### Target condDiagnostic Sequential
http://wwwRecruiting No Both 3/9/2020 Patients w ObservatioFactorial
http://wwwNot Recrui No 18 65 Both 3/4/2020 cross-secti ObservatioSequential
http://wwwRecruiting No 18 110 Both 3/3/2020 Interferon InterventioParallel
http://wwwNot Recrui No 18 90 Both 3/8/2020 CRRT groupInterventioParallel

http://wwwNot Recrui No Both 3/4/2020 Control gr ObservatioNon random
http://wwwRecruiting No 18 75 Both 3/2/2020 Lipoic acid InterventioParallel

http://wwwRecruiting No Both 3/3/2020 Patients i ObservatioCross-secti
http://wwwRecruiting No 18 Both 3/1/2020 Early corti InterventioParallel
http://wwwRecruiting No 18 70 Both 2/1/2020 COVID-2019EpidemilogSequential

http://wwwNot Recrui No Both 2/2/2020 treatment InterventioParallel
http://wwwRecruiting No Both ### PRE-GROUPObservatioNon random

http://wwwNot Recrui No Both 3/2/2020 ACEIs/ARBsObservatioSequential
http://wwwNot Recrui No Both 3/1/2020 Control gr InterventioParallel
http://wwwNot Recrui No 18 90 Both 3/2/2020 Group 2:35InterventioParallel
http://wwwNot Recrui No 18 80 Both 3/6/2020 Case seriesObservatioSingle arm
http://wwwNot Recrui No 18 99 Both ### patient gr ObservatioFactorial

http://wwwRecruiting No Both 3/3/2020 Case seriesEpidemilogSequential
http://wwwRecruiting No 18 Both ### group A:20InterventioParallel
http://wwwRecruiting No 18 75 Both 2/3/2020 Treatment InterventioParallel
http://wwwRecruiting No Both ### ExperimentInterventioFactorial

http://wwwRecruiting No Both 2/3/2020 ExperimentInterventioParallel
http://wwwNot Recrui No 18 Both 2/1/2020 Routine tr InterventioParallel
http://wwwRecruiting No 18 - Both ### ExperimentInterventioParallel

http://wwwRecruiting No 18 Both 2/1/2020 Routine tr InterventioParallel
https://cl Not recruitNo 18 Years 75 Years All 1-Jan-20 400 Observational
http://wwwRecruiting No Both ### ExperimentInterventioCluster ra
http://wwwNot Recrui No Male ### Case seriesObservatioSequential
http://wwwRecruiting No 18 65 Both 3/1/2020 Group 1:90InterventioParallel
https://cl Not recruitNo 18 Years N/A All 1-Mar-20 328 InterventioAllocation

http://wwwNot Recrui No 18 70 Both ### ObservatioObservatioSingle arm

https://cl Not recruitNo 18 Years 100 Years All ### 80 InterventioAllocation
https://cl Not recruitNo 18 Years N/A All 1-Apr-20 576 InterventioAllocation
https://cl Not recruitNo 10 Years 19 Years All 15-Oct-20 3428 Observational
http://wwwRecruiting No Both ### Control gr InterventioParallel
http://wwwNot Recrui No 0 99 Both ### Ordinary C ObservatioSequential
http://wwwRecruiting No 18 85 Both ### Case seriesHealth servSequential

http://wwwNot Recrui No Both ### The triple ObservatioCohort stu
http://wwwNot Recrui No 18 Both 2/1/2020 Case seriesInterventioSequential


http://wwwRecruiting No 18 85 Male ### Case seriesObservatioSequential
http://wwwRecruiting No 18 100 Both ### Case seriesObservatioCohort stu
http://wwwRecruiting No Male 2/1/2020 Case seriesObservatioSequential
http://wwwRecruiting No 18 Both ### ExperimentInterventioCross-secti
http://wwwNot Recrui No 18 80 Both 2/1/2020 Group 2:15InterventioNon random
http://wwwRecruiting No 20 88 Both ### Target condDiagnostic Sequential
http://wwwNot Recrui No 7 70 Both ### Case seriesInterventioSequential
http://wwwRecruiting No 18 Both ### interventi InterventioParallel

https://wwAuthorisedYes Femal ### 4000 Interventio 
http://wwwRecruiting No 16 75 Both ### High dose InterventioSingle arm

http://wwwNot Recrui No Male ### Target condDiagnostic Sequential

http://wwwNot Recrui No 1 100 Male 3/1/2020 Case seriesObservatioSequential
http://wwwNot Recrui No 0 86 Both ### Case serie ObservatioSequential
http://wwwNot Recrui No 12 Both ### Case seriesObservatioFactorial

http://wwwRecruiting No 23 94 Both ### non-cancerObservatioFactorial

http://wwwRecruiting No 18 Both ### severe patiObservatioSequential
http://wwwNot Recrui No Both ### Case seriesObservatioCase study

http://wwwRecruiting No 65 100 Both ### discharge ObservatioCase study

https://cl Not recruitNo 18 Years 90 Years All 7-Mar-20 120 Observational
http://wwwRecruiting No 18 80 Both ### Population ObservatioSequential
http://wwwNot Recrui No Both ### control gr InterventioParallel
http://wwwNot Recrui No 14 90 Both ### NIV group: ObservatioFactorial

http://wwwRecruiting No 2 89 Both 2/1/2020 Case seriesObservatioCase-Contr
http://wwwRecruiting No 18 80 Both ### Case seriesInterventioCohort stu

http://wwwRecruiting No Both 2/1/2020 Case seriesEpidemilogSequential
http://wwwRecruiting No 18 85 Both 2/1/2020 MSC groupObservatioSingle arm
http://wwwRecruiting No Both 2/1/2020 Case seriesInterventioNon random

http://wwwRecruiting No 20 80 Male ### Case seriesObservatioSequential
http://wwwRecruiting No 18 Both 3/7/2020 4 groups:2 ObservatioFactorial

http://wwwNot Recrui No 1 99 Both ### Case seriesEpidemilogSingle arm
http://wwwNot Recrui No Both 3/1/2020 Group 1:70ObservatioFactorial

http://wwwNot Recrui No 18 74 Both ### two groupsObservatioCase-Contr
http://wwwNot Recrui No 18 70 Both ### Case seriesInterventioSequential
http://wwwNot Recrui No Male 2/1/2020 Case seriesInterventioSequential
http://wwwNot Recrui No 18 ?? Both ### ObservatioObservatioFactorial
http://www.chictr.or No 14 90 Both 2/1/2020 case series ObservatioSequential
http://wwwRecruiting No 14 90 Both 2/1/2020 ECMO group

InterventioNon random
http://wwwRecruiting No 14 90 Both 2/1/2020 transnasal ObservatioSequential
http://wwwNot Recrui No 14 90 Both 4/1/2020 Exposed grObservatioFactorial

http://wwwRecruiting No 22 55 Male 3/5/2020 in hospita ObservatioSequential

http://wwwRecruiting No 14 90 Both 2/1/2020 case series ObservatioCase study
http://wwwNot Recrui No Both ### Target condDiagnostic Sequential

http://wwwNot Recrui No 12 85 Both 3/1/2020 Case seriesScreening Sequential
http://wwwRecruiting No 1 100 Both 2/9/2020 Target condDiagnostic Sequential
http://wwwRecruiting No Both 3/1/2020 Integrated ObservatioCohort stu

http://wwwNot Recrui No Both ### Group 1:20InterventioParallel

http://wwwRecruiting No 18 75 Both 2/1/2020 experimentObservatioSequential
http://wwwRecruiting No 18 75 Both 2/1/2020 ExocarpiumInterventioParallel
http://wwwNot Recrui No Both ### Target condDiagnostic Sequential
http://wwwNot Recrui No 0 18 Both 2/1/2020 Infection wBasic ScienFactorial
http://wwwRecruiting No 18 75 Both 2/4/2020 Control gr InterventioParallel
http://wwwRecruiting No 18 80 Both ### Two groupsBasic ScienFactorial
http://wwwNot Recrui No 18 Both ### experimentInterventioParallel
http://wwwNot Recrui No 18 Both 3/9/2020 experimentInterventioParallel

http://www.chictr.or No 18 55 Both ### Case seriesObservatioSequential
http://wwwNot Recrui No 16 Both ### Case seriesInterventioSingle arm

http://www.chictr.or No 1 80 Both 3/7/2020 1:132;2:13 EpidemilogSequential
http://wwwNot Recrui No 18 65 Both 3/5/2020 Control gr InterventioParallel

http://wwwNot Recrui No 2 65 Both ### Group A:60InterventioParallel
http://wwwNot Recrui No 18 Both ### Target condDiagnostic Sequential
http://www.chictr.or No 18 80 Both ### experimentInterventioParallel
http://www.chictr.or No 18 60 Both ### Case seriesObservatioSequential

http://wwwRecruiting No 18 60 Both ### Case seriesHealth servSequential
http://wwwNot Recrui No Both 3/1/2020 ExperimentInterventioParallel
http://wwwNot Recrui No Both 3/1/2020 treatment InterventioParallel

http://wwwRecruiting No Both ### Control gr ObservatioNon random
http://wwwRecruiting No 18 Both ### Case seriesInterventioSingle arm
http://wwwNot Recrui No 18 75 Both ### Positive d InterventioParallel
http://wwwRecruiting No 18 70 Both ### Routine tr Prognosis Parallel
http://wwwNot Recrui No 18 Both 3/9/2020 Case seriesObservatioSequential

http://wwwRecruiting No 18 65 Both 3/1/2020 Group 2:60InterventioParallel
http://wwwNot Recrui No 18 Both ### High dose InterventioParallel
http://wwwNot Recrui No 18 65 Both ### PhosphoricInterventioParallel
http://wwwNot Recrui No 18 75 Both ### PhosphoricInterventioParallel
http://www.chictr.or No 18 65 Both ### PhosphoricInterventioParallel
http://wwwRecruiting No 18 - Both ### eperimentaInterventioParallel
http://wwwNot Recrui No 18 96 Both ### Case seriesObservatioNon random
http://wwwRecruiting No 18 Both 3/3/2020 tumor pati ObservatioSequential
http://wwwRecruiting No 0 18 Both ### case series ObservatioSequential
http://wwwNot Recrui No 18 ND Both 3/9/2020 Chinese meObservatioFactorial
http://wwwNot Recrui No 18 ND Both 3/9/2020 Case seriesObservatioSequential

http://wwwNot Recrui No 18 Male 3/6/2020 Group 1:30ObservatioNon random
http://wwwNot Recrui No 18 80 Both ### experimentInterventioParallel

http://www.chictr.or No 1 90 Both 2/1/2020 Case seriesObservatioSequential
http://wwwNot Recrui No 18 65 Both 2/7/2020 Two cohortObservatioFactorial
https://cl Recruiting No 16 Years 99 Years All ### 150 InterventioAllocation
http://wwwRecruiting No 14 70 Both 3/3/2020 1:100;2:10 InterventioParallel
http://www.chictr.or No 18 65 Both 3/1/2020 ExperimentInterventioParallel
http://www.chictr.or No 12 Both ### Target condDiagnostic Factorial

https://cl Not recruitNo 18 Years 75 Years All 5-Mar-20 24 InterventioInterventi

http://wwwNot Recrui No 0.1 85 Male ### Case seriesObservatioSequential
https://cl Not recruitNo N/A N/A All ### 50000 Observational [Patient
http://wwwRecruiting No 20 50 Female 2/1/2020 Case seriesObservatioSequential
http://wwwRecruiting No Both ### Pirfenidon InterventioParallel
http://wwwRecruiting No 0 90 Both 2/5/2020 Diagnosed ObservatioSequential

http://wwwRecruiting No 0 100 Both 2/9/2020 COVID-19 ObservatioCohort stu
http://wwwNot Recrui No 11 18 Both ### SFBT groupInterventioParallel
http://wwwNot Recrui No 18 65 Both ### Group 1:30InterventioParallel
http://wwwRecruiting No Both ### Group 2:16InterventioHistorical
http://wwwNot Recrui No Both ### SARS-COV-2ObservatioFactorial

http://wwwRecruiting No 14 Both ### Case seriesInterventioNon random
http://wwwRecruiting No 38 70 Male ### Case seriesObservatioCohort stu
http://wwwRecruiting No 18 80 Both ### 1:80;2:40; InterventioNon random

http://wwwRecruiting No Both ### Critical gr ObservatioFactorial
https://cl Not recruitNo 18 Years N/A All 14-Feb-20 8 Observational
https://cl Recruiting No 6 Months 80 Years All 15-Feb-20 100 InterventioInterventi
https://cl Not recruitNo N/A N/A All ### 669 Observational

http://wwwRecruiting No Both 4/1/2020 Case seriesHealth servSequential
http://wwwRecruiting No 16 90 Both 2/1/2020 COVID-19 pObservatioSequential

http://wwwRecruiting No Both ### the patien Basic ScienSequential
http://wwwRecruiting No 18 80 Both ### Case seriesInterventioSequential
http://wwwNot Recrui No 18 80 Both ### experimentInterventioNon random
http://wwwRecruiting No 18 65 Both ### A:15;B:15; InterventioParallel
http://wwwRecruiting No 18 60 Both ### 1:36;2:36;3PreventionNon random

http://wwwNot Recrui No Both ### COVID-19 pObservatioSequential
http://wwwRecruiting No 18 75 Male 3/5/2020 ExperimentInterventioParallel

http://wwwNot Recrui No 1 99 Both ### EpidemilogSequential
http://www.chictr.or No 18 80 Both ### experimentInterventioParallel
http://wwwRecruiting No Both ### TricholomaInterventioParallel
http://wwwNot Recrui No 18 100 Both ### 1 the criti InterventioParallel
http://wwwNot Recrui No 18 ?? Both ### ExperimentObservatioNon random

http://wwwNot Recrui No Both 3/1/2020 Target condDiagnostic Sequential
http://wwwNot Recrui No Both ### tumor pati ObservatioFactorial

http://wwwRecruiting No Both 2/6/2020 Mild Type InterventioParallel
http://wwwRecruiting No 18 70 Both ### InterventioInterventioParallel
http://wwwNot Recrui No 18 - Both ### observatio ObservatioSingle arm
http://wwwNot Recrui No 18 85 Both 3/6/2020 control gr InterventioCase-Contr

Controlle
d: no
Randomis
ed: no
Open: no
Single
blind: no
Double
blind: no
Parallel
group: no
Cross
over: no
Other: no
If
controlle
d, specify
comparat
or, Other
Medicinia
l Product:
no
Placebo:
no
Other: no
https://wwAuthorisedNo Female3/5/2020 25 Interventio
http://ww Not Recrui No 18 Years no maximuBoth, male ### 60 observatio Allocation:
http://en.i Recruiting No 18 years 65 years Both ### 30 interventioRandomizati
http://en.i Recruiting No 18 years 65 years Both ### 150 interventioRandomizat
http://en.i Recruiting No 18 years 75 years Both ### 30 interventioRandomizat
Randomiz
ation: Not
randomiz
ed,
Blinding:
Double
blinded,
Placebo:
Not used,
Assignme
nt:
Parallel,
Purpose:
Treatmen
t, Blinding
descriptio
n: In this
study
patients,
nurse ,
superviso
r and
researche
r don't
know
which
group of
patients
will use
the
http://en.i Recruiting No 2 years no limit Both ### 125 interventiomedici
http://en.i Recruiting No 18 years no limit Both 3/3/2020 20 interventioRandomizat
Randomiz
ation:
Randomiz
ed,
Blinding:
Not
blinded,
Placebo:
Not used,
Assignme
nt:
Parallel,
Purpose:
Treatmen
t,
Randomiz
ation
descriptio
n:
Randomiz
ation will
be done
according
to the
blocks
randomiz
ation
method.
Regarding
to the
sample
size, 5
patients
http://en.i Recruiting No 18 years 75 years Both ### 50 interventiowil
http://en.i Not Recrui No 18 years no limit Both ### 70 interventioRandomizati

http://en.i Recruiting No no limit no limit Both ### 50 interventioRandomizat
https://jrc Not Recrui No >= 20age oNot applic Both ### 50 Interventiosingle arm
http://wwwNot Recrui No 18 Years 95 Years Both ### 5000 ObservatioN/A

https://cl Not recruitNo 14 Years 70 Years All 5-Feb-20 0 InterventioAllocation:
https://jrc Recruiting No >= 20age oNot applic Both ### 50 Interventiosingle arm
https://jrc Recruiting No >= 16age oNot applic Both 3/2/2020 86 Interventiorandomized
https://cl Not recruitNo 18 Years 80 Years All Feb-20 0 InterventioAllocation

https://up Recruiting No 1years-old 100years-oMale and 2/1/2020 500 ObservatioNot select
https://cl Recruiting No 6 Months 80 Years All ### 100 InterventioInterventi
https://cl Not recruitNo 18 Years N/A All ### 10 InterventioAllocation
https://cl Not recruitNo 18 Years N/A All 1-Mar-20 201 Observational
https://cl Recruiting No 18 Years 75 Years All 2-Mar-20 340 Observational

https://up Recruiting No Not applic Not applic Male and ### 9999 ObservatioNot select
http://wwwNot Recrui No 30 Years 70 Years Both ### 650 ObservatioN/A
https://cl Not recruitNo 18 Years 75 Years All 1-Apr-20 550 InterventioAllocation
https://cl Not recruitNo 18 Years 75 Years All 24-Feb-20 0 InterventioAllocation:

https://cl Recruiting No 21 Years N/A All 8-Mar-20 5000 Observational
https://cl Not recruitNo 18 Years N/A All ### 116 InterventioAllocation:
https://cl Not recruitNo 18 Years 100 Years All 25-Jan-20 0 Observational
https://cl Recruiting No 18 Years N/A All 9-Feb-20 10 InterventioInterventi
https://cl Not recruitNo 18 Years N/A All ### 200 Observational

https://cl Recruiting No N/A N/A All ### 1000 Observational
https://cl Recruiting No 18 Years 75 Years All 5-Mar-20 60 InterventioAllocation
https://cl Recruiting No 18 Years N/A All 1-Jan-20 500 Observational
https://cl Recruiting No 18 Years N/A All ### 5 InterventioInterventi
https://cl Not recruitNo 18 Years N/A All 1-Apr-20 400 InterventioAllocation:

http://wwwNot Recrui No 18 80 Both ### mild recov ObservatioFactorial
https://cl Recruiting No 18 Years N/A All ### 100 Observational

http://wwwNot Recrui No 18 50 Female ### Cesarean s ObservatioSequential
https://cl Not recruitNo 16 Years 100 Years All ### 100 Observational
https://cl Recruiting No 18 Years N/A All ### 80 Observational [Patient
https://cl Recruiting No 18 Years 50 Years Female 1-Jan-20 20 Observational [Patient
https://cl Not recruitNo 18 Years 80 Years All ### 500 InterventioAllocation:


http://wwwRecruiting No 1 80 Both ### Target condDiagnostic Sequential
http://wwwNot Recrui No 18 65 Both 4/1/2020 hDPSCs groInterventioParallel

http://wwwRecruiting No 18 Both ### Group M:30InterventioParallel
https://cl Not recruitNo 18 Years N/A All Mar-20 200 InterventioInterventi

http://wwwNot Recrui No 22 47 Both ### mindfulnesInterventioQuasi-rand
http://wwwNot Recrui No Both ### Case seriesObservatioCohort stu
http://wwwNot Recrui No 18 65 Both 4/1/2020 Control gr InterventioParallel

http://wwwNot Recrui No 18 98 Both ### Survival an ObservatioSequential

http://wwwNot Recrui No 7 101 Both ### Case seriesEpidemilogCase-Contr
http://wwwRecruiting No 18 75 Both ### 1:14;2:14; InterventioParallel

http://wwwRecruiting No 45 80 Both ### Homeopathi ObservatioSequential
http://wwwNot Recrui No 0 100 Both ### Case seriesObservatioCase-Contr
http://wwwNot Recrui No 18 80 Both 2/1/2020 ExperimentInterventioNon random

http://wwwNot Recrui No Both 3/1/2020 Case seriesObservatioSingle arm
http://wwwRecruiting No 18 ?? Both ### confirmed ObservatioFactorial
http://wwwRecruiting No 18 75 Both ### CM group: Treatment Quasi-rand
http://wwwRecruiting No 0 ?? Both ### Suspected InterventioParallel
http://www.chictr.or No 7 90 Both ### ExperimentInterventioCross-over
http://wwwRecruiting No 16 85 Both ### treatment InterventioNon random

http://wwwRecruiting No Both ### Light grou ObservatioFactorial
http://wwwRecruiting No Both ### COVID-19 gObservatioFactorial
http://www.chictr.or No 18 Both ### Case seriesObservatioSequential

http://wwwNot Recrui No Both 2/1/2020 Case seriesEpidemilogSequential
http://wwwNot Recrui No Both ### experimentInterventioParallel
Controlle
d: yes
Randomis
ed: yes
Open: yes
Single
blind: no
Double
blind: no
Parallel
group: no
Cross
over: no
Other: no
If
controlle
d, specify
comparat
or, Other
Medicinia
l Product:
no
Placebo:
no
Other:
yes
Other
specify
the
comparat
or: Best
clinical
https://wwAuthorisedNo Female ### 200 Interventioprac
Controlle
d: yes
Randomis
ed: yes
Open: no
Single
blind: no
Double
blind: yes
Parallel
group:
yes
Cross
over: no
Other: no
If
controlle
d, specify
comparat
or, Other
Medicinia
l Product:
no
Placebo:
yes
Other: no
Number
of
treatmen
t arms in
the trial:
3
https://wwAuthorisedYes Female ### 460 Interventio
Controlle
d: yes
Randomis
ed: yes
Open: no
Single
blind: no
Double
blind: yes
Parallel
group: no
Cross
over: no
Other: no
If
controlle
d, specify
comparat
or, Other
Medicinia
l Product:
no
Placebo:
yes
Other: no
Number
of
treatmen
t arms in
the trial:
2
https://wwAuthorisedNo Female ### 1000 Interventio
Controlle
d: yes
Randomis
ed: yes
Open: no
Single
blind: no
Double
blind: yes
Parallel
group:
yes
Cross
over: no
Other: no
If
controlle
d, specify
comparat
or, Other
Medicinia
l Product:
no
Placebo:
yes
Other: no
Number
of
treatmen
t arms in
the trial:
2
Controlle
d: yes
Randomis
ed: yes
Open: no
Single
blind: no
Double
blind: no
Parallel
group: no
Cross
over: no
Other: no
If
controlle
d, specify
comparat
or, Other
Medicinia
l Product:
yes
Placebo:
no
Other:
yes
Other
specify
the
comparat
or:
Standard
of care
https://wwAuthorisedNo Female ### 443 InterventioN
Controlle
d: yes
Randomis
ed: yes
Open: no
Single
blind: no
Double
blind: yes
Parallel
group: no
Cross
over: no
Other: no
If
controlle
d, specify
comparat
or, Other
Medicinia
l Product:
no
Placebo:
yes
Other: no
Number
of
treatmen
t arms in
the trial:
2
https://cl Not recruitNo 18 Years N/A All Apr-20 100 InterventioAllocation:
https://cl Recruiting No 18 Years N/A All ### 3100 InterventioAllocation
https://cl Recruiting No 18 Years 75 Years All 5-Mar-20 150 InterventioAllocation:

https://cl Recruiting No N/A 24 Years All 15-Oct-19 2300 Observational
https://cl Not recruitNo 18 Years N/A All 25-Feb-20 Expanded Access
https://cl Recruiting No 18 Years 80 Years All ### 140 InterventioAllocation:

https://cl Not recruitNo 18 Years N/A All 1-Jan-98 1302508 Observational
https://cl Not recruitNo 18 Years 65 Years All 1-Apr-20 30 InterventioAllocation:
https://cl Not recruitNo 18 Years N/A All Mar-20 1600 InterventioAllocation:

https://cl Recruiting No N/A N/A All ### 500 InterventioInterventi
https://cl Not recruitNo 18 Years N/A All Mar-20 1116 InterventioAllocation

https://cl Not recruitNo 18 Years 80 Years All ### 1 InterventioInterventi
https://cl Not recruitNo 18 Months N/A All ### 1220 InterventioAllocation
https://cl Not recruitNo 18 Years N/A All ### 49 InterventioInterventi

https://cl Not recruitNo N/A N/A All 1-Apr-20 100 Observational
https://cl Not recruitNo N/A 85 Years All Mar-20 50 InterventioAllocation

http://wwwRecruiting No 18 100 Both ### ordinary grObservatioFactorial
https://cl Recruiting No 18 Years N/A All ### 90 InterventioAllocation:

http://wwwNot Recrui No 10 85 Both ### Control gr Basic ScienFactorial
http://wwwNot Recrui No 18 80 Both ### Case seriesHealth Ser Sequential
https://cl Recruiting No 18 Years N/A All 24-Feb-20 170 Observational
https://cl Not recruitNo 18 Years N/A All ### 100 Observational [Patient
http://wwwNot Recrui No 18 80 Both ### ARBs GroupObservatioFactorial
http://wwwRecruiting No 18 80 Both 2/5/2020 ExperimentInterventioCase-Contr
http://wwwNot Recrui No 20 65 Both 4/3/2020 Medical peHealth Ser Sequential

https://cl Not recruitNo 18 Years 75 Years All 1-Apr-20 300 Observational
http://wwwNot Recrui No 18 N/A Both ### Rheumatic ObservatioFactorial

http://wwwNot Recrui No Both ### eye patch ObservatioFactorial
http://wwwRecruiting No 18 90 Both 2/1/2020 ExperimentInterventioSingle arm
http://wwwNot Recrui No / / Both ### Target condDiagnostic Sequential
http://wwwNot Recrui No 18 70 Both 4/1/2020 NintedanibInterventioParallel
http://wwwNot Recrui No 30 90 Male ### ObservatioSequential

https://cl Recruiting No 18 Years 100 Years All ### 500000 Observational [Patient
http://isr Recruiting No Both ### 500 InterventioProspectiv
http://wwwNot Recrui No 13 N/A Both 4/1/2020 COVID-19 wi

ObservatioFactorial
http://wwwNot Recrui No / / Both ### Target condDiagnostic Sequential

https://wwAuthorisedNo Female3/9/2020 3100 InterventioControlled
http://wwwNot Recrui No 18 80 Both 4/1/2020 Control:50 InterventioParallel
http://wwwRecruiting No 18 ? Both ### Mild:400;s ObservatioFactorial
http://wwwNot Recrui No 18 85 Both ### Group 1:10InterventioNon random

http://wwwNot Recrui No 20 30 Both 3/5/2020 experimentHealth Ser Diagnostic
http://wwwNot Recrui No 18 70 Both 5/1/2020 Different d Basic ScienDose comp
http://wwwRecruiting No 18 80 Both ### ExperimentInterventioCase-Contr
https://wwAuthorisedNo Female ### 80 InterventioControlled



https://wwAuthorisedNo Female ### InterventioControlled
https://cl Not recruitNo 14 Years N/A All 24-Oct-17 20 InterventioInterventi


https://an Recruiting No No limit No limit Both males 3/5/2020 400 ObservatioPurpose: Na
https://cl Recruiting Yes N/A N/A All ### 250 InterventioAllocation:
https://an Not Recrui No 18 Years 64 Years Both males ### 680 InterventioPurpose: Pr
https://cl Recruiting No 18 Years N/A All 8-Nov-18 800 InterventioAllocation:

https://cl Recruiting No N/A N/A All 6-Apr-20 226 InterventioAllocation:

https://cl Recruiting No N/A N/A All 9-Mar-20 300 Observational
https://cl Recruiting No 1 Year 90 Years All 1-Jan-20 50 Observational
https://cl Recruiting No 18 Years 70 Years All 6-Mar-20 4 InterventioInterventi
https://cl Not recruitNo 18 Years 55 Years All Apr-20 510 InterventioAllocation:

https://cl Recruiting No N/A N/A All 30-Jan-20 30 InterventioAllocation
https://cl Recruiting Yes 18 Years 99 Years All 21-Feb-20 440 InterventioAllocation:
https://cl Not recruitNo 18 Years N/A All Apr-20 66 InterventioAllocation

https://cl Recruiting No 12 Years N/A All 6-Mar-20 2400 InterventioAllocation
https://cl Not recruitNo 18 Years N/A All Mar-20 2500 InterventioAllocation

https://cl Not recruitNo 18 Years 80 Years All Mar-20 2000 InterventioAllocation:
https://cl Recruiting No 18 Years 75 Years All 5-Mar-20 90 InterventioAllocation:
https://cl Not recruitNo 18 Years 75 Years All 17-Feb-20 11 InterventioInterventi
https://cl Not recruitNo N/A N/A All 1-Jan-18 Expanded Access
https://cl Recruiting Yes 18 Years N/A All ### 3040 InterventioAllocation

https://cl Recruiting No N/A N/A All 3-Apr-20 200000 Observational
https://cl Recruiting No N/A 18 Years All ### 12500 Observational

https://cl Recruiting No 18 Years N/A All 9-Apr-20 580 InterventioAllocation:
https://cl Not recruitNo 18 Years 90 Years All ### 38 InterventioInterventi

https://cl Not recruitNo N/A N/A All 9-Mar-20 533 Observational
https://cl Recruiting No 18 Years N/A All 1-Apr-20 630 InterventioAllocation
https://cl Recruiting No 6 Months N/A All ### 440 InterventioAllocation

https://cl Not recruitNo 18 Years N/A All Apr-20 5 InterventioInterventi

https://cl Recruiting No N/A N/A Female 1-Jan-20 20 Observational [Patient
https://cl Recruiting No 18 Years N/A Female ### 1000 Observational [Patient
https://cl Not recruitNo 18 Years N/A All 1-Apr-20 0 InterventioInterventi
https://cl Recruiting No 18 Years N/A All Apr-20 1300 InterventioAllocation:
https://cl Recruiting No N/A 100 Years All 2-Apr-20 2000 Observational

https://cl Recruiting No 3 Years 99 Years All Apr-20 50 InterventioAllocation:
https://cl Recruiting No 25 Years 65 Years All ### 400 Observational
https://cl Not recruitNo 18 Years N/A All Apr-20 25 Observational

https://cl Recruiting Yes 18 Years N/A All 3-Apr-20 330 InterventioAllocation:
https://cl Recruiting No 16 Years N/A All 6-Apr-20 200 Observational

https://cl Not recruitYes 18 Years N/A All 6-Apr-20 180 InterventioAllocation
https://cl Recruiting No N/A N/A All 1-Apr-20 500 Observational [Patient

https://cl Not recruitNo 18 Years N/A All 1-May-20 150 InterventioAllocation:
https://cl Not recruitNo 18 Years N/A All 6-Apr-20 3000 Observational [Patient
https://cl Recruiting No 30 Years 79 Years All 2-Apr-20 54 InterventioAllocation
https://cl Recruiting Yes 18 Years N/A All ### 1000 Observational

https://cl Not recruitNo 18 Years 80 Years All 13-Apr-20 240 InterventioInterventi


https://cl Not recruitNo 18 Years 99 Years All Apr-20 50 Observational

https://cl Recruiting No N/A N/A All 1-Mar-20 5000 Observational
https://cl Recruiting No 30 Years 70 Years All ### 30 InterventioInterventi

https://cl Recruiting No 18 Years N/A All Apr-20 342 InterventioAllocation
https://cl Not recruitNo 18 Years 75 Years All Apr-20 436 InterventioAllocation

https://cl Not recruitNo 18 Years 45 Years Female 12-Apr-20 100 Observational

https://cl Recruiting No N/A N/A All ### 450 InterventioAllocation
https://cl Recruiting No 18 Years N/A All 30-Jan-20 120 Observational
https://cl Not recruitNo 18 Years 99 Years Female 1-Apr-20 150 InterventioAllocation
https://cl Recruiting No 18 Years 70 Years All 27-Jan-20 9 InterventioInterventi

https://cl Not recruitNo 18 Years N/A All 10-Jan-19 Expanded Access
https://cl Not recruitNo 18 Years N/A All 10-Jan-19 Expanded Access
https://cl Not recruitNo 18 Years N/A All 17-Apr-20 5000 Observational

https://cl Not recruitNo 18 Years 65 Years All May-20 120 InterventioAllocation:


https://cl Not recruitNo 18 Years 95 Years All Apr-20 25 InterventioInterventi


https://cl Not recruitNo N/A N/A All Apr-20 160 Observational

https://cl Recruiting No 8 Years 80 Years All Apr-20 100 Observational
https://cl Recruiting No N/A 18 Years All 7-Apr-20 250 Observational [Patient


https://cl Not recruitNo 18 Years N/A All 1-May-20 1300 InterventioAllocation:

https://cl Recruiting No 18 Years N/A All 1-Mar-20 1500 Observational

https://an Not Recrui No 18 Years No limit Both males ### 140 InterventioPurpose: Tr

https://an Not Recrui No 18 Years No limit Both males 5/1/2020 58 InterventioPurpose: Tr
http://isr Recruiting No Both ### 25 ObservatioObservatio
https://cl Not recruitYes 18 Years N/A All 20-Apr-20 240 InterventioAllocation:

https://cl Recruiting No 18 Years N/A All 3-Apr-20 220 Observational [Patient
https://cl Not recruitNo N/A 18 Years All 1-Apr-20 350 Observational [Patient
http://isr Recruiting No Both ### 510 InterventioInterventio
http://isr Recruiting No Female ### 500 ObservatioObservatio
https://cl Not recruitNo N/A 18 Years All Apr-20 914 Observational

https://cl Recruiting No N/A N/A All Apr-20 100 Observational
https://cl Not recruitNo N/A 15 MinutesAll 1-Apr-20 70 Observational [Patient
https://cl Recruiting No N/A N/A All ### 2500 Observational [Patient

https://cl Recruiting No 18 Years 75 Years All 7-Apr-20 3000 InterventioAllocation:

https://cl Recruiting No 18 Years 110 Years All 6-Apr-20 100000 Observational

https://cl Recruiting No 18 Years N/A All 28-Feb-20 100 Observational
http://wwwNot Recrui No 29 91 Both 1/1/2020 survival g ObservatioFactorial
http://wwwRecruiting No 18 45 Both 4/1/2020 Case groupObservatioFactorial

https://cl Not recruitNo 18 Years N/A All 1-May-20 200 InterventioInterventi
https://cl Not recruitNo N/A N/A All 1-May-20 20 Observational [Patient

http://wwwRecruiting No 0 100 Both 4/1/2020 Patient:30;ObservatioSequential
http://wwwRecruiting No 28 54 Male 3/1/2020 For the mi ObservatioCross-secti
https://cl Recruiting No 18 Years N/A All 10-Sep-19 120 Observational
https://cl Not recruitNo 18 Years 80 Years Female 10-Apr-20 207 Observational
https://cl Not recruitNo 18 Years 65 Years All 1-Jul-20 5 InterventioAllocation:

http://wwwNot Recrui No 25 65 Both 3/1/2020 common typ

InterventioParallel
https://cl Not recruitNo 18 Years 45 Years Female 5-Apr-20 80 Observational [Patient
https://cl Not recruitNo 6 Years N/A All 5-Apr-20 Expanded Access

https://cl Not recruitNo N/A N/A All Apr-20 150000 Observational

https://tri Not Recrui No ### 950 Interventio 

https://tri Recruiting No ### 2000 Observatio 

https://cl Not recruitNo 18 Years N/A All 1-Jun-20 334 InterventioAllocation:
https://wwAuthorisedYes Female4/3/2020 1000 InterventioControlled
https://an Not Recrui No 18 Years No limit Both males 4/7/2020 100000 ObservatioPurpose: Na
https://cl Not recruitNo N/A N/A All 1-May-20 200 Observational


https://an Recruiting No 18 Years No limit Both males ### 150 InterventioPurpose: T
http://isr Recruiting No Both ### 5000 InterventioRandomised
http://isr Recruiting No Both 4/2/2020 400 ObservatioMixed-meth
http://isr Recruiting No Both ### 70 ObservatioObservation
https://cl Not recruitNo 18 Years 89 Years All Apr-20 80 InterventioInterventi
https://cl Recruiting No 14 Years N/A All 3-Mar-20 10 InterventioInterventi

https://cl Not recruitNo 18 Years N/A All 1-Jun-20 200 InterventioAllocation
https://an Not Recrui No 18 Years No limit Both males ### 2500 InterventioPurpose: Tr
https://an Not Recrui No 18 Years 65 Years Both males ### 20 InterventioPurpose: Pr
http://isr Recruiting No Both 4/6/2020 4002 InterventioAdaptive (g

http://isr Recruiting No Both ### 10000 InterventioOpen-label

http://wwwNot Recrui No 18 80 Both ### interventi ObservatioNon random

http://wwwNot Recrui No Both 3/1/2020 NK cell gr InterventioParallel

http://wwwRecruiting No 18 50 Female 4/6/2020 Case seriesObservatioSequential

http://wwwRecruiting No 18 75 Both ### Case seriesInterventioSingle arm
http://wwwRecruiting No 14 75 Both ### Case seriesObservatioFactorial
http://wwwNot Recrui No 18 Both 3/2/2020 ExperimentInterventioSequential
https://cl Recruiting No 18 Years 89 Years All 10-Apr-20 100000 Observational [Patient
http://wwwNot Recrui No 18 100 Both 3/1/2020 Novel coro ObservatioSequential
http://wwwRecruiting No 0 120 Both 2/1/2020 Case seriesEpidemilogSequential

https://tri Not Recrui No ### 8000 Observatio 
https://tri Recruiting No ### 17000 Interventio 
https://an Not Recrui No 18 Years 80 Years Both males ### 60 ObservatioPurpose: Na

https://an Not Recrui No 18 Years 60 Years Females ### 200 ObservatioPurpose: Na
https://an Not Recrui No 18 Years 75 Years Both males ### 70 InterventioPurpose: Tr

https://tri Recruiting No ### 386 Interventio 

http://isr Recruiting No Both 4/6/2020 75 InterventioInterventio

http://isr Recruiting No Both 4/8/2020 2000 ObservatioSingle-cent
http://isr Recruiting Yes Both ### 3000 InterventioPragmatic o


http://wwwNot Recrui No 18 88 Both ### mild, modeObservatioSequential
http://wwwNot Recrui No Both ### Patients w ObservatioFactorial
http://wwwNot Recrui No 18 Both 4/9/2020 1:250;2:12 InterventioParallel

http://wwwNot Recrui No 18 80 Male 1/1/2020 1:50; ObservatioSequential

https://tri Not Recrui No ### 4000 Observatio 
https://tri Recruiting No 4/6/2020 354 Interventio 


https://wwAuthorisedYes Female ### 84 InterventioControlled


Phase Countries Contact Fi Contact La Contact AdContact EmContact Te Contact AffInclusion C Exclusion C
N/A China Yan Zhao 169 Donghudoctoryan +86 13995 EmergencyInclusion c Exclusion c
Exclusion criteria: 1. Fema
 2. Patients with know
 3. Patients with haem
Inclusion criteria:
 4. Patients
Patients aged
with chro
18 o
N/A China Ting Cai 41 Xibei St caiting@uc+86 13738 HwaMei Hos Criteria 5.
for diagnosis
Patients(meet
with arrh
all th
 Inclusion Criteria:

 
 Patients diagnosed with RT-
 
 Exclusion Criteria:
 
 Patients infected with othe
Phase 4 Pinhua Pan, Medical pinhuapan +86 13574810968 
Inclusion criteria: 1. Aged >=18 years
 2. Diagnosed of 2019-nCoV infec
RetrospectChina Yan, Zhao 169 Donghudoctoryan +86 13995 Emergency 3. Failed Exclusion
by c
Inclusion criteria: 1. Laboratory confi
 2. Aged > 18 years;
 3. Written informed
Exclusion consent
criteria: giv
1. Hype
0 China Xiaowei Xu 79 Qingchuxxw69@12+86 13605 The First A 4. Clinical
 2.
deterioration
Have immunoglob
despite
0 China Zhai Xiaowen 399 Wanyua zhaixiaow +86 64931 Children's Inclusion c Exclusion c
Inclusion criteria:
Exclusion
1. Meet
criteria:
the1.diagno
Patie
N/A China LU Zhenhui 725 Wanpintcmdoctor +86 13817 Longhua Hos 2. The 2.
acute stage
Pregnant,
is complicate
preparin
Inclusion criteria:
Exclusion
1. Suspected,
criteria: 1. mild,
Unab
N/A China Wang Tan 1478 GongnWangtan21+86 13756 Affiliated 2. The 2.
expert Cases
team of where
consultati
comp
Exclusion criteria: 1. Extre
 2. 1.
Inclusion criteria: Pregnant
Patientsorwith
lactati
co
0 Chao Xu 1 Fourth N 16497276 +86 15018720816 3. In
 2. Voluntarily thewritten
sign opinion of th
inform
Inclusion criteria: Pneumonia cases w
0 China Weiren Huang 3002 Sungapony8980 +86 13923 Shenzhen S A comprehensive
Exclusion c analysis was c

 
 - In sputum, throat swab,
 the nucleic acid of the no
Phase 4 China ; Yueping Li, MD, Mastelipipi007@ 020- 36052117; 

 
 - Patients visiting emergen
 
 
 -
Phase 4 China Panpan Hao, MD panda.how86-18560086593 
 
 - can use mobil phone or c
 
 - volunteer to take part in
 
 
 - can not use phone or com
 
N/A China ; Yuhong Dai;Yuhong Daeier_dai@ +86 13476229575;+8 
Inclusion criteria:
Exclusion
Confirmed
criteria: or
1. suspe
Patie
 1. Aged 2.
<= 75Those
years;with severe
 2. Patients
 3.with
Inability
newlyto diagnose
unders
0 China Xu Shuyun 1095 Jiefa sxu@hust. +86 13517 Tongji Hosp 3 4. Invasive ve
Inclusion criteria: (1) Patients diagno
N/A China Wu Wenjuan 1 Yintan R 88071718 +86 13397 Wuhan Jiny (2) Patients admitted
Exclusion c to the ICU
Exclusion criteria: 1. Patie
 2. Pregnant or lactati
Inclusion criteria:
 3. 1.
Patients
General/severe/
with activ
 2. Patients
 4.whose
Patients
viralwith
nucleic
tumo
a
0 China Li Jiansheng 156 Jinshu li_js8@16 +86 371-6 He'nan Uni 3. Patients
 5.who
Patients
are characterize
wi
0 China Xiangming Fang 299 Qingyanxiangming +86 13861 Wuxi PeoplInclusion c Exclusion c
Exclusion criteria: 1. Preg
 2. Combined with ca
0 China Wei Zhang Pulmonary zhangw119+86 13601 Shuguang Ho Inclusion c 3. Those with observ
Inclusion criteria:
Exclusion
1. patients
criteria: with
1. Preg
no
 2. Fever,
 2.
respiratory
People tract
with allergi
and o
 3. Aged 3.
18 to Severe
80 years;
Primary dis
4 China Tingrong Huang, Bangj6 Guangchafangbji@1 +86 0714- Huangshi H 4. Signed 4.
informed
Obstructive
cons pneum
Inclusion criteria: 1. Subjects have sig
 2. AgedExclusion
>= 18 and criteria:
<= 75 years.
1. Patie
4 China Ronghua Jin 8 Xitoutou,dinghuigu +86 13811 Beijing You 3. Met 2.
th Patients who have
Inclusion criteria: 1. Hospitalized pati
 2. Meet any one of the criteria f
 1) Respiratory
Exclusiondistress:
criteria:RP
1. >=
Preg
30
 2) At rest,
 2.
thePeople
oxygenwithsaturation
allergi
0 China Tingrong Huang, Bangj6 Guangchafangbji@1 +86 0714- Huangshi H< 3. Patients with serio
Inclusion criteria:
Exclusion
1. Patients
criteria: with
1. Seve
co
 2. Above 2.
18 years
Estimated
old (inclusive)
Time of
4 China Xiaoyin Huang Nanbaixianzjwzhxy@1+86 13819 The First A 3. Voluntarily
 3. There
sign written
is clearinform
evid

 
 - Confirmed 2019-nCoV in
 
 - 80 years = age = 14years
 
N/A China ;; Xiao-he Xiao, PD.;Rui- ;wrl7905@;+86 10 6 302 Militar - Within 72 hours after the
 
 1. Sign the informed conse
 
 2. Age =18 years, regardles
 
 3. Subjects with pneumon
Phase 4 
 - Adult aged >=18years old
 
 - Laboratory (RT-PCR) con
 lower respiratory tract sa
 
Phase 2/Phase 3 Taisheng Li litsh@263. 010-69155086 

 
 - 1. Aged between 18 and
 
 - 2. Laboratory (RT-PCR) a
N/A ; Yunqing Qiu, Master;X;xxw69@1 ;+86 1360 First Affil according
Exclusion criteria: 1. Rest
 2. Staff with respirato
N/A China Yongshi Jia 158 Shangtjiayongsh +86 13605 Zhejiang PrInclusion c 3. Staff who need the
Inclusion criteria: 1. Patients diagnos
 2. Underwent
Exclusionchest CT scan
criteria: 1. CT durim
0 China Bin Song 37 Guoxue songlab_r 86 28 854 West China 3. Able 2.
to complete
Pregnanttheandstudy.
lacta
Inclusion criteria:
Exclusion
1. Meet
criteria:
the1.diagno
Patie
N/A China LU Zhenhui 725 Wanpintcmdoctor +86 13817 Longhua Hos 2. Meet 2.
the TCM
Pregnant,
diagnostic
preparincrite
Exclusion criteria: 1. Fema
 3. Patients with haem
Inclusion criteria:
 4. Patients
Patients aged
with chro
18 o
N/A China Ting Cai 41 Xibei St caiting@uc+86 13738 HwaMei Hos
 Criteria 5.
for diagnosis
Patients(meet
with arrh
all th
0 China Huaqi Wang 1 Jianshe wanghuaq +86 15890 The First A Inclusion c Exclusion c
Exclusion criteria: (1) Tho
 (2) mentally ill subjec
 (3) those who are pre
 (4)1.those
Inclusion criteria: Age iswhonotuse
limiteot
0 Yongxiang Yi (5)
1 Kangfu Roian0126@1+86 13338 Nanjing Se 2. Clinical thoseis in accorda
diagnosis
0 China Yao, Rong 37 Guoxue 10370705 +86 18980 West ChinaInclusion c Exclusion c
Inclusion criteria:
Exclusion
1. Influenza
criteria: 1.patien
Patie
N/A China Zhao Yan 169 Donghudoctoryan +86 13995 Zhongnan H 2. From 2.
December
Clinical
1, data
2019istoseriFe
Inclusion criteria: Suspected cases of
0 China Deng Guofang 29 Bulan R jxxk1035@+86 13530 Pulmonary Comprehensive
Exclusion analysis based o
Exclusion criteria: 1. Know
Inclusion criteria:
 2. 1.
Hormone
Adults (defined
therapy a
 3.
 2. Patients Patients
with new typewithofdiab
cor
0 China Ronghui Du 28 Baofengbluesearh +86 15337 Wuhan Pul 3. The 4. Knownbetween
time interval co sym
Inclusion criteria:
Exclusion
1. Aged>
criteria:
181.years
Staffo
 2. Working
 2.time
Regulatory
in the front
studenline
N/A China Zhan Jie 111 Dade Rzhanjie34 +86 15818 Guangdong 3. The 3.
workingThose
department
who refused is th
Inclusion criteria:
Exclusion
(1) criteria:
Those who (1) mee
Imm
 (2) Those
 (2)
who Preparing
have beenpregna diagno
0 China Hongzhou Lu, Xiaoron 2901 Caolan luhongzho +86 18930 Shanghai Pu (3) Inpatients
 (3)aged
Patients
18 towith75 alle
yea
Inclusion criteria:
Exclusion
1. Aged
criteria:
>=18 1. to
Preg
70
 2. Diagnosed
 2. 2019-nCoV
Those who are infecte
alle
4 China Qin Ning, Meifang Ha 1095 Jiefa 31531955 +86 27 83 Tongji Hosp 3. Understand
 3. Severe
an cardiovascu
Inclusion criteria:
Exclusion
(Allcriteria:
the following
(Subjec c
 1. Aged 1.
>= 18Patients
years; with a his
 2. Meet 2.
all thePatients
following withcriteria
hem
4 China Xia Jinyu 52 Meihua xRiajinyu@m+86 13823 The Fifth A (1) Epidemiological
 3. Patients hist
0 China Cao Jun 117 Meiyuacaojuncn@+86 0510- Jiangsu Ins Inclusion Exclusion c
Exclusion criteria: 1) pneu
Inclusion criteria:
 2) 1)daily
common
treatmenttype ofpn
 2) aged 3)
18 to patients
75 years withold; confi
N/A China Wu Guolin 79 Qingchuwuguolin2 +86 13136 The First A 3) voluntary
 4)signing
those allergi
of written in
Exclusion criteria: 1. Aged
 3. Allergic to the test
 4. 1.
Inclusion criteria: The underlying
2019 adult patiedis
N/A China Xia Jiaan 1 Yintan R 31318629 +86 13871 Wuhan Jiny 2. The 5.
absolu CO
Inclusion criteria:
Exclusion
(1) criteria:
Comply with (1) Impth
 (2) Aged (2)
18-80Those
years.with severe
N/A China Lixin Wang 507 Zhengm wlx1126@h+86 18917 Shanghai P (3) Those (3)
who Pregnant
voluntarily women
partic
Inclusion criteria: 1. Patients with no
0 China Fang Xueling 79 Qingchu13588867 +86 13588 The First A Exclusion c
Inclusion criteria: 1. Suspected case:
N/A China Lu Hongzhou 2901 CaolanLuhongzho+86 18930 Shanghai Pu Patients in observation
Exclusion c period o
Exclusion criteria: 1. Peop
Inclusion criteria:
 2. 1.Combined
Meet thewith diagno
oth
 2. Pneumonia
 3. Patients
SeveritywithIndex hem
(PS
N/A China Yaosheng Zhang, Jia 5 Hai-Yun-Czysjsgzs@ +86 18134 Dongzhimen 3. Aged 4.
18- Combined with sev
Inclusion criteria:
 3. 1.ALTThe/ AST>
patients
5 ULN,wh
 2. Aged 4.
18 to Definite
85 years;diagnosis
4 China Xiaoling Xu 17 Lujiang xxlahh08@+86 18963 The First A 3. IL-6 ?Patients who do no
Exclusion criteria: 1) Know
 2) Confirmed hepatiti
Inclusion criteria:
 3) 1)Acute
Agedrespiratory
>=18 years
0 China Hu bo, Li wei 1277 Jiefa hubo@mail+86 13707 Union Hosp 2) Patients 4)with
According
new coronaviru
to the ju
Inclusion criteria:
Exclusion
(1) criteria:
aged >=18 (1)year
kno
0 China Pei Guangzhong 222 Zhengd50381850 +86 13839 People's H (2) real-time
 (2)fluorescence
patients with rt-pcr
mal
Inclusion criteria: 1. Aged >= 18 year
 2. Laboratory (RT-PCR) confirme
 3. Pneumonia confirmed with ch
 4. <= 8Exclusion
days sincecriteria:
illness 1.onset
Prega
4 China Chao Cao 59 Liuting caocdocto +86 574-8 Ningbo Firs 5. Willing
 2.
to Patients with seve
Exclusion criteria: (1) Pati
Inclusion criteria:
 (2)(1)Patients
Complywho withhav th
N/A China Huang Luqi; Li Zhiqian 16 Nanxiaohuangluqi +86 010-6 China Acad (2) Agree <b to participate in the st
0 China Kang Yan 37 Guoxue Kangyan@s+86 18980 DepartmentInclusion c Exclusion c
Inclusion criteria: 1. Suspected and c
18-65 years old; 1. Clear
criteria:
0 China Tong Xiaolin 856 Luoyu 25241708 +86 18908 Hubei Prov 3. Signing 2.
theSerious
generalprimary
informed di
0 China Pei Bin 15 Jiefang xyxzyxzh@ +86 18995 Xiangyang 1Inclusion c Exclusion c
Inclusion criteria: (1) Comply with th
 (2) TheExclusion
classification
criteria:
was(1)judged
Pati
 (3) Body (2)
temperature
Tracheal>intubatio
37.3 deg
0 China LIU QINGQUAN 23 Art Gall Liuqingqu +86 010-5 Beijing hos (3) Other problems t
0 China Chengping Wen 548 Binwenwengcp@1+86 571 8 Zhejiang C Inclusion c Exclusion c
Inclusion criteria:
Exclusion1. Non
criteria:
suspected
1. Suspc
 2. Participate
 2. Patients
in novel with
coronavir
seve
N/A China Qiu Jun 159 Tiansha97300753 +86 13881 Deyang inte 3. Novel 3.
coronavirus
People who pneumonia
could
Inclusion criteria:
Exclusion1. Aged
criteria:
>=18 1. years
Preg
 2. A novel
 2.coronavirus
The patients infection
had m
4 China Ying Kejing 3 Qingchunyingsrrsh +86 13588 Sir Run Run 3. According
 3.to Potential
novel coronaviru
violation
Exclusion criteria: 1. preg
 2. Documented allerg
Inclusion criteria:
 3. 1.Documented
Aged >=18 yearshisto
 2. Patients
 4. hasDocumented
been diagnosed histow
4 China Jiang Shanping 102 Yanjia shanpingj +86 13922 Sun Yat sen * WHO. 5.
Clinical
Documented
management histo
of
Exclusion criteria: 1) Any
 2) patients who have
 3) 1.
Inclusion criteria: noAdult
clinical or chest
aged >= 18
0 China Jianping Zhao 4)
1095 Jiefa zhaojp@tjh+86 13507 Tongji Hosp 2. Patients In unexplained
with the state of no o
vira
Exclusion criteria: (1) The
0 China Wen Chengping 548 Binwenwengcp@1+86 13906 Zhejiang C Inclusion c (2) It is not suitable f
 (2) Patients have oth
0 China Chengping Wen 548 Binwenwengcp@1+86 13601 Zhejiang C Inclusion c (3) Patients allergy o
Exclusion criteria: 1. Age>
 2. 1.
Inclusion criteria: After CPR. who me
Patients
RetrospectChina Wu Wenjuan 1 Yintan R 13468014 +86 13397 Wuhan Jiny 2. ECMO-treated
 3. Accompanied
patients with by o
0 China Lv Dongqing 1 Tongyanglvdq@enz +86 13867 Enze HospiInclusion c Exclusion c
Exclusion criteria: 1. Chro
Inclusion criteria:
 2. 1.Long-term
18 years applica
old <= a
0 China Zhan Zhang 99 Zhangzhdoctorzha +86 18062 Renmin Hos 2. Pharyngeal
 3. Based
swabs,on alveolar
the reseala
0 China Nianzhi Zhang 117 Meisha13505615 +86 13505 The First A Inclusion c Exclusion c
Inclusion criteria: 1. patients diagnos
 2. virus turned negative after tre
 3. agedExclusion
18-70 years criteria:
old; 1. Patie
 4. patients
 2. with
Pregnant
clear consciousn
or lactati
0 China Min Huang 11 Lingjiao 10258233 +86 13307 1. Xinhua a 5. Signing
 3.
thePatients
informedwho conhave
 3. Patients
Exclusion
diagnosed
criteria:
with1. pulm
Patie
 4. aged 2.
18-70Pregnant
years old;or lactati
0 China Jixian Zhang 11 Lingjiao jxzhang16 +86 13377 1. Xinhua a 5. patients
 3. with cle who have
Patients
Inclusion criteria: 1. Aged 18-75 year
 2. BodyExclusion
weight 40-100
criteria:kg1.and
Infec
BM
 3. Been 2.
Confirmed
Used withnon-steroida
commo
 4. With 3.
fever,Have
respiratory
severetract
liver ad
0 China Jun Lin 169 Donghuwdznyy@1+86 13971 Zhongnan H 4. Those who are kno
N/A China Chen Lei 37 Guoxuexleilei_25@ +86 18980 West ChinaInclusion c 2. Patients and healt
Inclusion criteria: 1. Patients with pn
N/A China Li Jiansheng 156 Jinshu li_js8@16 +86 371 6 The First A 2. To sign
Exclusion
informed c consent.
Inclusion criteria: 1) Pneumonia patie
 2) The Exclusion
type of pneumonia
criteria: 1)waspatieju
4 China LIU QINGQUAN, MIAO23 Back StrZJHTCM@F+86 13902 Beijing Hos 3) Informed 2)consent.
patients were not
 2. Patients with seve
4 China Zhongqi Yang, Minyo 16 Jichang yang_zhon +86 13688 The First A Inclusion c 3. Patients who have
Inclusion criteria:
Exclusion
1. 2019-nCoV
criteria: 1. Thos
infec
 2. nCoV 2.
nucleic
Patients
acid positive;
with a his
 3. Aged 3.
>=18 History
years; of hip or kn
0 China Dewei Zhao 6 Jiefang S zhaodewei +86 0411- Affiliated 4. 
Inclusion criteria:
 2. 1.pregnant
Patientsordiagnos
lactati
 2. Be between
 3. Patients
18-85 years
with ofmenag
N/A China Mao Wei 54 Youdianmaoweilw +86 0571- The First A 3. Informed 4.consent
Those who and are
signed
par
Inclusion criteria: SARI
 1. An ARI with history of fever o
N/A China Min Xie 1095 Jiefa xie_m@12 +86 18602 Tongji Hosp 2. Surveillan
Exclusion c
Inclusion criteria: Subjects participati
N/A China Nanshan Zhong, Zegu 151 Yanjingzheng862 +86 18928 The First A 1. General- Exclusion
severec hospitalized p
 2. Supplementation w
 3. 1.
Inclusion criteria: Patients
Aged >= with
18 seve
year
0 China Jun Guo 37 Guoxue guojun@wc+86 15388 West China 2. Patients 4.whoMalignant
meet thetumors;
diagno
 2. pregnant and lacta
Inclusion criteria:
 3. 1.Patients
patients complicat
with 20
0 China Li Jiansheng, Li Suyun 19 Renmin lisuyun20 +86 371 6 The First H 2. Sign 4.
informedClinica
consent.
Inclusion criteria: 1) Aged >= 18 yea
 2) Meet Exclusion
the diagnostic
criteria:criteria
1) Seveo
0 China Tengxiao Liang, Tong 5 Haiyuncanshanghong+86 010 8 Dongzhimen 3) The 2)
informed Obstruct
consent form.
Inclusion criteria: 1) Medical staff inv
 2) 2019-nCoV infection suspecte
 3) Voluntarily participate in this
0 China Wen Shenglin, Xia Jin 52 Meihua wenshl@mai +86 13312 Department 4) A Exclusion cr
0 China Zhang Zhongde 111 Dade Rdoctorzzd +86 13903 GuangdongInclusion c Exclusion c
N/A China Chengfeng Qiu 144 Jinxi R qiuchengf +86 14786 The First P Inclusion c Exclusion c
Inclusion criteria:
Exclusion
1. Sign
criteria:
the informe
1. Critic
 2. Aged (1)
>=18 years;
Respiratory failur
 3. Subjects
 (2)
diagnosed
Shock occurred;
as 2019-n
 (1) Detection
 (3)of Patients
2019-nCoV with nucl
othe
4 China Qu Jieming 197 Secondjmqu0906 +86 21 64 Ruijin Hosp (2) The 2 virus gene s
Inclusion criteria: 1. Patients with no
0 China Cai Hongliu 79 Qingchucaiicu@16 +86 13505 The First A Exclusion c
Inclusion criteria:
Exclusion
1. Conforming
criteria: 1. Seve
to th
 2. Aged 2.
betweenClear18evidence
and 65 year of b
0 China Xiaolin Tong 856 Luoyu Xiaolinton +86 13910 Hubei Prov 3. Signing 3.
thePatients
generalized withinform
seve
Inclusion criteria:
 2. 1.Documented
Aged >=18 years allerg
 2. Patients
 3.hasDocumented
been diagnosed histow
4 China Hong Shan 52 Meihua shanhong@+86 0756 The Fifth A 4. Documented histo
Inclusion criteria:
 2. 1.There
Diagnosed
are comorbi
as no
0 China Lanjuan Li /Xiaowei Xu79 [email protected] +86 0571- The First A 1) Basis 3.
of diagnostic
The investigator
criteria: "Nbe
Exclusion criteria: 1. Histo
Inclusion criteria:
 2. 1.Vascular
Aged 18-60embolism year
 2. Patients
 3.with
Suspected
clinical symptom
or estab
0 China Xue Zhigang 102 South xuezg@tong +86 15000 Hu'nan Yua 3. Voluntarily
 4. Female
sign thepatients
informed of
Inclusion criteria:
Exclusion
Inclusion
criteria: of1.case
Thecrp
 1. Common
 2.type
Accompanied
patient: with by fe
c
0 China Yanling Zhao 100 West Fo zhaoyl285 +86 13681 The 5th Me 2. Severe 3.
pat have
Inclusion criteria:
Exclusion
1. 16criteria:
to 75 years
1. Anyos
 2. Respiratory
 2. Patient
or blood refuses
samples to
0 China Liu Yingxia 29 Bulan R yingxialiu +86 755 6 The Third 3. Within 3.
7 days
Pregnant
of onset: or lactati
Onset
Exclusion criteria: 1. Have
0 China Pei Bei 15 Jiefang xyxzyxzh@ +86 18995 Xiangyang FInclusion c 2. Other circu
Inclusion criteria:
Exclusion
1. Patients
criteria: with
1. Seveco
 2. Above 2.
18 years
Estimated
old (inclusive)
Time of
4 Wuhan Wang Daowen, Zhao J1095 Jiefa dwwang@tj+86 13971 Department 3. Voluntarily
 3. There
sign written
is clearinform
evid
0 China Qiu Yunqing 79 Qingchuqiuyq@zju.+86 13588 The First A 2. Patients
Exclusion
with novel
c coronavir
4 China Zhang Zhan 238 Jiefan doctorzha +86 18962 Renmin HosInclusion c Exclusion c
Exclusion criteria: 1. Aller
 2. 1.
Inclusion criteria: Body
18 to weight
75 years <40ok
0 China Qiu Yunqing 79 Qingchuqiuyq@zju.+86 13588 The First H 2. Tested 3. Considered
positive for novel ascoro
seve
0 China Xie Chunguang 39 Shi-Er-Qxcg718@al+86 18980 Hospital of Inclusion Exclusion c
Inclusion criteria:
Exclusion
1. Aged
criteria:
18 to 1. 75
Hypeye
 2. Tested
 2.
positive
Bodyfor weight
novel<40 corok
0 China Yunqing Qiu 79 Qingchuqiuyq@zju.+86 13588 The First A reaction 3.
(RT-PCR)-based
Considereddiagno as seve
Inclusion criteria:
 2. 1.ALT/AST
Aged 18-65>5 UNL year
o
 2. been 3.
Confirmed
Severely withill2019-nC
patient
 3. Sign 4.
the ICF;Contraindication o
N/A China Wang Xinghuan/Ke He169 Donghuwangxingh +86 18971 Zhongnan H 4. no more 5.than
Pregnancy
10 days testing
from th
Inclusion criteria: Healthy children be
 (1) Main features:
Exclusion moderate
criteria: bod
1. Clinic
N/A China Su Wen 215 Zhongs78440452 +86 13659 Wuhan Hosp (2) Common
 2.manifestations:
Those who haveSym re
Inclusion criteria: (1) All patients wer
 (2) Clear
Exclusion
mind, cooperation
criteria: (1) withand
 (3) Men (2)
and womenPregnant aged and 18lact
an
0 China Yuan Yongming Room 18A 064699629 +86 18664 Shenzhen na (4) informed
 (3)consent
Personshas who beenare sp
Exclusion criteria: 1) ARDS
 2) ARDS caused by ot
Inclusion criteria:
 3) Patients
WHO grade are eligibl
III or I
 1) Aged 4)
18-75Patients
years; with mali
N/A China Zhang Wei 17 Yongwaizhangweil +86 13707 The First A 2) The <patient meets the ARDS d
Exclusion criteria: 1. ARDS
 2. 1.
Inclusion criteria: suffering
diagnosis from HBV
of 201
N/A China Jiang Hua 32 Second cdjianghu +86 028 8 Sichuan Ac 2. adult 3. severe
patients agedheart,
18-80liveryea
N/A China Xia Wenguang, An Cha11 Lingjiao DOCXWG@+86 13902 Hubei inte Inclusion c Exclusion c
18-70 yearscriteria:
old; 1. Patie
 3. patients
 2.with
Pregnant
clear consciousn
or lactati
0 China Wenguang Xia 11 Lingjiao docxwg@1+86 13377 1. Xinhua a 4. Signing 3.
thePatients
informedwho have
consent
18-70 yearscriteria:
old; 1. Patie
 4. patients
 2.with
Pregnant
clear consciousn
or lactati
0 China Chanjuan Zheng 11 Lingjiao chanjuanz +86 18971 1. Xinhua a 5. Signing
 3.
thePatients
informedwho consent
have
18-70 years
criteria:
old; 1. Patie
 4. patients
 2.
with
Pregnant
clear consciousn
or lactati
0 China Wenguang Xia 11 Lingjiao docxwg@1+86 13377 1.Xinhua af 5. Signing
 3.
thePatients
informedwith consen
men
Exclusion criteria: 1) Preg
 2) 1)
Inclusion criteria: Severe basic
patients disea
diagnos
 2) The 3) Other problems
classification was judged th
0 China 4)consent.
WANG YUGUANG, LI X23 Back StrZJHTCM@F+86 13902 Beijing Hos 3) Informed Patients have diffi
Inclusion criteria:
 2. 1.
Previous
aged 18serious
to 60 ye ch
 2. to be 3.
confirmed
Previous
withallergy
a expos to
0 China Wei Li 215 Zhongswhsdyyykj +86 13163 Wuhan 1st 3. with 4.
fever, Newly
positivediagnosed
results of2
N/A China ZHANG ZHONGDE, ZH 10 Poyang LZJHTCM@F+86 13902 Tianjin Uni Inclusion Exclusion c
N/A China Tian Feng 382 Wuyi Ro tflook@16 +86 13934 The SecondInclusion c Exclusion c
Exclusion criteria: 1. In th
Inclusion criteria:
 2. 1.
Patients
Age between
with psyc 18
0 China Xu Yong 85 Jiefang xuyongsmu+86 18234 The First H 2. The patient under isolation ob
Inclusion criteria: 1. Confirmed and s
 2. Meet Exclusion
the diagnostic
criteria:criteria
1. Pregfo
 3. Clinical classification
 2. People with is "heavy
allergi
4 China Ma Penglin 49 North Humapenglin +86 13810 Peking Univ 4. Aged 3.
18 to Severe
75 yearsbasic disea
Inclusion criteria: (1) Aged >=18 year
 (2) novel
Exclusion
coronavirus
criteria:
nucleic
(1) Itaci
is
 (3) The (2)
clinicalLight
typesorwere
severecommpa
N/A China Cheng Zhenshun 169 Donghuchzs1990@+86 02767 Zhongnan H (4) Informed
 (3)consent
Patientshas
withb dysa

 
 - High/moderate risk cont
 
 - Undergoing standard san
 
N/A France ;; Xavier Duval, MD;Xavi ;xavier.du ;01 40 25 Institut N - Written informed c

 
 1. Adult SARI patients with
 
 2. Absolute value of lymph
 
Phase 2 3. Severe respiratory failur
Inclusion criteria:
Exclusion
1) The
criteria:
confirmed
1) Anyp
 2) aged 2)
18 to Allergic
65 years;constitutio
New Treatm
China Le Aiping 17 Yongwaileaiping@ +86 13707 The First A 3) Real-time
 3)fluorescent
Being too old RT-PCR
with
Exclusion criteria: 1) Patie
 2) Patients whose ini
 3) 1)
Inclusion criteria: Patients
Complywithwithseve
the
0 China Huang Luqi 16 Nanxiaohuangluqi +86 010-6 China Acad 2) Agree 4) It is difficult
to participate in tto adm
 
 - Adult
 
 - PCR confirmed noval cor
 
 - Symptoms developed m
 
 - PaO2/FiO2 < 200 mmHg
 
Phase 2/PhChina Bin Du, MD dubin98@g8610-6915-5036 - Positiv
N/A China You Shang 1277 Jiefa you_shang +86 15972 Union HospInclusion c Exclusion c
Inclusion criteria:
Exclusion
1. 16
criteria:
to 75 years
1. Anyos
 2. Respiratory
 2. Patient
or blood refuses
samplesto
0 Liu Yingxia 29 Bulan R yingxialiu +86 755 6 Shenzhen t 3. A novel
 3.
coronavirus
Pregnant nucleic
or lactatiac
Exclusion criteria: (1) Diag
N/A China Kequn Chai 234 Gucui Rckqmzygzs +86 13906 Tongde HosInclusion c (2) Diagnosed with m
Inclusion criteria: 1. novel coronaviru
 (1) 1 days
Exclusion
beforecriteria:
onset, 141. Exclu
had
0 China Huang Yi Xi'an Chesthuang-yi- +86 13319 Xi'an Chest (2) during
 2.
theExclude
14 daysthose
beforewho on
Inclusion criteria:
Exclusion
1. New
criteria:
coronavirus
1. Preg
 2. Meet 2.
the diagnostic
People with criteria
allergi
fo
4 China Zhong Nanshan / Song151 Yanjia ylsong70@+86 020 3 The First A 3. Pneumonia
 3. Severe
Severitybasic
Index
disea
(PS

 
 - 18-75 years old ,no gend
 
 - According to Diagnosis a
Phase 2 China ;; XingHuan Wang, profe;znyylcsy@;18971387 Wuhan Univ infection(Trial Version 4)
0 China Wanhong Yin 37 Guoxue doctorwhy +86 13518 DepartmentInclusion c Exclusion c
Inclusion criteria:
Exclusion
(1) criteria:
Those who (1) mee
Imm
 (2) Inpatients
 (2)aged
Preparing
18 to pregna
75 yea
0 China Qianxue Chen 99 Jiefang chenqx666+86 027-8 Renmin Hos (3) Voluntarily
 (3) Patients
receive treatmen
with alle
Inclusion criteria: 1. COVID-19 diagno
 2. Excess specimens for clinical t
N/A China Hong Zhao 8 Xi-Shi-Ku zhaohong_+86 13810 Peking Univ 3. SignExclusion c consent f
the informed
Inclusion criteria:
Exclusion
1. aged
criteria:
between
1. preg1
 2. no history
 2.of history
gynecological
of psychiat di
N/A China Hua Lu 37 Shi-Er-Q19242380 +86 18980 Chengdu Un 3. willing 3.
to join
take
this
sedatives
researchinan t
 2) (1)
Inclusion criteria: G-6PD defect (Fav
Confirmed patie
 (2) Aged 3)
fromPregnancy, especi
18 to 80 years, m
0 China Yu Hongzhi 4)with
890 Jin'gu [email protected]+86 22 58 Haihe hospi (3) Patients Patients who
positive conti
detecti
4 China Hongzhou Lu 9th Floor, luhongzho +86 21-37 Jiangxi Qin 2. Meet Exclusion
the diagnostic
c criteria fo
Inclusion criteria:
Exclusion
1. Aged
criteria:
>=181. years
Patie
 2. Severed
 2.COVID-19
Patientspatients,
who have m
 RR>=30 3.
times/min;
Patients with shoc
N/A China Wang Shaogang 1095 Jiefa lingqing1 +86 15827 Tongji Hosp Rest 4. Patients combined
0 China Mingxing Xie 1277 Jiefa xiemx@hus+86 13607 Union HospInclusion Exclusion c
Inclusion criteria:
Exclusion
(1) criteria:
Comply with
(1) It th
is
N/A China Donghui Huang 53 Jidajin 13600001 +86 0756- Guangdong (2) Agree (2)
to paPregnant women
Exclusion criteria: Exclusio
 1. Have a history of d
Inclusion criteria:
 2. (1)
female
Inpatients
patientsaged
wh
0 China Lu Hongzhou 2901 Caolanluhongzho +86 18930 Shanghai Pu (2) Persons 3.diagnosed
People with 2019
Inclusion criteria:
Exclusion
1. Inpatients
criteria: 1.aged
Prev
 2. Confirmed
 2. patient
Patientsdiagnosed
diagnosed
0 China Bende Liu 1 Culture Aliubende9 +86 13907 First Peopl Cl 3. Patients diagnosed
RetrospectChina Gang Xu 1095 Jiefa xugang@tjh+86 13507 Tongji HospInclusion c Exclusion c
Exclusion criteria: 1. Hype
Inclusion criteria:
 2. 1.Body
Aged weight
18 to<4075 ye
k
0 China Shentu Jianzhong?Wu 79 [email protected] 1.4E+10 The First A 2. Patients 3.with
Considered
novel coronavir
as seve
Inclusion criteria: 1. Meet the diagno
N/A China Yao-sheng Zhang/Ting-5 Hai-Yun-Cysz3129@1+86 18610 Dongzhimen 2. Meet Exclusion
the diagnostic
c criteria fo
N/A China XIONG YAN 363 Furongluyibingli +86 18328 West ChinaInclusion c Exclusion c
Inclusion criteria: 1. aged 18-70 year
 2. 2019 new coronavirus nucleic
 3. meetExclusion
the national diagnosis
criteria: 1. sevec
 4. subjects
 2.onset withinand
pregnant 8 days
nurs(
3 China Ke Hu 99 Zhangzhhukejx@16+86 18971 Renmin Hos 5. subjects 3.or subjects
a received l
Inclusion criteria:
Exclusion
Subjects
criteria:
whoSubject
met
 1. Male 1.
or female
pregnant
patients
or lactati
aged
 2. willing
 2.
to sign
Malignant
informed tumors,
conse
2 China Jian Bo and Chuanzhu 28 Fuxing Rboj301@si +86 13801 Chinese PL 3. Based 3.
on theThose
criteria
whoforhave
susp
r
0 China Gong Shouping 157 West 5tshpingg@1+86 13709 The SecondInclusion c Exclusion c
 2. Patients with a his
4 China Chaoqian Li 6 Shuangyo25347766 +86 13807 DepartmentInclusion c 3. The researchers ju
Exclusion criteria: 1. Com
 2. Malignant tumor o
 3. pregnant or lactati
 4. suffer from severe
0 China Nanshan Zhong 151 Yanjia linling@gir +86 13902 The First A Inclusion c 5. H
Inclusion criteria: 1. In line with the d
N/A China Qingping Wu 1277 Jiefanwqp1968@+86 13971 Union Hosp< Exclusion c
Inclusion criteria: 1. Aged 18 to 80 ye
 2. People
Exclusion
who hadcriteria:
ineffective
1. Theprp
New Treatm
Chinese Feng WANG 151 Yanjia 41247573 +86 13710 The First A 1) living, 2.
studying,
Peopleworking
who havetogea
Exclusion criteria: Patient
0 China Gong Shouping 157 West 5tshpingg@1+86 13709 the SecondInclusion c Investigator consider
 2. Within
Exclusion
1 weekcriteria:
of onset;
1. Any s
 3. Meet 2.
the diagnostic
The patientcriteria
may bo
0 China Xiaoguang Tong 6 Jizhao RoTongxg@y +86 13820 Tianjin Hu 3. Those who have co
0 China Qing Zhou 238 Jiefan qingzhou. +86 13971 Renmin HosInclusion Exclusion c
Inclusion criteria: 1. Female of after m
0 China Shixuan Wang 1095 Jiefa sxwang@tj+86 027-8 Tongji Hos 2. Meet Exclusion
the pneumonia
c diagnos
Inclusion criteria: 1)2019-nCoV-cured
0 China XiaoWang Qu 102 Luo-Jiaquxiaowan+86 15526 The First P 2)Sign Exclusion
informed cconsent.
Exclusion criteria: 1. The c
 1) Respiratory failure
Inclusion criteria:
 2) 1.Shock
Agedoccurs;
18 to 70 ye
N/A China Zhang Dingyu 1 Yintan R 18138863 +86 13507 Wuhan Jiny 2. Patients 3)with
Combined
severe novel
failure
coo
Inclusion criteria:
 3. Subjects
ALT / AST> who 5 ULN,
meet
 1. Will 4.
sign written
Expectedinformed
survivalconi
4 China Huji Xu 415 Fengyaxuhuji@sm+86 13671 Shanghai C 2. Ch 5. Patients diagn
0 China Lianru Gao 6 Fucheng Rlianru666 +86 18600 The Sixth Inclusion c Exclusion c
Inclusion criteria:
Exclusion
1. Volunteer
criteria: 1.toPlan
par
 2. Aged 2.
18-65Hospitalized
years, male for or fem
ot
 3. Weight
 5.
>= 40kg
Combined
and <=100kg,
with ser
N/A China Jing Liu 52 Meihua liujing25@ +86 13844 The Fifth A 4. Medical
 6.staff
Hasduring
fever,the
runnnove
Exclusion criteria: (1) Hyp
 (2) Favism;
 (3) Pregnancy;
 (4) Abnormal coagula
Inclusion criteria:
 (5)(1) In linewith
People withmedi
ethi
 (2) Patients
 (6)with positive
Severe detecti
anemia;
 (3) Chest CT confirmed
 (7) pulmona
Hypocalcemia;
N/A China Chen Xiangdong 1277 Jiefa xiangdong +86 15071 Union Hosp (4) Hospitalized patients with fe
4 China Hongyi Chen 167 HongduChenhongy+86 13807 Nanchang N 2. PneumoniaExclusion c
patients with new
N/A China Tang Jianyuan 39 Shi-Er-Qtangjiany +86 13910 Hospital of Inclusion c Exclusion c
Exclusion criteria: 1. Prev
0 China Mingxing Xie 1277 Jiefa xiemx@hus+86 13607 Union HospInclusion c 2. Previous severe em
RetrospectChina Haifa Xia, Xiangdong 1277 Jiefanxiangdong +86 15071 Union HospInclusion c Exclusion c
 2. RT-PCR
Exclusion
positive criteria:
for 2019-nCo
1. Inves
0 China Yin Zhenyu Room 507, Yinzy@xmu+86 13950 Zhongshan 3.
H The 2.
clinicalAs
symptoms
judged by areinves
slig
Inclusion criteria: 1. The diagnosis co
 2. Clinical
Exclusion
classification
criteria:is1.norma
High
N/A China Xuebing Yan 9 Kunpeng yRxbxuzhou +86 15205 Affiliated 3. Subject
 2.
agedThe doctor believe
>=18
Inclusion criteria: 1. Voluntarily sign
 2. MaleExclusion
or female criteria:
aged 18 1. and
Fema o
2 China Zhaohui Tong 8 Workers 13910930 +86 13910 Beijing Cha 3. According
 2.to Males
the "Diagnosis
or femalesaw
 2. Patients with men
N/A China Jiang Hong 650 Xinsongjhong.pku +86 15301 Shanghai Ge Inclusion c 3. Minors
Inclusion criteria:
Exclusion
(1) criteria:
Adult aged (1) >=1
The
 (2) Laboratory-confirmed
 (2) Patients with 2019-n
seri
3 China Baofeng Yang 194 Xuefu Ryangbf@em+86 133 04Heilongjian (3) Chest (3)
imagingPatients
(CT) confirmed
wi
Inclusion criteria: 1. aged >=18 years
 2. Gender
Exclusion
limitation;
criteria: 1. patie
 3. Patients
 2.must
Patients
be ablewithto auto
sign
0 China Peng Hu 301 Yancha189176831+86 18917 Shanghai 10 4. Be willing
 3.toH provide stool and
RetrospectChina Zhou Min 1095 Jiefa minzhou@t+86 15002 DepartmentInclusion c Exclusion
Exclusion criteria: (1) Sub
 (2)(1)
Inclusion criteria: Female patients
Age 18-70 yearso
 (3)
 (2) Clinical Highly allergic
symptoms, con
signs, and
N/A China Luo Zhigang (4)
35 Jiefang 70688539 +86 13907 Second Hos (3) Clinical Coagulation disor
symptoms,
 2. With risk factor of COVID-19;
 3. Access to nCapp platform;
N/A China Chunxue Bai 180 Fenglinbai.chunxu+86 18621 Zhongshan 4. to beExclusion
able to complete
c a 1 ye
N/A China Tao Li 28 South Dixuntao26@+86 18980 West ChinaInclusion c Exclusion c
Inclusion criteria: (1) Patients with m
 (2) Aged more than 18 years old
N/A China Tang Jianyuan 39 Shi-Er-Qtangjiany +86 13910 Affiliated (3) Informed
Exclusion
consent
c of the pati
 3. 1.
Inclusion criteria: ALT
The/ AST> 5 ULN,
patients wh
 2. Aged 4.
18 to Expected
85 years; life<1 we
4 China Hongliang He 17 Lujiang 44271370 +86 15956 The First A 3. IL-1ÃŸ 5.
elevated
Definite
(using
diagnosis
Elisa m
Inclusion criteria: (1) Meet NCP critic
 (2) Volunteer
Exclusionto criteria:
participate1. Patie
in th
 (3) The 2.
selectedPregnant
patients orwere
lactatib
0 China Fang Lei 1200 Cailu fanglei58 +86 021-5 Faculty of (4) No 3.
seriousPa ment
Inclusion criteria:
Exclusion
1. Aged
criteria:
18 to1. 60
Patie
ye
 2. Inpatients
 2.whoPregnant
meetor thelactati
diag
0 China Fang Min 110 Ganhe fangmin19 +86 18930 Tuina Insti 3. Understand
 3. Paand agree to
Inclusion criteria:
Exclusion
1. The
criteria:
age at1.the
In thti
4 China Yin Zhenyu 201-209 HuYinzy@xmu+86 13950 Zhongshan 2.H The 2.
changeAccord
of typical viral pn
Inclusion criteria: 1. Male or female,
 2. 2019 new coronavirus nucleic
 3. Diagnosed
Exclusionas moderate
criteria: 1.to Malig
sev
1-Feb China Robert Chunhua Zhao 5 Shantiao zhaochunh+86 010-6 institute o 4. Wi 2. The clinical predicti
Exclusion criteria: 1. critic
Inclusion criteria:
 2. 1.Patients
Aged >=60with years
eye d
 3.
 2. Patients Severe liver
confirmed withdiseas
nove
4 China Feng Cao 28 Fuxing Rfengcao88 +86 13911 Chinese PL 3. Those 4. Patients
without broad
Inclusion criteria: 1) Male and female
 2) Severe
Exclusion
patients
criteria:
(in any1)case:
Caser
 3) Within
 2)
12 days
Pregnant
after illness
and lacta on
4 China Zhao Yan 169 Donghudoctoryan +86 13995 Zhongnan H 4 3) The subjects recei
0 China CHEN Xinyu 95 Shaoshachenxinyu +86 13807 The First A Inclusion c Exclusion c
Inclusion criteria: 1. The neonates de
N/A China Jun Tang 20 Third S tj1234753 +86 18180 West China 2. The Exclusion c
newborn,whose mother h
Exclusion criteria: 1)One o
Inclusion criteria:
 Respiratory
1) Aged >=distress,
18 year
 At
 2) In line with rest, oxygen satur
the diagnostic crit
4 China Xin Zheng 1277 Jiefa Xin11@hot+86 18602 Union Hospi 3) Severe Atrial
pneumoniaarterial
indexoxygen
(PSI
 who had diagnosed a
4 China Zhuoli Zhang 8 Xishiku S zhuoli.zh +86 13901 The First h Inclusion c who was allergic to 4
Inclusion criteria: (1) nurses with wo
 (2) registered
Exclusionnurses
criteria:
who(1) areadva
qu
N/A China Caixia Xie 32 West Se8999578@+86 13699 Sichuan Ac (3) nurses (2)
whonurses
volunteered
during to thep
Exclusion criteria: (1) Posi
 (2) Respiratory failur
 (3)(1)
Inclusion criteria: People
Aged with
18-65metayea
 (4)
 (2) Virus active
nucleic acid tuberculosi
test is posi
N/A China Chen Hong 1095 Jiefa chenhong1+86 13296 Tongji Hosp (3) Lung (5) Massive
CT showed pulmona
multiple pat
Inclusion criteria: 1. Aged >18 years;
 2. Laboratory (RT-PCR) confirme
RetrospectChina Lyu Dongqing 1 Tongyanglvdq@enz +86 13867 Enze Hospi 3. LungExclusion
involvement confirmed
N/A China Peng Yudong 1277 Jiefa am-penicil +86 13886 Union HospiInclusion c 2. Patients with syste
 2. A history of fertility or sexual
0 China Shixuan Wang 1095 Jiefa sxwang@tj+86 02783 Tongji Hos 3. Meet the pneumonia
Exclusion c diagnos
Exclusion criteria: 1. The s
Inclusion criteria:
 2. 1.Those
Patients
withor severe
his/h
0 China Dong Liang 1377 Jiao- dl5506@12+86 18560 Qilu Hospit 2. Those< diagnosed with mild or
Exclusion criteria: 1. The p
 2. 1.
Inclusion criteria: People withold
18 years heart
<= a
0 China Zhan Zhang 99 Zhangzhdoctorzha +86 18062 Renmin Hos 2. Who 3.
are in Peo
close contact with
Exclusion criteria: 1)One o
Inclusion criteria:
 Respiratory
1) Aged >=distress,
18 year
 2) In line
 At
with rest,
the diagnostic
oxygen satur crit
4 China Xin Zheng 1277 Jiefa Xin11@hot+86 18602 Union Hospi 3) Severe pneumonia
 Artial index
arterial (PSI
oxygen
Exclusion criteria: 1. Invol
Inclusion criteria:
 2. 1.Pregnant
Severe patients
or breastf
 2. Aged 3.
35 years
Presence
old to of
74other
years
 3. Patients
 4.
or Expected
authorized life
family
is les
4 China Junbo Ge 180 Fenglinjbge@zs-ho-64041925 Zhongshan 5. Allergy to ALA or d

 
 1. Age =18 years at time of
 
 2. Laboratory (RT-PCR) con
 
Phase 3 China ; Bin Cao, Professor;Yin caobin@zr +01084206264; 3. Lung involvement confir
Inclusion criteria: 1. Diagnosed Nove
 2. Aged 18 to 65 years;
4 China Yang Yi 4 Garden H15326774 +86 18971 Hubei Hospi 3. The Exclusion
time interval
c between sym

 
 - The neonates with COVID
 
 
 - The neonates with majo
N/A China 

 
 - people who lived in or ou
 spread of COVID-19
 
 - without gender and a
 
N/A China ;; Jiahong Dong, M.D;Xi ;fengxiaob ;+86 1322 Beijing Ts 

 
 1. Age =18 years;
 
 2. Laboratory (RT-PCR) dia
Phase 2 ; Jinglin Xia, MD;Jinglin ;xiajingli ;0577-555 First Affil fifth edition of the Chine

 
 
 2. The laboratory (RT-PCR)
Phase 2 ; Jinglin Xia, MD;Jinglin ;xiajingli ;0577-555 First Affil CoVID-19 (refer to the fift
Inclusion criteria:
Exclusion
1. aged
criteria:
between
1. Hear1
 2. clinical
 2.
dignosied
New myocardial
2019-nCovisp
 3. Cured 3.
within
Severe
one month
liver and
of di
ki
1 China Nijun 20 Chazhong
nijun1000 +86 19890 The First A 4. consious,em
 4. Oxygen saturation
Exclusion criteria: 1. Hear
Inclusion criteria:
 2. 1.
NewAgedonset
18-80
of myo
year
 2. Meet 3. Blood pressure:
the diagnostic criteriamo
 3. Blood 4. Body90-150
pressure temperature
/ 60-1
N/A China Ni Jun 5. Blood o
20 Chazhonnijun1000 +86 19890 The First A 4. Extrem
 1. For the 2019-nCoV infecti

 
 
 Diagnosed with 2019-nC
 
Phase 1 China ;;;; Kunling Shen, MD,Ph ;;;xubaop ;;;8610596 Beijing Chi 1. Respiratory or blood

 
 1. CT image is characteristi
 
 2. 2019-ncov infection (po
 
N/A China Yang Jin, MD whuhjy@si 8.61E+12 3. In compliance with the 2

 
 - High risk of COVID-19
 
 - RT-PCR test result of SAR
 
 
 - Not available for RT-PCR
N/A China ;; Chunxue Bai;Chunxue ;bai.chunx ;+8618621 Shanghai Re 
Inclusion criteria:
Exclusion
1) confirmed
criteria: 1)or
patie
sus
 2) be able
 2)
to understand
patients with themen
con
N/A China Dong Shang 9 West Sectshangdong+86 18098 Institute o 3) voluntarily
 3) patients
participatewith
in serio
this

 
 
 
Phase 3 China Bin Cao, Professor caobin@zr 1.08E+09 3. Lung involvement confir

 
 - Men and women aged 1
 
 - In line with the new coro
Phase 1/PhChina ; Jianqi Lian, MD;Sicao Lliangjq@f +86-13571892829;+86 (trial version 4) issued by
 
 1. Aged between 18 and 7
 
 2. Fever (armpit temperatu
N/A Hongzhou Lu, Master lunliweiy 021-37990333 temperature

 
 - Patients with pulmonary
 
 - Age 18-65
 
Phase 2 China ; Chenghai Liu, PhD;Chechenghaili 8621-20256521; - 2019-nCoV nucleic acid n
Inclusion criteria: Moxibustion interv
 Participants
Exclusion
inclusion
criteria:
criteria:
(1) Pati
 1. Aged (2)
18 to 75
Those
years
with
old;malign
 2. Those (3)
that meet
Personsonewith
or more
a me
0 China Xiaorong Chang Hanpu Sciexrchang19 +86 0731 Hu'nan Uni (1)In the (4)
pa preg
0 China Zhongyu Zhou 4 Huayuan 22094479 +86 18672 Hubei ProvInclusion c Exclusion c
Inclusion criteria: 1. confirmed clinica
 2. inpatients have confirmed clin
RetrospectChina Kunlun He 28 Fuxing Rhekl301@a+86 010 6 Key Labora 3. the CTExclusion
imagescare complete, t
Inclusion criteria:
Exclusion
Thiscriteria:
study intends
(1) Excl
N/A China Yan Hao; Xiaoping Luo1095 Jiefa haoyaner@+86 13971 Tongji Hosp 1. Epidemi
 (2) Exclude pneumon
0 China Lu Yibin 1 Siyi Road luyb6810@+86 13937 Xinyang CenInclusion c 2. Pregnant or lactati
Inclusion criteria: 1. Confirmed or cli
> 1 year;criteria: 1.With
0 Rui Pan 136 Jingzh 55815147 +86 13986 Xiangyang C 3. Volunteers.
 2.refuse to traditiona

 
 - The patients who were d
 factors) and severe cases
 
 - Aged 18 to 85 years;
Phase 2 China ; Ying Fu;Wan-Jin Chen fuying199 +86;+1386061359 <
Inclusion criteria: (1) Aged 20-45 yea
0 China RongJin Lin 20 Chazhongnplrj@126 +86 13809 The First A (2) Understand
Exclusionandc willing to pa
Exclusion criteria: 1. Cann
Inclusion criteria:
 2. 1.
Those
Agedwho
18 to
are
75alle
ye
 2. Inpatients
 3.with
Critical
novel
patients
coronav
m
N/A China Zhang Dingyu 1 Yintan R 18138863 +86 13507 Wuhan Jiny 3. Agree (1)
and sign
Respira
the informed c
Exclusion criteria: 1. Othe
 2. Known to be allerg
0 China Jianzhong Liu 4 Garden Hljzwd@163+86 13307 Hubei ProvInclusion c 3. Women during lac

 
 1. Epidemiological history
 Hubei province or exposu
 
Phase 1 China ;; Liang Peng, Doctor;We;xwx1983@;+8613760 Third Affil 2. Sympto
 
 1. Epidemiological history
 Hubei province or exposu
 
Phase 1 China ;; Liang Peng, Doctor;We;xwx1983@;+8613760 Third Affil 2. Sympto

 
 - 1. Male or female, aged
 
 - 2. Pneumonia that is jud
 
Phase 1 China ; ZHU, Professor;GUO, wulingzhu 00863733029089;008 - 3. Laboratory confirmati
Exclusion criteria: Allergy
0 Ma Xiaorong 157 West 5tmaxr0910 +86 13992 the SecondInclusion c Pregnancy
Inclusion criteria: 1. Age is not limite
0 China Yongxiang Yi 1 Kangfu Roian0126@1+86 13338 Nanjing Se 2. Confirmed
Exclusiongroup:clinical
c diag
Exclusion criteria: 1. AST a
 2. bilirubin> 1.5 x ULN
Inclusion criteria:
 3. 1.AtFirst
visit diagnosis
1, calculate o
0 China Huilan Zhang 1095 Jiefa huillanz_ +86 15391 Tongji Hos 2. Epidemiological
 4. Patientshistory
withTrave
pote
0 China Li Caixia N1 Shangchli_caixia@z+86 15268 The Fourth Inclusion c Exclusion c
Exclusion criteria: 1. Pneu
Inclusion criteria:
 2. 1.Clear
Aged bacterial
from 18infeto
 2. According
 3.with
Subjects
the clinical
who have dia
0 China Jianqing Xu 2901 Caolanxujianqing +86 18964 Shanghai Pu 3. Positive
 4.
result
There
forare
nucleic
seriousacid
n
Exclusion criteria: (1) kno
 (2)(1)
Inclusion criteria: women who year
aged >=18 are b
0 China Shao Fengmin 7 Weiwu Roguyuesunn+86 15037 He'nan Prov (2) positive
 (3)
COVID-19
partic nucleic ac
Exclusion criteria: 1. Pneu
RetrospectChina Chuxiao Shao 289 Kuocangscx1818@1+86 0578 Lishui CentInclusion c 2. Not receiving antiv
RetrospectChina Ziqiang Zhang 389 Xincunzzq1419@1+86 18721 Tongji HospInclusion c 3. Cancer patients.
N/A China Jihui Lyu 118 Wenquanlvjihui@13 +86 010 6 Beijing GerInclusion c Exclusion c
 2. With trachea dysfu
 3. pregnant women,
N/A China Hu Bing 37 Guoxue hubingnj@+86 18980 West ChinaInclusion c 4. Patients with diffic
Inclusion criteria:
Exclusion
1. Suspected,
criteria: (1)mild,
Kno
 2. Aged (2)
>= 18 years;
Unwilling to coop
0 China Wang Tan 1478 GongnWangtan21+86 13756 Affiliated 3. Patients (3)
whoPatients
voluntarily
withparti
men
RetrospectChina Zhenhua Zhang 678 Furongzzh1974cn +86 13215 The SecondInclusion c Exclusion c
Inclusion criteria: 1. Front line medic
 2. Participate in the prevention
 3. Voluntary
Exclusion
to finish
criteria:
psychologi
1. refus
N/A China Ming Chen 136 Jingzh 55815147 +86 13797 Xiangyang C 4. without 2.
psychological
with mentalhistory
disord
Inclusion criteria:
Exclusion
1. Upon
criteria:
the1.judgm
The s
1 China Yongxiang Yi 1-1 Zhongfuhcm20070 +86 13584 Nanjing Se 2. According
 2.to The
thesubject
new typesuffers
of
 2. Underwent
Exclusion chest
criteria:
CT scan
1. CTdurim
RetrospectChina Kaihu Yu 228 Jingui 20662556 +86 13508 Xianning Ce 3. Able 2. Pregnant
to complete theand lacta
study.
Inclusion criteria: 1. Confirmed or cli
>= 2 years;
criteria: 1. With
0 China Ming Chen 136 Jingzho55815147 +86 13797 Xiangyang C 3. Volunteers.
 2. Patients who refus
Inclusion criteria: 1. be over 18 years
 2. 2019-nCoV infected patients c
RetrospectChina Feng Li 2901 Caolan dr_lif08@ +86 18121 Shanghai Pu 3. Subjects
Exclusion
and their
c families (or
 2. It conforms
Exclusion tocriteria:
the diagnostic
1. Serio
0 China Kaijiang Yu 23 Youzheng drkaijian +86 13303 The First A 3. Sign 2. Obstrucconsent for
the informed
N/A China WANG Jing 169 Donghuwangjing9 +86 18186 DepartmentInclusion c Exclusion c
N/A China Jiemin Zhu Room 222, jieminzhu +86 15960 Xiamen UniInclusion c Exclusion
N/A China Junxue Wang 415 Fengyadocd1@sin+86 18917 Shanghai C 2. PneumoniaExclusion patients
c with new
Inclusion criteria: (1) Adults aged >=1
 (2) a novel coronavirus infection
0 China Wei Yang 37 Yiyuan Shydyangw +86 13845 The Fourth (3) Hospitalized
Exclusion patients
c with fe
RetrospectChina Li Jiangping 1 Benxi Str 10784044 +86 18602 Puren HospInclusion Exclusion c
Exclusion criteria: 1. No m
Inclusion criteria:
 2. 1.
Patients
novel coronaviru
who had r
 2. enteral
 3.
nutrition
patientssupport
with hypetrea
0 China Lijia Deng 94 West Str27216302 +86 17723 Ganzi Hospi 3. No use 4.
of Fat
patients
emulsion
withtaboo
seve
Inclusion criteria: 1. Patients with co
 2. TCM syndrome differentiation
 3. Aged between 18-75 years ol
4 China Liu Hua/Wang Qian 1200 Cailu yyliuhua@ +86 18930 Shanghai Un 4. V Exclusion c
Exclusion criteria: (1) Age
 (2) Patients with seve
0 China Meiping Chu 1215 Guangchump198 +86 15052 Wuxi Fifth Inclusion c (3) Pregnant and lact
N/A China Bin Zhan 16 Railway 40630252 +86 13678 The Thirte Inclusion c 2. Patients and healt
1 China Lijia Deng 94 West Str27216302 +86 17723 Ganzi HospiInclusion c Exclusion c
Inclusion criteria: 1) Any age;
 2) Meet Exclusion
the diagnostic
criteria:standard
1) Liver
 3) Voluntarily
 2) Psychosis,
accept TCM orsyndr
cogn
New TreatmChina Bi Ying-fei 88 Changlinyingfei19 +86 13920 First Teach 4) Agree 3)
to sign
Those
informed
who aconse
RetrospectChina Zhenjie Hu 12 Jiankangsyicu@vip. +86 13933 The Fourth Inclusion c Exclusion c
Inclusion criteria:
Exclusion
1. Aged
criteria:
18 to1. 80
Patieye
0 China Zhou Jia 110 Ganhe pdzhoujia +86 18017 Yueyang Ho 2. Patients 2.
with
Patients
novel coronavir
wh
Inclusion criteria:
Exclusion
1) The
criteria:
confirmed
1) Anyp
 2) aged 2)
18 to Allergic
65 years;constitutio
0 China Shao Yi 17 Yongwaifreebee99 +86 13576 The First A 3) The 3)
time interval
Severebetween
basic disea th
Inclusion criteria:
Exclusion
1. Patients
criteria: volunte
1. Peop
2 china Zhiyong Peng 169 DonghuPengzy5@h+86 18672 Central So 2. Patients 2.
whoHaving
werereceived
diagnosed Va
N/A China Daisy Dexing Zhang 4/F, Schoolzhangdxda +852 2252 JC School Inclusion c Exclusion c
0 Cancelled Cancelled wdxjy@wh 123 Cancelled Inclusion c Exclusion c
N/A China XIONG YAN 363 Furongluyibingli +86 18328 West ChinaInclusion c Exclusion c
Exclusion criteria: 1) Child
RetrospectChina Chen Hao 116 North S10418633 +86 023 6 Chongqing Inclusion c 2) lack of important c
Inclusion criteria:
Exclusion
(1) criteria:
Age 18 to (1)80Pati
ye
 (2) Respiratory
 (2) Patients
specimen withwereknop
4 China Liangdan Sun 218 Jixi Ro ahmusld@ +86 13856 First Affil (3) Clinical
 (3)
classification
Patients with
is mild
seveo
 2. Non-suspected
Exclusion criteria:
and non-confi
1. Susp
 3. Front-line
 2.medical
Patientsstaffs
with in
seve
de
4 China Feng Cao 28 Fuxing Rfengcao88 +86 13911 Chinese PL 4. Participate
 3. People
voluntarily
whoand
couldsig
 2. Patients with confirmed
Exclusion criteria: 1. cases
Patie
 (1) Epidemiology
 2. Patientshistory;
with serve
4 China Shen Ning 49 Huayuanshenning1 +86 15611 Peking Univ (2) Clinical
 3.manifestations
Patients with(epide
iden
Inclusion criteria:
Exclusion
1. Age
criteria:
18 to1 75
Patien
Ye
 2. Diagnosed
 2 Patients
with COVID-19,ac
with serve
4 China Shen Ning 49 Huayuanshenning1 +86 15611 Peking Univ 3. Sever 3
COVID-19,
Patientsexcept
with identi
shoc
 2. Patients with seve
4 China Hua Shucheng 71 Xinmin Sshuchengh +86 13756 The First HoInclusion c 3. Severe liver diseas
 1. Subjects
Inclusion criteria: Patients whowith meet
prev
 1. Sign 2.
writtenPatients
informed with prev
consen
4 China Wenxiang Huang 3. Patients with s
1 Youyi Roawenxiang_ +86 13883 The First A 2. Chinese
Inclusion criteria: (1) Aged >=18 year
 (2) Novel
Exclusion
coronavirus
criteria:
pneumon
(1) Mee
N/A China Xie Liangdong Chizhuling 25904100 +86 13707 Fifth Peopl (3) The (2)
patientSevere
himselfprimary di
participa
RetrospectChina Kaihu Xiao 165 Xinchexiaokh1@1+86 19923 Chongqing Inclusion c Exclusion c
Inclusion criteria: 1. Patients withmil
 2. Patient
Exclusion
cough criteria:
score > 1;
1. Expe
4 China Wei Zhang 17 Yongwaizhangweil +86 0791- The First A 3. Aged 2. Patients with asthm
 2. Death is expected
4 China Liu Dong 1095 Jiefa ld_2069@1+86 13507 Institution Inclusion c 3. There is clear evid
Exclusion criteria: 1. Mee
Inclusion criteria:
 2. 1.
Meets
Staff any
of tongji
contrai
ho
RetrospectChina Liu Dong 1095 Jiefa ld_2069@1+86 13507 Tongji Hosp 2. Aged 3.
>=18 Pregnant
years. women,
Inclusion criteria: (1) 18â€“65 years o
 (2) Diagnosed
Exclusion ascriteria:
mild to modera
(1) Pati
 (3) Be willing
 (2)toPatients
sign informed
are pregnco
N/A China Yaokai Chen 109 Baoyu yaokaiche +86 023-6 Chongqing (4) The (3)
clinicalPatients
assessmenthaveandaspc
Inclusion criteria:
Exclusion
1. Hospital
criteria: workers
1. Patie
RetrospectChina Yu Jia 99 Zhang-Zyogaqq116+86 18062 Renmin Hos 2. Aged 2. >=18 Patients
years old.who are n
Inclusion criteria:
 1. Subjects
Patients whowith meet
prev
 1. Sign 2.
writtenPatients
informed with
consen
prev
4 China Wenxiang Huang 1 Youyi Ro wenxiang_ +86 13883 The First A 2. Chinese
 3. Patients with s
Exclusion criteria: 1. Seve
 2. 1.
Inclusion criteria: The patients
Aged 18- 80were
yea
0 China Peng Hu 74 Lingjian hp_cq@16 +86 13608 The Second 2. Pneumonia
 3. Patients
patientswith
withcont
new
Inclusion criteria: 1. Male or female o
 2. NovelExclusion
coronavirus
criteria:
infection
1. Patie
is
 3. The 2.
diagnosis
Pregnancy
of severeorcoron
lacta
N/A China Yaokai Chen 109 Baoyu yaokaiche +86 13638 Chongqing (1) Re 3. Researchers believ
Inclusion criteria:
 2. 1.
Severe
Informed
renalconsen
impa
 2. Confirmed
 3. infection
Severe liver with
diseas
201
4 China Huawei Mao 136 Secondmaohwei@+86 13928 Chongqing 3. Compliance 4. Pre-exist
with the interven
 
 1. Subjects or their legal re
 agree not to participate i
Phase 4 ; Ronghua Jin;Huiguo D ;dinghuig ;+86-1391 Beijing You a
RetrospectChina Wang Hailong 165 Xinchewangjinlo +86 15923 Three GorgInclusion c Exclusion c
Inclusion criteria: 1. Aged > 18 years;
 2. COVID-19
Exclusion
coronavirus
criteria: 1.
nucleic
Child
 3. Chest 2.
imaging
Serious
has clear
cardiopulm
viral p
0 China Li Shusheng 1095 Jiefa shushengl +86 13971 Department 4. Respirat
 3.

 
 1. Recruited subjects inclu
 confirmed 2019-n-CoV in
 
 2. NEWS of =1 upon recrui
 
Phase 2 Hong Kong ; ; Ivan FN Hung, MD FRC;ivanfn@g ;+862 225 The Univer 

 
 - Who agree to participate
 
 
 - Confirmed NCIP patients
N/A China ;; Yan Liu;Xiaotian Sun;Y;xiaotian ;+86-0106 The Fifth M 

 
 (1) Age = 18 years. (2) Clinic
 pneumonia include: on the
Phase 3 China ; Huilan Zhang, PD;Huil huilanz_7 15391532171; following

 
 1. Male or female, aged at
 
 2. Laboratory confirmation
Phase 1 China ; Lei Shi, MD,PhD;Lei S shilei302 86-10-66933333;86-1 chain reaction (RT-

 
 1.Willingness of study parti
 consent; 2.Male or female,
Phase 1 ; Jie-ming Qu, MD.,PhD.;jmqu0906 ;+86-21-6 Ruijin Hosp confirm
Inclusion criteria:
Exclusion
(1) criteria:
Aged >=18 (1) year
Pati
 (2) novel
 (2)
coronavirus
Pregnant pneumoni
or lacta
RetrospectChina Xiaoyang Lu 79 Qingchuluxiaoyang +86 13605 The First A (3) Patient
 (3) Patients whose G
 2) Patients with prev
RetrospectChina Zhang Huafen 79 Qingchuzhanghuaf +86 13757 The First A Inclusion c 3) The investigator b
Exclusion criteria: 1) < 18
 2) pregnant and lacta
N/A China Wang Hongyang 225 Changhhywangk@v+86 13801 The Third AInclusion c 3) patients with men
Exclusion criteria: (1) Com
Inclusion criteria:
 (2)1.Combined
Aged 18 to with
75 ye
m
 2. Real-time
 (3)fluorescence
Pregnant orRT-PC
lacta
4 China Xu Zhihua Mianyang C11217338 +86 18508 Mianyang C 3. Sequencing
 (4) Suffer
of virus genes in r
Inclusion criteria: 1. Laboratory confi
 2. Clinical classification is mild o
 3. LungExclusion
involvement confirmed
criteria: 1. Patie
0 China Chuantao Zhang 39 Shi-Er- 10357887 +86 13880 Affiliated 4. Hospitalised
 2. Pawith: Fever: axill

 
 - all patients suspected of
 
 
 - patients' data are not av
N/A China 

 
 1. Adult male or female pa
 
 2. The newly diagnosed CO
N/A ; Shuiping Zhou, PhD;Yi ;heyi@tasl ;86-022-8 Tasly Pharm the "Guidance of Diagno
0 China Guojun Zhang 1 Jianshe zlgj-001@ +86 13673 The First A Inclusion c Exclusion c
N/A China Yunxia Zuo 37 Guoxue zuoyunxia +86 18980 DepartmentInclusion c Exclusion c
18 to 90criteria:
years; 1. Preg
0 China Mei Heng 1277 Jiefa hmei@hust+86 13886 Union Hosp 3. Sign 2.
the written
Patients
informed
with mencon
Inclusion criteria: 1. Patients who we
RetrospectChina Jiang Shujuan , Jinan, S docjiangs +86 15168 Department 2. Patients
Exclusion c
who agreed to enroll
Exclusion criteria: (1) Chro
 (2)Patients
Inclusion criteria: Cardiorenal
with insuffi
new
N/A China Liu Yi 324 Jing-Wu15168888 +86 18660 Shandong P (3) Pregnant women
Exclusion criteria: 1. preg
Inclusion criteria:
 2. 1. blood
agedpurification
>=18 years
 2. laboratory
 3. conformed
patients hadSARS-C
other
0 China Xiaowei XU 79 Qingchuxxw69@12+86 13605 The First A 3. critically
 4.ill and require
allergic intens
to dimethy
Exclusion criteria: (1) kno
Inclusion criteria:
 (2)(1) women
aged >=18
who year
are b
0 China Li Suyun 19 Renmin 38797527 1.39E+10 The First A (2) positive
 (3)COVID-19
partic nucleic ac
Inclusion criteria:
ExclusionThiscriteria:
study intends
(1) Excl
N/A China Yan Hao; Xiaoping Luo1095 Jiefa haoyaner@+86 13971 Tongji Hosp 1. Epidem (2) Exclude pneumon
Exclusion criteria: 1) <14 y
Inclusion criteria:
 2) 1. pregnant
Have any women;
of the
 (1) travel
 3)
history
ICUor hospital
residence
stayhi<
RetrospectChina Minghao Fang 1095 Jiefa Fangmh@tj+86 15071 Emergency (2) close 4)
contac The necessary clin
Exclusion criteria: 1. Age <
 2. Pregnant;
Inclusion criteria:
 3. 1. Patient
Meetsis2019
irritable
nov
RetrospectChina Shusheng Li 1095 Jiefa shushengl +86 13971 Eergency / 2. Under 4.
non-invasive
Intubation-mechan
ventilatio
N/A China Ye Gu 85 Heping Ssylykjk@1 +86 18502 Shenyang S 2. Pneumonia
Exclusion patients
c with new
N/A China Chen Xiao 627 Wuluo cxfn817@1+86 13986 Central TheInclusion c Exclusion c
N/A China Ye Wan 1999 Guank41743383 +86 13806 Xiamen Med Inclusion c Exclusion c
Inclusion criteria: COVID-19 group:
 1. Age>Exclusion
= 18 years criteria:
old, noCOVID-
gende
 2. Patients
 1. with
Patients
covid-19without
determ s
0 China Hu Liu 107 Huanhudrliuhu@g +86 13866 Anhui Canc 3. Total 2.
bilirubin
Patients
<=1.5who
UNL,used asp
Inclusion criteria: Patients diagnosed
 Mild group
RetrospectChina Ying binwu 37 Guoxue binwuying +86 18980 West China Diagnosed Exclusion
patients
c classified as
Exclusion criteria: (1)Peop
Inclusion criteria:
 (2)(1) people
Chinesewho residen
can't
 (2) People
 (3)people
aged between who18 can't
and
N/A China Zhongyuan Xia 238 Jiefan wenqin-19 +86 13808 Renmin Hos (3) People
 (4)people
have electronic
who can't
socia
Exclusion criteria: 1. Any s
Inclusion criteria:
 2. 1. Patients
Aged >=18who years
have
 2. Clinically
 3. diagnosed
No clinical patients
manifesw
4 China Huilan Zhang 1095 Jiefa huilanz_7 +86 15391 Department (1) real-time
 4.fluorescent
Known allergy RT-PCRor h
Inclusion criteria: 1. Adult patients co
 2. Patients with clear
Exclusion manifestati
criteria: 1. Patie
0 China Li Shusheng 1095 Jiefa shushengl +86 13971 Tongji Hosp 3. Patients
 2. requiring
Pregnant oxygen
women. the
RetrospectChina CHEN Xinyu 95 Shaoshachenxinyu +86 13807 The First A Inclusion c Exclusion c
Exclusion criteria: (1) Fem
Inclusion criteria:
 (2)(1) Patients
Patientsallergic
aged fr t
4 China Chen Chunbo 101 Weimi gghicu@16+86 13922 Maoming Pe (2) Mild (3)
patientsPatients
with confirmed
who are
Inclusion criteria:
 2. 1. Acute
Real-time
respiratory
fluored
0 China Xiuming Song 528 ZhanghXiumingso +86 13817 Shuguang Ho 2. Confirmed
 3. as Patients
a novel with
coronav
diab
Inclusion criteria: (1) Aged 18 years o
 (2) Real-time
Exclusion fluorescent RT-PCR
criteria: (1) Kno
 (3) Clinical
 (2)classification is comm
Mild and severe p
0 China Yuanrong Dai 109 Xueyua13968888 +86 13857 the Second (4) Signed informed
 (3) Combinedc with se
0 China Kang Yan 37 Guoxue Kangyan@s+86 18980 West ChinaInclusion Exclusion c
Inclusion criteria: 1) Confirmed or cli
 2) Those who have been identifi
 3) Inpatients
Exclusion agedcriteria:
18 to 751) Patie
year
0 China Zhijun Fang 100 Cross fangzjnj@h+86 13372 Affiliated 4) Vo 2) According to the r
Inclusion criteria: 1. Written informe
over 18 years;
criteria: 1. Resp
 3. Fullfill
 2.
the diagnostic
Comorbiditiescriteriainclu
o
0 China Xuemei Li 1 Shuai-Fu-lixmpumc +86 13911 Peking Uni 2019-nCoV 3. diagnosis
Concurrent confirmed
use of
Inclusion criteria: Must meet all of th
 1. aged 18 to 75 years male or fe
 2. BodyExclusion
Weight 40-100kg,
criteria: 1.andaccoB
0 Wang Hao Zhiyin Avenwanghaohh+86 13901 Huo-Shen-S 3. to meet the diagnostic
 Note: those who criteria
com
 2. Patients who are d
4 China Chen Zhenshun 169 Donghuchzs1990@+86 13627 Zhongnan HInclusion c 3. Severe immunosup
Exclusion criteria: 1. COVI
 (1) Those who refuse
 (2)1.Pregnant
Inclusion criteria: COVID-19 women
suspe
 (3)Patients
 1.1 Diagnostic withsuspec
criteria for men
 1.1.1 History
 2. of non-COVID
Epidemiology:health
0 China Xufang Sun 1095 Jiefa s_186277 +86 18627 Department (1) Those who refuse
N/A China Jie Luo 32 Renmin 18219024 +86 0719 Shiyan TaihInclusion c Exclusion c
Inclusion criteria: 1. Criteria for inclu
 (1) Comply
Exclusion
with criteria:
the diagnostic
(1) Patic
 (2) Above
 (2)
2 years
Complicated
old; liver
N/A China Zhang Wei 42 Wenhuazhagnweij
R +86 13505 Affiliated 2 (3) Have other seriou
RetrospectChina Yanling Shi Departmentakidney_d +86 0577 The First A Inclusion c Exclusion c
Inclusion criteria: (1) All confirmed a
N/A China Yong Huo No.8 Xishikdrhuoyon +86 13901 Peking Univ (2) Voluntarily
Exclusionagree c to enter th
Inclusion criteria: 1. Written informe
over 18 criteria: 1. Resp
 3. Fullfill the diagnostic
 2. Comorbiditiescriteria o
inclu
0 China Xuemei Li 1 Shuai-Fu-lixmpumc +86 13911 Peking Uni 2019-nCoV 3. diagnosis
Concurrent confirmed
use of
Inclusion criteria:
Exclusion 1) confirmed
criteria: 1)orpatie
sus
 2) be able
 2)to understand
patients with themencon
N/A China Wei Yao 9 West Sect41148433 +86 17709 Dalian Medi 3) voluntarily
 3) patients
participatewith
in serio
this
Inclusion criteria: 1. Eligible patients
 2. Were identified as laboratory
N/A China Wu Caineng 16 Jichang wucaineng +86 13580 The First A 3. ThoseExclusion
who need c intubation in
Inclusion criteria: 1. patient with nov
 2. patients with type 2 diabetes;
betweencriteria:
18-80 years
1.diabe ol
N/A China ZHOU JIAN 600 Yishan zhoujian@s+86 18930 Shanghai Si 4. With 2.previous
effective flash history
glucoseofm
Inclusion criteria: 1. Confirmed and s
 2. Medical
Exclusion
staff ofcriteria:
anesthesiolog
1. Gene
RetrospectChina Zongze Zhang 169 Donghuzhangzz@w+86 13971 Zhongnan H 3. Voluntary 2.participation
Medical staffinwith the
Inclusion criteria:
 1) 1. Respiratory
Aged 18 tofailure
70 ye
 2)
 2. Patients with Shock occurs; infe
pneumonia
N/A China Bende Liu 3) cas
1 Culture Aliubende9 +86 13907 First People 3. Confirmed Combined failure o
Inclusion criteria: (1) registered nurs
 (2) to combat the new coronavir
0 China Pang Yong-li 600 Tianhepangi88@1+86 15626 The Third A (3) volunteer
Exclusion c
to participate in th
Retrospective study Chengxian Guo 138 Tongzi gchxyy@16+86 0731- The Third XInclusion Exclusion c
N/A China Bin Li 110 Ganhe 18930568 +86 18930 Yueyang Hos Inclusion c Exclusion c
0 China CAI YU 473 Hanzhecaiy_kf@1 +86 18702 Wuhan Four Inclusion c Exclusion c
Inclusion criteria:
Exclusion 1. Aged
criteria:
>= 18
1. Patie
year
 2. Patients
 2. clinically
Severediagnosed
cardiovascu a
0 China Jianfeng Zhou 1095 Jiefa zhougene@+86 027 8 Department 3. Severe/critical
 3. Patients pat with clinic
Inclusion criteria:
Exclusion 1. Aged>=
criteria:18,
1. Critic
male
 2. Fever,
 axillary
i. Patients
temperature
with respi>
 3. Consistent
 ii. with
Patients
the clinical
with shoc di
0 China Ye Feng/ Yang Zifeng/ 151 Yanjia yefeng@gir+86 13710 The First A 4. Patients
 who iii. Patients
sign informed
with oth co
Inclusion criteria:
Exclusion (1) criteria:
Aged 18(1) to 75
Com y
 (2) Real-time
 (2)fluorescent
Malignant tumor
RT-PCR
0 China Lunxu Liu No.37 Guoxlunxu_liu@+86 18980 West China (3) The (3)
sequence pregn
of virus genes
Inclusion criteria: 1. Conform to the w
 2. Conform to the diagnostic crit
N/A China Xie Chunguang 39 Shi-Er-Qxcg718@al+86 18980 Hospital of 3. OverExclusion
18 years cold
N/A China Xie Chunguang 39 Shi-Er-Qxcg718@al+86 18980 Hospital of Inclusion Exclusion c
Inclusion criteria: 1.No age restrictio
 2. Clinically
Exclusion
confirmed
criteria:
2019-nCo
1. Patie
0 China Jianfeng Zhou 1095 Jiefa zhougene@+86 027-8 Department 3. Patients 2. withPatients
willingness
not provid
and
Inclusion criteria: 1. Those who meet
 2. Over 18 years old (including 1
4 China Zhong Nanshan/Zhang385 North Xjiactm@16 +86 0311- Shijiazhuan 3. At the Exclusion
time ofcenrollment, the
Inclusion criteria: 1. The patient sign
 2.The age of the patient is 18 or
 3. COVID-19 patients diagnosed
0 China Cao Bin Cherry Bloscaobin_be 1.39E+10 China-Japan 4. NucleicExclusion
acid posic
 
 - The participants were di
 
 - Participants received anti
 
 - Written the informed co
 
Phase 2/PhChina ;; Hongzhou Lu, Ph.D;Ho;luhongzh ;+86-021- Shanghai Pu 
Inclusion criteria: 1. Patients with co
 2. Above 18 years old (inclusive)
 3. At the time of enrollment, the
4 China Zhong Nanshan/Zhang385 Xinshi jiactm@16 +86 0311 Hebei Yilin 4. Voluntarily
Exclusionsign
c written i
 Inclusion criteria.

 
 1. 2019-nCov (SARA-Cov-2
 
 2. Older than 18 years old
 
Phase 2/PhChina Xiuling Shang Fujian Prov 3. Meet the diagnostic crit
Inclusion criteria: 1. No physical disco
16 yearscriteria:
old and Ifabove;
one o
N/A China Tang Jianyuan 39 Shi-Er-Qtangjiany +86 13910 Hospital of 3. Take (1)
the medicine recommen
Has fever, cough,
Inclusion criteria:
 2. 1.pregnant
Pneumonitis
and lacta
pati
 2. Meet 3.
the standard
Combining of TCM
severesy
0 China Wang Dazhong 33 Huanghe13803818 +86 13803 Zhengzhou 3. Sign 4.the informed
Clinical consent.
researcher
Exclusion criteria: 1. The p
Inclusion criteria:
 2. Patients
The patients
of stomato
were
 1. The 3.
visitingThe
datapatients
of patients
was cu
1 China Jingzhi Ma 1095 Jiefa majingzhi +86 13871 Tongji Hosp 2. The 4.
pati The patients was u
Inclusion criteria: 1. Male and female
 2. Clinically diagnosed with Coro
 3. Increased interleukin-6;
Exclusion criteria: 1. Case
 4. Sign 2.
the informed
Allergicconsent;
to Favipira
 5. Subjects
 3. who
Pregnant
can take and
medici
lacta
4 China Guiqiang Wang 8 Xishiku S john13121 +86 13911 Peking Univ 6. Agree 4.
to collect
Subjects
cl received

 
 1. Age = 18 years;
 
 2. Clinically diagnosed pati
Early Phase 1 Jianping Zhao, Ph.D. Zhaojp88@ 1.35E+10 accordance with the crite
Inclusion criteria: 1. including confirm
 2. residence in Jingzhou for mor
 3. Aged 16-65 years;
N/A China Deng Xiaopeng 47 Taqiao R49637569 +86 13872 Jingzhou M 4. self-volunteered.
Exclusion c
N/A China Wang He 33 HuangheWH9400@1+86 15937 Zhengzhou Inclusion c Exclusion c
Inclusion criteria:
Exclusion
1. Suspected
criteria: 1.COVID
CT im
RetrospectChina Lu Guangming 305 East Z cjr.luguan +86 13951 Jinling Hos 2. Patients
 2.confirmed
Incompletewithetiolog
etiolo
 
 1. Aged >=18 years;
 
 2. Novel coronavirus pneu
 
N/A 3. The patient himself parti

 
 - Nurses who work > 37 ho
 
 
 - Nurses with one or more
 
N/A ; Mark B Loeb;Mark Lo ;loebm@mc;90533400 McMaster U
 - Nurses

 
 1. age range: 10-19;
 
 2. full-time students in the
 
 3. nationality: China;
 
 4. exposure context: COVID
 
N/A 2. Patients with othe
N/A China Honghua Ye 41 Xibei St yehonghua+86 13505 HwaMei Hos Inclusion c 4. Patients wi
Exclusion criteria: (1) befo
 (2) malignancies;
 (3) the presence of s
RetrospectChina Feng Gao 1095 Jiefa 13971587 +86 13971 Tongji HospInclusion c (4) 7 days before adm
Inclusion criteria: Stage I and ii healt
 Stage 3:
 1. Clinical manifestations:
 (1) Fever;
Exclusion criteria: Stage 1
 (2) normal
 Stage
or decreased
3: white b
 (3) CT pulmonary
 1. Patients
exudation;
who cannOr
0 Shiyue Li 151 Yanjia lishiyue@ +86 13902 The First A 2. I
RetrospectChina Prof. Christopher CK L Departmentchris.kcla +852 3505 The ChinesInclusion c Exclusion c
N/A China Li Lanjuan 79 [email protected] +86 13906 The First A Inclusion c Exclusion c
Inclusion criteria:
Exclusion
1. Aged
criteria:
>=18 1. years
Preg
 2. Symptoms
 2. Patients
of novel coronavir
with adva
0 Wen Jianli 98 Fenghuazywenjian +86 15186 The Third A 3. Positive 3.
nucleic
Suspected
acid test
cases.
of no
Inclusion criteria: 1. positiveness of n
 2. newly-onset pneumonia in a C
 3. typical symptoms of pneumon
RetrospectChina Jiang Xie 2 Anzhen Ro frank7820 +86 13161 Beijing Anz 4. live in Wuhan cin the past
Exclusion
Inclusion criteria: 1. Patients aged fro
 2. conformed
Exclusion to criteria:
epidemic1.histor
peop
 3. fever 2.
and respiratory
the researcherssymptomju
 4. normal
 3.
or decreased
those wholeukocyt
cannot
0 China Qun Luo 151 Yanjia luoqunx@1+86 13710 State Key L 5. conformed
 4. anyto imagi
significant clin
Exclusion criteria: (1) pati
 (2) infants and young
 (3) patients with unc
N/A China Yang Si-Jin 182 Chunhulykyk3160 +86 15228 Affiliated Inclusion c (4
0 China Zhang Sheng 1095 Jiefa aloof3737 +86 18971 Tongji HospInclusion c Exclusion c
N/A China Xu Jie 280 Mohe Rdr.xu@ali +86 13501 Shanghai N 2. Clinical
Exclusion c of 2019 - nC
diagnosis
Inclusion criteria: All patients who m
 Epidemiological history:
RetrospectChina Luo Xiaoping 1095 Jiefa xpluo@tjh.+86 027-8 Tongji Hos 1. travel
Exclusion
or residence
c history of
Inclusion criteria: The mild cases wer
N/A China Tiejun Wang 116 Zhuodatiejunwan +86 13277 Department 1) respiratory
Exclusion failure
c requiring m
Inclusion criteria:
Exclusion
(1) criteria:
mild / general
(1) Patip
 (2) Aged (2)
>=18 Patients
years; more tha
1 China Li Xugui 279 Luoyu spine672@+86 13807 Hubei 672 (3) Obtain (3)
patients'
Patientsinformed
with seve
co
Exclusion criteria: 1. Disch
N/A China Xu Shuyun 1095 Jiefa sxu@hust. +86 13517 Tongji HospInclusion c 2. Discharge cases w
Inclusion criteria:
Exclusion
(1) criteria:
Patients(1) diagno
CT r
N/A China Xu Haibo 169 Donghuxuhaibo11 +86 13545 Wuhan Univ (2) There (2)
are CTIncomplete
image examina clinica
Inclusion criteria: 1. patients with no
 2. Fever,
Exclusion
respiratory
criteria:
tract1)and
Ordin
o
 3. Aged 2)
18 to Patients
80 years;with aller
4 China Bangjiang Fang 725 Wanpinfangbji@1 +86 18917 Longhua Hos 4. Signed
 3)
informed
Patientscons with mali
Inclusion criteria: 1. COVID-19 patien
0 China Liming Xia 1095 Jiefa Lmxia@tjh.+86 13607 Tongji Hosp 2. ViralExclusion
pneumonia c manifestatio
Inclusion criteria:
Exclusion
1. Above
criteria:7 years
1. Toooly
 2. Meet 2.
the diagnostic
Non-neoplasticcriteriacoo
 3. Clear 3.
consciousness
Impaired and consciou
stabl
0 China Yibin Hao 33 Huanghehaoyibin0 +86 15903 Zhengzhou 4. V 4. Those who cannot
Inclusion criteria:
Exclusion
1. Adult
criteria:
aged1. >=18
Any s
 2. Patients
 2.infected
Knownwith allergy
neworcoh
N/A China Zhang Dingyu 1 Yintan R 18138863 1.35E+10 Wuhan Jiny 3. In the 3.
stateIncrease
of no oxygenin alanine
at re
Human
pharmaco
logy
(Phase I):
no
Therapeu
tic
explorato
ry (Phase
II): no
Therapeu
tic
confirmat
ory -
(Phase
III): no
Therapeu
tic use
(Phase
IV): yes
Portugal;G W.W. van Bentum-PuiUniversite w.w.puijk- +31(0)887 University Inclusion crExclusion cr
Inclusion criteria:
 2. 1. Patients
Male orwith
female
maligp
 2. Willing
 3.
to signPatients
informed
who conse
have
New TreatmChina Dou Qifeng 88 Jiankan douqifeng +86 13503 the First A 3. novel 4.
coronavirus
There was
novelevidenc
coron
Exclusion criteria: 1. Exclu
 2. Exclude medical st
N/A China Yan Hao, Xiaoping Luo1095 Jiefa haoyaner@+86 13971 Tongji HospInclusion c 3. Exclude if the med
0 China Ning Qin 1095 Jiefa qning@vip.+86 027-8 Tongji HospInclusion c Exclusion c
Inclusion criteria:
patients(1)whoAgew
RetrospectChina Ye Tu 1095 Jiefa whtuye@1+86 18986 Tongji Hosp (2) patients
 (2) who pneumonia
received with
patieni
N/A China Xia Tian 241 Peng-Lhcwy100@+86 13871 Wuhan ThirInclusion c Exclusion c
N/A China Zhengrong Mao 19 Renmin mR aozheng +86 18695 The First A Inclusion c Exclusion c
Exclusion criteria: 1) Aged
Inclusion criteria:
 2) 1) Pregnant;
Meets COVID-19
 2) Critically
 3) ill COVID-19 as patients
an co
RetrospectChina Yi Bian 1095 Jiefa bianyi252 +86 15102 Eergency / 3) length 4)
of stay Insufficient
in ICU >=24medica
hou
Inclusion criteria:
Subjects(1)must
Infeu
N/A China Junming Wang 1095 Jiefa eyedrwjm +86 13886 Tongji hosp (2) Fever (2)
and/or Patients
respiratory
with myc
sym
Inclusion criteria:
Exclusion Patients
criteria:
mustPatient
mee
 1. Patients
 1.admitted
The clinical
to hospital
data ar
RetrospectChina Lingli Dong 1095 Jiefa tjhdongll +86 18672 Tongji Hosp 2. Patients
 2.identified
The ageasofany
the rheu
pati
RetrospectChina Qian Guoqing 59 Liuting guoqing.q +86 15888 Ningbo FirsInclusion c Exclusion c
Inclusion criteria:
Exclusion 1. tumor
criteria:
group:
(1) Tho
 (1) Aged (2)
>=18 Complicated
years; with
 (2) Diagnosed
 (3) as Patients
a malignant
duringtumpe
RetrospectChina Zhihua Wang, Xiangli 1095 Jiefa zhwang_hu+86 13607 Tongji Hos (3) The (4)
diagnosis Immune
and treatment
dysf
Retrospective study Liang Wang 1095 Jiefa wang6@tjh+86 13971 Tongji HospInclusion c Exclusion c
Retrospective study Xin Li 1277 Jiefa 31444082 +86 13797 Union HospiInclusion c Exclusion c
Inclusion criteria:
Exclusion
1. Those
criteria:
who1. meet
Incom
RetrospectChina LIU DONG 1095 Jiefa ld_2069@1+86 13507 Tongji Hosp 2. In-patients
 2. Those
admittedwhich
in design
the re
Inclusion criteria: 1. Confirmed case:
 (1) epidemiological history:
1 China Wang Hua-bing 241 Peng-L27322554 +86 15377 Wuhan 3rd 1) travel history or
Exclusion cr residence his
Retrospective study Yuan Yadong 215 Hepingyuanyd11 +86 15833 The SecondInclusion c Exclusion c
Exclusion criteria: 1. Tran
1 China Peng Jian 241 Peng-L54116340 +86 18627 The Third Inclusion 2. Patient with only o
0 China Wu Kaifeng 98 Fenghuakiphoonw +86 13788 The Third AInclusion c Exclusion c

 
 - Wuhan residents;
 
 - novel coronavirus pneum
N/A Laboratory tests revealed
Exclusion criteria: 1. A pre
N/A China Wang Tan 1478 GongnWangtan21+86 13756 Affiliated Inclusion c 2. With other major d
Inclusion criteria: (1) Patients with N
 (2) Inpatients
Exclusionaged >18 years
criteria: (1) Deaold
0 China Jing-Guo Cheng Wenzhou Me wzwsjcjg@+86 13857 WenZhou Me (3) Patients
 (2)Know the
Basic inform suc
diseases
Exclusion criteria: 1) Age
Inclusion criteria:
 2) 1)Pregnant
The diagnosis
women; m
RetrospectChina Zhigang He 1095 Jiefa 10976858 +86 18827 Eergency / 2) Patients
 3)receiving NIV or
Incomplete MV
inform
N/A Lihui Wang 13 North Q84961499 +86 13832 Cangzhou PInclusion c Exclusion
Inclusion criteria:
Exclusion
1. Aged
criteria:
18 to
1. 80
Rena ye
 2. Diagnosed
 2. as
Relative
COVID-19
/ absolute
pneu
N/A China Jing Chen 12 Wulumuq money_09 +86 13816 Huashan Ho 3. ad 3. Pregnant women,
N/A China Guo Zhang 6 Taoyuan zhangguog +86 13978 The PeopleInclusion c 2. Patients developed
N/A China Xiong Chen 169 Donghuzn_chenxi +86 13995 Zhongnan HInclusion c Exclusion c
Exclusion criteria: (1) Past
Inclusion criteria:
 (2)1.Patients
Patientsinfected
diagnos
0 China Xie yuanlin 311 Yingpan12867794 +86 13975 The First H According to the
 (3) "New with
Patients Coronavmal
Exclusion criteria: 1. not q
Inclusion criteria:
 2. 1.
Pregnant
novel coronaviru
or lactati
N/A China Zhu Bo 3 Yunxing R27477014 +86 13995 Xiangyang 1 2. age 3.
unlimited,
Patients
malewith
and fema
seve
Inclusion criteria: (1) Currently partic
N/A China Zhang Yue 1120 Lianhzyzy1933@+86 18823 Clinical R (2) Voluntarily
Exclusionparticipate
c in this
0 China Qingyou Zheng 1333 Xinhuzhengqing +86 18601 Shenzhen HInclusion Exclusion c
Inclusion criteria: (1) Aged >18 years
RetrospectChina Xia Hong 1 Xiyuan Pl97023653 +86 13699 Xiyuan Hos (2) canExclusion
completecthe wechat qu
RetrospectChina GuoLin Song 32 Feishan ant000999 +86 13985 The SecondInclusion Exclusion c
Inclusion criteria:
Exclusion
1) Comply
criteria:with
(1) Pati
the
N/A Chian Guoqin Sun 241 Peng-L70798689 +86 18971 Wuhan Thir (2) Complete
 (2)clinical
Patientsdata
whose
of pati
da
Inclusion criteria:
Exclusion
1. Critical
criteria:patients
1. Preg
 2. airway
 2.
intubation
Combined withwith
mecha sev
RetrospectChina Shusheng Li 1095 Jiefa Shushengl +86 13971 Tongji Hosp 3. voluntarily
 3. Patients
joined this
with
study
lungw
RetrospectChina Hong Wang 1229 Gudunhongwang +86 0571 Zhejiang HoInclusion c Exclusion c
Inclusion criteria: 1. confirmed with C
 2 olderer
Exclusion
than 65criteria:
years; 1. decla
RetrospectChina Cuntai Zhang 1095 Jiefa ctzhang04 +86 15927 Department 3. meet 2.
the critically
importantill criteria
data mia
Exclusion criteria: (1) Oth
 (2)(1)
Inclusion criteria: Serious
novel mental
coronavir ill
N/A China Burenbatu 1742 Huoli nmbrbt89 +86 18804 Affilated H (2) According
 (3)to Susthe diagnostic s
Inclusion criteria: 1. Male and female
 2. Patients with confirmed COVI
 3. Need to continue the antiviru
 4. AgreeExclusion criteria:
to sign the 1. Case
informed co
 5. Able 2. Pregnant
to ingest, absorband andlacta
tol
4 China Zhao Yan 169 Donghudoctoryan +86 13995 Zhongnan H 3. The subjects partic
 2. Endotracheal intubation patie
1 Wen Jianli 98 Fenghuazywenjian +86 15186 The Third A 3. Patients with off-line
Exclusion c extubati
Inclusion criteria:
Exclusion1. Aged
criteria:
18-651. Med
year
 2. Meical
 2.
workers
Occupation
normal isworkinot
N/A China Fengbin Liu 16 Jichang liufb163@ +86 020-3 the First 3. Auqired
 3.theMedical
informed consen
 2. ARDS patients according to th
RetrospectChina Fenglin Liu 12 Lieshishxkyylfl@1 +86 13953 Shandong P 3. Patients in ICUc met the VAP c
Exclusion
Inclusion criteria:
Exclusion1. Patients
criteria: who
1. Agedwe
RetrospectChina Fenglin Liu 12 East Lie xkyylfl@1 +86 13953 Shandong P 2. Severe
 2.
ARDSAccompanied
patients accordi by o
Exclusion criteria: 1. youn
Inclusion criteria:
 2. 1.doconfirmed
not fulfill the
withcrC
 2. ICU admission;
 3. declared clinical de
RetrospectChina Hongyu Gao 1095 Jiefa hygao@tjh.+86 13886 Department 3. meet 4.
the critically
importantill criteria
data mia
14 years criteria:
or more;1. Hem
0 China Fenglin Liu 12 East Lie xkyylfl@1 +86 13953 Shandong P 3. diagnosis
 2.ofIntracranial
ARDS according
pressu
Inclusion criteria:
Exclusion1. confirmed
criteria: 1.critica
If the
 2. grouping
 2.criteria:
aged <meet
14 years;
the cli
RetrospectChina Minghao Fang 1095 Jiefa fangmh@tj+86 15071 Department (1) the2. 1.Pneumothorax;
Patients who we
RetrospectChina Fenglin Liu 12 East Lie xkyylfl@1 +86 13953 Shandong P 2. ARDS 3.
patients
Severe
are asthma
defined or Ac
N/A China Hui Zhong 37 Guoxue zhonghui3 +86 18980 West ChinaInclusion c 2. Patients without th
RetrospectChina Fenglin Liu 12 East Lie xkyylfl@1 +86 13953 Shandong PInclusion c Exclusion c
0 China Huanqin Han 57 South R huanqinha +86 13828 Affiliated 2. Patients
Exclusion c
with COVID-19 confir
Inclusion criteria: 1. Volunteers who
>=18 years;
criteria: 1. Viral
 3. Patients
 2.diagnosed
Patients with
are notacute su
 (1) Laboratory
 3. Participation
(RT-PCR) confirmin oth
0 China Xiang Cheng 1277 Jiefa nathancx@+86 15972 Union hosp (2) Lung in Other circumstanc
 4.
0 China Peng Sun 1111 XianxSP2082@sh+86 18121 Tongren HoInclusion c Exclusion c
RetrospectChina Lijia Demi 94 West Str27216302 +86 17723 Ganzi HospiInclusion c Exclusion c
Inclusion criteria:
ExclusionPneumonia
criteria: 1.cases
Suspw
0 China Guangtao huang 149 Dalian haitao314 +86 18085 Affiliated A comprehensive
 2. Pneumonia
analysiscaused
was c
Inclusion criteria:
Exclusion(1) criteria:
Comply with(1) Patith
RetrospectChina Wei Li 215 Zhongs78440452 +86 18995 Wuhan Hosp (2) Complete
 (2)clinical
Patientsdatawhose
of patida
Inclusion criteria:
Exclusion
1. Aged
criteria:
18 to
1. 75
Critic
ye
0 China Pinhua Pan, Yehong K 87 Xiangya pinhuapan +86 13574 Xiangya Hos 2. The 2.
diagnosis
Known
of new-type
allergiesco
Inclusion criteria: 1. Intervention gro
 (1) Aged 18 to 50 years;
 (2) Diagnosed
Exclusionascriteria:
a depression
(1) otheo
 2. Non-intervention group: with
 (2) complicating
0 Yuan Yang 1095 Jiefa yuanyang7 +86 13995 Tongji Hos (1 (3) taking antidepres
N/A China Jingfeng Zhang Room 711, jBingfengz +86 15706 Hwa Mei HoInclusion c Exclusion c
 2. Patients who are c
1 China JIAN PENG 216 Guansh13758526 +86 13907 Wuhan thirInclusion 3. Patients with prev
Exclusion criteria: (1) Fem
Inclusion criteria:
 (2)(1)
Patients
aged between
with alle1
4 China Hu Linhui 101 Weimi hulinhui@l+86 13580 Maoming Pe (2) Common
 (3)type
Pa patients with
Exclusion criteria: 1. Prev
RetrospectChina TAO WANG 1095 Jiefa wt7636@1+86 13971 Tongji HospInclusion c 2. The patients' med
Inclusion criteria:
Exclusion
1. Aged
criteria:
18 to
1. 80
Patie
yr
N/A China Yingjia Xu 801 Heqingxuyingjia@+86 18017 Shanghai Fi 2. Diagnosed
 2. as
Patients
COVID-19
participati
pneu
Exclusion criteria: 1. Exclu
 2. 1.
Inclusion criteria: Dead children;
COVID-19 infecti
0 China Wang Xiaowen 100 Hongkob5477@16+86 15907 Department 2. Children 3. Sign
with to reject
kidney thisHp
injury:
 2. Aged 18 to 65 years;
4 China? Yang Yi 4 Garden H15326774 +86 18971 Hubei Hospi 3. The Exclusion
time interval
c between sym
Exclusion criteria: 1) < 18
 2) pregnant and lacta
N/A China Wang Hongyang 225 Changhhywangk@v+86 13801 The Third AInclusion c 3) patients with seve
Exclusion criteria: (1) preg
 (2)(1)
Inclusion criteria: ALT/AST > 5 times
aged 18-80 yea
 (3)
 (2) severe definite
(including diagnosis
critical risk
4 China Min Zhang NO.85 Wujimaggie_zh +86 18121 Shanghai G (3) blood (4)
CRP and
patienESR were mor
Inclusion criteria: 1. Those who agree
 2. AdultExclusion
aged >=18years
criteria: old,
1. Parti
ma
0 China Cai Qingxian 29 Bulan R 41180423 +86 13760 The Third 3. The 2. Lowwith
inpatients bodymild
weight
or cop
Inclusion criteria: 1. Those who agree
 2. Adults
Exclusion
aged >=18years
criteria: 1.old,
Parti
m
0 China Zhang Yu 1277 Jiefa whxhzy@1+86 13971 Union Hospi 3. The 2.
inpatients
Withwith
bleeding
mild ororco b
Exclusion criteria: 1. With
Inclusion criteria:
 3. 1.
Patients
Aged between
taking oth 1
4 China Zhaofen Lin,Wansheng415 Fengyalinzhaofen +86 13601 Shanghai C 2. In accordance
 4. Notwith NCP to
suitable criter
par
Inclusion criteria:
Exclusion
1. Patients
criteria: who
1. Age<we
RetrospectChina Fenglin Liu 12 East Lie xkyylfl@1 +86 13953 Shandong P 2. ARDS 2.
patients
Accompanied
according to bytho
N/A China Song Ying 439 Xuanhu16473805 +86 13668 YongchuanInclusion c Exclusion c
Exclusion criteria: 1. Thos
Inclusion criteria:
 2. 1.
Pregnant
The patient
or lactati
sign
 2. Aged 3.
18-80Serious
years; basic disea
0 China xiao wei 4.coronavirus
8 Hangkong99xw@sina+86 071 6 Jingzhou Fi 3. the novel Expected deathnovelwi c
Inclusion criteria:
 2. 1.
Patients
Patientswith
who hemag
 2. Aged 3.
>16 years
Withold;
severe coagu
 3. Patients
 4.
with
WithCRPactive
morebleedi
than
N/A China Qin Wang 1630 Dongfqinwang_ +86 13621 Renji Hospi 4. The 5.
severe Pregnant
or critial patients w
RetrospectChina Zhanlian Huang 600 Tianhezhanlianh +86 13580 The Third AInclusion c Exclusion c
Inclusion criteria: Epidemiological his
 1. History of residence or travel
 2. Exposure history to resident o
RetrospectChina Hanwei Chen 8 Fuyu Roadocterwei +86 18922 Guangzhou< Exclusion c
0 China Gao Jun 167 Fangdon 13816012 +86 13816 The SecondInclusion c Exclusion c
Inclusion criteria:
Exclusion
1. From
criteria:
January
1. Pneu1,
RetrospectChina Chen Lei 26 Yuancunchenlei0n +86 13570 The Sixth A 2. From 2.
JanuarPatients with incom
0 China Zunyuan Liu 67 Dongchaly29.love +86 18263 Liaocheng Inclusion c Exclusion c
0 China Zhu Fengxue 11 Xizhimenfxzhu72@1+86 13911 Peking UnivInclusion c Exclusion
4 China Hong tao 17 Yongwaiht2000@vi+86 13803 The First A Inclusion c Exclusion c
Inclusion criteria:
Exclusion
1. Upon
criteria:
the1.judgm
The s
0 China Bi Xiaohui 33 Zhongyu52471295 +86 15618 Luohu hosp 2. According 2.toThethesubject
new typesuffers
of
0 Zhu Haibing 8 East Fuy zhb-ck@16+86 13826 Central HosInclusion c Exclusion c
Inclusion criteria:
 2. 1.
Pregnant
Patientsorwithlactati
co
0 Wei Wei 1 Fourth N wwei@chin+86 13729 Guangzhou 2. Voluntarily
 3. Insign
thewritten
opinion inform
of th
 2. Cardiogenic dyspn
 3. Life expectancy<24
Inclusion criteria:
 4. 1.
Pregnant
Aged>=18 and/or
yearsla
 2. Diagnosed
 5. as
There
severe
is a and
statecritic
of
N/A China Gao Dengfeng 157 Xiwu Ro gaomedic +86 15091 The Second 3. Being 6.
treated
Previously
in the ICU.
complic
 (2) Patients with acti
 (3) Organ transplant
RetrospectChina Qingping Shi 287 Changhsir_shi@1 +86 13855 The First A Inclusion c (4) Patients with men
Exclusion criteria: (1) asth
Inclusion criteria:
 (2)(1)patients
age: 18-75
withyearseve
1 China He jing 16 Jichang sakeonel@+86 13760 The First A (2) compliance
 (3) thewithrisk
the
stratificati
pneumo
RetrospectChina Fenglin Liu 12 East Lie xkyylfl@1 +86 13953 Shandong PInclusion c Exclusion c
Inclusion criteria:
Exclusion
(1) criteria:
Corresponding
1. With
0 China Li Xiaodong 856 Luoyu lixiaodon +86 13908 Hubei Prov (2) Imaging
 2.manifestations
Severe primary Fibro
dis
 3. ALT / AST > 2-fold
Inclusion criteria:
 4. 1. Sign thesurvival
Expected writtenti
 2. Aged 5.
18-80With
yearsserious
old; liver d
0 China Wei Xiao 8 Hangkong99xw@sina+86 18972 Jingzhou Fi 3. Meet 6.
the diagnostic
Patients taking
criteriao fo
Inclusion criteria:
Exclusion
(1)Aged
criteria:
>=18 (1)years
Kno
 (2) Novel
 (2)
coronavirus
Mild or nucleic
critical pa
ac
 (3) Clinical
 (3)
classification
Severe liver is ordin
disea
1-Feb China Weiping Cai 627 Dongfegz8hcwp@+86 020-8 Guangzhou (4) I <
Inclusion criteria: 1) Confirmed or cli
 2) Those who have been identifi
 3) Inpatients
Exclusion
agedcriteria:
18 to 75 1) Patie
year
0 China Haibin Ni 100 Cross nhb_2002 +86 15312 Affiliated 4) Vo 2) According to the r
 2. Pregnant and lacta
 3. People with allergi
4 China Qingling Zhang 151 Yanjia zqling68@ +86 13609 The First A Inclusion c 4. Severe basic disea
Inclusion criteria:
Exclusion
1. over
criteria:
18 years
1. Inves
old
 2. Patients
 2.
diagnosed
Not suitablewithforCovid
in
N/A China Zhi Zhang 100 Hainin 16683890 +86 13621 Shanghai Fi 3. Have 3.
64-rowPatients
high-resolution
who cannC
Inclusion criteria: 1. Conforming to th
 2. Aged between 18 and 65 year
0 China Xiaodong Li 856 Luoyu lixiaodon +86 13908 Hubei Prov 3. Signing Exclusion
the generalized
c inform
 2. 1.
Patientsorwith
lactati
co
0 Chao Xu 1 Fourth N 16497276 +86 15018 Guangzhou 2. Voluntarily
 3. Insign
thewritten
opinion inform
of th
Inclusion criteria:
 2. 1.
Pregnant
Patientsorwith
lactati
co
 3. Insign
thewritten
opinion inform
of th
Inclusion criteria:
Exclusion
Subjects
criteria:
who1. meet
Serio
 1. Meet 2.
the requirements
With pneumonia of thein
4 China Jinghua Mao 60 Jingjing hbjzyyywl +86 071 6 Jingzhou Ce 2. Aged 3.
18 With one of follow
Inclusion criteria:
Exclusion
1. Patients
criteria: who
If subje
me
 2. Aged 1.
18-75Be years
dysphagia
male orand fem
 3. Serious
 2.
patient
Complicated
meet onewith of t
4 China Jinghua Mao 60 Jingjing hbjzyyywl +86 071 6 Jingzhou Ce 3. Alle
Inclusion criteria:
Exclusion
1. Meet
criteria:
the1.require
Serio
 2. Aged 2.
18 to With
65 years
pneumonia
male or in f
4 China Ying Deng 22 Second surewin00 +86 13500 The Sixth A 3. The 3.
intervalWith
fromonetheofonset
followo
Inclusion criteria:
Exclusion
Confirmed
criteria: or
1. suspe
Patie
 1. Aged 2.
between
Those 18-85
withyears
severeol
 2. Patients
 3.
with
Inability
newlytodiagnose
unders
N/A China Jingzhi Ma 1095 Jiefa majingzhi +86 13871 Tongji Hosp 3. 4. Invasive ve
Inclusion criteria: 1. The patient sign
 2. patient aged >=18 years old;
 3. COVID-19 patients diagnosed
0 China Cao Bin 2 Yinghua Scaobin_be +86 13911 China-Japa 4. NucleicExclusion
acid positive
c within 72
Inclusion criteria:
 2. 1.
Researchers
Medical staff who ofa
RetrospectChina Zhongze Lou 59 Liuting lorenzo_8 +86 0574- Ningbo Firs 2. Patients
 3.
with
Thenew-coronary
investigator isp
 2. aged 18 or above;
N/A China Baoshan Cao 49 North Gacaobaosha +86 15611 Peking Univ 3. informed
Exclusion
consent
c and ability
Inclusion criteria: 1. Children aged 0-
 2. Agreed to participant in the s
N/A China Liu Zhisheng 100 Hongkoliuzsc@12 +86 027-8 Wuhan Chil 3. Can Exclusion
cooperatecrwith the later
 2. 1.
Inclusion criteria: A case of a pregna
Compliance with
RetrospectChina Miao Qing 1 Xiyuan Plmiaoqing5 +86 13910 Xiyuan Hos 2. Aged 3.>=18 Incomplete
years. case.
Inclusion criteria:
 2. 1.
A case
Compliance
of a pregna
with
RetrospectChina Miao Qing 1 Xiyuan Plmiaoqing5 +86 13910 Xiyuan Hos 2. Aged 3.>=18 Incomplete
years. case.
N/A China Meizhen Lin 111 Dade Rlmzmay@1+86 18922 The SecondInclusion c Exclusion c
Inclusion criteria:
Exclusion
1. Male
criteria:
or female
1. Sevea
 2. Patients
 2.
with
Multiple
confirmed
organ nove
fail
 3. Diagnosed
 3. as
Pregnant
moderateor lactati
cases
0 China Kaijiang Yu 23 Youzheng drkaijian +86 0451- The First H 4. Volunta
 4. Cases with maligna
N/A China Huang Keqiang 300 Taizih hkq12312 +86 15287 Wuhan AsiaInclusion c Exclusion c
 
 1. = 18 years old;
 
 2. Diagnosed as serious or
 Clinical management of 2
 
Phase 2 China ;; Zhiyong Peng, profess ;pengzy5@;+8618672 Wuhan Univ<
Exclusion criteria: 1. Peop
4 China Xin Zheng 1277 Jiefa xin11@hot+86 027 8 Union HospInclusion c 2. People with high-r

 
 - confirmed mild COVID-1
 
 
 - unable to take oral medi
 
 - pregnancy or breast feed
 
Phase 2 Korea, Repu Sung-Han Kim, MD.Ph shkimmd@a 82-2-3010-3114 
Inclusion criteria:
Exclusion
(1) criteria:
diagnosed (1)aspati
a
 (2) aged (2)
14 to patients
70 years whose
old; su
0 China Jia Lijun 725 Wanpinljjia@shut +86 13585 Cancer Inst (3) (3) endotracheal intu
Inclusion criteria:
Exclusion
1. Aged
criteria:
18 to
1. 65
Patie
ye
0 China Jing Xu Room 319, 1l 8604501 +86 18604 Harbin Peiy 2. The 2.
eligiblePatients
subjectswith
(male bloo
an
Inclusion criteria:
 1) 1.Respiratory
Aged 18 tofailure
70 ye
 2. Patients
 2)
withShock
pneumonia
occurs; infe
N/A China Bende Liu 1 Wenhua Aliubende9 +86 13907 First peopl 3. Confirmed
 3) cas
Combined failure o
 2. Cardiogenic dyspn
 3. Life expectancy<24
Inclusion criteria:
 4. 1.
Pregnant
Aged>=18 and/or
yearsla
 2. Diagnosed
 5. as
There
severe
is a and
statecritic
of
N/A China Gao Dengfeng 157 Xiwu Rogaomedic +86 15091 The Second 3. Being 6.
treated
Previously
in the ICU.
complic
Inclusion criteria: 1. Common inpatie
 2. Patients who are older than 1
0 China Zairong Wei 149 Dalian 18811699 +86 15208 Affiliated 3. Consenting
Exclusionorcthe guardian of
 2. 1.
co
 3. Insign
thewritten
opinion inform
of th
Inclusion criteria:
 2. 1.
Pregnant
co
0 Chao Xu 85 Kefeng 16497276 +86 15018 Guangzhou 2. Voluntarily
 3. Insign
thewritten
opinion inform
of th
N/A China Jin Yang 1277 Jiefa whuhjy@si+86 13554 Union HospInclusion c Exclusion c

 
 - 1. Age = 18, age = 75, ge
 
 - 2. novel coronavirus diag
Early Phase 1 ; Liwei cheng, doctor;X ;xiaoyang ;18986033 Research o plan. (severe patients me
N/A China Kun Ye 6 Taoyuan yezi5729@+86 18978 The PeopleInclusion c Exclusion c
 
 - Anyone volunteer to par
 
 
 - Anyone non-voluntary to
Phase 2 France ;; FrÃ©deric DUTHEIL;Lis;promo_int;04737549 University 
0 China Jiao Xianfa 33 Huanghe27835378 +86 13674 Zhengzhou Inclusion c Exclusion c
0 China CHEN Hui 58 Shenlonchenhhust +86 13437 Union HospInclusion Exclusion c
 (2) The investigator j
Inclusion criteria:
 (3)(1)Patients
Patientswithagedseve
1
 (2) Clear
 (4)
diagnosis
pregnant
of patients
and lact w
0 China Meng Jie 138 Tong-Zimengjie@c+86 13607 The Third X (3) Voluntarily
 (5) Those
join the who
trialhave
ands
Inclusion criteria: (1) Fever patients;
 (2) peoples
Exclusion
who criteria:
need to (1)screen
limi
 (3) patients
 (2)forLack
possible
of sample
infectioinf
 (4) Age (3)
and gender
unable areornot
failure
limitt
N/A China Pengfei Pang 52 Meihua pangpf@mai +86 18902 The Fifth A ( (4) Abnormal results
RetrospectChina Pei Bin 15 Jiefang xyxzyxzx@ +86 18995 Xiangyang 1Inclusion c Exclusion c
Inclusion criteria:
Exclusion
(1) criteria:
To include 1) Patie
confi
Retrospective study Fan Li 415 Fengyafanli0930 +86 13564 Department (2) Among 2)theChildren,
patie pregnant
Exclusion criteria: 1) Have
Inclusion criteria:
 2) 1.Have
Aged suicidal
11-18 idea
year
 2. GAD-7 3)
scoreNot
above
willing
10;to let t
 3. willing
 4)
to participate
Currently this
taking stud
ps
N/A China Shitao Chen 19 Xin-Jie- kittychen +86 15967 Mental Heal 4. Have 5
stable internet and quie
Exclusion criteria: 1. Othe
 2. Weakness affects p
 3. Communication ba
 4. Already participate
N/A China Haihang Yu Zhuangyu Ryuhaihang 8.61E+12 Ningbo KanInclusion c 5. Take psychotropic
Inclusion criteria:
Exclusion
(1) criteria:
Patients(1) withPati
m
 (2) Those
 (2)
who Patients
meet thewith diagnos
neo
0 China Jing Li 1 Xiyuan Plxyyylijing +86 15901 Nursing De (3) Those (3)
who Patients
meet thewith diagnos
men
Inclusion criteria: (1) aged 18-60 yea
 (2) BMI in the normal range (1+/
 (3) diagnosis
Exclusion
of lung
criteria:
cancer,
(1) had
bre
 (4) ASA (2)
grade I-II;
used albumin and
N/A China Yang Jinfeng 283 Tongzi 31597770 +86 13875 Hu'nan Can (5) no (3) had a history of c
Inclusion criteria: 1. Aged >14years o
RetrospectChina Rengbin Ji 41 Xibei St rengbinji +86 13989 HwaMei Hos 2. The Exclusion
diagnosis cconforms to the
N/A China YY Chen 61 West Ji chenyinyi +86 13637 Hu'nan ProvInclusion Exclusion c
Exclusion criteria: (1) thos
 (2) pregnant and lact
 (3)(1)
Inclusion criteria: severe basic disea
all patients with
0 China Gang Sun 28 Fuxing Rsunok301 +86 13501 PLA Genera (2) aged (4) seriousapproved
>=18 years, renal dam b
Exclusion criteria: 1. aged
Inclusion criteria:
 2. 1.after
patients
cardiopulmon
who me
N/A China Zhaohui Tong 8 Worker Stongzhaoh +86 13910 Beijing Ch 2. patients 3.with
accompanied
s by o
 2. Severe liver functio
 3. Severe renal impa
4 China Chunli Liu 151 Yanjia chunli@gir +86 13560 The First A Inclusion c 4. Have any coexistin
RetrospectChina GAO Hong 29 Bulan R 13603035 +86 13603 Shenzhen T 2. AgedExclusion
older than 18 years.
Inclusion criteria: (1) Patients with no
 (2) Patients with novel coronavi
Retrospective study Tang Hao 415 Fengyatanghao_0 +86 13816 Department (3) Patients
Exclusion
meetc the clinical sus

 
 - admission to ICU
 
 - adult (=18 years old)
 
 - confirmed case of 2019-
N/A Hong Kong polymerase chain rea

 
 - Healthy and Covid-19-po
 
 - The interval between the
Phase 1 China ;; Lung-Ji Chang;Lung-Ji ;c@szgimi. ;+86(755)8 Shenzhen G patients. The onset of sy

 
 - Patients with novel coro
 swab test of viral nucleic
 
 
N/A China Qiong Gong, MD. Renmin Hos - Patien
N/A China Jie Lin 41 Xibei St linjie1992 +86 15258 Hwa Mei HoInclusion c Exclusion c
0 China Feng Zhen 17 Yongwaifengzhenl +86 13970 The First A Inclusion c Exclusion c
RetrospectChina Changqing Hu 352 Renmin13966906 +86 13966 DepartmentInclusion c Exclusion c
Inclusion criteria: 1. Diagnosed COVI
RetrospectChina Chen Jian 52 Meihua chenjn@mai +86 13926 The Fifth H 2. Suspending
ExclusionCOVID-19
c patient
0 China Liujie 37 Guoxue liudr@out +86 18980 West ChinaInclusion Exclusion c
 2. Patients diagnosed with nove
 3. Patients
Exclusion
>=21 criteria:
days since 1. Patie
the fi
0 China Zhang Dingyu 1 Yintan Ro18138863 +86 13507 Wuhan Jiny 4. The 2.diagnosis
Patients
of pulmonary
with recefi
Inclusion criteria: 1. Patients who ha
betweencriteria:
18 to 801.years
Patie
N/A China Luping Lin 627 Dongfe13533550 +86 13533 Guangzhou 3. the subjects 2. Theparticipating
compliancethe of
Inclusion criteria:
Exclusion
(1) criteria:
Aged 18(1) to 65
Fem y
N/A China Bin Zhang/Yinong Ye 81 Lingnan FSYYN001 +86 18038 Department (2) Patients (2)
with
ALTmild
is higher
or normal
than
Inclusion criteria:
Exclusion
1. Aged
criteria:
between
1. Fami 1
 2. Able 2.
to understand
Subject allergic
the conteto
1 China Zhu Fengcai 172 Jiangsuiszfc@sina +86 025 8 Jiangsu Pro 3. Able 3.
and willing
Woman to complete
who is prea
0 China Jiang Shujuan 324 Jing-Wudocjiangs +86 15168 Shandong P 2. Patients Exclusion
who agreed
c to enroll
Exclusion criteria: Exclusio
Inclusion criteria:
 (1)1.There
novelwascoronaviru
no rap
RetrospectChina Tian Lin 52 Meihua tianlin@ma+86 0756 The Fifth A 2. Willing to participate
 (2) Subjects who in rapid
cou
RetrospectChina Huang Hui 41 Erling 39340681 +86 13825 HuiZhou Mu Inclusion c Exclusion c
Inclusion criteria:
Exclusion
1. Patients
criteria: with
1. Patie
CO
0 China Qianjin Lu 139 Renminqianlu586 +86 731-8 The 2nd Xi 2. Age- 2.
and sex-matched
Those who refusenorma
 (2) Maternal patients
 (3) Pediatric patients
 (4)Meet
Inclusion criteria: Suicide
thedeath casfo
criteria
RetrospectChina Binru Wang 241 Pengli wanbr2000+86 13554 Wuhan Thir 1. clinical
 (5)
manifestations:
Transferred to ho
 2. Pregnant and lacta
Inclusion criteria:
 3. 1.
Lopinavir/ridonavi
Male and female
2-Mar China Zhaohui Tong 8 Worker Stongzhaoh +86 13910 Beijing Cha 2. Patients
 4.
previously
Cases of diagnosed
r
Inclusion criteria:
Exclusion
1. Pharyngeal
criteria: 1. Patie
swab
 2. Males 2.
and females
Patients aged
with 18mento
0 China Chuo Li 8 Huaying gz8hlc@12+86 15989 Guangzhou 3. Participant
 (2) ALT/AST increase
 (3)(1)
Inclusion criteria: Severe
Aged patients
18 yearswo
 (4) Pregnancy;
 (2) Voluntarily signed informed
0 China Xinghuan Wang (5) HIV
169 Donghuwangxingh +86 027 6 Zhongnan H (3) Hospitalized positive
patients diagno
RetrospectChina GuoLin Song 32 Feishan ant000999 +86 13985 The SecondInclusion Exclusion c
Inclusion criteria:
Exclusion
1. Eligible
criteria:patients
1. Intub
 2. Were 2.
identified
Pregnancy,
as laboratory
severe
N/A China Li Bixi 627 Wuluo bxlee@soh+86 13397 Central The 3. Those 3.
who Those
need intubation
patients has in
Inclusion criteria: (1) Medical staff in
 (2) People aged between 18 and
N/A China Zhongyuan Xia 238 Jiefan wenqin-19 +86 13808 Renmin Hos (3) People
Exclusion
have electronic
c socia
Exclusion criteria: (1) Ree
 (2)(1)
Inclusion criteria: The
TheCTpatients
image can wi
RetrospectChina Wei Wang (3)
1095 Jiefa wwang@vip+86 13871 Tongji Hosp (2) CT was Patients
positive withfirst
for the pleu
ti
Exclusion criteria: The clin
 1) Respiratory failure
Inclusion criteria:
 2) 1.Shock
Agedoccurs;
18 to 70 ye
N/A China Binghong Zhang 99 Zhang-Zzbhong62 +86 13886 Renmin Hos 2. Patients with
 3) severe COVID-1
Combined failure o
Inclusion criteria:
Exclusion
1. Aged
criteria:
>=18 1. years
Gest
 2. The 2.
person,Patients
who is diagnosed
with aller
N/A China Ting Cai 41 Xibei St caiting@uc+86 13738 HwaMei Hos3. Patients with othe
Inclusion criteria:
 2. 1.
Pregnant
Female and patients
lacta
 2. SARS-CoV-2
 3.Havenucleic
malignant
acid testtump
N/A China Chengyun Liu 1277 Jiefa chengyunl +86 18007 Union Hosp 3. Lung<CT exam
Inclusion criteria:
Exclusion
1) Those
criteria:
who1) have
Acco
 2) Be over
 2)
18 Those
years old
who(includin
are alle
N/A China Dawei Wang 100 Shizhi cleverwd +86 025-5 Affiliated 3) Voluntarily
 3) Pregnant
sign written or la
inform
Exclusion criteria: 1. sNCP
 2. WHO grade III or IV
 3. 1.
Inclusion criteria: Malignant
Patients tumor
are eligi
1 China Ye Xiaoqun 1 Minde Ro51120166 +86 0791 The Second 2. The 4.
patientsLactating
met thewomen
diagnoso
RetrospectChina MINGLI LIU 480 Shuang39595618 +86 13761 Shanghai KInclusion c Exclusion c
Inclusion criteria: 1. novel coronaviru
Exclusion criteria:for
 2. No contraindications 1. Patie
MR e
0 China Ying-kun Guo 20 South R gykpanda +86 18180 West China 3. understand
 2. Contraindications
the potential risks
 2. Stay in hospital for 3 days or m
18 or above;
criteria: 1. Confi
0 China Hongmei Tao 52 Meihua 13926946 +86 13926 The Fifth A 4. Info 2. KPS > 30 points.
Inclusion criteria:
Exclusion
o becriteria:
enrolled,
Youallcan
th
 1) the confirmed
 1) anypatient
situation
(orthat
lega
 2) Aged 2)
18-65allergic
years, gender
constitutio
not
4 China Li Lanjuan 79 [email protected] +86 13906 The First A 3) the time
 3)intpatients w
Exclusion criteria: (1) any
 (2)(1)
Inclusion criteria: allergic
aged 18constitutio
to 70 y
4 China Gong Guozhong 139 Renmingongguozh+86 13873 The Second (2) Light (3)
and heavy
seriouspatients
basic dise
with
Inclusion criteria: 1) > 18 years of age
 2) identify the patients infected
 3) the patient
Exclusion completes
criteria: 1.
CTthose
exa
N/A China Zhang Lina 87 Xiangya zln7095@1+86 15874 Intensive C 4) sign 2.
the informed
the patient
consent.
or his g
Inclusion criteria: 1. Pharyngeal swab
 2. AgesExclusion
betweencriteria:
18 to 851.years
Patie
0 China Fan Zhong 8 Huaying gz8hzf@12+86 18122 Guangzhou 3. Su 2. Patients judged by
0 China Wei Zhang 17 Yongwaizhangweil +86 13707 The First A Inclusion crExclusion c
 2. Other serious med
 3. 1.
Inclusion criteria: Not
Agedsuitable for ga
18 years ol
4 China Guochao Shi 197 Secondshi_guoch +86 13918 Ruijin Hosp 2. Meet 4.
the novel
Preg coronavirus p
Human
pharmaco
logy
(Phase I):
no
Therapeu
tic
explorato
ry (Phase
II): no
Therapeu
tic
confirmat
ory - Exclusion criteria: - P
(Phase -Child less than 12 ye
III): yes -Known hypersensitiv
Therapeu -Feeding
tic use -Retinopathy
(Phase Inclusion criteria:
 -Known
 - Women
deficit inand
G6P
IV): no - Teenager
 -Refusal
girls and to
boys
participat
aged m
France IHU MÃ©diterranÃ©e19-21 Boul line.medd 00334 13 7Fondation - Persons -Patient
who have given their f
N/A Germany Sven Laudi Liebigstras anaesthesi +49 341 97Klinik fÃ¼r Inclusion c Exclusion c
2-Mar Iran (Islam Hossein Khalili Departmentkhalilih@tu+98 21 669Tehran UniInclusion c Exclusion c
2-Mar Iran (Islam Amir Hossein JamshidiNo 847, Behjamshidi.a +98 21 556Iran UniverInclusion Exclusion c
2-Mar Iran (Islam Hossein Khalili Departmentkhalilih@tu 9.82E+10 Tehran UniInclusion c Exclusion c
2 Iran (Islam Dr Ehsan Aali Bahonar en.aali@gm+98 28 333Qazvin UnivInclusion c Exclusion c
3 Iran (Islam Farzaneh Dastan Dr. Masih f_dastan@s+98 21 261Shahid Behe
Inclusion Exclusion
3 Iran (Islam Dr Hossein Poustchi Shariati Hoh.poustch +98 21 824Tehran UniInclusion c Exclusion c

 
 1.Meet the definition of sev
 
 1. Shortness of breath,RR=
 
 2. In a resting state:SPO2=
 
Phase 4 China ; Qing Ning, Professor;Qqning@vip.+8613971521450; 3. P
2 Japan Tetsuya Nakamura 3-39-15 Sh nakamurt@ -8906 Gunma Univ Inclusion c Exclusion c
Inclusion criteria: Patients suspected
N/A France;Fra Enrique Casalino 46 rue Henenrique.ca 3.31E+10 APHP qSOFAExclusion
>=1 (respiratory
c rate Ã¢?
 
 1. 14-70 years old
 
 2. 2019 novel coronavirus
 
 3. Subjects voluntarily parti
 
N/A China Faming Zhang, MD; PHD The Second 
 - Aged between 18 and 80
 
 - One of them:
 
N/A China XIAN SHEN, phd The 2nd Af 1. Laboratory (RT-PCR) a

 
 - Patients confirmed with
 "Pneumonitis Diagnosis a
N/A China ; Yang Jin;Yang Jin whunjy@1 13554361146;135543 

 
 1. Laboratory diagnosis:
 
 - Respiratory specimen
 
N/A China Yimin Li, PhD, MD The First A - The viral gene sequen

 
 1)2019-nCoV nucleic acid te
 of viral pneumonia.
 
 
Phase 4 China ; Qing Ning, Professor;Qqning@vip.+8613971521450; 1. Patients who meet any

 
 1. 2019-nCoV nucleic acid
 
 2. CT of the lung conforme
 
 
Phase 4 China ; Qing Ning, Professor;Qqning@vip.+8613971521450; 1. Patients wh
 
 1. Age:18~55 years old, un
 
 manifestations.
 
Phase 3 China ; Qing Ning, Professor;Qqning@vip.+8613971521450; 3.
Not applic Japan,Asia Keibun Liu Takebayashkeiliu040 028-626-5 Saiseikai Inclusion crExclusion c

 
 - Laboratory (RT-PCR) con
 lower respiratory tract sa
 
Phase 1/PhChina ;; Lung-Ji Chang, PhD;Lu ;c@szgimi. ;+86(755)8 Shenzhen G - The interval between the

 
 1. Volunteers who have un
 
 2. Age =18 years, gender u
 
 3. Patients diagnosed with
N/A China <

 
 
 
Phase 2/PhChina ;; Wei Zhang;Jiang-Rong ;; ;; Jingzhou Ho 3. Hospitalised with Fever(

 
 
 - Diagnosed with CONVID1
N/A China SARS-Cov-2 infection; CT

 
 - It conforms to the diagno
 
 - Age from 18-75, regardle
 
Phase 2 China ; Haibo Cheng, phD;Lei 36399490 13815857118;139512 - The patient informed co
Not applic Japan Junko Terada 1-21-1, To registry.c 3.32E+08 National CeInclusion crExclusion c
N/A France Enrique Casalino 46 rue Henenrique.ca 3.31E+10 Assistance Inclusion Exclusion c

 
 
 2. Patients diagnosed with
Phase 2/Phase 3 Lin Chen chenlin_t 8.61E+12 guideline "Pneumo

 
 1. Male or female, 18 year
 
 
N/A China 3. Laboratory confirmation
 
 - At least 21 years
 
 - Has stayed in Singapore
 
 
 - Below 21 years
 
Phase 2 Singapore ; ; Jean Liu, PhD;Jean Liu ;jeanliu@y ;66013694;Yale-NUS C - Has stayed in Singa

 
 
 2. Those who meet the dia
Phase 2/PhChina ;;;; Dong Shang, M.D.;Jian;;;;franlj ;;;;8610-6 Wuhan Leis confirmed infection with

 
 
 - Diagnosed with 2019-nC
N/A China 2019-nCoV infection; CT

 
 1. Patients diagnosed as CO
 
 1. mild patient: fever,re
 pneumonia can be see
 
Phase 3 China ; Qing Ning, Professor;Qqning@vip.+8613971521450; 

 
 1. Agrees to the collection
 
 2. Male or non-pregnant fe
 
Phase 4 China ;; SHAOXIAN HU, M.D;YI;yuyikai@1;+1 (484) Tongji Hosp 

 
 - All patients >18 years of
 inclusion.
 
 - Healty age-matched volu
Phase 3 
 - all patients treated for C
 
 
 - Chronology not compati
Phase 1 France ;; Joe-Elie Salem, MD, ;nguyen.le ;00331584 Clinical In 

 
 - Patients with mild and se
 pneumonia according to
 
Phase 4 China - Plan for New C

 
 - (1) Age =18 years. (2) Lab
 Lung involvement confirm
 
 
N/A China 

 
 COVID-19 positive accordin
 
 
 - Participants in other clin
 
Phase 1 Jordan ; Adeeb M AlZoubi, Ph. adeebalzou+962795337575;+962 -
Inclusion criteria:
Exclusion
(1) criteria:
Outpatient(1) you
and
RetrospectChina Kun Xiao 28 Fuxing R45595789 +86 13716608331 (2) The (2)
body temperature
refuse to sign highe
info

 
 - Patients diagnosed with
 
 - Aged between 18-75
 
 - Willing to sign the i
 
N/A China ;; Xiaoju Zhang, PhD;Ziq ;13781919 ;+86-1378 Henan Provi Exclusion Crite

 
 - 18 years old upon study
 
 - Healthcare personnel ex
Phase 3 ; ; ; ; ; ; ; ; Jorge Rojas-Serrano, MD,
;;;;;;;;lf
PhD.;Rogelio
;;;;;;;;+52
Perez-Padilla,
National MD;Felipe
In Jurado-Camacho,
physicians, nurses,
MD. chem
MSc;I
 
 Patients hospitalized for CO
 
 
 none
Phase 1 Italy ;; Augusto Di Castelnuo ;dicastel@n;32890356 IRCCS Neu 
Inclusion criteria:
Exclusion
1) About
criteria:
one1) mont
POSI
N/A China Wenliang Fan 1277 Jiefa fwl@hust. +86 027 8 Union Hosp 2) No other
 2)neurological
Those who disease
cannot

 
 - Admitted to intensive ca
 
 - suspected or verified CO
 
 
 - Pregnancy or breastfeed
 
Phase 4 Sweden ;; Robert Frithiof, MD. P ;robert.fri ;07365634 Uppsala Uni - Preexisting
RetrospectChina Shen Chan 745 Wuluo sunnyabs1 +86 18986 Maternal aInclusion Exclusion c

 
 - Patients went to the feve
 
 
 - none
N/A China ; Wenhong Zhang, Doctzhangwenh13801844344;+86 21 

 
 1. age >18 years old
 
 2. identify the patients infe
 
 3. the patient completed C
 
N/A China ;; Zhang Li Na, MD;Zhao ;56212264 ;+8613667 Xiangya Hos 4. sign the info

 
 - pregnant women with la
N/A Italy Gabriele Saccone, MD gabriele.s 8.17E+08 

 
 1. Signed informed consen
 
 2. negative pregnancy test
 
 3. COVID-19 confirmed by
 
Phase 3 ;;;;;;; Carmen Hernandez-CÃ¡
;;;;;;;cmh ;;;;;;;5487 National In 4. Severe COVID-19 diseas
Inclusion criteria: 1. Myopia teenage
N/A China Xianli Du 5 Yan-Er-D lilibestev +86 15192 Shandong E 2.The cornea
Exclusionis c
 2. age < 18 years;
 3. Participating in an
 4. refuse to sign the i
N/A Tianwang Li 466 Xinganlitian-wa +86 13710 GuangdongInclusion c 5. individuals who su
0 China Haixiao Chen 150 Ximen cShenhx@e +86 13706 Taizhou HosInclusion c Exclusion
Inclusion criteria:
Exclusion
(1) criteria:
Aged 18-65 (1) Rec
yea
 (2) Voluntarily
 (2) Severe
participate
liver indisea
this
N/A China Prof. Qingsong Ye; Dr 238 Jiefan 20215851 +86 027 8 Center for (3) Diagnosed
 (3) with
Patients
severe
withpneu
kno
Inclusion criteria:
Exclusion
1) Positive;
criteria: 1) Thos
N/A China Fan Yang 1277 Jiefa fyang@vip +86 027 8 Union Hosp 2) There 2)
is a CT
Patients
examination
who are in uo
N/A Wei Min 321 Zhongsh82464790 +86 15850 Nanjing UniInclusion c Exclusion c
N/A China Yuan-hao Wu 314 West Andoctor.wu +86 022 2 First Teach Inclusion c 2. Combining system
Inclusion criteria: 1. Diagnosed as CO
 2. Aged >=18 years;
 3. Diagnosed
Exclusionas critical
criteria:ill1.patien
Susp
RetrospectChina Hong Qiu 1095 Jiefa tjqiuhong +86 13986 Tongji Hosp 4. 2. Pregnancy and lac

 
 - Adults healthcare worke
 
 - Chronic patients with at
 
 
N/A Italy ;; Maurizio Cipolla, MD; ;antonio.g ;+3939200 Medical di - People that have been in
N/A China Xianli Du 5 Yan-Er-D lilibestev +86 15192 Shandong EInclusion Exclusion c
N/A China Zheng Xue 699 Hongfezhengxue. +86 17717 China Euro Inclusion Exclusion
Inclusion criteria: (1) Have a clear his
 (2) TwoExclusion
consecutive
criteria:
positive
(1) Pati
nuc
 (3) No (2)
clinicallyPatients
relevanthave
sympto
no
N/A China Qiuling Shi 1 Yi-Xue-Y qshi@cqmu+86 023-6 Department (4) Patient (3)
voluntary.
Patients with unc
Exclusion criteria: (1) Basi
0 China Zhuang-Gui Chen 600 Tianhechenzhuan +86 13600 DepartmentInclusion c (2) Not willing to par
RetrospectChina Zhongyuan Xia 99 Zhangzhwanzimili +86 17762 Renmin HosInclusion Exclusion cr
RetrospectChina Daoyuan Si 126 Xiantaisidaoyuan +86 13578 China-JapanInclusion Exclusion c
N/A Xiandong Meng 28 Dianxin wchmhcmx+86 18980 West ChinaInclusion c Exclusion c
RetrospectChina Zhang Rong 183 Yiling 13972046 +86 13972 Yichang CenInclusion c Exclusion c
N/A China Yan Hao, Xiaoping Luo1095 Jiefa haoyaner@+86 13971679960, 13 Inclusion c 2. The guardian does
Inclusion criteria: 1. History of conta
 2. During the 14-day clinical obs
 3. Nucleic
Exclusion
acid test
criteria:
positive
1. Have
twic
 4. Without
 2.any
Patients
clinically
norelevan
willing
N/A China Xiaojun Tang 1 Yi-Xue-Y tangxiaoj +86 13668 School of 3. Patients with cons
Inclusion criteria: Patients with Covid
 (1) clinical and inpatient data ar
N/A China Wei Wang 1095 Jiefa wwang@vip+86 13871 Tongji Hosp Must include:
Exclusion c routine on a
blood
Inclusion criteria: 1. male and female
 2. positive result of test for 2019
 3. Clinical
Exclusion
diagnosed
criteria:
with1.pneum
seve
 4. onset 2.
within pregnant
7 days (severe
and nurs ca
2 China Jin Ronghua 8 Xi-Tou-Ti jin_eagle@+86 13901 Beijing You 5. the info
 3. subjects received l
Inclusion criteria: (1) Inpatients in ou
 (2) AgeExclusion
and gender are not
criteria: (1)limit
Pati
 (3) The (2)
PT-PCRPatients
test is positive
with inco or
RetrospectChina Pengcheng Luo 241 Peng-Lpluo@whu.+86 13507 Wuhan Thir (4) There is a complete
 (3) There aremedical
patient
 2. Those who cannot
Inclusion criteria:
 3. 1.Suicide-prone
Those who meet by t
0 China Fu Liran 33 Huanghefuliran@1 +86 15837 Zhengzhou 2. The 4.
patientpregnant
was conscious,
women, w
N/A China Zhang Yi 33 Huanghenicole861 +86 13837 People's h Inclusion c Exclusion c
Inclusion criteria:
 2. 1.Patients
The diagnosis
with seve of
Retrospective study Qingta Meng 238 Jiefan mengqt201+86 13995 Department 2. Patients 3.with
Patients
invasivewhose
mechan co
Inclusion criteria: 1. patients with no
 2. Fever, respiratory
Exclusion tract1)and
criteria: noveo
 3. Aged 2)
18 to The
80 years;
age is less tha
N/A China Wei Lu 725 Wanpinicuwei@16+86 18917 Longhua Hos 4. Signed informed
 3) cons
Patients with aller
Inclusion criteria: (1) a patient who m
 (2) stable
Exclusion
condition,
criteria:
normal(1) pati
cog
0 China GAO Tian-lin 349 Hangzh22356581 +86 18930 The First R (2) patients combine
RetrospectChina Jun Shao 98 Nantongsjun1982@+86 18051 Nothern Ji Inclusion c Exclusion c
Inclusion criteria:
Exclusion1. Patients
criteria: with
1. Thossev
 2. Aged 2.
>=18 Patients
years, bothwithmenallera
N/A China Peiyang Gao 39 Shi-Er- gaopy930 +86 18980 Hospital of 3. Agree 3.
to participate
Cases where comp
 2. Without the inform
0 China Sun Hongyuan 88 Changlinsunhongy +86 18222 First Teach Inclusion c 3. Unable to coopera
 2. Non-fever non-new
Inclusion criteria:
 3. 1.Fever
During
caused
the outbr
by ot
N/A China Peiyang Gao 39 Shi-er- gaopy930 +86 18980 Hospital of 2. Comply 4.
wi Patients with tube
Inclusion criteria: 1. Novel coronaviru
 (1) there
Exclusion
were travel
criteria:
history
1. Havin
or r
0 China Lei Genping Plus 2 Wei leigenpin +86 13609 Affiliated (2) During
 2.
theMycoplasma
14 days before pneu on
Inclusion criteria:
Aged >=18 (1) year
Kno
 (2) 2019-nCoV
 (2) Acute
pneumonia
infection
is dia
of
4 China Li Shi-yue 151 Yanjia lishiyue@ +86 13902 the First A (3) Patient's
 (3) condition
The function
has reach
of liv
 2. previous arrhythm
 3. previous chronic re
Inclusion criteria:
 4. 1.hemodynamic
Novel coronaviru inst
4 China Hu Xingxing 100 Shizi S huxingxin +86 17327 Jiangsu Pro 2. Respiratory
 5. se rate in calm state
 2. patients with malig
Inclusion criteria:
 3. 1.patients
patients with
agedseve
16
 2. they 4.
were willing
recentto orsign
participa
the i
RetrospectChina Zhe Xu 100 West 4txuzhe302 +86 15001 Diagnosis, 3. The 5. evid
novel coronavirus nucleic
Inclusion criteria:
Meet the(1)diagn
Criti
 (2) Aged (2)
18-85TCM years;
diagnosis of
N/A China Zhongde Zhang 111 Dade Rdoctorzzd +86 13903 Guangdong (3) To agree (3) toPatients
participate
whoincann
the
0 China Mingxing Xie 1277 Jiefa xiemx@hus+86 13607 Union HospInclusion Exclusion c
Exclusion criteria: 1. A com
Inclusion criteria:
 2. 1.
ThePatients
estimatedconfirm
surv
0 China Jin Yang 1277 Jiefa whuhjy@si+86 13554 Union Hosp 2. Those 3.
without
The broad-spectru
patient's med
Inclusion criteria:
Exclusion
1. Normal
criteria:and
1. Pneu
seve
 2. Viral 2.
nucleicHave
acidcontraindica
test is negati
 3. Aged 3.
>= 18Mental
years; disorders,
N/A China Ming Wu 17 Lujiang ahslyywm +86 18655 The First A 4. Patients
 4.
with
Patients
c wit
Inclusion criteria:
Exclusion
(1) criteria:
Comply with
(1) Criti
th
 (2) Aged (2)
>= 18Patients
years; who can
N/A China Huang Luqi; Ruan Lia 16 Nanxiaohuangluqi +86 010-6 China Acad (3) Agree (3)
to participate
Patients with
in theseve
tr
RetrospectChina Cao Guoqiang 10 Changji cgq1963@ +86 023 6 Daping HosInclusion c Exclusion c
Inclusion criteria:
Exclusion
1. Patients
criteria: discharg
1. Pneu
 2. Adults
 2.
overHave
18 years
contraindica
of age w
0 China Chengqi He 37 Guoxue hxkfhcq@1+86 18980 West China 3. Study 3.
participants
Mental aredisorders,
willing
Inclusion criteria: (1) RT-PCR detectio
 (2) Gene sequence
Exclusion of the(1)
criteria: virus
Subi
0 China Yan Kang 37 Guoxue kangyan_h +86 18980 West China (3) (2) Subjects who rece
Human
pharmaco
logy
(Phase I):
no
Therapeu
tic
explorato
ry (Phase
II): yes
Therapeu
tic
confirmat
ory -
(Phase
III): no
Therapeu Exclusion criteria: 1.
tic use 2. Stage 4 severe chr
(Phase 3. Pregnancy or brea
IV): no 4. Allergy to any stud
Belgium Laurens Liesenborghs Herestraat laurens.liesenborghs UZ Leuven Inclusion c 5. Any medical c
0 China Shan Chunlei 1200 Cailu shanclhap +86 18616 Shanghai UnInclusion c Exclusion c
Human
pharmaco
logy
(Phase I):
no
Therapeu
tic
explorato
ry (Phase
II): yes
Therapeu
tic
confirmat
ory -
(Phase
III): yes
Therapeu
tic use
(Phase
IV): no
France;CanDirection des OpÃ©rat1 avenue PiPublic-Registry-MA-F Sanofi-avenInclusion c Exclusion
Human
pharmaco
logy
(Phase I):
no
Therapeu
tic
explorato
ry (Phase
II): no
Therapeu
tic
confirmat
ory -
(Phase
III): no
Therapeu
tic use
(Phase
IV): yes
NetherlandMarc J. M. Bonten HeidelbergM.J.M.Bon 00318875 5University Inclusion c Exclusion c
Human
pharmaco
logy
(Phase I):
no
Therapeu
tic
explorato
ry (Phase
II): yes
Therapeu
tic
confirmat
ory -
(Phase
III): no
Therapeu
tic use
(Phase
IV): no
Germany Project management, Wilhelmstrdiane.egg 4.97E+12 UniversitÃ Inclusion c Exclusion
Human
pharmaco
logy
(Phase I):
no
Therapeu
tic
explorato
ry (Phase
II): no
Therapeu
tic
confirmat
ory -
(Phase
III): yes
Therapeu
tic use Inclusion criteria: 1. Adult pati
(Phase 2. Confirmed
ExclusionSARS-2-CoV-2
criteria: 1.in
IV): yes 3. Admitted
 2. toASAT/ALAT
the hospital> 5wa
ti
Norway Sect. Clin. Imm. & InfeSognsvannsandreas.b 4.72E+09 Oslo univer 4. Subjects
 3. (orAcute
legallyco-morbid
authoriz
Human
pharmaco
logy
(Phase I):
no
Therapeu
tic
explorato
ry (Phase
II): yes
Therapeu
tic
confirmat
ory -
(Phase
III): no
Therapeu
tic use
(Phase
IV): no
United Ki Jody Brookes Mailpoint jody.broo 2.38E+09 Synairgen Inclusion c Exclusion c

 
 - 1. Subjects must have a d
 hours of the administrati
 
Phase 2 United Sta ; Colin Broom, MD;Col ;clinicalt ;713-579-9Pulmotect, - 2. Subjects who have no

 
 - Adult =18 years of age at
 
 - Has laboratory-confirme
Phase 3 France ; Florence Ader, MD;Fl ;florence. ;+33 (0)4 7 Hospices Ci commercial or public hea

 
 - Male and female, 18-75
 
 - Patients previously diagn
Phase 2/PhChina ; Shumin Wang, Phd.;S shuminwa +86 13488760399;+8 is no more than 14 days;
 
 - Parents/legal guardians
 consent for participation
 
Phase 2 United Ki ;; Matthew Snape, Profes;info@ovg.;01865611 University - Male or Female, aged 0 -

 
 - Age 18 or older.
 
 - Confirmed Covid-19 infe
 
 - ARDS
 
 - ICU patient
 
 
Phase 2 Thomas C Pitts, M.D. Drpitts@h 6.47E+09 - Active Neiss

 
 1. Age =18 years
 
 
 3. PaO2/FiO2 < 300 or SpO
 
Phase 2 ; Chong Lei, MD, PhD;L ; ; Fourth Mil Exclusion Crit
 Study Participants

 
 These are of two types:
 
 A. Adult volunteers (exact a
N/A William Schilling, MD William@t +66 2 203-6333 frontline (i.e. patient contac

 
 1. Age: 18-80 years old, ma
 
 2. Covid-19 confirmed case
 
 3. Comply with any of the
 
 - Dyspnea, RR = 30 time
N/A China ;;; Yihai Cao, Dr;Yuguo Ch;;jiaojiao ;;1856008 Qilu Hospit
 The inclusion criteria are:

 
 1. age over 60 years;
 
 2. informed consent to par
 
 The exclusion criteria are:
 
N/A ; PÃ©ter Hegyi, MD, Ph;hegyi200 ;+3670375 Insitute fo 1. confirmed COVID-19 inf
 
 - We identify individuals a
 care practice for at least
 
 
Phase 2 - We

 
 - Confirmed SARS-CoV-2 in
 
 - COVID-19 patient in stab
 
 
Phase 4 Mahmoud M.A. Abulme
mabulmeat 9.67E+11 - Tube feeding o

 
 - 1. Subjects must have do
 test for the virus within 7
 
Phase 2 ; Colin Broom, MD;Col ;clinicalt ;713-579-9Pulmotect, - 2. Su

 
 - COVID-19 pneumonia pa
 
 
 - Patients who were youn
 
Phase 2 China - Patients who had underg

 
 - healthy asymptomatic he
 
 
 - SARS-CoV-2 positive or s
Phase 2 United Ki ; ; ; ; ; ; ; ; James C Moon;Gabriel;;;;;;;bart ;;;;;;;0757 BHC & UCL 

 
 - Household contact of ind
 individual evaluated at N
Phase 2/PhUnited Sta ; Elizabeth Oelsner, M ;eco7@cum;212-305-9Columbia Un
 se
 
 - COVID-19 positive patient
 samples
 
 
N/A France ; Joe-Elie Salem, MD-P joe-elie.s 01 42 17 85 31;01 42 - Patients for which electroc

 
 - According to the risk stra
 (accessed on March 24th
Phase 2 Lucio Manenti, MD [email protected]+11 S

 
 - In case of doubt of inters
 
 - Positive swab test of SAR
 
 - Interstitial pneumonia
 
N/A Italy ; Salvatore Corrao, MD;s.corrao@ti+390916662717;+390 - Sig

 
 - Adult patients (>18 years
 
 - Confirmed COVID-19 infe
 within 48 hours of testin
 
Early Phase 1 ; Paul;Paul ;M_paul@r;+972-50- Rambam M -

 
 - Being between the ages
 
 - To continue their active
 period.
 
Phase 3 Turkey ;; Ipek Yeldan, Prof.;Eren;erenavcil ;+9005320 Istanbul Un - Spending time at ho

 
 - Age> 18 years old
 
 - patients with acute resp
N/A FranÃ§ois Lellouche francois.le 418-656-8711 pneumonia (viral and no
 
 - All consecutive patients
 
 - Age >18 years,
 
 - Clinical diagnosis of COV
 
Phase 3 Italy ;; Fabrizio Cantini, MD;F ;fbrzcanti ;+3934080 Hospital of - Patients shou

 
 - Signed the informed con
 
 
 - Dysphagia or symptoms
N/A China Zhuan Liao, MD Changhai H 
 
 - Positivity to covid-19 scr
 
Phase 2/PhItaly ; LUCA GALLELLI;LUCA Ggallelli@uni3339245656;3339245 - In escin group: Low resp

 
 - Patients undergoing ANY
 obstetrics
 
 AND
 
Early Phase 1 Aneel Bhangu A.A.Bhang +44 1216272949 - The patient had COVID-19
Inclusion criteria:
Exclusion
1. The
criteria:
nucleic
1. Have
acid
 2. The 2.
patientSerious
has fevernausea,
or / and
vo
0 China Hong wenxin 627 Dongfewinsonho +86 13729 Guangzhou 3. Aged 3.
>=18 Taking
years old.
drugs that m

 
 1. High risk close contact w
 period, including one day
Phase 3 Canada ;; Darrell Tan, MD FRCP ;Attia.Qam ;416-864-6St. Michael cl

 
 - age >=18 yrs
 
 - positive for reverse trans
 respiratory syndrome (SA
 
N/A Italy Cesare Perotti, MD Foundation - Acute res
 
 - suspected COVID-19 pati
 
 - known COVID-19 patient
 
 
 - confirmed disease differ
N/A Italy ;;;; Riccardo Inchingolo, ;;;;liberta ;;;;003904 Fondazione 
 Key Inclusion Criteria:

 
 1. Patients were diagnosed
 (COVID-19) Treatment G
 
Phase 3 China ;; Hao Li, Professor;Hao L;xyhpliha ;+0086-13 Xiyuan Hos 2. Patients received a com
Inclusion criteria:
Exclusion
1. People
criteria:aged
1. a bet
his
N/A China Zhongyuan Xia 238 Jiefan wenqin-19 +86 27 88 Wuhan Univ 2. People
 2.
havemedical-care
electronic social
work
0 China Xiaomei Guo 1095 Jiefa xmguo@tjh+86 13971 Tongji HospInclusion c Exclusion c

 
 1. Sign written informed co
 
 
 3. Conforms to the NCP Cr
Phase 1/PhChina ;; Min Liu, A.B;Min Liu, ;gwzxlium ;13668072 Chongqing Diagnosis

 
 - Highly suspected/confirm
 
 
 - Patients that opt-out
N/A Netherland ; Folkert W. Asselbergs f.w.asselb +31 (0) 88 755 5555;+ 

 
 - COVID-19 infected patie
 
 - Age 18 years or older
 
 - Presence of pneumonia
 
Phase 3 ; FrÃ©dÃ©ric ADNET, ;frederic. ;+33 1-48- Assistance - PaO2/FiO2 < 300 mm Hg
 
 Cohort 1:
 
 - Females and males over
 
 - Willing to share demogra
 
Phase 1 United Sta ; Daniel R Karlin, MD, ; +1 (201) 212-6643; - Willing to follow app use
Inclusion criteria:
Exclusion
Healthy
criteria:
group:
Uninfec
hea
 normal normal
group: diagnosed
group: patien
those
0 China Xiuyong Li 1088 Yinghlxy7111@1+86 13505 2nd People' severe severe
group: diagnosed
group: patient
those w
Inclusion criteria:
Exclusion
1. Chinese
criteria:emerge
1. Have
 2. Aged 2.
>= 18Taking
years; antipsychoti
N/A China Xuezhong Yu 1 Shuai-Fu-yxzpumch +86 13601 Peking Uni 3. Meet 3.
ethical
Participating
standards and in clin
b

 
 - Case are adults age = 18
 COVID-19
 
 - Controls are patients adm
 
N/A Hong Kong ; Paul CHAN; paulkscha +852 35053339;+852 <

 
 - Patients >/= 18 years old
 
 - Hospitalised with PCR-co
 
 
N/A ; Joost Wauters, MD Ph;joost.wau ;00321634 UZ Leuven; - Age < 18 years old
Inclusion criteria:
Exclusion
1. Patients
criteria: meet
1. Miss
D
 2. Over 2.
18 years
28 day
old; follow-up is
 3. Patients
 3.
with
Co-infection
hypertension,di
with i
RetrospectChina Zhang Hua-nian 100 Hong Kwhet_ctr@+86 027 8 Wuhan Wome 4. Co 4. Discontinuation of
Exclusion criteria: 1. Hear
Inclusion criteria:
 2. 1.
Blood
Patients
pressure
with <9
ne
 2. Aged 3.
>=18 Blood
years; oxygen satu
1 China Jiang ZhiXia 149 Dalian jzxhl@126 +86 19385 Affiliated 3. The 4.
limbs function
Respiratoryis soun
freque
Inclusion criteria:
Exclusion
1. Informed
criteria: 1.consen
Neve
 2. Aged 2.
20-65Having
years; a history of
N/A China Yaqin Zhu 500 Quxi R zyq1590@ +86 13817 Ninth Peopl 3. Dental 3.
emergency
Drug abusers.
medical sta

 
 - Meeting the criteria for d
 positive swap.
 
 
Phase 3 Egypt ; Mahmoud Tantawy, ;drmtanta ;+2012218 Misr Unive - Children below 5 years o
 
 1. SARS-CoV-2 positive
 
 2. Age >17 years and < 80
 
 3. P/F < 250 mmHg
 
 4. Bilateral pneumonia (infi
 
Phase 2/PhItaly ;; Francesco Salton, MD ;francesco ;34869862 University 5. C

 
 - Age = 18 years of age
 
 - Informed consent
 
 - COVID-19 confirmed by e
 
 
Phase 3 Canada ;;; Richard Whitlock, MD ;;ACT.Pro ;;905-297- Population - Known glucose-6-
 Group 1
 
 
 - Aged 18 to 75 years old
 
 - Individuals with a clinica
Phase 1/Phase 2 Paolo Gisondi paolo.giso +39 0458122547 confirmed by the Investig
Exclusion criteria: 1. uncle
 2. participants are no
Inclusion criteria:
 3. 1.
malignancy;
Rheumatic disea
 2. Residents
 4.inpregnancy
Hubei province;
or abor
RetrospectChina Lingli Dong 1095 Jiefa 39317673 +86 02783 Tongji Hosp 3. > 18 5.
years old.
breast-feeding.
RetrospectChina Li Chen 150 Jimo R leetangba +86 13585 Shanghai OInclusion Exclusion c
Inclusion criteria:
Exclusion
(1) criteria:
Aged 181. toWith
90 y
 (2) Patients
 2.with
witha malignant
definite diagn
tum
 (3) Expected
 3.survival
Participated
time in> 10
othd
1 China Feng Ganzhu 12 Guangchzhu16352 +86 18951 Huangshi H (4) Serology:
 4. HIV
Severe
antibody
allergicnegati
hist
 (2) Sample size less t
 (3) Samples with sev
0 China Xiang Changgang 1 Wenhua A18971327 +86 18971 The First P Inclusion c (4) The researchers b
Inclusion criteria:
Exclusion
1) Aged
criteria:
18 to
1) 70
Prevye
4 China Xianglin Yuan 1095 Jiefa yuanxiangl +86 13667 Tongji Hos 2) Infection
 2)with
Combining
new coronaviru
with ot
Inclusion criteria:
Exclusion
(1) criteria:
Aged 18-70-yea
(1) Pati
 (2) Non-medical
 (2) Patients
staff and
withstaff
sevew
N/A China Ou Cehua 25 Taiping oucehua@s+86 15608 Affiliated (3) Patients
 (3)
withPatients
non-newwhocoron
are
Inclusion criteria:
Exclusion
1. Aged
criteria:
18 to
1. 75
in pr
ye
 2. mild 2.
or normal
to determine
patients; the h
 3. not using
 Patients
chloroquine
suffering
phosph
fro
0 China Xiao Fei 52 Meihua xiaof35@sy+86 13380 The Fifth A 4. under 3.
the gastroscope,
patients suffering
there
Exclusion criteria: ???????
N/A Li Wan 1095 Jiefa wanli0604 +86 13638 Tongji HospInclusion Incomplete medical h
 
 - Patients with suspected
 
 
 - Unwillingness to particip
N/A Germany ;; Tienush Rassaf, MD;M;matthias. ;+4920172 University 

 
 - 18 years or older
 
 - Suspected or known Cov
 
Phase 3 United Sta ; ; Daniel Mollura, MD; ;dgebow@ ;415-244-1Rad-AID; - Image procedure perform
Not Applic United Kingdom Inclusion c Exclusion cr
Inclusion criteria:
Exclusion
1. Hospitalized
criteria: 1. Miss
bet
RetrospectChina Lingli Dong 1095 Jiefa 39317673 +86 027-8 Tongji Hosp 2. Diagnosed
 2. with
< 12 years
COVID-19.
old.
 (2) Sample size less t
 (3) Samples with sev
0 China Xiang Changgang 1 Wenhua A18971327 +86 18971 the First P Inclusion c (4) The researchers b
RetrospectChina Fan Rong 87 Xiangya fanrong34 +86 13808 DepartmentInclusion c Exclusion c
Human
pharmaco
logy
(Phase I):
no
Therapeu
tic
explorato
ry (Phase
II): no
Therapeu
tic
confirmat
ory -
(Phase
III): yes
Therapeu
tic use
(Phase
IV): no
France;Bel Christelle DELMAS 8 rue de la rqrc.siege 3.32E+10 INSERM Inclusion c Exclusion c
Exclusion criteria: 1. Anot
 2. Another sleep diso
 3. 1.
Inclusion criteria: Current using
Insomnia hypn
diagno
N/A China Hongqiang Sun 4.happened
51 Huayuansunhq@bjm+86 10 82 Peking Univ 2. Insomnia Individuals wh the
after
Exclusion criteria: (1) pati
Inclusion criteria:
 (2)(1)
combined
patients with
with ade
 (2) patients
 (3)
aged
intolerance
18-80 yearsto car
old
N/A China Shen Chengxing 600 Yishan shencx@sjt+86 18501 Shanghai Si (3) patients who
 (4) signed
regular f informe
Inclusion criteria: 1. Clinical manifest
 2. Pulmonary CT results indicate
RetrospectChina Zejin Liu 300 Taizi zejinliu@1 +86 18963 Wuhan Asia 3. Apparently
Exclusionhealthy
c physical e
 2. Patients with confirmed cases
 (1) Epidemiology
Exclusion criteria:
history;1. Patie
N/A China Dongyang Liu 49 North Huliudongyan+86 18610 Peking Univ (2) Clinical
 Patients with identifi
manifestations (epide
Inclusion criteria:
 (2)(1)
Pregnant
severe or or critica
lacta
 (2) 18-85
 (3)
yearsALTold;/ AST > 5-fold
0 China Weiqin Li 305 Zhongsliweiqindr +86 13951 Eastern the (3) Obtaining
 (4)informed
The diagnosis
consent;
of r
Inclusion criteria: 1. aged between 2
 2. generally well;
0 China LI HANG 8 Cao-Lan-Zdrlihang@ +86 13693 Peking Univ 3. ableExclusion
to understand
c and sign a
Inclusion criteria:
Exclusion
1. Healthy
criteria:male
1. Patie
or
1 China Chenyu Zhang 163 Xianlincyzhang@n+86 13913 Nanjing Uni 2. Male 2.
body Patients
weight 50kg,
who fema
often
Exclusion criteria: 1) Preg
Inclusion criteria:
 2) 1)
High-resolution
Male or female CTp
 2) Willing
 3)
to sign
Acuteinformed
interstitial
conslu
2 China Fu-Sheng Wang 100 West Fofswang30 +86 010-6 The Fifth M 3) Confirmed
 4) cases who meet "N
Human
pharmaco
logy
(Phase I):
no
Therapeu
tic
explorato
ry (Phase
II): no
Therapeu
tic
confirmat
ory -
(Phase
III): no
Therapeu
tic use Inclusion criteria: Recent (=2wee
(Phase - Presence of acute hypoxic resp
IV): yes ? saturation
Exclusion
below
criteria:
93% on -
minim
P
Belgium HIRUZ CTU C. Heymanshiruz.ctu@ 3.29E+09 University ? PaO2/FiO2
 - mech
below
Human
pharmaco
logy
(Phase I):
no
Therapeu
tic
explorato
ry (Phase
II): yes
Therapeu
tic
confirmat
ory -
(Phase
III): no
Therapeu Exclusion criteria: â€
tic use â€¢ Denial of written
 â€¢ â€¢
Any patient
Age 18
case
or
IV): no â€¢ Both â€¢
gendersSerum AST value
Greece Regulatory Affairs de 14th Km Nasoumelas@ 3.02E+15 Uni-Pharma â€¢ For â€¢
womenQTc of childbearing
interval in re
Human
pharmaco
logy
(Phase I):
no
Therapeu
tic
explorato
ry (Phase
II): yes
Therapeu
tic
confirmat
ory -
(Phase
III): no
Therapeu
tic use
(Phase
IV): no
NetherlandJurjan Aman De Boelela [email protected]+10 Amsterda Inclusion c Exclusion c
Human
pharmaco
logy
(Phase I):
no
Therapeu
tic
explorato
ry (Phase
II): no
Therapeu
tic
confirmat
ory -
(Phase Exclusion criteria: 1.
III): no 2. History of psoria
Therapeu Inclusion criteria:
 3. 1.
Tinnitus,
Hospitali
reduce
tic use 2. Adults
 4.18 year
Visual
or older
impairme
(Phase 3. Moderately
 5. Known
severeadverse
disease r
IV): yes 4. SARS-CoV-2
 6. Pregnancy
positive nasoph
Norway Department of Infecti Sykehusveijan.erik.b 4.77E+09 Akershus Un
 5. Signed
 7.informed
Prolonged
consent
QT in
m
Human
pharmaco
logy
(Phase I):
no
Therapeu
tic
explorato
ry (Phase
II): yes
Therapeu
tic
confirmat
ory -
(Phase
III): no
Therapeu
tic use Inclusion criteria: 1. Hospitalized
(Phase 2. Diagnosed to be COVID-19 PO
IV): no 3. Oxygenation
Exclusioncriterion:
criteria: 1.
Denmark CRO Martinistr s.borregaa 4.94E+12 CTC North Oxygen 2.
saturation
Known positive
=93% (eith
He
Human
pharmaco
logy
(Phase I):
no
Therapeu
tic
explorato
ry (Phase
II): yes
Therapeu
tic
confirmat
ory -
(Phase
III): no
Therapeu
tic use
(Phase
IV): no
Italy Trial Information SuppGrenzacherglobal.rochegenentec F. HoffmanInclusion c Exclusion c

 
 - Written informed consen
 
 - Has been previously diag
 Corona-like viral infectio
 
Phase 2 Canada Jeremy D Road, MD Professor 1

 
 printing and distributing
Phase 3 China cor

 
 - age more than 18 years
 
 - accord with the clinical d
 of Novel coronavirus pne
 
N/A China Bing Sun, MD ricusunbi 8.6E+13 <
 Inclusion criteria of Cohort

 community acquired pneum
 
 Cohort 1:
 
Phase 2 China ; Jennifer Ho, MD, PhD;;ifan@ans ;+86 186 2 Ansun Biop Subjects must meet all of th
Human
pharmaco
logy
(Phase I):
no
Therapeu
tic
explorato
ry (Phase
II): no
Therapeu
tic
confirmat
ory -
(Phase
III): yes
Therapeu
tic use
Exclusion
 -
criteria:
Patient -
majeR
IV): no - Infection
 -COVID-19
Saturation
confirmÃ©
capillaire
France chef de projets 4 rue Larre DRCI-Promo2.41E+08 CHU Anger - Diagnostic
 - por
DÃ©faillance dâ€™
Human
pharmaco
logy
(Phase I):
no
Therapeu
tic
explorato
ry (Phase
II): no
Therapeu
tic
confirmat
ory -
(Phase
III): no
Therapeu
tic use
(Phase
IV): yes
France project manager URCIP - Ba carine.lab 33(0)4771 URCIP- CHUInclusion c Exclusion c
 
 - The subject has to grant
 informed consent form b
Phase 3 Thailand Subsai Kongsaengdao,skhongsa@ 6.68E+10 

 
 1. Laboratory confirmed C
 specimen and/or detecti
 
Phase 2 United Sta ; Lorenzo Berra;Lorenz lberra@mg+16176437733; 2. Hospital admission wit

 
 
 2. Scheduled to work with
 
 
Phase 2 Lorenzo Berra, MD lberra@mg 1.62E+10 1. Previous documented S
Inclusion criteria:
Exclusion
1. criteria: 1.
 2. Admission
 2. to Patients
an intensive
treatedc
Not Applic Australia;Hong Kong;Taiwan, Province Of China;Indonesia;Korea, Republic Of 

 
 1. At the time of randomiz
 Hypoxemia can be define
 
Phase 3 United Stat ; Stanley Lewis, M.D;Je ;jho@ansu ;858-452-2Ansun Biop 
Inclusion criteria:
Exclusion
Participants
criteria: Particip
eligible
 1. Completion
 1. History
of the
ofwritten
allergy io
Phase 4 Australia 2. Male 2.
or female
Contraindication t

 
 1. Admitted to the intensiv
 diagnosis;
 
Phase 3 Canada ;;; FranÃ§ois Lamontagn ;;marie-he ;;819-346- UniversitÃ 2. Currently treated with a

 
 - Hospitalised
 
 - Adults 18 year or older
 
 - Moderately severe disea
 
 - SARS-CoV-2 positive nas
 
Phase 4 Norway ;; Olav Dalgard, MD PhD;odalgard@;+47 92616Akerhus Uni 
 
 - Documented COVID-19 i
 assay) for SARS-CoV-2
 
Phase 1/PhDenmark ; Lars Ã˜stergaard, Pro ;olesoega ;+45 2499 Head of De - Less than 48 hours since

 
 1. Age > 70 years
 
 2. ICU-Admission
 
 3. Infection or suspected in
 
 
 1. Age <70 years
Phase 1/PhDenmark;F Christian Jung, MD contact@vi 2.12E+09 

 
 - Patient admitted to a Da
 department
 
 - Age >18 years
 
 - Hospitalized <48 hours
 
Phase 2 Denmark Jens-Ulrik StÃ¦hr Jen jens.ulrik 4.53E+09
Human
pharmaco
logy
(Phase I):
no
Therapeu
tic
explorato
ry (Phase
II): yes
Therapeu
tic
confirmat
ory -
(Phase
III): no
Therapeu
tic use
(Phase
IV): no
Denmark Sponsor/Investigator Nordre Fasalars.erik. 4.54E+09 The Parker Inclusion c Exclusion c
 
 1 ) Any adult or child or me
 who presents an infectious
 
N/A France ; Philippe VANHEMS, M;philippe. ;04 72 11 Service Hy 2) Suspect Ca

 
 - 1. Suspected cases (form
 
 Meet the following 2 at the
 
Phase 1 China ;; Yao Xie, Doctor;Yao Xi;xieyao00 ;8610-843 Department Epidemiological history The

 
 1. Age 18 to 80.
 
 2. Confirmed COVID-19 dia
 
Phase 2/PhChina;Italy ; Yuguo Chen, Dr;Jiaoji ;jiaojiaop ;(086)053 Qilu Hospit 3. Accord with any of the f

 
 - Willing and able to provi
 procedures (participants
Phase 3 United Sta ; Gilead Study Director; ;GileadClin ;1-833-445Gilead Scie y

 
 1. Positive for RNA of SARS
 
 2. Hypoxemic
 
 3. Severe COVID-19
 
N/A China ;; Zuojiong Gong, MD;Zu;zjgong@1 ;027-88999Renmin Hos 4. If female, subject must n

 
 - SARS-CoV-2-infection wi
 
 - vv-ECMO therapy
 
 
 - pregnancy, breastfeedin
N/A Germany ;; Alexander Supady, Dr ;alexander ;+4976127 University 

 
 - Healthy adults aged 18-5
 
 - Able and willing (in the In
 requirements.
 
Phase 1/PhUnited Ki ; Andrew Pollard, Prof; ;vaccinetr ;01865 61 University - Willing to allow t
 
 - Confirmed cases of Covid
 
 - Mild to severe clinical pr
Phase 3 Pakistan ;; Umar Farooq, PhD;Um;dean@ayu;00923219 Khyber Med National Ea

 
 printing and distributing
Phase 3 China Hongzhou Lu, Ph.D luhongzho-37990268 cor

 
 - Admitted to intensive ca
 
 - Adult (aged over 18 year
 
Phase 2 China - Anticipate a length of ICU

 
 1. Admitted to a hospital w
 
 2. Subject (or legally autho
Phase 3 United Sta 20-0006 Central ContaDMIDClinic 1.3E+10 to

 
 A subject must meet all of t
 study:
 
Phase 1 United Sta 20-0003 Central ContaKPWA.vacc 1.21E+10 1. Provides written inform

 
 1. Clinically diagnosed with
 
 2. Increased interleukin-6
 
 3. Sign the informed conse
 
N/A China ; Guiqiang Wang;Guiqi ;john1312 ;13911405 Peking Univ 4. Subjects who can take m

 
 1. Male or female, aged =
 
Phase 1 Brazil ; Florentino de Araujo florentino +55 19 991232882;+5 chain reaction (RT-PCR) f
 
 - COVID-19 pneumonia pa
 
 
 - Patients who were youn
 
Phase 2 China - Patients whose entire st

 
 - Any person interested in
 complete the pre/post su
 
N/A United Sta ; ; Rebecca E Wells, MD, ;rewells@w;336-716-2Wake Fores Exclus

 
 who can provide informe
Phase 3 United Sta ; Gilead Study Director; ;GileadClin ;1-833-445Gilead Scie 

 
 - Any permanent medical
 written consent to partic
 
 - Having a social security i
 
N/A France Pierre HAUSFATER, M pierre.hau 3.31E+10 

 
 - Blood donors whose last
 
 
N/A China - Blood donors whose blo

 
 - Provision of informed co
 
 - Exposure to a COVID19 c
 contact, OR
 
Phase 3 United Sta ; David Boulware, MD, ;covid19@ ;61262499 University - Symptomatic C
 Inclusion Criteria (case defin

 
 - Consented adults (age =1
 
 - COVID-19 suspicious and
 
 - Admitted to hospital or a
 
Phase 3 Andres Orlandini, MD aorlandini + 54 341 4450210 - Fever (with
 1. Laboratory-confirmed SA
 public health assay in an
Phase 2 Vietnam ; Guy Thwaites, PhD. M;jday@oucr;+84 8 392 University hospital admission in the

 
 - Men or women 18 to 80
 consent
 
 
Phase 1 United Sta ; ; Ruanne V. Barnabas, ;;meigs@u ;;206-520- University - Had

 
 1. Confirmed SARS-CoV-2 i
 
 2. Self-reported symptoms
Phase 3 Canada ;;; Luanne Metz, MD;Mich;;luanne.m ;;403-944- University 

 
 1. Male or female, aged at
 
Phase 2 China ; Fu-Sheng Wang, MD, P;shilei302 ;86-10-66 The fifth m chain reaction (RT

 
 - Aged 18-75 years old;
 
 - Pneumonia patients with
Phase 4 China Yahong Chen, MD Ascletis Ph RT-PCR and clinical mani

 
 - DoD-affiliated personnel
 emergency-essential civi
N/A Sandi K Parriott sandi.k.par301-619-6824 Armed Forces w
 Inclusion Criteria for a case:

 
 1. Patients who meet the r
 respiratory infection sym
 
Phase 3 Spain ; oriol Mitja, PhD;Oriol MitjÃ
oriolmitja 0034 934651072; 

 
 - Formally serving medica
 
 
 - pregnant women;
 
Phase 3 China ; Zhongji Meng;Zhongji zhongji.m 18971905757;+86-18 - severe chronic diseases w
 
 - Critical/Intensive care or
 
 - Admission for/with acute
Phase 3 France ;; Stephane LEGRIEL, MD;neurocovi ;33139638 Ictal Group than 4 weeks, but usua

 
 - flu-like symptoms
 
 - a viral test order for COV
 
 - confirmed COVID-19
 
 - concern for exposure to
 
N/A United Sta ; Becky Smith, MD;Mar ;mark.sen ;919-684-3Duke Unive Exclusion Crite

 
 1. Males and females aged
 
 2. Probable or confirmed i
 
Phase 3 Brazil ; OtÃ¡vio Berwanger, P ;aro.clinic ;+55 (11) Hospital Is - Need for oxygen supp

 
 - Adult (age = 18 years)
 
 - Confirmed OR suspected
 
 - Confirmed: Positive as
 
Phase 2 United Sta ; Samuel M Brown, MD ;Valerie.A ;80150746 Intermounta
 - Suspe

 
 1. < 18 years-old, and
 
 2. Present to a participatin
 
 3. Undergo SARS-CoV-2 te
 
 
Phase 1 Canada ;; Stephen Freedman, ;stephen. ;40395577 University 1) Refusal

 
 1. Patients who meet the r
 respiratory infection sym
 
Phase 4 Javier Crespo, MDPhDjaviercre 9.42E+08 2. Aged =
 
 - Positive laboratory test f
 
 - Upper respiratory sympt
 
Phase 2 United Sta ; ; Christopher Tignanell ;;Covid19t ;;612-624- University 
 
 - Able to understand the c
 consent
 
Phase 1 China ;; Zhu Fengcai;Guan Xu ;; ;; Jiangsu Pro - Able and willing

 
 - Laboratory-confirmed SA
 (PCR), result from any sp
Phase 2/PhUnited Sta ; Clinical Trial Managem;clinicalt ;844-734-6Regeneron 

 
 - SARS-CoV2 Infection diag
 
 - CT-scan confirmed multi
 
 - Need of oxygen therapy
 
Phase 2 Italy -
 Inclusion criteria: (1) Adult p

 (3) Patients who are intuba
 SARS-CoV2 by positive rt-PC
 
Phase 2 United Sta ; ; Lorenzo Berra, MD;Lo ;lberra@mg;+1617643 Massachuse 

 
 - ARDS associated with CO
 
 - Medical necessity for en
 
Phase 2 United Stat ; Jonathan C Javitt, MD ;rbesthof ;+1484254 NeuroRx, In - Physician determination

 
 - Presumptive positive lab
 with recent exposure to
 
Phase 2 United Sta ; ; Christopher Tignanell ;;Covid19t ;;612-624- University - Negative
 
 - flu-like symptoms: myalg
 
 - Chest X-Rays
 
 - COVID-19 biological test
 
 
N/A Italy;Roma ; ; Alexandru Burlacu, Le ;;alexandr ;;0040744 University - patient r

 
 - Able to consent and agre
 
 - Coming to The Everett C
 
N/A United Sta Ethan Berke, MD UnitedHeal - Ev

 
 - Patients with suspected
 intensive care units
 
 
Phase 3 Brazil ;; Alexandre Biasi, PhD; ;;fzampier ;;+55 11 9 Hospital d - Need for oxygen supplem

 
 1. Clinical and radiological
 
 2. Positive microbiological
 
N/A Italy ;; Giuseppe GRITTI, MD; ;g.gritti@a ;+39.0352 ASST PAPA 3. Diagnosis of acute respi

 
 - COVID-19 PCR positive (w
 
 - COVID-19 PCR pending
 
 - COVID-19 high clinical su
 
 
N/A United Sta Rahul Kashya, MBBS Mayo Clini - Patie

 
 1. > 6 months of age
 
 2. Has laboratory-confirme
Phase 2 Canada commercial or public hea
 
 - informed consent was gi
 
 - age = 18
 
 - able to complete the que
 
 - country of residence: Ge
 
Phase 2 Germany ;;; Andreas StrÃ¶hle, Pro;;antonia. ;;+4930450CharitÃ©-U Exclus

 
 - COVID-19 positive
 
 - Oxygen saturation <92%
 
 - Able to provide informed
 
 - Receiving oxygen by non
 
N/A United Sta ; Jeffrey Miller, MD;Jef ;jeffrey.m ;404-778-7Emory Univ -

 
 Patients affected by COVID1
 
 
 -
N/A Italy ; ; ; ; ; ; ; ; Guido Iaccarino, MD; ;;;;;;;guia ;;;;;;;+390 Federico II University;Inversity
 of Milan, BICOCC

 
 1. Should be at least 18 ye
 
 2. Male or female,
 
 3. Diagnosed with COVID-1
 
Phase 3 United Sta ; Shyamasundaran Kotti;pzheng@ ;(202) 751 Institute o 4. Able to sign the

 
 1. Any gender
 
 2. No age limit
 
 3. Informed consent for pa
Phase 2 Italy ; Francesco Perrone, M ;f.perrone@;+3908159 Istituto Na consent cannot be expre

 
 - Patients admitted to hos
 
Phase 2 Italy Giovanni Landoni, Pro landoni.gi 3.9E+11 char
 
 - pregnant women with la
Phase 2 Italy Gabriele Saccone gabriele.s 3.39E+09 

 
 1. Pregnant women or wom
 
 2. Able to give informed co
 
Phase 2 United Sta ; ; Vanessa Vacoby, MD, ;PRIORITY ;(415) 754 University 3. Diagnosed with COVID-1
 Inclusion criteria, general:

 
 - Sufficient German langua
 
 - Providing informed cons
 
N/A Germany ; Gunther Meinlschmidt,gunther.me+49 30 300117;+49 (0) Inclusion criteria for the arm

 
 - Patients must be 18 year
 
 - Hospitalized with COVID
Phase 2 United Sta Michael Joyner, MD Mayo Clini SARS-CoV-2 RT-PCR testi

 
 - Infection with COVID-19
 by thorax CT-scan sugges
Phase 3 France;Mo Vincent DUBEE vincent.du 2.41E+08 cli

 
 - Adults = 18 years of age
 
 - Approval from the patien
 
 - Admitted as an inpatient
 
Phase 2 United Sta ; ; Pankti Reid, MD, MPH;pankti.re ;77370212 University - Fever,

 
 - Patients / caregivers trea
 symptomatic infection by
 
N/A France ; Isabelle PELLEGRIN;Is isabelle.p 05 57 82 11 50;05 57 - men and women, adults
 
 - Age > 18 years old
 
 - Expected ICU stay of > 48
 
 - Bilateral Viral Pneumoni
 
 - Orotracheal intubation f
 
Phase 2/Phase 3 ;; Filippo Annoni, MD;R ;;filippo. ;;0032(0)4 Erasme hosp
 

 
 Clinical diagnosis of COVID-
 
 
 Previous history of allergy t
Phase 1/PhIran, Islam ; ; ; ; Alireza Ghaffarieh, M ;;;alireza ;;;+1-608- Regenerati 

 
 - Medical Physicians in Mi
 
 
 - none
N/A Egypt ;; Aliae Mohamed-Hussei;aliaehuss ;01222302 Assiut Univ 
 Inclusion criteria:

 
 1. Adults >18 years of age
 
 2. Informed consent
 
 3. A confirmed diagnosis o
Phase 3 United Sta ; ; Girish B Nair, MD;Joa ;joanne.g ;248-898-0William Be 90% on room

 
 - Norwegian adult
 
 
 - Unable to consent
N/A Norway ; Arne SÃ¸raas, MD, Ph Arne.Vasli +4790652904;+47906 

 
 ability to understand and
Phase 2 Italy ; LUCA GALLELLI;LUCA Ggallelli@uni3339245656;3339245 
 
 - Hospitalized with COVID
 PCR of any specimen; e.g
Phase 3 United Sta ; Clinical Trials;Refe ;global-ro ;888-662-6Hoffmann-L 

 
 1. Adult patients, 18 years
 
 2. Confirmed SARS-2-CoV-
 
 3. Admitted to the hospita
 
Phase 2/Phase 3 ;;;;;;; Paul Aukrust, MD, Pro ;;;;;;;pauk ;;;;;;;0047 Oslo Univer 4. Subjects (or legal

 
 - People who are feeling s
 
 - People who are feeling s
 
Phase 2/PhUnited Sta ; ; Mark Shapiro;BEAT19.;info@beat;(415) 754 xCures; - People who are not f

 
 
 - Moderate to severe COV
 
 - Hospitalized patient
 
Phase 2 Canada Barbara Goodall barbara.go(902) 292-0132 - Willing and able to provi

 
 - 16 years or above
 
 - Patient requiring hospita
 
 - Clinical or Radiological e
 
Phase 3 United Ki ;; Ravindra Prof. Gupta, ;richard.s ;01223 34 University - Acute respir

 
 
 
 - Not currently requiring in
 
 - Receiving oxygen by face
 
N/A United States 
 
 Patients >18 years old with
 temperature >37.5 degrees
Phase 2 Spyridon Deftereos spdeftere 3.07E+11 sustaine

 
 - Over 18 years of age
 
 - Employed by one of the
 
 - Provide a signed and dat
 
Phase 3 Australia ; Prof Nigel Curtis;Prof ;nigel.curt ;+613 934 Murdoch Ch - Pre-rando

 
 1. Age =18 years.
 
 2. Healthcare worker base
Phase 2 United Sta ; ; ; Michael S. Avidan, M ;;;lindayu ;;;314-273 Washington high risk of developing C

 
 - HIV disease
 
 (PCR) or other commerci
 
N/A United Sta Dima Dandachi, MD dandachid@
573-884-8728 

 
 - Adult, Age>44 years, com
 
 - Confirmed COVID-19, via
 days
 
Phase 3 United Sta ; 
Brandon Webb, MD;Va;Valerie.A ;80150746 Intermounta Excl

 
 1. Male or female patients
 
 2. Hospitalised;
 
 3. Confirmed or suspected
 
Phase 4 ; Manu Shankar-Hari, ;ndaba.ma ;07961949 Guys and S 4. National Early Warning

 
 1. Males and females, at le
 consent;
 
Phase 3 United Sta ; ; Jean-Claude Tardif, M ;;jean-cla ;;514-376- Montreal H 2. Patient must have recei
 
 - Subjects must be 18 yea
 
 - Close contact* exposure
 hours of receipt of plasm
Phase 2 ; Shmuel Shoham, MD; ;TOID_CRC ;410-614-6Johns Hopk 

 
 All the ED patients positive
 following symptoms:
 
 - fever
 
 - cough/dyspnea
 
Phase 2 ; Guido Bertolini, MD;G;Guido.ber ;+39 035 4 Istituto di 

 
 diagnosis of pneumonia; Co
 given informed consent.
 
 
Phase 1/PhItaly ;; Geltrude Mingrone, M;anna.capro;+3906301 Fondazione age lower than 18 years; pr

 
 - SARS-CoV-2 infection con
 
 - Positive imaging: consoli
Phase 2 Denmark ; Lars Erik Kristensen, ;lars.erik. ;0045 381 The Parker infiltration either by CT-s

 
 authorized representativ
 
Phase 2/PhItaly ; Emanuele Nicastri, M ;sobi.imm ;+46 8 697 Direttore D 2. Documented presence o

 
 public health assay in an
Phase 2/PhFrance Olivier HERMINE, MD [email protected]+08 
 Inclusion criteria :

 
 Participants must be =18 ye
 pneumonia and have one o
Phase 2/PhCanada;Fra ; Clinical Sciences & O ;Contact- ;800-633-1Sanofi; or
 
 1. Aged 18-90 years
 
 2. The patient is likely to fu
Phase 2/Phase 3 ; Anders Kjellberg, MD; ;anders.kje;+4681237 Karolinska intubation, ventilator-ass

 
 - turkish physicians
 
 - work active in pandemic
 
 
 - work in another country
 
 - retired physicians
N/A Turkey 
 - Adult (=18 years)
 
 - Male or female
 
 - Hospital personnel (expe
 
Phase 3 Netherland Thijs ten Doesschate, t.tendoess 3.16E+10 
 - Adults (>= 18 years) adm
 
 - Severe confirmed COVID
N/A France ;; Muriel FARTOUKH, P ;muriel.fa ;01 56 01 Assistance parenchymal infiltrate; a

 
 1. Male or female, aged 18
 
 2. Provided informed cons
 
Phase 3 Justin Slagel jslagel@sl 1.92E+09 3. Virological or serologica

 
 I (first step):
 
 - Admission to hospital
 
 - Male or non-pregnant fe
Phase 2 Switzerlan ; Peter M. Villiger, Pro ;stephan.r ;+41 31 63 University known risk factors (art
 
 - age 18 years or older;
 
 - positive reverse-transcri
 in a respiratory tract sam
 
Phase 4 Spain ; JesÃºs Villar, MD;JesÃ ;jesus.vil ;+3460686 Hospital Un -

 
 - Affiliated with or benefiti
 
 - State of health compatib
 
 
N/A France Bruno HOEN, Pr bruno.hoen+33 1 40 61 37 60 
 - COVID-19 induced adult
 
 - PaO2/FiO2 is less than 2
N/A United Sta ; Jie Li, PhD;Jie Li, PhD ;Jie_Li@ru ;312-947-0Rush Unive HFNC trea

 
 - Must have confirmed an
 involvement of lung tissu
 
Early PhaseUnited Sta Robert W Alexander, MD Global All - Must be clear of any vira

 
 1. Patients included in the
 
 2. Patients belonging to on
 
Phase 2/PhFrance Olivier HERMINE, MD [email protected]+08 - Group 1: patients not

 
 - all known cardiovascular
 
 1. all spectrum of coron
N/A Romania ;; Alexandru Burlacu, MD;;alexandr ;;0040744 University angiopl

 
 ED patients positive to or su
 following symptoms:
 
 - fever
 
 - cough/dyspnea
 
N/A ; Guido Bertolini, MD;G;guido.bert;+39 035 4 Istituto di - res
 
 - Healthy subjects
 
 
 - Drugs
 
 - Surgery
 
 - Neurology diseases
 
 - Rheumatic diseases
 
N/A CÃ©sar Calvo Lobo, P cescalvo@ 91 394 1544 <

 
 - A healthcare worker at hig
 
 - Persons primarily workin
Phase 3 United Sta ; Radha Rajasingham, M;covid19p ;612-626-8University staff, tri

 
 The following persons may
 
 - A patient of any age mee
N/A Switzerlan ; ; Claire-Anne Siegrist, ;claire-ann ;+4179553 Professor o confirmed case definition

 
 1. Informed consent from
 
 2. Male or female, aged =
 
Early Phase 1 ; Luciana Ferrara;Carl ;carla.cci ;+55 11 99 Azidus Bras 3. Laboratory confirmation

 
 1. The patients must be 18
 
 2. Patients who opt in to c
 
 3. Patients must have the
Phase 4 <

 
 - Classified as having SSc b
 
 - PROMIS Anxiety 4a v1.0
 
 - Have regular, reliable int
 
N/A ; Brett D Thombs, PhD;M
;carrier.m ;514-340-8Lady Davis 
 
 - Confirmed case: Criticall
 suspected case and who
Phase 2 Mexico ;;; Silvio A. Ã‘amendys-S ;;;snamen ;;;+52 55 Instituto N He

 
 - Patient with CHD as defi
 
 - Covid-19 infection over t
 
 Exclusion criteria:
 
N/A France ;; Pascal AMEDRO, MD- ;p-amedro@
;04 67 33 UH MONTPE
 - Patient w

 
 - Patients who consent to
 information to be gained
 
 - Patients =18 years old
 
N/A United Sta ; ; Sreekanth Vemulapallli;kristine. ;919-668-0Duke Unive

 
 1. person who are working
 case
 
 2. Their first degree relativ
 
N/A Turkey ; Mahir M Ozmen, Profes
ozmenmm@g
+905324246838;+905 

 
 - All patient admitted in IC
 Biological Risk" (REB) bef
 
N/A France ;; Julien Poissy, MD,PhD ;julien.pois;03204444 University H - Clinical i

 
 Recipient:
 
 1. COVID-19 Patients
 
 2. Consent to attend the st
 
 3. Age 30 to 70 years
 
 4. Don't be intubated
 
N/A Iran, Islam Majid Saeedi, Ph.D. Vice-Chanc 5.
 
 - Clinical suspicion of COV
 
 
 - Age less than 18 years
 
N/A Denmark ; SÃ¸ren H Skaarup;SÃ¸ ;soeska@r ;28911869 Aarhus Univ - Previous enrollment in th

 
 - Recent ( = 6 days of flu-li
 malaise prior to randomi
 
Phase 3 Belgium ; Bart Lambrecht, MD, ;anja.delp ;+32-9-33 University - COVID-19 diagnosi
 Inclusion criera :

 
 - Patient = 18 years old an
 
 - Laboratory proved infecti
 days
 
Phase 3 France ;; Camille TAILLE, MD, P ;camille.ta ;+33 1 40 Assistance - Hospita

 
 - All users of the https://w
 
 
 - not applicable
N/A France ;; Fabrice DENIS, MD;Fa ;f.denis@c ;24168294 Jean Berna 

 
 - Adults aged 18-90
 
 - Confirmed laboratory CO
 
 - Meeting severe or critica
Phase 3 Vasilios Polymeropou vasilios. 2.03E+09 

 
 - Recent (=2weeks prior to
 COVID-19 infection
 
Phase 4 Belgium;Ita ; Bart Lambrecht;Anja ;anja.delp ;+32-9-33 University - Presence of acute hypox
 
 - Probable or confirmed in
 
 - Moderate/severe ARDS d
 =5cmH20)
 
Phase 3 Brazil ; Luciano Cesar Pontes ;luciano.a ;+5511992 Teaching Director
 of Teaching
- Dev & Research Instit

 
 - Volunteer to participate
 
 - Being pregnant
 
 - Aged between 18 - 45
 
 - To understand Turkish
 
N/A Turkey ; Ayse Zengin AlpÃ¶zgenazengin@is(212) 866 37 00 43144 - Spend most of th

 
 Covid + Patients hospitalize
 intensive care secondary to
 
N/A France ;; Emilie Garrido-Pradali ;francois.s ;; ASSISTANC -

 
 - Documented COVID19 p
 infiltrates on chest x-ray
Phase 2 United Sta Antonio Abbate, MD, PhD Virginia C wi

 
 - Aged 18 years or over.
 
 - Able to provide written c
 
 
 - Any participants that wit
 
N/A ; Ara Darzi, Prof;Fahad ;f.iqbal@im;07588550 Institute o 
 Inclusion criteria

 
 1. Hospitalized patient
 
 
 3. Randomization within 7
 
Phase 2/PhUnited Sta ; ; Daniel Freilich, MD;Je ;jennifer.v ;60754769 Bassett Me<
 
 - Primary case: laboratory
 chain reaction (PCR), or F
N/A French Gui ; ; Claude Flamand, PhD; ;cflamand@;+33 5 94 Institut Pa 

 
 Laboratory (RT-PCR) con
Phase 3 China Ming Li, M.D. mlid163@1 8.61E+12 

 
 - Female sex
 
 - Greater than or equal to
 
 - English-speaking
 
N/A ; Mike Foley;Rachael S ;rachael.s ;1-541-601Director D - Established obstetrics/gy

 
 1. Chinese patients, aged 1
 
 2. Diagnosis of COVID-19, a
 
Phase 1/PhChina ; Zhou Qi, Doctor;Wang;wangliu@i;+86-0106 Institute o 3. According to the diagno
 Inclusion Criteria:Fulfilling a

 
 
 2. Hospitalized participant
Phase 2/PhColombia ; ; Juan M Anaya Cabrera;anayajm@g
;+57 321 2 Universidad 
 Inclusion Criteria Donor:

 
 
 - must have been hospital
Phase 1 COVID-19 SARS-CoV-2 RT

 
 - Adults (age =18 years) un
 theatre, this includes obs
 
Early PhaseSpain ; Enrique M San Norberesannorbe 0034686754618;0034 - Either before or after sur

 
 - =18 years old with clinica
 to SARS-CoV-2 AND
 
Phase 1 Michael Eddleston m.eddlest 0131 242 3867 - presenting to the Roy
 
 - Age = 18 years old (Sub-s
 
 - Competent and capable
 
Phase 2 United Sta ; ; Ravi Amaravadi, MD;A;amelia.a ;215-509-5University - Have access to a smart d

 
 - A contact person from co
 
 - Medical staff exposed fro
 
Phase 3 ; Yong Goo Song, Profes;imfell@yu ;82-2-2019Gangnam Se
 - Persons exposed

 
 - Patients with mild COVID
 
 - Patient within 7 days fro
Phase 2 Joon Young Song, MD infection@82-2-2626-3052 diagnosis (SARS-CoV-2 R

 
 - confirmed COVID-19 pati
 reverse-transcriptase po
N/A China pharyngeal swab sp
 Prevention Study Inclusion

 
 1. Capable of understandin
 to the requirements and
 
Phase 2 ; Jeremy Road, MD;Chris;chris@san;778-899-0Vancouver 2. Men

 
 1. Male or female subjects
 
 2. Confirmed COVID-19 inf
 
N/A United Sta ; ; Raj Makkar, MD;Siegf ;srogy@cap;818-618-5Cedars-Sin 3. In critical co

 
 - Age at least 18 years
 
 - Laboratory confirmed di
 
N/A United Sta ; Michael Joyner, MD;M;USCOVIDp;507-255-4Mayo Clinic - Admitted to an acute car

 
 - All adult patients > 18 ye
 oncological treatment or
 
Phase 1 Janneke Cox, Dr janneke.co 03211 33 76 51 
 
 - Being 65 years old and o
 
 - Being in social isolation d
 
 - Spending at least 1 week
 
N/A 
 - Age:
 
 At least 18 years of age at t
 
 - Type of Subject and Diseas
 
Phase 2 Documented or confirmed S

 
 - Must have positive naso
 within the previous 48 ho
 
 - Age = 45 years
 
Phase 4 United Sta ; Brian Kendal, MD;Tri ; ; Providence - Not hosp

 
 - 1) Aged 18 or above;
 
 - 2) Laboratory-confirmed
 
 - 3) Pre-existing liver cirrh
 
N/A China ; ; ; ; ; ; ; ; Mingkai Chen, MD;Xia;;;;;;;;;;;; ;;;;;;;;;;;; Renmin Hos 

 
 1. Age = 18 years old.
 
 2. Hospitalized patient (or
Phase 2 Spain ;; Felipe GarcÃa, MD;Felipe
;fgarcia@cl;+3493227
GarcÃa, MD;FelipeHospital
GarcÃa, ClÃ
MD 
nic de Barcelona;
an emergency departme

 
 - Men and non-pregnant w
 
 - Known diagnosis of hype
 
 - Current use of ACEi or AR
 
Phase 4 Ireland ;; John William McEvoy ;johnwilli ;+353 9 15 National Un -
 
 - Adults of 18 years and ab
 been approved for down
N/A United Sta ; Tim D Spector;Victori ;victoria.v ;02071886 King's Coll 
 INCLUSION CRITERIA

 
 1. age >=60 years OR age 1
 
 1. chronic lung disease
 
 2. chronic cardiovascula
 
Phase 4 Marta Duda-Sikula, M marta.dud 48 71 784 00 34 

 
 
 2. Patients belonging to on
 
Phase 2 Olivier HERMINE, MD [email protected]+08 - Group 1: patients not

 
 - Age = 18 years
 
 - Negative PCR and negati
 
 - Healthcare worker at Ho
 
Phase 3 Spain ; Jose MuÃ±oz GutiÃ©rr;jose.muno;60877407 Barcelona I - Female participants: neg

 
 - UK resident
 
 - Age =16 years
 
 Exclusion Criteria: none
Phase 2 Adrian Martineau, Ph a.martine 4.42E+11 

 
 Definitely positive COVID-19
 
 
 Patients with acute respirat
 
 1. Spo2<60%
 
Phase 2/PhIran, Islam ; ; Siamack Afazeli;Siamac;Dr.afazel ;+9891213 Fasa Univer 
 
 - COVID-19 infection diagn
 
 - Need for supplemental o
 
 - 12 years of age or older
 
N/A Canada ;;; Steven Chan, M.D.;Vik;;steven.c ;;416-946- Princess M 

 
 - Adults (age =18 years) w
 Acute Respiratory Syndro
 
N/A Chuck Moser cmoser@ta984-234-0268 - SARS-CoV-2 conf

 
 1. high probability CT thor
 day of inclusion
 
N/A Belgium ;; Michiel Thomeer, MD,;michiel.t ;+3289327 Ziekenhuis 2. positive COVID-19 nasop

 
 1. 18-70 years old (includin
 
 2. Infection with new coro
Phase 2 Huilan Zhang, PD Huilanz_7 1.54E+10 test. P

 
 - Male and Female patien
 
 - COVID-19 confirmed pos
 
N/A ; Michael Gordon, MD; ;klewando ;480-583-0HonorHealt - High risk for complicatio

 
 1. Male or female, 18 year
 
 
Phase 1/PhChina ; Yan Liu, MD;Yan Liu, 44782285 +8613387517458;+86 3. Laboratory confirmation

 
 - > 18 years old
 
 - Suspected of COVID-19 i
 
 Exclusion criteria :
 
Phase 3 ; Mehdi BENCHOUFI, M;mehdi.ben;+33(0) 6 3 Assistance - Patients on whom the ul
 
 required for the study an
 
Phase 2 United Sta ; Sabine Hazan, MD;Sa ;sabineha ;805-200-7ProgenaBi 2. Healthy male or female

 
 - Documented COVID-19 p
 (nasopharyngeal swab (N
Phase 2 Fabio Ciceri, MD ciceri.clini +39 02 2643 at co

 
 - who haven't been exerci
 isolation period
 
 - Who are willing to exerc
 
N/A Turkey ;;; Ayse Zengin AlpÃ¶zgen;;azengin@;;+90 (212 Istanbul Un 

 
 1. Age = 18 years and = 64
 
 2. Able and willing to unde
Phase 2 ; Upinder Singh;Upinde ;usingh@st;65072340 Professor ( written informe

 
 - Subject (or authorized le
 before beginning any stu
 
Phase 2 Spain ; Pere Domingo, MD, P pdomingo@; - Understand and agree to

 
 - Evidence of a positive SA
 three days
 
 - Not currently hospitalize
 
Phase 3 United Sta ; ; ; Catherine Oldenburg, ;;ACTIONTr;;(415) 51 University - Willing and able

 
 In order to be eligible to pa
 following criteria:
 
 1. Male or female, age > 1
 
N/A United Sta ; Scott Gorenstein;Davi Scott.Gore 516-663-8498;212-56 2. Positive
 Inclusion Criteria:Fulfilling a
 
 
 2. Hospitalized participant
Phase 2 Colombia ; ; Juan M Anaya Cabrera;anayajm@g
;+57 321 2 Universidad 

 
 - All gender patients aged
 
 - Patients with SARS-CoV-
N/A Italy ; Roberto Giacomelli, roberto.gi 0039 0862 434742;08 involvement, hospitalize
 Inclusion Criteria

 
 1. Patients 18 years and ol
 
 2. Confirmed SARS-CoV-2 I
 
 3. Serious or life-threateni
 
 Serious:
 
Phase 1 Mexico ; JosÃ© Fe Castilleja-L ;servando ;+5218112 Hospital S <

 
 â€¢ Health Care workers wi
 
 
 - Allergy to hydroxychloro
 
Early PhaseMexico - History of bone

 
 - Must be =18 years at the
 
 - Understand and volunta
Phase 3 Germany Diane Egger-Adam, Drdiane.egg 4.97E+12 related assessments

 
 - patients with COVID-19:
 or sputum, no age limit
 
Phase 2 Germany ;;;; Robert W KÃ¶rner, Dr.;;;;robert. ;;;+49 221 Children's - control group: any respir

 
 
 - Able to understand the c
 consent
 
Phase 2 ; Fengcai Zhu, MD;Wen;wangwj@j;8625-837 Jiangsu Pro - Able and willing
 
 - 20 years and older
 
 - Hospital and RBHS health
N/A United Sta ; ; Jeffrey L Carson, MD; ;;jeffrey. ;;732-235- Rutgers Bio patients/shift) in emerge

 
 - Patients with proven SAR
 consistent with COVID-1
 
Phase 2 United Sta ; ; Sabiha Hussain, MD;St;;hussaisa ;;732-235- Rutgers, Th - Ability to measure and q

 
 - All subject except exclud
 
 
 - subject diagnosed as CO
N/A Egypt ; Aliae Mohamed-Hussealiaehusse 01222302352;+20122 

 
 - Children < 18 years old
 
 - Admitted in French pedia
 
 - With a confirmed COVID
Phase 2 France Corinne Levy, MD corinne.lev 1.49E+08 

 
 - COVID-19 positive inpati
 before randomization.
 
N/A France ;; Claire-Marie RANGON;ayavchitz ;(0)1 48 03 Fondation - Inpatient showing at leas

 
 - Patients between 18-80
 
 - Confirmed HCoV-19 infe
 
 - Temperature above 38.0
 
Phase 1/PhDenmark Jens Kastrup, Profess jens.kastr 4.54E+09 - Pulmonary symptoms an

 
 - Patients included in the C
 
 - COVID-19 cases not requ
Phase 2/Phase 3 David Saadoun, MD P david.saa 6.73E+08 according to the WHO
 
 
 2. Currently hospitalized o
 
Phase 3 United Sta ; Boyd Taylor Thompson;coldmixo ;617 726-4 Massachuse 3. Symptoms of acute resp

 
 1. Adult male and female h
 
 2. Healthcare workers with
 
Phase 2 United Sta Peter A McCullough, MD, MPH Baylor Hea â€¢ One day or more of e

 
 
 2. Age =/>40 or diabetes o
 
 3. Requires hospital admis
N/A United Ki ;; Prapa Kanagaratnam, ;alena.mar ;07776 22 Imperial C 
 - Age > 18 years old
 
 - Collection of the subje
 
 - Patient registration on
 
N/A France 
 - admission to the intensiv
 
 - with a proven COVID infe
 
 - agree with participation
 
Phase 1 France ;; Pierre Asfar, MD, PhD;;piasfar@c ;+3324135 CHU Angers<

 
 - Older than 18 years of ag
 previously tested positiv
 
N/A Denmark ;;;;; Henrik Ullum, Prof., ;;;;hennin ;;;;+4526 Rigshospita - Participant is outside the
 
 - patients hospitalized wit
 
 - Eligible for different sam
 
N/A ;; Pierre PATOZ, Pharm ;;ppatoz@c;;0320694 CH Tourcoi - Beneficiary subject affilia

 
 1. Female and male patien
 
 
 3. Hospitalized at Hasharo
 
Phase 2 Israel ; Zivit Harpaz;Zivit Harp;Zivit@canf;+972-3-9 Can-Fite B 4. Di

 
 1. COVID-19 has been diag
 as sputum or nasopharyn
N/A China ; Guiqiang Wang;Guiqi ;john1312 ;13911405 Peking Univ 

 
 - Non-severe symptomatic
 gastrointestinal symptom
N/A Spain ; Manuel J Castillo, MD ;mcgarzon ;+34 6494 Universida respiratory i

 
 - Completed Informed Con
 
 - Age = 18 years old
 
 - Individual is currently wo
Phase 3 ; Adrian Hernandez, MD;rachel.e. ;919-668-5Duke Unive receive hea

 
 - greater than 18 years of
 
 - COVID-positive status
 
 - Being monitored in an ou
 
N/A ; Sherry Mansour, MD, ;sherry.ma ;412 716 0 Yale Univer - Yale New Haven

 
 - All patients with laborato
 
 
 - Suspected cases of COVI
N/A China 
 
 - Outpatients = 18 years p
 who test positive for COV
 
N/A United Sta Milind Desai, M. D. The Clevela - Women of child bearing

 
 - Adults (men and women
 
 - At least one nasal swab p
 treatment
 
Phase 2 France ; Jacques Cadranel, MDjacques.ca 1 56 01 66 73;01 56 0 

 
 
 - Presentation to the ED w
 
 - Patient displays at least o
 
Phase 2 United Sta ; N. Stuart Harris, MD, nsharris@m617-724-3290;617-72 

 
 - Residents in the following
 rectal surgery, general surg
N/A Italy neurological

 
 - Positive reverse transcrip
 syndrome coronavirus 2
 
 - Age 18 and older
 
Phase 4 United Sta ; David Levine, MD;Da dmlevine@617-732-7063;617-73 Exclusion Criteria

 
 - Indian males and female
 
 - All the employees of Ma
 
 
Phase 4 India ;; Sujeet Jha, MRCP (U.K;sujeet.j ;+9199106 Max Health 

 
 - Capable to and does pro
 
 - Able to understand and
Phase 1 Canada ;;; Eric L Sievers, MD;M ;;;bd@sym ;;;(604) 42 Chief Medic for all study visits
 
 - Valid informed consent.
 
 - All Covid 19 positive pati
 infection.
 
N/A Lars Wik, MD lars.wik@m91728966 - Patients with typic

 
 - Age >18 years admitted
 
 - Confirmation of infection
 
 - Hypoxic respiratory failu
Phase 1 United Sta ; ; Matthias Salathe;Matt;msalathe ;91358860 University 

 
 - In-patients fulfilling the f
 
 SARS-CoV-2 infection In-pati
 observational study
 
Phase 2 Germany ;; Anselm Gitt, MD;Anse ;gitta@klil ;+49 621 5 Stiftung IH 

 
 - confirmed COVID-19 defi
 
 
 - none
Phase 4 France CÃ©dric Annweiler, M.D., Ph.D. University 

 
 - Adult subjects =18 years
 
 - Quarantined as suspecte
 
 - Asymptomatic upon enro
 
N/A - All subjects give written
Inclusion criteria:
Exclusion
Inclusion
criteria:
Criteria:
Exclusio
 â€¢ Score
 â€¢
of greater
Current
thanpsychos
or equ
 â€¢ Aged â€¢
at least
Imminent
18 yearssuicid
 â€¢ Sufficient
 â€¢English
Current language
substan
 â€¢ Access
 Noto teleconferencing
access to internet
Not Applic Australia 
 
 - At least 18 years of age o
 
 - Clinically evident or othe
 
Phase 2/PhNetherland ; ; A Vlaar, MD;Korinna P;korinna.pi ;+49 89 41 University - SARS-CoV2 infection con

 
 - Age over 18
 
 - A person diagnosed with
 
 - Asymptomatic
 
 
Phase 2/Phase 3 ; Lee Goldstein, MD;Le ;goldstein_;972-4-64 HaEmek Med
 - chronic lung disea

 
 - Participants with diagno
 Reaction (PCR)
 
Phase 1 United Sta ; Clinical Sciences & O ;Contact- ;800-633-1Sanofi; - Time between onset of s

 
 - Hospitalisation in the acu
 in St Nicolas during the is
 
N/A France Cedric ANNWEILER, Mceannweile(+33)241354725 Ex
Not Applic Australia Inclusion c Exclusion c
Not Applic Germany Inclusion crExclusion c

 
 - Patient enrolled in a PAC
 
 - PACE organization contra
 
Phase 4 United Sta ; ; ; Veronique Michaud, P;;; ;;; Tabula Ras Exclusion

 
 - Adult (>18 years) within
 suspected COVID-19 infe
Phase 3 
 Donor Inclusion Criteria:

 
 - Age greater or equal to 1
 
 - Able to donate blood pe
 
Early PhaseUnited Sta ; ; Maria Lucia Madariag ;mlmadari ;773-270-2University - Prior diagnosis of COVID
 
 - Patients admitted to ICU
 positive SARS-Cov-2 PCR
 
 - Patient > or= 18 years
 
N/A France ;; CLAIRE ROGER;CLAIRE ;claire.ro ;00334666 Nimes Unive
 

 
 activities.
 
Phase 2 ; Javier CortÃ©s;Alicia GarcÃ
;alicia.gar
a ;+34 611 2 IOB Institu 2. Male or nonpregnant fe

 
 - Patients admitted to the
 congestion and/or dyspn
 
Phase 3 United Sta ; Efstratios KoutroumpaEfstratios 4123203161;412-320- Exclusion

 
 Group 1:
 
 - Diagnosed with RA, PsA,
 conventional synthetic d
N/A Denmark ;; Salome Kristensen, M ;l.uhrenho ;+45 2170 Department

 
 Suspected covid-19 infectio
 
 
 Age >18 years
N/A Christopher Inchley, chris.inch 90069276 
Phase I/II United Kingdom Inclusion crExclusion c
Not Applic United Kingdom Inclusion crExclusion c

 
 - Judged to be healthy by
 examination and vital sig
 
Phase 1 United Sta ; ShuPing Yang, MD, PhD;clinical.t ;(267) 440 Inovio Pha - Able and willing to comp

 
 - 1st Line Consultation in P
 
 - All reasons for consultati
 
Phase 3 France ; FranÃ§ois Dubos, MD ;francois.d ;02044598 University H - Informed and written co
 
 - Patients that have been
 
 
 - Patients that do not have
N/A United Ki Harry Hothi, PhD harry.hoth +44 (0) 20 8909 5847? 

 
 - from covid 19 positive m
 
 - newborn mothers had n
 
 
 - from covid 19 negative m
 
N/A Turkey <

 
 - Healthcare workers of th
 
 - Patients of the Departme
 
N/A Switzerlan ; ; Guido Beldi, Prof. Dr. ;Guido.Bel ;03163282 University - Written informed consen

 
 - Patients with diagnosed
 
 - Increase in work of brea
 
Phase 1/PhMexico - Presence of lung change

 
 1. Confirmed COVID-19, an
 or nasopharyngeal swab
N/A China ; Guiqiang Wang;Guiqi ;john1312 ;13911405 Peking Univ 

 
 - Patients discharged (dec
 diagnosis or a COVID-19
 
 
N/A Spain ; IVAN J NUNEZ GIL, MDibnsky@ya 0034 913303002;913 - Th

 
 - Age: 18 years or older (in
 
Phase 1/PhUnited Sta ; Claire Xu, MD, PhD;US;US.Info@ ;240-767-6I-Mab Biop chain reaction (PCR
 
 - Age: = 18 years old
 
 - Persons having given the
 weeks.
 
N/A Jean-Baptiste Mr FASSjean-baptis04 78 86 12 05 - Persons affiliated to a so

 
 1. Participant is willing and
 
 2. Participant is 18-75 year
 
Phase 3 United Sta ; ; ; William W O'Neill, ;;whipcovi ;;313-574- Henry Ford 3. Participant does not hav

 
 - COVID-19 positive patien
 
 - Treated at the Health Ins
 
Phase 4 Mexico ; JosÃ© Meneses Calde;drmendie ;+52-722-2Hospital M - With risk factors to get c
0 Guihua Liu 18 Daoshanlgh198706 1.84E+10 Inclusion c Exclusion c
Inclusion criteria: 1. suspicion of COV
N/A China Sanlian Hu 600 Yishan liuliu902 +86 18930 Shanghai Ji 2. agedExclusion
>16 years.c

 
 1. Adults residing in the Un
 understanding and readi
Phase 4 United Sta Rama Jager, M.D. rjager@bea(708) 620-4608 against

 
 - Confirmed or suspected
 
 - Patients admitted to ICU
 vasopressors.
 
Phase 1/PhFrance Xavier Monnet, MD.P xavier.mo +33 01 45 21 35 39 - Monitored by

 
 - Positive COVID-19 test
 
 - Outpatient
 
 - Age >/= 19 y.o.
 
 
 - Allergic reaction to trane
 
Phase 2 United Sta ; ; Timothy J Ness, MD P ;tness@ua ;20590797 University 
 
 - Patient with COVID-19 co
 in-charge physician,
 
 - =18 years old,
 
Phase 2 ; ; ; ; ; ; ; ; ; Philippe LE CONTE, P ;;;;;;;;;Fr ;;;;;;;;;33 University - Not requiring respi

 
 required for the study an
 
Phase 2 United Sta ; Sabine Hazan, MD;Sa ;sabineha ;805-200-7ProgenaBi 2. Healthy male or female

 
 - Participants that, after re
 objectives, possible risks
Phase 3 Spain ; Rosa Polo, MD,PhD;M ; ; Plan Nacion 

 
 1. Hospitalized male or fem
 
 2. Diagnosed to be COVID-
 
 3. Signed Inform Consent F
 
 
Phase 2 Austria;D ; Sonja HÃ¶ller, Dr.;He sonja.hoel 43 1 865 6 ;The Capita 1. Any patie

 
 - All consecutive patients w
 because of severe form (eg
Phase 2 France ; Denis DOYEN;Denis D ;doyen.d@c;00334920 CHU de NIC inc
Inclusion criteria:
Exclusion
1. Patients
criteria: with
1. Patie
Co
RetrospectChina Yun Liu 300 Guangzyanggang2 +86 18601 the First A 2. Patients
 2.
diagnosed
The medical
withrecord
Coro
Exclusion criteria: 1. Parti
Inclusion criteria:
 2. 1.
Patients
Aged 18-45
with hype
year
 2. Inpatients;
 3. People with other
N/A China zhu pengfei 473 Hanzhehappyzhup 8.61E+12 Wuhan Four 3. According
 4.to the novel
Patients withcorona
othe

 
 
 2. Patients with C-reactive
 infusion)
 
Phase 2 Xavier Mariette, MD, xavier.mar 1.45E+08 3
 
 Subjects enrolled in the tria
 
 - Confirmed COVID-19 pne
Phase 2 ; Nishant Gupta, MD;Ni ;guptans@u;51355848 University the pres

 
 warranting a chest CT sca
 
 
N/A France Gilles MANGIAPAN, gilles.mang 3.32E+10 - Patient not a

 
 - Clinical criteria for suspic
 respiratory infection (rhi
N/A ; Delphine Garrigue, M ;Delphine.g;03 20 44 University H s

 
 - 12 intubated and mecha
 single time point (29/03/
 
 
 - None
N/A Bjorn Stessel, Dr bjorn.stes 3.21E+09 
 - 1. Patient or guardian m
 applicable) before any st
 
Phase 2 Germany ;; Andreas Hochhaus, Pro;ruxcoflam ;+49 3641; University - 2. Male and female patie
 Inclusions:
 
 1. Trauma patients presen
 
 2. Trauma patients presen
 
 Exclusions:
 
N/A United Sta ; ; Jose L Diaz-Miron, MD;jose.diaz ;720-777-6University 1. Patie
 Patient groups

 
 1. COVID-19+ (n=140) All p
 eligible for this group.
 
Phase 4 ;; Sam (Saidi) Mohiddin, ;;d.hardin ;;020 7377 Barts & Th 2. COVID-19+ Myocardial i
Inclusion criteria: 1. Adult >= 18 year
 2. Laboratory confirmed COVID-
N/A Christopher KC Lai 1/F Lui Chechris.kcla +852 5569 Chinese Un 3. Provide
Exclusion
directcclinical care to
Inclusion criteria: All medical team m
N/A China Chen Li 149 Jimo R leetangba +86 13585 Shanghai O The subject
Exclusion
whocsigned an infor
 Inclusion Criteria

 
 - Adult (age = 18 years)
 
 - Admitted to the hospital
 
Phase 4 ; Niels van Royen, MD ;Roland.v ;+3124361 Radboud Un
 - Confirmed SARS-CoV-2 in

 
 1. Aged 18-65 years;
 
 2. Voluntarily participate in
 
Phase 1/PhChina ;; Prof. Qingsong Ye, P ;qingsongy ;+8615858 Center for 3. Diagnosed with severe p

 
 All subjects participating in
 
 1. According to the Diagno
N/A China ; Zhang Ze Guang, doct zheng862018928868242;86-20- 

 
 
 
 - None
N/A United Sta ; ; Tushar Patel;Robert ;brannock ;904-953-2Mayo Clinic 

 
 - Patient is 18 to 80 years
 
 - Patient must have histol
 
N/A China ; Qinglei Gao, Dr.;Qingl qingleigao +86-13871127473;+8 - Chemotherapy must be

 
 - The inclusion criteria are
 subjects in the age range
 
N/A ; Syed MR Kazmi, FCPS; ;farhan.ra ;03052225 Aga Khan U Exclusion

 
 - Dysfunctional worry rela
 about the topic (e.g. risk
N/A Sweden ;; Erik M Andersson, Ph ;erik.m.an ;+4673671 Karolinska 
Inclusion criteria: 1. Meet the history
 2. Meet Exclusion
the discharge
criteria:
standards
1. Patie
0 China Yingshuai Li 11 Beisanhuliyingshu +86 13681 Beijing Uni 3. Meet 2.
the diagnosis
Patients standar
who have
Inclusion criteria: 1. Confirmed cases
25-65 years;
criteria: 1. With
 3. Asexual difference;
 2. Patients with malig
 4. Clinical stage
 3. (light, common
Pregnant women;
1-Feb China Zhenlin Zhao Floor 10, B zhaozl200 +86 13828 Shenzhen R 5. Immunology
 4. HIV standard:
positive.periph

 
 1. Voluntarily participating
 informed of the study an
Phase 3 Italy Giuliano Rizzardini, Md ASST Fateb 

 
 - endometriosis patients
 
 - no psychiatric illness
 
 - no antidepressant use
 
 
N/A Turkey - women who had not end

 
 Patients eligible for inclusio
 criteria:
 
N/A ; Novartis Pharmaceutic;novartis. ;41613241 Novartis P Written patient informed co

 
 - Nursing home resident w
 
 - Nursing home resident w
 
 - fever
 
N/A Achille TCHALLA, MD achille.tch +33 5 55 05 86 26 -

 
 - Patients with acute resp
 based on assistant clinici
 
 
N/A Spain ;;; Miguel Guia;Antonio E;;miguelg ;;0035191 Hospital G -
 
 
 - Age above 18 years
 
 - Women of childbearing a
Phase 3 Germany ;; Benjamin MordmÃ¼ller
;diane.egg ;+4970712 University contraception for t

 
 - physicians working in en
 
 
 - physicians not working in
N/A United Stat Mohamed Alboraie, alboraie@a 2.01E+11 

 
 1. men and woman age 18
 
 2. Not hospitalized;
 
 3. Has recently tested SAR
 
Phase 2 United Sta ; Eric J Lenze, MD;Ange ;stevens.a ;(314)362- Washington 4. Currently symptomatic w

 
 - between the ages of 18-
 
 - works from home
 
 - works in the office befor
 
 
Phase 2/Phase 3 Ayse Zengin AlpÃ¶zgeazengin@is 9.06E+11 - have any systemic

 
 1. Suspected cases of COV
 epidemic;
 
 2. Adult aged 18 or over, a
 
Phase 2 Brazil Marcus Lacerda, MD marcuslac +55 92 99114 7633 3. No

 
 - All clients and health car
 
 
N/A United Sta ; John W Sanders, MD, ;jwsander ;336-70-C Wake Fores - Health care workers who
 
 - Adults admitted to hospi
 are believed to be =50 ye
Phase 3 Nigeria;Pak ; ; Haleema Shakur-Still; ;;haleema. ;;+44 207 London Sch 
 The NetherJesper Weehuizen j.m.weehu 8.88E+08 Inclusion c Exclusion c

 The NetherThomas Timmers [email protected]+10 Inclusion c Exclusion c

 
 1. Age 18 years or older
 
 2. Hospitalization with a su
N/A Julio A Chirinos juliochi@p 215-573-6606 clinical presentation with

 
 - All patients visiting the E
 the following years: 2017
 
 
Phase 1 Israel ; Roi Anteby, MD;Roi A roi.anteby 19293011120;+97254 
 
 1. Confirmed SARS-CoV-2 (
 
 2. Either gender
 
 3. Symptomatic for examp
 
Phase 3 ; Javed Akram, FRCP;S ;shehnoor ;+92 321 4 University 

 
 - Participants =18 years of
 randomization
 
 
Phase 4 

 
 - Are hospitalized with pn
 
 - Are able and willing to gi
Phase 2 ; Call 1-877-CTLILLY (1- ;ClinicalTr ;1-317-615Eli Lilly a representative can p

 
 - >18 years
 
 - Accept study
 
 - live with an addiction
 
 Exclusion criteria:
 
 - not being able to answer t
Phase 2/PhFrance ;; HÃ©lÃ¨ne Donnadieu-;h-donnadi;04673370 University 

 
 - Patient over the age of 1
 
 - Diagnostic COVID-19 by
 
 - Hospitalisation in resusc
N/A France ;; Pierre-Emmanuel FAL ;pierre-em ;33 3 69 55Service de 

 
 - Willing to participate on
 
 
 - No
Phase 2 Indonesia ; ; Tjhin Wiguna, PhD;Tj ;;twiga00 ;;+628129 Dr Cipto M 
Human
pharmaco
logy
(Phase I):
no
Therapeu
tic
explorato
ry (Phase
II): yes
Therapeu
tic
confirmat
ory -
(Phase
III): no
Therapeu Inclusion criteria: â€¢ All types
tic use â€¢ Male/female participants
(Phase â€¢ Age>18
Exclusion
y.o. criteria: â€
IV): no â€¢ Signed
 â€¢
informed
Patients
consent
with kn
fo
France â€¢ No â€¢
restriction
Patients
on Eastern
current
Co
Human
pharmaco
logy
(Phase I):
no
Therapeu
tic
explorato
ry (Phase
II): no
Therapeu
tic
confirmat
ory -
(Phase
III): yes
Therapeu
tic use
(Phase Exclusion criteria: -Pa
IV): no Inclusion criteria:
 -mechanical
 -Recent ventilati
(=6 da
Belgium HIRUZ CTU C. Heymanshiruz.ctu@ 3.29E+09 University -COVID-19
 -clinical
diagnosisfrailty
confirmed
scale a
 Donor Eligibility Criteria:

 
 - Age 18-60
 
 - A history of a positive na
 
 - At least 14 days from res
 
Phase 2 ; Michele L Donato, MD;;Marifiel. ;551-996-5Hackensack 
Exclusion criteria: Confirm
 
 Refusal by participan
 
Not Applic Australia Inclusion c Any o
 
 -1. Patients with age above
 pneumonia in the ward acc
 
Phase 1 2. Unders

 
 - Adult inpatients >18 yea
 
 - Positive PCR COVID-19 te
 
 - CT evidence of interstitia
 
N/A United Sta ; Jeffery S Kuo, MD;Joh ;englemd9 ;985-768-8Ochsner He
 1. Male or female adult = 1
 
 2. Subjects with mild-to-m
Phase 2 United Sta Kush Dhody, MBBS, Mkushd@ama
301-956-2536 2019 infection

 
 - to. Covid 19 positives b. So
 odynophagia, respiratory di
 
 c. Age between 18 years an
 
Phase 2 Colombia ; ; ; yohanny andrade, re ;;eduardoi ;;+573007 Genesis Fo Cri

 
 - Patients with diagnosis o
 
 
 - Patients refuse to partici
N/A 
 - INCLUSION CRITERIA:

 
 In order to be eligible to pa
 following criteria:
 
 - 18 years of age and olde
 
Phase 2 United Sta ; ; Joyce Y Chung, M.D.;A;alison.gi ;(240) 665 National In - Able to re
 
 - patients under investigati
 
 - patients that are positive
 
 
Phase 2 United Sta ; Matthew Yocum, MD; ;yocum00 ;612-626-8University - ultrasound contrain

 
 - = 18 years of age
 
 - Histologically confirmed
 
 - Receive systemic therap
N/A Belgium ;; Hannelore Denys, MD,;heini.kan ;+32 9 332 Medical On antica
Human
pharmaco
logy
(Phase I):
no
Therapeu
tic
explorato
ry (Phase
II): yes
Therapeu
tic
confirmat
ory -
(Phase
III): no
Therapeu
tic use
(Phase
IV): no
Greece President of the Boar 88 Michalainsepsis@o 3.02E+11 HELLENIC I Inclusion Exclusion c
Not Applic Australia Inclusion c Exclusion c
CTSU,
Nuffield
Departme
nt of
Populatio
n Health
University
of Oxford
Richard
Doll
Building
Old Road
Campus
Phase II/III United Ki Michelle Nunn recoverytr - Inclusion criExclusion cr

 
 - Age = 18
 
 - COVID-19 Confirmed Cas
 
 - Tympanic Temperature o
Phase 4 ;;;;; Ilad Alavi Darazam, ;;;;;sina.i ;;;;;+9891 Shahid Behe
 
Inclusion criteria: Diagnosis of IBD: C
Not Applic Australia Distress:
Exclusion c
Not Applic Australia;Austria;Belgium;Brazil;Bulgaria;Croatia;Cyprus;Czech Republic;De Inclusion criExclusion c
Not Applic United Kingdom Inclusion crExclusion cr

 
 - Male or female aged 18
 
 - Hospitalized (or docume
Phase 2/PhUnited Sta ; Joaquin Espinosa, PhD;bari-covi ;(720) 507 University department) with sympt

 
 - 1. NCP with severe acute
 of arterial oxygen over fr
 
N/A China ;; Yun Long;Yun Long, M;ly_icu@al ;+8610169 Peking Uni 

 
 - Liver, Heart, Lung or Kidn
 diagnosis of COVID-19
 
Phase 1 Alana Burns [email protected] 
 
 - COVID-19positive(+) ARD
 
 - ratio of partial pressure a
N/A Germany ; Peter Rosenberger, Pr ;peter.ros ;+4970712 +49707129 =10
Inclusion criteria: 1. Age 18 years and

 2. Confirmed
Exclusion
SARS-CoV-2
criteria: 1.byCurre
nuc
 3. Able 2.
to be randomised
Currently receiving
within
Phase 3 Australia;New Zealand 4. Expected
 3.toCurrently
be remain taking
an inp
LP
Exclusion criteria: â€¢
 â€¢ Previously diagn
Inclusion criteria:
 â€¢ Adult
Previously
(18+ years
diagn
ol
 (a) confirmed
 â€¢COVID-19
Known tosympto
be pre
Phase 0 Australia (b) symptom
 onset within the pa
Clinical
Trials Unit
Warwick
Medical
School
University
of
Warwick
Not Applic United Ki Keith Couper k.couper@ 4.42E+11 Inclusion crExclusion cr
Phase III Indonesia;Iran;Norway;Peru;Qatar;South Africa;Spain;Switzerland;Thailand;A Inclusion crExclusion cr

 
 - Any employee of Lake Fo
 
 - Age greater than 18 year
 
 
Phase 4 Andrew Gostine, MD andrew.go (312) 695-0061 - Age less than 18 years-

 
 - Patients:
 
 - Age>18y
 
 - Admission to the parti
Phase 4 France ;; Elie AZOULAY, MD Ph ;nancy.ken ;14249999 APHP; during the COVID-19 p

 
 
 - Telephone consultation
 
 
 - New patient in the depa
N/A France ;; GÃ©rard Amarenco, Ph
;greengrc ;01560175 Sorbonne U 
 
 - Type 2 Diabetes Mellitus
 
 - Age = 18
 
 - Confirmed COVID-19
 
Phase 4 United Sta ; Gianluca Iacobellis, ;giacobell ;30524336 University - Mild COVID-19 define
Inclusion criteria:
Exclusion
(1) criteria:
patients(1)diagno
bod
 (2) patients
 (2)
after
heart
discharge;
rate at rest>
 (3) patients
 (3)
agedcontinuous
18 to 80 oxyge
years
0 China Jinghua Qian 48 Xinxi Roydkfedu@1+86 18600 Beijing Spo (4) patients
 (4)
voluntarily
patien agree to
Inclusion criteria: 1. Discharged patie
 2. WithExclusion
dyspnea criteria:
symptom 1. (mM
Dysp
 3. Aged 2.
18~75Resting
years old;
heart rate>
 4. Have 3.
and can use smart
Adjusting phono
dosage
N/A China Li Jianan 300 Guangzlijianan@n +86 13705 Jiangsu Pro 5. Obtain the Combined
 4. consent of uncontr
the sub
N/A China Liping Jia 11 Kaopeng41025513 +86 15171 HuanggangInclusion Exclusion c
Inclusion criteria:
Exclusion
1. Students
criteria: 1.
cursing
Staff
N/A Bolivia DIANA MARIA CESPEDSuit 29, U dicespede +86 15549 Wuhan Univ 2. Students 2.currently
Incomplete registered
inform
Exclusion criteria: 1) left h
 2) pregnancy and lac
Inclusion criteria:
 3) 1.liver
Aged
failure
18 years
MELDol
 2. diagnosed
 4) with
a history
viral of
pneumon
deep v
0 China Enhai Cui 198 Hongqikjkceh@12+86 13857 Huzhou Cen 3. voluntary
 5)informed
cases that consent
the
RetrospectChina Bai Xiaoxia 1 Xueshi R baixiaoxia +86 13957 Women's HoInclusion c Exclusion c

 
 1. Aged 21 to 80 years.
 
 2. History of close contact
 
Phase 3 ; Rupesh Agrawal, MD; ;rupesh_ag;6357100 Tan Tock S 3. Absence of symptoms re

 
 - Patient age =18 years, co
 
 - Within 48 hours of positi
 
 
Phase 2 United Sta ; ; Adam Spivak, MD;Chris;christina ;80121387 University - Patien

 
 - Patients with PCR confirm
 
 
 - Age >18
 
Phase 2/PhNetherland ; Bart Rijnders, MD, Ph ;b.rijnder ;+3110703 Erasmus Me<
 
 - Age 18 to 65 (inclusive)
 
 - Confirmed COVID-19 infe
Phase 2/PhUnited Sta ; ; David Ho, M.D,;Yang L;yl4459@c ;21230462 Columbia Un under emergency use au
N/A China Junxue Wang Zhiyinhu A docd1@sin 1.89E+10 Huoshensha 2. Pneumonia
Exclusionpatients
c with new
 2. Previous history of
 3. 1.
Inclusion criteria: Inability
Patientstoaged
commu14
 4.fluorescence
 2. Real-time Patients withrt-pcr
acqu
N/A China Ying Fan 600 Yishan fanyingsh +86 13918 Shanghai Ji 3. The 5.
respiratory
Patients
tractwith
specime
malig
Inclusion criteria: (1) Comply with th
 (2) Patients
Exclusion
=18 years
criteria:
of 1.Serio
age wit
4 China Yun Lin 1277 Jiefanfrank0130 +86 13986 Union Hosp (3) Agree 2.Obstructi
to participate in the
 The NetherDiederik van Wijk DF.van.Wi 088-085-7589 Inclusion c Exclusion c

 
 - Individual currently work
 ("healthcare worker") in
 
Phase 2 United Sta ; ; Emily O'Brien, PhD;L ;laura.we ;+1 919 66 Duke Unive - Ag

 
 - Male and female residen
 
Phase 3 Matthew Bardin, Pha matthew.b813-282-8544 of the protoco
 
 - All genders
 
 - Age > 18 yrs and < 90 yrs
 
 - Must have laboratory co
 
 - Must provide informed c
 
Phase 2 United Sta ; Latha Dulipsingh;Lath Latha.Duli 860-714-4402;860-71 - Must

 
 All mission critical personne
 Flight Medicine Clinic unabl
Phase 2 United Sta ; ; ; ; ; Angela Phillips, PhD; ;;;;usaf.p ;;;;703-69 11 MDG;NM 
Inclusion criteria:
Exclusion
1. Aged
criteria:
>181.years
Patieo
RetrospectChina Rui Zeng 37 Guoxue zengrui_0 +86 028-8 West China 2. patients
 2.
diagnosed
Give up treatment
COVID-19
N/A China Weng Jianping 17 Lujiang wengjp@us+86 0551- the First A Inclusion c 2. Patients developed
 The NetherFemke Hooijberg f.hooijber 2.02E+08 Inclusion c Exclusion c
 The NetherFrank Bosch frank.bos 3.12E+10 Inclusion c Exclusion c
 The NetherJAH VAN Oers jah.vanoer 1.32E+08 Inclusion c Exclusion
 The NetherHamza Yousuf hamza@ham 00 31 20 444 22 44 Inclusion c Exclusion c

 
 - Any faculty, staff, or train
 being in the study
 
 
 -
N/A United Sta ; ; ; Patty Lee, MD;Sangeeta
;;erika.rat ;;919-681- Duke Unive 
 Inclusion Criteria (each of th

 
 1. Adults (aged =18 years)
 
 2. Confirmed diagnosis of C
 
 3. Hospitalized in the ICU f
 
Phase 2 United Sta ; David E Leaf, MD, MM;deleaf@b ;617-525-7Brigham an 4
Inclusion criteria: Positive for COVID
Not Applic Australia Admission
Exclusion
or being
c considered f
Human
pharmaco
logy
(Phase I):
no
Therapeu
tic
explorato
ry (Phase
II): no
Therapeu
tic
confirmat
ory -
(Phase
III): yes
Therapeu
tic use Exclusion criteria: Su
 1. Subjects
Shock requiring
meeti
IV): no 1. Age 2.
= 18 year/old
Acute respirator
France Carla VANDENABELE DRCI HÃ´pitcarla.vand +33140 27 ASSISTANC 2. Chronically
 3. Circulatory
treated withassi
RA
Not Applic Australia Inclusion c Exclusion
Exclusion criteria: â€¢ Kn

Inclusion criteria:
 â€¢ â€¢Currently
Aged 18breastf
to 75
 â€¢ Laboratory
 â€¢ Known
confirmed
maculop
SARS
 â€¢ Advised
 â€¢ to self-manage
Known cardiacCOV
d
Phase 2 New Zealand â€¢ In â€¢
the Investigatorâ€™s
Know renal dis
opi
 The NetherHarm Jan Bogaard hj.bogaar +31020 444 1896 Inclusion c Exclusion
Human
pharmaco
logy
(Phase I):
no
Therapeu
tic
explorato
ry (Phase
II): yes
Therapeu
tic
confirmat
ory -
(Phase
III): no
Therapeu Inclusion criteria: Patients with S
tic use 1. age Exclusion
= 18 years
criteria:
and = 1.
75 yea
(Phase 2. SARS-CoV-2
 infection
less confir
than
IV): no 2.
swap)In the opinion of
Germany Sixten KÃ¶rper Helmholtzss.koerper@ 4.97E+10 IKT Ulm 3. severe
 disease defined
i by a
Human
pharmaco
logy
(Phase I):
no
Therapeu
tic
explorato
ry (Phase
II): no
Therapeu
tic
confirmat
ory -
(Phase
III): yes
Therapeu
tic use
(Phase
IV): no
France REC 12 rue dub patrick.ca 3.31E+10 CENTRE HOInclusion c Exclusion
Human
pharmaco
logy
(Phase I):
no
Therapeu
tic
explorato
ry (Phase
II): no
Therapeu
tic
confirmat
ory -
(Phase
III): yes
Therapeu
tic use
(Phase
IV): no
France Clinical research proj 133 Avenuel.lamrani@ 3.31E+10 Groupe Hosp
Inclusion c Exclusion c
Exclusion criteria: â€¢
 â€¢ Allergy to Zn
 â€¢ Severe hepatic im
Inclusion criteria:
 â€¢ â€¢eGFR
Consenting
equal to ad
or
Phase 1 / Australia â€¢ Hospitalized wit
Northum
bria Sleep
Research
Laborator
y
Northum
bria
University
Not Applic United Ki Greg Elder g.elder@no+44 (0)191 227 3241 Inclusion crExclusion cr
Human
pharmaco
logy
(Phase I):
no
Therapeu
tic
explorato
ry (Phase
II): no
Therapeu
tic
confirmat
ory -
(Phase
III): no
Therapeu
tic use
(Phase
IV): yes
Spain SCREN-UICEC profesor mafibucicec. 3.49E+14 FIB-HCSC Inclusion c Exclusion c
Human
pharmaco
logy
(Phase I):
no
Therapeu
tic
explorato
ry (Phase
II): yes
Therapeu
tic
confirmat
ory -
(Phase
III): no
Therapeu
tic use
(Phase
IV): no
Spain LOLA SERNA GUIRAO LUIS FONT [email protected] FFIS Inclusion c Exclusion c
Epidemiol
ogy,
Biostatisti
cs and
Preventio
n
Institute
(EBPI)
University
of Zurich
Hirscheng
raben 84
Not Applic Switzerlan Jan Fehr jan.fehr@u+41 44 634 46 79 Inclusion c Exclusion cr
Nuffield
Departme
nt of
Primary
Care
Health
Sciences,
University
of Oxford
Radcliffe
Observat
ory
Quarter,
Woodstoc
k Road
;
Nuffield
Departme
nt of
Primary
Care
Health
Sciences,
Phase III United Ki Emma;Juli Ogburn;All Uni principle@ +44 (0)800 ; Inclusion crExclusion cr
Human
pharmaco
logy
(Phase I):
no
Therapeu
tic
explorato
ry (Phase
II): no
Therapeu
tic
confirmat
ory -
(Phase
III): no
Therapeu
tic use
(Phase
IV): yes
Spain Emilio Garcia Cabrera Calle Casti secretaria@delosclini Delos Clini Inclusion c Exclusion c
Human
pharmaco
logy
(Phase I):
no
Therapeu
tic
explorato
ry (Phase
II): no
Therapeu
tic
confirmat
ory -
(Phase
III): yes
Therapeu
tic use
(Phase
IV): no
Spain Epidemiologist Plaza de Creunate.ara 3.49E+10 Eunate AranInclusion c Exclusion c
Human
pharmaco
logy
(Phase I):
no
Therapeu
tic
explorato
ry (Phase
II): no
Therapeu
tic
confirmat
ory -
(Phase
III): yes
Therapeu
tic use
(Phase
IV): no
France Clinical Research Dire 29 rue [email protected]+10 HÃ´pital F Inclusion c Exclusion c
Human
pharmaco
logy
(Phase I):
no
Therapeu
tic
explorato
ry (Phase
II): no
Therapeu
tic
confirmat
ory -
(Phase
III): yes
Therapeu
tic use
(Phase
IV): no
Spain Unidad de EnfermedadCamino de gutierrez_ 3.5E+10 FISABIO Inclusion c Exclusion
Inclusion criteria: Laboratory confirm
RetrospectChina Jinzhi Lu 8 Hangkongjinzhilu2 +86 18163 The First A all COVID-19 p c
Exclusion
Inclusion criteria: 1. Patients with clin
RetrospectChina Qianjin Lu 139 Renminqianlu586 +86 13797 The Second 2. HaveExclusion
exposurec to people with
Human
pharmaco
logy
(Phase I):
no
Therapeu
tic
explorato
ry (Phase
II): no
Therapeu
tic
confirmat
ory -
(Phase
III): yes
Therapeu
tic use
(Phase
IV): no
Spain Jose MuÃ±oz GutiÃ©rCalle Ross jose.munoz 3.49E+14 ISGlobal Inclusion c Exclusion c
Inclusion criteria:
Exclusion
1. Aged
criteria:
above
1. Fami
18 y
 2. Able 2.
to understand
Subject allergic
the conte
to
2 China Zhu Fengcai 172 Jiangsujszfc@sina-83759357 Jiangsu Pro 3. Able 3.
and willing
Woman to complete
who is prea
Retrospect?? Shengtian Zhao 324 Jing-W39813984 +86 15153 Shandong PInclusion c Exclusion c
Exclusion criteria: (1)Uncl
Inclusion criteria:
 (2)Insufficient
(1)Completesample
samp
N/A China Zhang Chunyan 28 Fuxing Rrebrcca@1+86 18810 Chinese PL (2)New (3)Contaminated
coronavirus-infectedsam pn
0 China Tangshaohua Kang-Le-Fatsh006@16+86 13858 Wenzhou Ce Inclusion c Exclusion c
 The NetherAlienke Wijmenga-Monsuur alienke.wi NA Inclusion c Exclusion c
 The NetherMarion Frenken marion.fr 040-8888380 Inclusion Exclusion
 The NetherFrank Bosch frank.bos 3.12E+10 Inclusion c Exclusion c
 The NetherMargriet Dijkstra m.j.dijkstr +31 50 3610468 Inclusion c Exclusion c
Human
pharmaco
logy
(Phase I):
no
Therapeu
tic
explorato
ry (Phase
II): no
Therapeu
tic
confirmat
ory -
(Phase
III): yes
Therapeu Exclusion criteria: â€
tic use Inclusion criteria:
 â€¢ â€¢
Pregnancy
COVID-19
(Phase â€¢ Age 
18 years
â€¢ Prisoners
or older
IV): no â€¢ Presence
 â€¢ ofNaproxen
pneumonia allerg
France Eldoie SOLER DRCI, 1 av elodie.sol +3301 44 8Assistance â€¢ PaO2/FiO2
 â€¢ Severe
< 300 mmrenal
Hgfailu
or
Human
pharmaco
logy
(Phase I):
no
Therapeu
tic
explorato
ry (Phase
II): yes
Therapeu
tic
confirmat
ory -
(Phase
III): yes
Therapeu
tic use
Exclusion
 1.
criteria:
At least
 1.
18 y
IV): no 2. Clinically
 2.evident
Intubated
or otherwise
> 48h at
NetherlandClinical Research an Winzerlaer korinna.pil +4989414 InflaRX G â€¢ Chest
 3.
X-ray
Patients
or CT-scan
who dem
or M
Human
pharmaco
logy
(Phase I):
no
Therapeu
tic
explorato
ry (Phase
II): no
Therapeu
tic
confirmat
ory -
(Phase
III): yes
Therapeu
tic use
(Phase
IV): no
France Project manager URCIP - Ba arnauld.ga 33(0)4771 CHU Saint Inclusion c Exclusion c
Human
pharmaco
logy
(Phase I):
Therapeu
tic
explorato
ry (Phase
II): yes
Therapeu
tic
confirmat
ory -
(Phase
III):
Therapeu
tic use
Exclusion
 I1.
criteria:
Age E1
18 or o
IV): no I2. Histologically
 E2. Fororcohort
cytologically
2 only
France Julien GAUTIER 28 rue Lae julien.gaut +33426 55 Centre LÃ I3. E3. Contraindication
Human
pharmaco
logy
(Phase I):
no
Therapeu
tic
explorato
ry (Phase
II): no
Therapeu
tic
confirmat
ory -
(Phase
III): yes
Therapeu Exclusion criteria: 1.
tic use Inclusion criteria:
 2. 1.Age
Grossesse =ou18allait
yea
(Phase 2.Admitted
 3.toCorticothÃ©rapie
ICU within 48 hou
IV): no 3.Confirmed
 4.orInfection
highly suspected
bactÃ©r
France DRCI 1, [email protected] 4.Acute 5.
hypoxemic
Absencerespiratory
de consen f
Human
pharmaco
logy
(Phase I):
no
Therapeu
tic
explorato
ry (Phase
II): yes
Therapeu
tic
confirmat
ory -
(Phase
III): no
Therapeu
tic use
(Phase
IV): no
Spain Xavier Solanich More Feixa Llarg [email protected]+10 Dr. Xavier Inclusion c Exclusion c
Human
pharmaco
logy
(Phase I):
no
Therapeu
tic
explorato
ry (Phase
II): yes
Therapeu
tic
confirmat
ory -
(Phase
III): no
Therapeu
tic use
(Phase
IV): no
Spain UICEC Sant Pau Sant QuintÃ
epenag@sa
77-79 3.49E+10 INSTITUT Inclusion c Exclusion c
Human
pharmaco
logy
(Phase I):
no
Therapeu
tic
explorato
ry (Phase
II): no
Therapeu
tic
confirmat
ory -
(Phase
III): yes
Therapeu
tic use
(Phase
IV): no
Spain Clinical Trials Depart PÂº Castellana 127-1 3.49E+10 Effice Inclusion c Exclusion c
Human
pharmaco
logy
(Phase I):
no
Therapeu
tic
explorato
ry (Phase
II): yes
Therapeu
tic
confirmat
ory -
(Phase
III): yes
Therapeu
tic use Exclusion criteria: Un
 Participants
 Participants
with criti
m
IV): no Laboratory-confirmed
 Any contraindication
SARS-CoV
France;HunMedical Information 410 Thamesuk-medical 4.48E+11 sanofi-ave Onset of Any
COVID-19
medical conditio
Human
pharmaco
logy
(Phase I):
no
Therapeu
tic
explorato
ry (Phase
II): no
Therapeu
tic
confirmat
ory -
(Phase
III): yes
Therapeu
tic use
(Phase
IV): no
Spain Anabel SÃ¡nchez Carretera anabelsan 3.49E+10 FundaciÃ³nInclusion c Exclusion c
Condition Interventi Primary o results dat results da results url RetrospectiBridging fl Bridged ty results yes no
2019-nCoVsurvival g duration of in hospital;in hospital mortality; No 0
Novel CoroCase serie Length of hospital stay; No 0
2019 NovelDrug: arbi mortality Yes 0
Novel CoroCase serie inhospital length;inhospital mortality;ECMO Yes 0
Novel CoroexperimentFatality rate; Yes 0

Novel Corocontrol gr Time fo fever reduction;Time of nucleic aci Yes 0
Novel CoroexperimentLung function; Yes 0
novel coro Case serie Conversion rate of mild and common type pat
No 0
novel coro ExperimentTime to disease recovery; Yes 0
Novel CoroGold StandSEN, SPE, ACC, AUC of ROC; Yes 0
CoronavirusDrug: ArbidThe rate of virus inhibition Yes 0
Cardiovascular Death; Cardiovascular Death Yes 0

Virus; Pneumonia GHQ-12(general health questionnaire-12) Yes 0
Novel CoroGold Standadetection of SARS-CoV-2 nucleic acid;SEN; Yes 0
Novel Corocase series 28-day mortality and 90-day mortality.; No 0
Novel CoroExperimentSt. George's Respiratory Questionnaire; Yes 0

Novel CoroGold StandChest CT findings;Epidemiological history;L Yes 0
Novel CoroTCM Group:Length of hospital stay;fever clearance time;Yes 0
Novel Coroexperiment14 day outcome of the subjects, including: r No 0
Novel CoroExperimentBody temperature returns to normal time;P Yes 0
severe nov experiment14 day outcome of the subjects, including: r No 0
Novel Coroexperimenta
Time to Clinical recovery; No 0
PneumoniaDrug: ConveTime to complete remission of 2019-nCoV i Yes 0

2019-nCoVOther: bas Virus negative conversion rate in the first w Yes 0
2019-nCoVOther: Sta Lower Murray lung injury score;Lower Murray

Yes 0
2019-nCoVDrug: lopinThe incidence of composite adverse outcom Yes 0
novel coro Case seriesPSQI; No 0
Novel Corocase series imaging feature; Yes 0
Novel Coroexperiment Number of worsening events; Yes 0
Novel CoroConventionLength of hospital stay; No 0

Novel CoroExperimentLength of admission;mortality rate; No 0
Novel CoroExperimentrate of cure; No 0

COVID-19 Case seriesclinical features and risk factors;validity and Yes 0
Novel CoroCase seriesIncidence of co-infection; No 0
novel coro Gold StandSensitivity of detection of NCP;Specificity of Yes 0
novel coro control gr ECG;Chest imaging;Complications;vital sign Yes 0
Emotional Case seriesSelf-rating depression scale, SDS;Self-Rating No 0

Novel CoroExperimentTime of viral nucleic acid turns negative;AntiYes 0
Novel CoroGeneral paChest imaging (CT); No 0
2019 NovelexperimentLength of stay;Length of severe;oxygenation Yes

i 0
Novel CoroGold StandPositive/Negtive;SEN, SPE, ACC, AUC of ROC Yes 0
Novel CoroChinese tr TCM symptom score;Antifebrile time;The time

Yes 0
Novel CoroThymosin tProportion of patients with a lung injury sc No 0
Novel CoroControl gr TCM symptoms efficacy; Yes 0
novel coro Normal groTCR sequencing;BCR sequencing;HLA sequenYes 0
novel coro Case seriesTime for body temperature recovery;Chest CT

Yes 0
Novel CoroControl gr Antipyretic time;Pharyngeal swab nucleic ac Yes 0
new coron control gr cure rate; No 0
novel coro ExperimentCompletely antipyretic time: completely an No 0
novel coro Case serie 2019-nCoV nucleic acid turning negative timeYes 0
Novel CoroExperimenttime and rate of temperature return to normYes 0
Novel CoroCase seriesTime to clinical recovery; No 0
novel coro experimentRate of conversion to severe or critical illnes Yes 0

novel coro Case serieslength of stay;length of stay in ICU;Antibio No 0
novel coro Control gr the negative conversion ratio;the proportio No 0

novel coro control gr PSI; Yes 0
novel coro control gr Antipyretic time; Yes 0

novel coro Treatment Cure rate;The cure time;The rate and time a Yes 0
Novel CoroObservatioCD4+;CD3+;HAMA;HAMD;STAI; Yes 0
Novel CoroExperimentClinical and laboratory indicators;Viral load; No 0
novel coro Experimentviral negative-transforming time;30-day causYes 0
novel coro experimentThe incidence of adverse outcome within 14 Yes

d 0
novel coro (ordinary) Recovery time;Ratio and time for the generalYes 0
novel coro treament gRelief of clinical symptoms and duration; Yes 0
Novel CoroCase serie Inpatient mortality; No 0

novel coro Experiment28-day survival;Inflammatory factor levels; Yes 0
novel coro experimenta

vital signs (Body temperature, blood pressu Yes 0
Novel CoroExperimentChest CT;Routine blood test;liver and renal Yes 0

Self-rating depression scale, SDS;Self-Rating Yes 0
novel coro experimentpulmonary function;St Georges respiratory Yes 0
Time to Clinical recovery; No 0
Epilepsy, Epilepsy g Physical and mental health; No 0
novel coro Case serie Clinical characteristics;TCM syndrome; No 0

novel coro control gr CURB-65;PSI score;Mechanical ventilation tim
Yes 0
novel coro Case seriesTime for body temperature recovery;Chest XYes 0
novel coro A:Critical CT of lung;CT and MRI of hip; No 0
novel coro Suspected blood routine examination;CRP;PCT;Chest CT;No 0
Novel Coronon-severeincidence;mortality; No 0
Novel CoroExperimentthe condition worsens and develops into seveYes 0
novel coro Vitamin D ROX index; Yes 0
novel coro Group 1:TCDuration of PCR normalization;Clinical symp Yes 0
novel coro ExperimentCritically ill patients (%); Yes 0
novel coro doctors groPhysical examination;Nucleic acid;Oxygena Yes 0

novel coro ExperimentTime to completely antipyretic time:completYes 0
Novel CoroCase seriesEpidemiological history;haematological;Firs No 0
novel coro ExperimentVirus negative conversion rate in the first w Yes 0
novel coro Gold StandLymphocyte subpopulation analysis;CytokineYes

d 0
Novel CoroExperimentIncidence of onset at home / designated iso No 0
novel coro mild-modervirus nucleic acid negative-transforming tim Yes 0
Novel CoroexperimentMortality in patients; No 0

Novel CoroExperimentpulmonary function;Novel coronavirus pneum
No 0
Novel CoroControl gr CT scan of the lungs;Nucleic acid detection oYes 0
novel coro Group A:alpDeclining speed of Novel Coronavirus by PCRNo 0
novel coro control gr PSI; Yes 0
novel coro Low dose gTime to disease recovery; No 0
novel coro ExperimentThe incidence of composite adverse outcom Yes 0

The time when the nucleic acid of the novel No 0
novel coro ExperimentaTime to viral negativity by RT-PCR;Time to c Yes 0

novel coro single arm blood routine;urine routines;CRP;PCT;ESR;cr No 0
novel coro A:Baloxavi Time to viral negativityby RT-PCR;Time to cl Yes 0
novel coro DRV/c grouTime to conversion of 2019-nCoV RNA resultYes 0
novel coro Experimenta

body temperature;Whole blood count and five
Yes 0
Novel CoroExperimentChest CT scan;Nucleic acid of novel coronavirYes 0
Novel CoroTwo groups:Time to leave ventilator on day 28 after rec No 0
novel coro experimentaPatient survival rate; No 0

novel coro Case seriesall available outcome; Yes 0
Novel Coroexperimentpulmonary function;Antipyretic time;Time ofYes 0
novel coro experimentpulmonary function;St Georges respiratory qYes 0

new coronaexperimentpulmonary function;St Georges respiratory Yes 0
novel coro control gr Antipyretic time;Time of virus turning negatiYes 0
novel coro CommunityViral nucleic acid detection;CT Scan of the Yes 0

novel coro Case seriesTCM syndroms; Yes 0
Mental hea1:Simplify State anxiety; Yes 0
novel coro Psychologi the score of Hamilton depression scale;the s Yes 0
Novel CoroExperimentpneumonia severity index (PSI);Incidence of Yes 0
Novel CoroCase serie The novel coronavirus nucleic acid negative Yes 0
CoronaviruBiological Number of Participants with presence of 20 Yes 0
2019 nCoV,Other: sta lung injury score Yes 0
Novel CoroExperimentCure rate;Mortality; Yes 0
novel coro Group A:trathe rate of remission; Yes 0

CoronavirusOther: Sta Lower Murray lung injury score;Lower Murray
Yes 0
Novel CoroCase seriesthe daily treatment intensity; Yes 0
novel coro Control groBlood routine tests, Liver function examinat No 0
Novel CoroExperimentBody temperature;TCM syndrome integral;Mur

No 0
Novel CoroCase seriesDistribution of 'B' line around lungs of bot No 0
Novel CoroGroup 1:Xupneumonia severity index (PSI); No 0
Pneumonia,Biological Oxygenation index Yes 0

novel coro Gold Stand28day mortality; Yes 0
Novel CoroExperimentCD8+ T cells numbers;CD4+ T cell numbers;NK

Yes
c 0
Novel CoroCase seriesSARS-CoV2 Nucleic Acid Quantification; No 0
Novel CoroAdolescentmenstruation changes;TCM body constitutioYes 0
Novel Corocontrol gr Chest CT;Whole blood cell analysis;Recover Yes 0
Novel CoroCombinatioClinical recovery time; No 0
Novel CoroCase serie Cortisol;ACTH;Form of Adrenal tissue; Yes 0

Novel CoroSevere gro M mode echocardiography;two-dimensionalNo
e 0
Novel CoroExperimentTCM symptom score;Becomes negative timeNo

o 0
Novel Corosevere NCPSevere NCP group: Time to clinical improvemNo 0
Novel CoroCase seriesThe changes of clinical symptom, laboratory No 0

Novel CoroCase seriesAcute kidney injury; Yes 0
Novel CoroCase seriesclinical cure rate;Incidence of mechanical v No 0
Novel coro Case serie Release rate of discharge standards for isola Yes 0
Novel CoroExercise pr Mood index; Yes 0
Novel CoroExperimentThe days from positive to negative for viral nYes 0
Novel CoroExperimentClinical index; Yes 0

Novel CoroCase seriesSelf-rating depression scale; Yes 0
Novel Coro1:inhalate viral negative-transforming time;30-day causNo 0
Novel CoroExperimentClinical symptoms;Blood routine;the viral l No 0
Novel Corocase series ICU hospitalization days;Death rate; Yes 0
Novel CoroInterventi Proportion of COVID-19 close contacts who Yes 0
CoronaviruHumanisticrecovery time; Yes 0
Novel Corocontrol gr Chest imaging;RNA test of COVID-19;Time toYes 0

Novel CoroSevere gro Death;Recovered;Discharged; No 0
Novel CoroCase seriesmenstruation changes; No 0
Novel CoroCase serie NA; Yes 0
Novel CoroExperimentImprovement of clinical symptoms (Clinical i Yes 0

Novel CoroExperimentTTCI (Time to Clinical Improvement); Yes 0
Novel CoroExperimentThe nucleic acid of the novel coronavirus is Yes 0
anxiety an Case seriespsychological scale;Intestinal flora abundan No 0
Novel CoroExperimentRecovery rate; Yes 0
PneumoniaGanovo / r Rate of composite advers outcomes:SpO2,PaONo 0

Novel CoroExperimentQuality of life;Anxiety assessment;Depres Yes 0
Novel CoroLight grou Three-dimensional ultrasound;Two-dimension No 0

Novel Corogeneral an CT image of lung of close contact medical st Yes 0
Novel CoroHydroxychlClinical recovery time; Yes 0
Novel CoroExperimentSARS-CoV-2 DNA;SARS-CoV-2 antibody levels;

Yes 0
Novel CoroLow-dose grTime to Clinical Recovery; Yes 0
Anxiety; N pneumoniaSelf-Rating Anxiety Scale;Self-Rating Depres Yes 0
Novel CoroExperimentTime to Clinical recovery; No 0
novel coro Mild Groupgut microbiome;Fecal metabolomics;Blood roYes 0

Novel CoroCase seriesClinical characteristics; Yes 0
Novel CoroCase serie Coronavirus nucleic acid markers negative r No 0
Novel CoroTraining:N Accuracy; Yes 0

Novel Corocollege st Mental health status; Yes 0
Novel CoroGroup 1:Tr hospital stay;Discharge rate;Site-specific h Yes 0
Novel Corocontrol gr cure rate; No 0
Novel CoroControl gr lung function;ADL;6min walk; Yes 0
Novel CoroControl gr Length of hospital stay; Yes 0
Novel CoroChloroquinClinical recovery time;Clinical recovery tim No 0
pneumonitiexperimentImproved respiratory system function (bloodNo 0
Novel CoroexperimentArterial Blood Oxygen Saturation;TTCR,Time Yes 0
Novel CoroExperimentTime to Clinical Recovery; No 0

Novel CoroControl gr TCM syndrome; Yes 0
Novel CoroCOVID-19 pCoVID-19 Perinatal Outcomes; No 0
Novel CoroexperimentDisappearance rate of fever symptoms; Yes 0
Novel Corohydroxychloxygen index;max respiratory rate;lung radi Yes 0
NO Case seriesHSCS;SCSQ;GHQ-12; No 0
Novel CoroExperimentthe rate of Coronary virus nucleic acid nega Yes 0
novel coro Gold StandCytokine detection;Lymphocyte subpopulatioYes 0
Novel Corocommon gro

blood cell count;C-reactive protein (CRP);art Yes 0
Novel CoroGold StandaSARS-COV-2 nucleic acid;SEN, SPE, ACC, AUCYes 0

Novel CoroExperimentTime to Clinical recovery;Butyrate in feces; No 0
Novel CoroA1:HydroxyNumber of patients who have progressed to Yes 0
Novel CoroexperimentRecovery time; Yes 0
Novel Corocontrol gr SOFA; Yes 0
2019-nCoVDrug: RemdTime to Clinical recoveryTime to Clinical Re Yes 0
Novel CoroControl gr Recovery time;Pneumonia psi score; Yes 0
Neonatal Infection;Pe The SARS-CoV-2 infection of neonates born Yes 0
Susceptibil Other: mobipositive number diagnosed by national guideYes 0
COVID-19 Drug: thal Time to Clinical recoveryTime to Clinical Re Yes 0
COVID-19 Drug: plac Time to Clinical Improvement (TTCI) Yes 0

2019-nCov one group:RPCL;HRQL;IPAQ;PASE; Yes 0
Novel CoroGroup 1:EigPost-traumatic stress disorder checklist;Clini Yes 0
2019-nCoV The incidence of long-term adverse outcomeYes 0
2019 NovelDrug: Plac Oxygenation index (PaO2/FiO2);Pneumonia sYes 0
COVID-19 Other: nCa Accuracy of nCapp COVID-19 risk diagnostic Yes 0
Novel CoroControl gr Psychological status;Treatment compliance;To

Yes 0
2019-nCov;Drug: RemdTime to Clinical Improvement (TTCI) [Censor Yes 0
2019-nCoVsDrug: Mepl2019 nCoV nucleic acid detection Yes 0

2019 NovelDrug: XiyanClinical recovery time Yes 0
Pulmonary Drug: N-ac High-resolution computed tomography (HRCT)

Yes 0
Novel CoroCase serie mood assessment; Yes 0

Novel coro Case serie pulmonary iconography; Yes 0
Novel coro Gold StandCT;SEN, SPE, ACC, AUC of ROC; No 0
Novel CoroMonitor caEpidemiological characteristics;clinical fea No 0
Novel CoroLight and Epidemiological and clinical characteristics; No 0
pediatric Case serie temperature;respiratory symptoms; Yes 0
CoronaviruDrug: Fing The change of pneumonia severity on X-ray Yes 0
Novel CoroCase seriesPCL;PSQI;FSI; Yes 0
Novel CoroExperimenta
Pharynx swabs, lower respiratory tract samplNo 0
Novel CoroExposure gLung CT;TCM symptoms; No 0
CoronaviruOther: ComSurvival rate Yes 0

Coronavirus Positive rate of 2019 Novel Coronavirus RNAYes 0
Novel CoroBiological: Number of participants with treatment-relatYes 0
CoronaviruCase serie Inhospital time; Yes 0
Novel CoroGold StandSEN, SPE, ACC, AUC of ROC; No 0
Novel CoroPirfenidon K-bld questionnaire survey;Refers to the pul Yes 0

Novel CoroCase seriesblood RNA; Yes 0
Novel CoroGroup 2:OnViral load;Clinical features;Inflammation;Pu No 0
Novel CoroCase serie Sputum/nasal swab/pharyngeal swab/lower Yes

resp 0
Novel CoroCase serie cure rate;virus negative rate;time of virus neYes 0
Novel CoroMild groupEpidemiological and clinical characteristics; Yes 0

psychologicCase seriesGHQ-20; No 0
Digestive The experi During the operation, the patient's volume oYes 0
novel coro Case serie Critically ill patients (%);Mortality Rate; No 0

Novel CoroCase seriesBlood Routine;Liver function;Blood electroly No 0
psychologi InterventioPsychological questionnaire; Yes 0
Novel CoroCase serie Time to disease recovery;Exacerbation (transNo 0
Novel coro case series imaging feature; Yes 0

Novel CoroTwo groupsTemperature;Respiratory symptoms; Yes 0
Novel CoroCase seriesClinical indicators; Yes 0
Novel CoroHigh infla Inflammation factor; No 0

job burnouBurnout pono; Yes 0
Novel CoroCase seriesQuality of Life;Epidemic Prevention Medica No 0
Novel CoroExperimentRate of composite advers outcomes: SpO2, PNo 0
Novel CoroExperimenttemperature;respiratory rate;Blood oxygen No 0

Novel CoroCase seriesINR;PT;TT;APTT;FIB;DD; Yes 0
NRS 2002 score;BMI;triceps skinfold thickne Yes 0
Novel CoroRoutine treClearance rate and time of main symptoms (fYes 0
Novel CoroExocrine g Lung CT; Yes 0
Geriatrics the elderly health status;Mental health status; No 0

Novel CoroGold StandSEN, SPE, ACC, AUC of ROC; Yes 0
Novel CoroCase seriesClinical symptoms;TCM syndrome;Lung imagin

No 0
Novel CoroCase seriesClinical characteristics; No 0
Novel CoroExperimentLength of hospital stay;Discharge time of ge No 0
Novel CoroExperimentRoutine physical examination;Vital signs: b Yes 0
cytokine r Case serie the relive of CRS; No 0

BiopsychosGeneral poQuality of life;Socio-demographcis and otherNo 0
Cancelled Cancelled; Yes 0
Novel CoroExperimentMood index; No 0
Novel CoroCase seriesROC;calibration curve; Yes 0
Novel coro ExperimentCOVID-19 nucleic acid detection time from po

Yes 0
Novel CoroExperimentBlood routine examination;Chest CT;Arterial Yes 0
Novel CorohydroxychloTime to Clinical Recovery, TTCR; Yes 0
Novel CorohydroxychloTTCI (Time to Clinical Improvement); Yes 0
Novel CoroExperimentviral negative-transforming time;30-day causYes 0
Novel CoroExperimentNegative conversion rate of COVID-19 nucleiYes 0
Clinical recovery time;Pneumonia Severity InNo 0
COVID-19 Case seriesClinical symptoms;Test result;Examination reYes 0
novel coro Kesuting sycough; Yes 0

Validity observation index; Yes 0
novel coro Case seriesThe proportion of patients diagnosed with Yes 0
Novel Coroarm A:RibavThe time to 2019-nCoV RNA negativity in patNo 0
Novel CoroCase seriesexposed factors;latent period;preventive meYes 0
Novel CoroLow-dose gNegative conversion rate of 2019-nCoV nucleYes 0
Novel Corocontrol grotime to recovery.; Yes 0
Novel CoroExperimentSOFA score; Yes 0
novel coro ExperimentTime to clinical recovery; Yes 0

Novel CoroDrug: basicNegative conversion (%) of 2019-nCOVRNA inYes 0
Novel CoroCase seriesWorsening condition;Death;Heart fatty acid Yes 0
2019 novelCase seriesLung ultrasound index;Right ventricular funcYes 0
Novel CoroDrug: Inter Time to negative NPS Yes 0
Novel CoroDiagnostic Screening accuracy Yes 0
Novel CoroDrug: pirf K-BILD;blood gas;Finger pulse oxygen;chest Yes 0
2019 NovelBiological: Size of lesion area by chest radiograph or C Yes 0
CoronaviruBiological Adverse reaction (AE) and severe adverse re Yes 0
Novel CoroCase serie ALT; Yes 0
Novel CoroCase serie Unplanned shutdowns; Yes 0
Novel CoroCase seriesviral load;virus genotyping;Classification of Yes 0

Clinical therapeutic course;Pathogenic dete No 0
Novel CoroexperimentTime to Clinical Recovery (TTCR); Yes 0
CT Scores Other: CT 7-day mortality Yes 0
CoronaviruDrug: T89 The proportion of patients with normal leve Yes 0

Novel CoroExperimentTempreture;Virus nucleic acid detection; No 0
Novel CoroCase seriesintrusion;avoidance; No 0
Novel Corocase series Immunity function;cytokines;viral load; Yes 0
Novel CoroCase seriesclinic outcome; No 0
Novel CoroExperimentPulmonary function;6 minutes walking dista No 0
Novel CoroExperimentMortality; No 0
Novel CoroAzvudine PSputum/nasal swab/pharyngeal swab/lower Yes

resp 0
Novel Coromonitor casChild Stress Disorders Checklist evaluation; Yes 0
2019 novelCase seriesin-ICU mortality;mortality of 28 days; No 0
Novel CoroGroup 2:co28-day mortality;ICU 14-day mortality; Yes 0
Novel CoroExperimentRate of composite advers outcomes: SPO2, PNo 0

Novel CoroCase seriesA cycle threshold value (Ct-value); No 0
Novel CoroMedical st PSS-14; Yes 0
Novel CoroGold StandVolatile organic compounds, VOCs;SEN, SPE, Yes 0
Novel CoroPatients w Pulmonary image findings;Relevant clinical Yes 0
sleep disor cross-secti Pittsburgh sleep quality index; Yes 0
Novel CoroInterferon Incidence of side effects; Yes 0
Novel CoroCRRT groupChest imaging;Oxygenation index;ExtravasculYes 0

Novel CoroControl gr TCM syndrome; Yes 0
Novel CoroLipoic acid Progression rate from mild to critical/severe Yes 0
Novel CoroControl gr fever clearance time;Effective rate of TCM No 0
Novel CoroExperimentaReal-time fluorescent RT-PCR detection of p No 0

Novel CoroPatients i length of stay;length of stay in ICU;Hospital No 0
Novel CoroControl grolasting time of fever;lasting time of novel No 0
Novel CoroCase serie 28 day mortality; Yes 0
Novel CoroCase serie Cure rate; No 0
Novel CoroEarly corti The time of duration of COVID-19 nucleic aciNo 0
Novel CoroCOVID-2019Nuclei acid test of SARS-CoV-2 of conjuncti No 0

Lung injurytreatment gPaO2 / FiO2 or respiratory rate (without ox No 0
Novel CoroPRE-GROUP1
disease incidence;Duration of PCR normalizaNo 0
Novel CoroACEIs/ARBsratio of severe cases; Yes 0
Novel CoroCase serie Cardiac injury;Death in hospital and/or EndoYes 0
Novel CoroCase serie 28 day mortality; Yes 0
Novel CoroControl gr Psychological status; No 0
Novel CoroGroup 2:SMO

SpO2 during intubation;the total time of in Yes 0
Novel CoroCase seriestime in range; Yes 0
Novel Coropatient groCT image of lung; Yes 0
Novel CoroCase seriesClinical symptom improvement rate: improveYes 0
Novel CoroCase seriesMental status;Social support; Yes 0

Novel CoroCase seriesClinical characteristics; Yes 0
Novel CoroCase serie cure rate;duration of hospitalization;days of Yes 0
Novel CoroExperimentMRC breathlessness scale;6MWD; No 0
novel coro ExperimentSafety; No 0
Novel Corogroup A:Ar Main symptom relief time; Yes 0
Novel CoroTreatment Clinical symptoms;Blood routine;BiochemicalNo 0
influenza ExperimentCRP;ESR;PCT;Tn;Mb;D-Dimer;blood routine eNo 0

novel coro ExperimentSevere conversion rate;Oxygenation index;20No 0
novel coro Case seriesCytokines; No 0
suspected Routine treClinical symptoms (fever, weakness, cough) Yes 0
novel coro Experimentthe number of days between randomised groYes 0

Coronavirus Numbers of participants with different ClinicYes 0
Novel CoroRoutine treClinical symptoms (fever, weakness, cough) Yes 0
Pneumonia Caused byMortality;The time interval of Nucleic acid Yes 0
novel coro Experimenta

Inccidence of 2019-nCoV pneumonia; No 0
Novel CoroCase serie Improvement of symptoms; No 0
Novel CoroCase seriesnosocomial infection ratio of SARS-Cov-2; No 0
Novel CoroGroup 1:FaClinical cure rate; No 0
COVID-19; Drug: RecoThe incidence of side effects;The incidence oYes 0
Novel CoroCase serie mental health status and influence factors; No 0

psychologi ObservatioSymptom Checklist 90; Yes 0
Novel CoroCase serie chest CT images; No 0

COVID-19 Drug: LopinClinical recovery time Yes 0
CoronaviruDevice: N9 RT-PCR confirmed COVID-19 infection Yes 0
Mental Dis Other: Exp The prevalence and incidence changes of c Yes 0
Novel CoroControl gr serum albumin;siderophilin;prealbumin;lungNo 0
Novel CoroOrdinary C Laboratory inspection index;Oxygen therapyNo 0
Novel CoroCase seriesCT; No 0

Novel CoroCase seriesTransmission dynamics of COVID-19 in Hong No
K 0
COVID-19 The triple white blood cell;lymphocyte;creatinine;CRP; No 0
Novel CoroCase serie CK-MB;CTnI;neuron-specific enolase,NSE;BUN;

No 0
Novel CoroCase seriesDeath; No 0

Fibrosis a ExperimentHRCT pulmonary fibrosis score; No 0
Novel CoroCase seriestemperature;Systemic symptom;Respiratory No

s 0
Novel CoroCase seriesRT-PCR test for SARS-CoV-2; Yes 0
Novel CoroCase serie Single cell sequencing; No 0
COVID-19 Case seriesMaternal and neonatal morbidity; No 0
Novel CoroCase serie Discharge rate; No 0
COVID-19 Experimenta
Average discharge time;WBC;ALT, AST, gama-G
No 0
Novel CoroCase seriesClinical outcomes after discharge; No 0
Novel CoroGold StandPrecision;SEN, SPE, ACC, AUC of ROC; No 0
Novel CoroGroup 2:Tr 14 day outcome of the subjects, including: r No 0
Novel CoroGold Standasensitivity;SPE; No 0
Novel CoroCase seriesSCL-90 scale; Yes 0
Novel CorointerventioClinical improvement time of 28 days after r No 0

Severe
Communi
ty
Acquired
Pneumoni
a 
MedDRA
version:
20.1
Level: LLT
Classifica
tion code
10010120
Term:
Communi
ty
acquired
pneumon
ia
System
Organ
Class:
10000000
4862
 Timepoint(s) of evaluation of this end point: Yes True parent
Novel CoroHigh dose group:routine treatment + MSc (2 x10^6 / kg No 0
Novel CoroCase seriesEpidemiological characteristics;SARS-CoV-2 IgYes 0

Novel CoroGold StandRNA of 2019-nCov;SPE, SEN, ACC, AUC of ROYes 0
Novel CoroCase seriesLaboratory inspection index;Imaging examinaNo 0

Novel CoroCase seriesLiver function; No 0
Novel Coro Case seri ymphocyte subsets; No 0
Novel CoroCase serie Mortality of ICU 28-day; No 0
Novel CoroCase seriesOcular Symptoms; No 0
Rheumatic Case seriesClinical features; Yes 0

COVID-19 Case seriesEpidemiological features; No 0
Novel Coronon-cancerlynphocyte;cytokine;cancer history;order of No 0

Novel CoroCase seriesQuantitative CT characteristic; No 0
Novel Corosevere pat age;sex;comorbidities;chest-CT examination;No 0
Novel CoroCase seriestime and rate of cure; proportion and time No 0
Novel CoroCase seriesblood biochemistry; No 0

Novel CoroCase seriesmortality;effective rate; No 0
Novel Corodischarge discharg time; No 0

Novel CoroGold Standard:Epidemiological history + CT + clinical No 0
COVID-19;EOther: sev Success rate of intubation;Infection rate of Yes 0
Novel CoroPopulation Confirmed 2019-ncov pneumonia; No 0
Novel Corocontrol gr The time for the positive nucleic acid of th No 0
Novel coro NIV group: Dose of analgesic and sedative drugs;28-day No 0

Novel CoroCase serie 28-day prognosis; No 0
Novel CoroCase seriesdeath;Number of failure organs;Length of hos

No 0
Novel CoroCase seriesEpidemiological characteristics;clinical fea No 0

Anxiety; N Case seriesanxiety; No 0
Novel CoroMSC group:Oxygenation index (arterial oxygen partial prNo 0
Novel CoroCase serie 2019-ncov-RNA;Chest CT;Routine blood tes No 0
novel coro Case seriesPsychological assessment; Yes 0

Novel CoroCase seriesSARS-CoV-2; No 0
Novel Coro4 groups:NPSQI;PPHQ-9;GAD-7;PTSDChecklist-Civilian VNo 0

Novel CoroCase seriesClinical characteristics according to TCM; No 0
Novel CoroGroup 1:Tr Mortality rate; No 0
Novel CoroCase seriescytology;proteomics;chest X-ray;Oxygenatio No 0

Novel Corotwo groupsthe clinical, laboratory and the radiologic chaYes 0
Novel coro Case seriesCritical illness ratio; Yes 0
Novel CoroCase serie nucleic acids probing;blood routine;blood b No 0
Novel CoroExperimentTime to Clinical Recovery; No 0
Novel CoroCase seriesLength of stay in ICU;Diaphragm movement;No 0
SomatopsycObservatioChinese health status scale;Self-rating Anxie Yes 0
Novel Corocase series ICU hospitalization days;The recurrence rate No 0
Novel CoroECMO group

Inpatient mortality;ICU hospital stay; No 0
Novel coro Case seriesin-ICU mortality; Yes 0
Novel Corotransnasal PaO2;PaCO2; No 0
Novel CoroExposed gr14-days mortality;28-days mortality; Yes 0

Novel Coroin hospita SARS-CoV-2 virus;sex hormones;sperm quali No 0
Novel Corocase series mortality;ICU hospital stay;mechanical ventilNo 0
End-stage Case series:Levels of anxiety, stress and depression; No 0

Novel Corocase series Tempreture;cough;dyspnea;Blood Routine;AtNo 0
Novel CoroGold Standdetection of SARS-CoV-2 RNA;SEN, SPE, ACC Yes 0
Novel CoroExperimentTime to Clinical Improvement (TTCI); No 0

Novel CoroCase serie SAA;Detection of respiratory pathogen ser No 0
Novel CoroCase seriesBlood oxygen saturation; Yes 0
Novel CoroGold StandSensitivity, specificity and accuracy; No 0
Novel CoroIntegrated Mortality rate;Common-severe conversion rat

No 0
Lung CT; Yes 0
Novel CoroGroup 1:miPHQ-9;GAD-7;PHQ-15;PSS-14;ISI;SHARPS;ACTYes 0

Novel CoroCase seriesAbnormalities on chest CT;Exposure to sourcNo 0
blood RT;ABG;blood clotting function;liver a No 0
Novel CoroExocarpiumCough Score;Expectoration score; No 0
Novel CoroGold Standcure rate;propotion of progression;SEN, SPE No 0
Corona Vir Case serie all-cause death;fatal arrhythmias; No 0
Novel CoroInfection wtemperature;heart rate;respiratory rate;blo No 0
Novel CoroControl groRecovery time;Pneumonia psi score; No 0
Novel CoroTwo groupsLymphocyte grouping; No 0
Novel Coroexperimentchest computerized tomography;Nucleic acidNo 0
Novel CoroexperimentTime to Virus Eradication; Yes 0
Novel CoroexperimentTime to Virus Eradication; No 0
Novel CoroExperimentblood gas;SOFA score; Yes 0
Novel Corocase series Pulmonary function;Cardiac function;neural No 0

Mental heaCase seriesComprehensive psychological assessment;MeNo 0
Novel coro Experimenta

The percentage of patients who convert to mo
No 0
Novel CoroCase serie CRP;IL-6;TNF-alpha;IL-8; Yes 0

Novel CoroGold Standfalse positive rate of SARS-CoV-2 IgM antib No 0
Novel Coro1:Throat swCT image features;Fever;Throat swab virus nYes 0
Novel CoroControl gr Status of immune function;The time of nucleiYes 0
Novel CoroGold StandIn-hospital mortality;ACC, SEN, SPE, ROC; Yes 0

Novel CoroGroup A:Secough;agitation; Yes 0
novel coro Gold StandLung ultrasound;Chest computed tomography Yes
( 0
The time when the nucleic acid of the novel Yes 0
Novel CoroCase seriesTime to disease recovery;Time and rate of Yes 0

Sleep; Nov Case seriessleep status and related factors of insomnia;No 0
novel coro ExperimentIFN-gama;TNF-alpha;Blood routine index;TimYes 0
novel coro Case serie Ventilation-free days;mortality; Yes 0
Novel CoroCase seriestreatment effect; No 0
novel commtreatment group :Ba duanjin; No 0

Novel Corocase series:Outcome; No 0
Novel coro Control gr CT Scan-Chest; No 0
Novel coro ExperimentEndotracheal intubation rate;mortality;RatioYes 0
Novel CoroCase seriesThe negative conversion rate and negative coYes 0
Novel CoroPositive dr lasting time of fever;lasting time of novel No 0
2019-nCoVRoutine tr Complete Blood Count;CRP;blood coagulatioNo 0
Novel CoroCase seriesascultation; No 0

Novel CoroGroup 2:WeMedical imaging improvement rate in patientNo 0
novel coro High dose Time to disease recovery; Yes 0
Novel CoroExperimentTime to disease recovery; Yes 0
Novel CoroPhosphoricTime of conversion to be negative of novel c Yes 0
Novel CoroPhosphoricMortality rate; Yes 0
Novel CoroPhosphoricTime of conversion to be negative of novel c No 0
Novel CoroGold Standadetection of SARS-Cov-2 nucleic acid;SEN, A Yes 0
Novel CoroeperimentaTime to clinical recovery after randomizationNo 0
Novel CoroCase serie SDS;SAS;PSQI; Yes 0
malignant tumor pati impact on the treatment of tumor patients; No 0
Novel Corocase series Clinical characteristics;Clinical outcomes; No 0
novel coro Chinese meImaging; Yes 0
Novel CoroCase seriesDisease Severity;Imaging;Syndrome Feature Yes 0

Novel CoroGroup 1:BaGAD-7; Yes 0
Novel CoroexperimentTime and rate of novel coronavirus become Yes 0

Novel CoroCase seriesDEATH; No 0
Vitamin C; Drug: Steri Ventilation-free days Yes 0
novel coro Two cohort2019-nCoV RNA;2019-nCoV antibody;Chest Yes 0
COVID-19 Drug: HydroViral load Yes 0
Novel Coro1:meditati Self-rating depression scale;self-rating anxi Yes 0
Novel CoroExperimentTemperature returns to normal for more than

Yes 0
Novel CoroExperimentClinical symptom improvement rate: improveYes 0
Novel CoroExperimentVentilation-free days;mortality; Yes 0
Novel CoroGold StandPositive/Negtive;False positive of rate ; Yes 0
novel coro ExperimentTime to disease recovery; Yes 0
Novel CoroExperimentTime to disease recovery; Yes 0

novel coro Case serie Patientsâ€™ general information: epidemiolog
Yes 0
COVID-19 Biological Disppear time of ground-glass shadow in theYes 0

Novel CoroCase series25(OH)D; No 0
Stress, Psychological Stress Yes 0
Novel CoroCase seriesT lymphocyte subsets; Yes 0
Novel CoroCase serie Neonatal outcome; No 0
Severe CO Pirfenidon HRCT score; No 0
Novel CoroDiagnosed Metagenomics Sequencing; No 0

Novel coro COVID-19 demographic information;exposure history;clNo 0
Novel CoroGold StandSEN, SPE, ACC, AUC of ROC; No 0
Novel CoroSFBT groupGAD-7;STAI-Y (C); Yes 0
Novel CoroGroup 1:psPittsburgh sleep quality index;Self-rating anxYes 0
novel coro Experimentinsomnia;anxiety;depression;comfort; No 0
cancer Group 2:th postoperative complication;occupancy rate of

No 0
2019-nCOVSARS-COV-2Serum SARS-COV-2 RNA;Swallow swab SARSNo 0

novel coro Case seriesclincical characteristics; No 0
Novel CoroCase serie nuclear acid test of faeces;nuclear acid tes No 0
Novel CoroCase serieshospital mortality; No 0
Novel Coro1:7/5000 The biochemical indicators; No 0

Novel CoroCritical gr T lymphocyte count; Yes 0
Novel CoroCase seriesClinical Characteristics, Treatments and ProgNo 0
COVID-19 28 day mortality Yes 0
Treat and Biological: Proportion of subjects with positive T cell Yes 0
Pneumonitis survival status No 0

Novel CoroCase seriesAbnormalities on chest CT; Yes 0
Novel CoroGroup 1:LiuMaximal inspiratory pressure;Respiratory muYes 0
Novel CoroCOVID-19 paLength of hospital stay; No 0
Novel CoroCase seriesClinical characteristics and risk factors; No 0

Novel Corothe patien Nucleic acid; No 0
Novel CoroCase seriesPulmonary function evaluation;Changes in blNo 0
COVID-19 experimentsyndrome;nucleic acid of nCoV-19; No 0
Novel CoroA:Long-actiCOVID-19 nucleic acid negative conversion raNo 0
Novel Coro1:Low doseadverse reactions 7 days post injection; No 0
Novel CoroCase seriesVenous Thrombosis; Yes 0
Novel coro Case seriesImmune response multiomics; No 0

Novel CoroCOVID-19 pTime to negative conversion of severe acute Yes 0
Novel CoroGold Stan RNA;DNA; No 0
Novel CoroGold StandPT-PCR test;SEN, SPE, ACC, AUC of ROC; No 0
improvement or recovery of respiratory sympNo 0
Novel CoroCase seriesRNA of Coronavirus; Yes 0
Novel CoroExperimentaClinical recovery rate of day 7; No 0

Novel Coronavirus Pn prognosis; No 0
novel coro experimentthe lowest SpO2 during intubation; Yes 0
sleep disor cross-secti Pittsburgh sleep quality index;hospital anxie No 0
Novel CoroGold StandCT image;sensitivity;Specificity;Time efficien Yes 0
Novel CoroExperimentImprovement of clinical symptoms (Clinical i Yes 0
Novel CoroTricholomaAlbumin;Cellular immune indicators (total l No 0
Novel Coro1 the criti SP02;lesions of lung CT;temperature;Blood Yes 0
Novel CoroExperimentCompared with the control group, the positi Yes 0
Novel CoroExperimentaChanges of serum inflammatory factors;PatieYes 0

Novel CoroCase seriesBlood routine test; No 0
Novel CoroGold StandFirst pass perfusion i;Delayed enhancement Yes 0
malignant tumor pati psychological states; No 0

novel coro Mild Type The time required for RNA Yin conversion o Yes 0
Novel CoroInterventionovel coronavirus nucleic acid clearance rateNo 0
Novel Coroobservationauto B line method;Semi-automatic manual me

Yes 0
Novel Corocontrol gr novel coronavirus nucleic acid; Yes 0

2019 - nC Case seriesdetection of virus nucleic acid; Yes 0
Novel CoroExperimentViral nucleic acid test; No 0
Patients wi Trade Main Objective: To shorten the period of viruNo 0

;J12.8 - Ot Interventi genetic and epigenetic risk profiles Yes 0
COVID-19 InterventioComplications of the treatment. Timepoint: No 0
COVID-19. InterventioResponse to the treatment (Significant clinic No 0
COVID-19 Interventi Complications of the treatment. Timepoint: No 0
Novel CronInterventioCough. Timepoint: Daily. Method of measureNo 0
COVID-19 pInterventioClinical response to therapy. Timepoint: Da No 0
COVID-19 InterventioResponse to the treatment (improvement ofNo pa 0
COVID-19. InterventioClinical recovery (composite) within 14 days Yes 0
2019-nCoVDrug: MethRate and time of entering the critical stage; Yes 0

COVID-19 InterventioClinical response. Timepoint: Every other d No 0
patients i oral adminiexpected value and 95% CI of ratio of C-reac Yes 0
Covid-19 c Patients suED time interval [Time ### Yes 0

COVID-19 COther: pla Number of participants with improvement f Yes 0
patients i oral adminiexpected value and 95% CI of ratio of C-reac Yes 0
COVID-19 i Immediate Proportion of subjects with clearance of S Yes 0
Novel Cor Drug: RecoRate of aggravation;Time to clinical recover Yes 0
Novel CoroCombinatiorecovery Yes 0
COVID-19 Drug: RecoViral load over time;Time course of body te Yes 0
2019-nCoVDrug: Abid Time for lung recovery;Rate of disease remi Yes 0
2019-nCoVDrug: AbidoRate of disease remission;Time for lung rec Yes 0

2019-nCoVDrug: Osel Rate of comprehensive adverse outcome Yes 0
COVID-19 1.Date of ECMO discon ### No 0
Pathogen I Biological: Lower Murray lung injury score;Clinical imp Yes 0
2019-nCoV;Drug: ImmuTime to Clinical Improvement (TTCI) Yes 0
CoVID-19;COther: sta Mean clinical recovery time (hours) Yes 0
SARS-CoV-2;Outcome,all-cause mortality Yes 0
COVID-19 Drug: TCM Chest CT absorption;The relief / disappear Yes 0

COVID-19 none ### Yes 0
Prepared
ness and
responsiv
eness of
french
Hospital
and ED by
electronic
survey.
Head of
Emergenc
y
Departme
nt will be
questionn
ed.
 Covid
-19,
Prepared
ness,
Responsiv
eness,
Emergenc
y, Quality,
Organizati
on,
Formatio
n,
Resources
,
Managem
ent,
Interoper
abi Head of dePrepredness measureme ### Yes 0
COVID-19 Drug: Huai Mortality rate Yes 0
COVID-19 Biological Size of lesion area by chest imaging;Blood o Yes 0

CoronaviruBehavioral Depression, Anxiety and Stress Scale;Assess Yes 0
COVID-19;SDrug: Yinh changes in the ratio of PaO2 to FiO2 from baYes 0
2019-nCoV Occupancy rate in the intensive care unit (I Yes 0
COVID-19 Drug: SildenTime of entering the critical stage;Rate of enYes 0
Covid-19;S Drug: Toci Proportion of Participants With Normalizat Yes 0
Coronavirus;SARS Change in viral expression in association to Yes 0

CoronaviruDrug: Any Renal failure Yes 0
Corona Vir Drug: Tetr Survival rate Yes 0
COVID-19;COther: nonThe risk factors analysis for the death;The m Yes 0
Use of Ste Biological RT-PCR results;CT Scan;Clinical outcome Yes 0
fever; Nov Case seriestemperature;novel coronavirus;Influenza vir Yes 0
CoronaviruOther: oxy Incidence of respiratory failure Yes 0
COVID-19;SDrug: Plac Symptomatic COVID-19 infection rate Yes 0

COVID-19 Severe COVID-19 Yes 0
Novel Coromild recov brain volume;white matter;brain function; Yes 0
COVID-19;Organ DysfunAcute Kidney Injury Yes 0

Cesarean dCesarean sefever;Chest CT;cough;;Anesthesia during cesYes 0
COVID-19 Diagnostic Sensitivity, spectivity turnaround time of t Yes 0
Novel Coronavirus Pn characteristics of cardiopulmonary ultrasou Yes 0
Infection V Other: pre Maternal and perinatal outcomes Yes 0
COVID-19;SDrug: Hydr All-cause hospital mortality Yes 0

Myopia Case seriesAxle length;Visual acuity;corneal diopter;Te No 0
Rheumatic Case seriesmedication possession ratio;selfrating anxietNo 0

Novel CoroGold Standproteomics;metabonomics;SEN, SPE, ACC, A No 0
Novel CorohDPSCs groTTCI; Yes 0
Novel CoroGold Standsensitivity;accuracy;specificity; Yes 0

Novel CoroCase serie Incidence of medical adhensive-related injurYes 0
Novel CoroGroup M:Pla

Self-assessment of sleep quality;Efficient o No 0
Novel CoroCase seriesTime of death;The hospitalization time; Yes 0
CoronavirusDevice: Vi Number of patients with contrasting results Yes 0

Myopia; NoCase serieseye axial length;corneal diopter;Tear film r No 0
Sleep, stre mindfulnesAnxiety level;Sleep; No 0
Novel CoroCase seriesDemographic data;Epidemiological characteris

No 0
Novel CoroControl gr Hospital stay or death ratio of experimental Yes 0

Novel CoroCase seriesRate of COVID-19, distribution, time of ons No 0
Novel CoroCase seriesECG; No 0
Novel CoroCase seriesmental state; No 0
Novel CoroSurvival a clinical features of COVID-19 patients and risNo 0
Novel CoroCase seriesEpidemiological characteristics;clinical fea No 0
Novel CoroCase serie IgG antibody;IgM antibody;Throat swab virusNo 0
Novel CoroCase seriesRT-PCR test for Covid-19;CT image;Covid-19 Yes 0

Novel CoroExperiment Clearance time of virus RNA; No 0
Novel CoroCase seriesPT-PCR test; Yes 0
Novel Coro1:Blank;2: TCM Syndrome Scale; No 0

Chronic di HomeopathiPatient satisfaction; No 0
Novel CoroCase seriesClinical features and prognosis; Yes 0
Novel CoroExperimentQuantitative table of main symptom grading;Q

No 0
Novel CoroCase seriesModified dyspnea index scale;St.George's ReYes 0

Novel CoroCase serie mortality; Yes 0
Novel CoroCase serie fatality rate;the ratio of patients transform No 0
Novel Coroconfirmed traditional Chinese medicine symptom; No 0
Novel CoroCM group:XBody temperature returns to normal time;AfNo 0
Novel CoroSuspected Incidence of COVID-19 pneumonia;COVID-19No 0
Novel CoroExperimentThe change of TCM syndrome integral of defiYes 0
Novel CoroExperimentPO2/FiO2;ROX INDEX; No 0
Novel Corotreatment gtime till the SARS-CoV-2 clearance; No 0
Novel CoroExperimentInflammation absorption on Chest CT; Yes 0

Novel CoroLight grou Two-dimensional ultrasound;M mode echocar
No 0
novel coro COVID-19 gPatients' general information: epidemiologi Yes 0
Novel CoroCase serieswalking distance;oxygen saturation;heart ratYes 0
Novel CoroexperimentThe time to 2019-nCoV RNA negativity in patYes 0

Novel CoroCase seriesEpidemiological and clinical characteristics; No 0
Novel Coroexperimentpulmonary function; No 0
novel coro ExperimentNeutrophil count;Lymphocyte count;Monocyt

Yes 0
COVID-19
 Med
DRA
version:
20.0
Level: LLT
Classifica
tion code
10038700
Term:
Respirato
ry
infection
System
Organ
Class:
10000000
4862
;
Therapeu
tic area:
Diseases
[C] - Virus
Diseases
[C02] ProducTimepoint(s) of evaluation of this end point: No 0
Novel Coroexperimenta Oxygen Inhalation Frequency;Oxygen Intake Yes 0
Corona
virus
infection
 Med
DRA
version:
20.1
Level: PT
Classifica
tion code
10053983
Term:
Corona
virus
infection
System
Organ
Class:
10021881
-
Infections
and
infestatio
ns
;
Therapeu
tic area:
Diseases
[C] - Virus
Diseases
[C02] Trade Timepoint(s) of evaluation of this end point: Yes True parent
SARS-
CoV-2
infection
 Med
DRA
version:
20.0
Level: HLT
Classifica
tion code
10047490
Term:
Virus
identifica
tion and
serology
System
Organ
Class:
10000000
4848
;
Therapeu
tic area:
Diseases
[C] - Virus
Diseases
[C02] Trade Timepoint(s) of evaluation of this end poin Yes 0
Acute
coronavir
us
disease
2019
 Med
DRA
version:
20.1
Level: PT
Classifica
tion code
10053983
Term:
Corona
virus
infection
System
Organ
Class:
10021881
-
Infections
and
infestatio
ns
;
Therapeu
tic area:
Diseases
[C] - Virus
Diseases
[C02] Trade Timepoint(s) of evaluation of this end point: Yes 0
SARS-
COV-2
infection
 Med
DRA
version:
21.1
Level: LLT
Classifica
tion code
10037373
Term:
Pulmonar
y disorder
System
Organ
Class:
10000000
4855
;
Therapeu
tic area:
Diseases
[C] - Virus
Diseases
[C02] Trade Timepoint(s) of evaluation of this end point Yes 0
COVID-19
 Med
DRA
version:
20.0
Level: LLT
Classifica
tion code
10051905
Term:
Coronavir
us
infection
System
Organ
Class:
10000000
4862
;
Therapeu
tic area:
Diseases
[C] - Virus
Diseases
[C02] ProducMain Objective: To assess whether SNG001 isYes 0
COVID-19 Drug: Plac Severity of COVID-19 Yes 0
Corona ViruOther: Sta Percentage of subjects reporting each severitYes 0
Novel CoroDrug: favipTime of Improvement or recovery of respira Yes 0

Serogroup Procedure:Feasibility of developing a UK based sero ep Yes 0
CoronaviruDrug: Eculizumab Yes 0
CoronaviruDrug: Nitri SARS-free patients at 14 days Yes 0
COVID19;CoDrug: Plac Symptoms severity of COVID-19;Number of Yes 0
COVID-19 Drug: Beva The time from randomization to clinical im Yes 0
SARS-CoV- Behavioral Primary composite rate of intensive care uni Yes 0

Covid-19, Drug: ACE iIncidence of influenza No 0
COVID-19 Dietary Su Change from baseline serum monocyte chemoat

Yes 0
COVID-19 Drug: PUL- Prevention of COVID-19 Yes 0
COVID-19;Acute Kidney
Rate of Acute Kidney Injury Yes 0
Health Car Diagnostic Seroconversion to SARS-CoV-2 positivity Yes 0
COVID-19;CDrug: Hydr Number of participants with symptomatic, Yes 0

COVID-19;M
Diagnostic Incidence of acute myocardial events in COVYes 0
CoronaviruDrug: ColchHospital discharge;Clinical improvement Yes 0
Hospitaliz Dietary Su In-hospital mortality Yes 0
COVID-19 Other: The Number patients developing severe infectio Yes 0
Healthy Pe Other: DeteBeck Depression Scale;Health-Related QualityYes 0
CoronaviruDevice: Au Duration of interventions;The number of int Yes 0

PharmacoloDrug: BaricThe percentage of patients requiring transfe Yes 0
GastrointesDevice: No Technical success Yes 0
CoronavirusDrug: stan Clinical status evaluated in agreement with Yes 0
COVID-19;CProcedure:30-day mortality Yes 0
Novel CoroExperimentProstaglandin E2; No 0
CoronaviruDrug: LopinMicrobiologic evidence of infection Yes 0
COVID-19 Other: hy death Yes 0

CoronaviruDiagnostic Lung ultrasound grading system for COVID- Yes 0
COVID-19 Drug: TradiLength of hospital stay (days) Yes 0
sleep disor cross-secti PSQI; No 0

Novel Coroordinary grChest computed tomography (CT); No 0
COVID-19 Biological Side effects in the treatment group;Clinical Yes 0
COVID-19; CardiovascuThe incidence of cardiovascular complicatio Yes 0
COVID-19 Drug: 2: S Mortality all causes at day30 Yes 0

COVID-19;CoronavirusDataset size Yes 0
Novel CoroControl gr CRP;SAA;IL-6;PCT;tRNA; Yes 0
depressionCase seriesThe score of PHQ-9; Yes 0
CoronavirusOther: No Microbiological;Virological;Clinical Yes 0
CoronavirusOther: Pat Host genetic variation;Immune host responseYes 0
Novel CoroARBs GroupIncidence of ARDS;Mortality within 28 days; No 0
Novel CoroExperiment6minu tewalkingtest,6MWT;mMRC;Rating ofNo

P 0
Novel CoroMedical peASDS;PSS;PHQ;GAD; Yes 0
COVID-19 Dietary Su Rate of recovery from positive to negative Yes 0

Severe AcuDrug: MethComposite primary end-point;death;Admission
Yes 0
CoronaviruDrug: Chlo Inpatients: Invasive mechanical ventilation Yes 0
CoronaviruDiagnostic Point prevalence of COVID-19 infection Yes 0
rheumatic Rheumatic Infection; No 0

Novel Coroeye patch aQuality of sleep; No 0
Corona Vir ExperimentChest Imaging;lung function;ADL; No 0
Novel CoroGold Stand2019-nCov IgG; No 0
Novel CoroNintedanibFVC; Yes 0
Cervical sp Case seriesPhone time before and during the outbreak;PYes 0
Novel Coroexperiment 2019-ncov nucleic acid yin rate;Blood 2019- No 0
Novel Coronavirus Pn Success rate of intubation;Exposure classificaNo 0

Cardiovasc Diagnostic All-cause mortality Yes 0
COVID-19 Other: No CT or Xray images from COVID-19 patients Yes 0

COVID-19 (SPatients wiTime from COVID-19 tes4/1/2021 Yes 0
Novel CoroCOVID-19 wBlood cell number;Biochemical markers;MetYes 0
Novel CoroGold StandSPE, SEN, ACC, AUC of ROC; No 0

Novel CoroCase seriesCure rate;improvement rate; No 0
COVID-19
- Has
laborator
y-
confirme
d SARS-
CoV-2
infection
as
determin
ed by
PCR, or
other
commerci
al or
public
health
assay in
any
specimen
< 72
hours
prior to
randomiz
ation.
- Illness of
any
duration,
and at
least one
of the
following:
â€
¢Clinical
assess Trade Timepoint(s) of evaluation of this end point: Yes 0
Acute Inso Group 1:si Sleep diary;The insomnia severity index;SleeNo 0
Novel CoroControl:NAExposure time in the medical cabin;HospitaliNo 0
Novel CoroGold StandaSARS-CoV-2 antibody;SEN, SPE, ACC, AUC of No 0
Novel CoroMild:No;se Safety;Effectiveness; No 0
COVID-19 Group 1:Rohospital mortality; No 0

Novel Coroexperimentbody surface temperature; No 0
Novel CoroDifferent d Safety and tolerance; Yes 0
Novel CoroExperimentElectrocardiogram;St George's Respiratory QNo 0
Acute
hypoxic
respirator
y failure
of COVID-
19
patients
 Med
DRA
version:
21.1
Level: LLT
Classifica
tion code
10074615
Term:
Hypoxic
respirator
y failure
System
Organ
Class:
10000000
4855
;
Therapeu
tic area:
Diseases
[C] - Virus
Diseases
Possible
preventio
n of
pneumon
ia from
SARS-
CoV-2 in
patients
staying
home and
improving
symptom
s of SARS-
CoV-2
pneumon
ia in
patients
treated in
hospital
 Med
DRA
version:
20.0
Level: LLT
Classifica
tion code
10035738
Term:
Pneumoni
a viral
NOS
System
Orga Trade Timepoint(s) of evaluation of this end point: Yes 0
Covid19 is Trade Timepoint(s) of evaluation of this end point Yes 0

SARS-
COV-2
infection
 Med
DRA
version:
21.1
Level: LLT
Classifica
tion code
10037373
Term:
Pulmonar
y disorder
System
Organ
Class:
10000000
4855
;
Therapeu
tic area:
Diseases
[C] - Virus
Diseases
Severe COVI ProducTimepoint(s) of evaluation of this end point Yes 0

COVID-19 in Trade Primary end point(s): ;Secondary Objective: No 0
RespiratoryDrug: Nitri Measure the safety of 160ppm inhaled nitricYes 0
Pneumonia,Drug: Hydr The virological clearance rate of throat swabYes 0
COVID-19;NDrug: Meththe incidence of treatment failure in 14 daysYes 0
Influenza Drug: DAS1Percent of subjects who have returned to ro Yes 0

Patient att Trade Timepoint(s) of evaluation of this end point: Yes
Le critÃ¨re de jugement
0 principal est le dÃ©cÃ¨s quelle qu
covid-19
 Med
DRA
version:
20.0
Level: LLT
Classifica
tion code
10070267
Term:
SARS
virus test
positive
System
Organ
Class:
10000000
4848
 Med
DRA
version:
21.1
Level: PT
Classifica
tion code
10022519
Term:
Intensive
care
System
Organ
Class:
10042613
- Trade Timepoint(s) of evaluation of this end point Yes 0
SARS-COV-2Drug: Oral SARS-CoV-2 eradication time Yes 0
CoronaviruDrug: Nitri Reduction in the incidence of patients with Yes 0
CoronavirusDrug: InhalCOVID-19 diagnosis Yes 0
2019 SARS-C
In patients Mortality [At hospital discharge or 28 daNo 0
Lower RespDrug: DAS1Percent of subjects who Return to Room Air Yes True parent
COVID-19 InOral 500mgNumber of sick days (SDS) during the study pYes 0
Sepsis;Vit Drug: Vita Number of deceased participants or with perYes 0
Corona ViruDrug: Hydr Rate of decline in SARS-CoV-2 viral load Yes 0

Corona ViruDrug: CamoDays to clinical improvement from study en Yes 0
COVID-19;Elderly Patien
Survival Yes 0
Virus DiseaDrug: Azit Number of days alive and discharged from hoYes 0
SARS-
CoV-2
infection
 Med
DRA
version:
20.0
Level: LLT
Classifica
tion code
10070267
Term:
SARS
virus test
positive
System
Organ
Class:
10000000
4848
;
Therapeu
tic area:
Diseases
[C] - Virus
Diseases
Infection V Other: nosonosocomial infection Yes 0
New CoronDiagnostic Detection sensitivity is greater than 95%;DetYes 0
CoronavirusDrug: Beva Partial arterial oxygen pressure (PaO2) to fraYes 0
COVID-19 Drug: RemdThe Odds of Ratio for Improvement on a 7-poYes 0
COVID-19 Drug: DAS Improved clinical status;Return to room air Yes 0
CoronaviruDevice: vv interleukin-6 (IL-6) level after 72 hours Yes 0
CoronaviruBiological Assess efficacy of the candidate ChAdOx1 nCYes 0

COVID19 Drug: Hydr National Early Warning Score equal to zero Yes 0
Pneumonia,Drug: DarunThe virological clearance rate of throat swabYes 0
Critically I Other: Nutr28-day all cause mortality Yes 0
Corona ViruOther: Pla Percentage of subjects reporting each severitYes True parent
Corona Vir Biological Frequency of solicited local reactogenicit Yes 0
COVID-19 Drug: Favi Clinical cure rate Yes 0
COVID-19 Biological: Disappear time of ground-glass shadow in thYes 0

COVID-19;Hypertensi Rate of Death Yes 0
Migraine DBehavioral:Helpfulness of the session;Platform effectiv Yes 0
COVID-19 Drug: RemdThe Odds of Ratio for Improvement on a 7-poYes 0
Sars-CoV2 Other: blo Quantify the proportion of patients with d Yes 0
Blood DonaOther: QueDifferences of attitude about blood donatio Yes 0
Corona Vir Drug: Hydr Incidence of COVID19 Disease among those wh

Yes 0
COVID-19 Drug: ColchAll-cause mortality Yes 0

SARS-CoV-2Drug: Chlo Viral clearance time Yes 0
COVID-19;CDrug: Hydr Polymerase chain reaction (PCR) confirmed Yes 0
COVID-19 Drug: Hydr Composite of hospitalization, invasive mechaYes 0
Corona Vir Biological Size of lesion area and severity of pulmonaryYes 0
COVID-19 Drug: GanoRate of composite adverse outcomes Yes 0
CoronaviruDrug: Remdesivir No 0
COVID-19 Drug: Anti Effectiveness of chemoprophylaxis assessed Yes True parent
2019 NovelDrug: reco new-onset COVID-19 Yes 0

COVID-19;En
Other: Fol prevalence Yes 0
COVID-19;SARS-CoV-2;C
Number of participants who experience inpaYes 0
CoronaviruDrug: Hydr Evaluation of the clinical status Yes 0
COVID-19 Drug: Hydr COVID Ordinal Outcomes Scale at 14 days Yes 0
COVID-19;SOther: ExpoClinical characteristics of children with S Yes 0
COVID 19;I Drug: Hidr Incidence rate of new COVID-19 cases in botYes 0
Corona Vir Drug: Losa Hospital Admission Yes 0
COVID-19 Biological Safety indexes of adverse reactions Yes 0
COVID-19 Drug: Sari Percent change in C-reactive protein (CRP) leYes 0
SARS Pneu Drug: Toci arrest in deterioration of pulmonary functi Yes 0
SARS (SeveDrug: Nitri Change of arterial oxygenation at 48 hours Yes 0
Acute RespDrug: AviptMortality;PaO2:FiO2 ratio Yes 0
Corona Vir Drug: Losa Sequential Organ Failure Assessment (SOFA)Yes 0

COVID-19;PDiagnostic COVID-19 positive X-Rays;COVID-19 negativeYes 0
Infections, Diagnostic Accuracy of patient administered tests Yes 0
CoronavirusDrug: Hydr Evaluation of the clinical status Yes 0
Severe Acute Respira Cohort A: reduction of the need of invasive vYes 0
CoronaviruOther: obs ICU and hospital mortality of COVID-19 pati Yes 0
COVID-19 Drug: LopinEfficacy of Intervention Yes 0

Anxiety Re Diagnostic Characteristics of COVID-19-related anxiet Yes 0
COVID-19 Device: G Change in Oxygen Saturation by Pulse OximeYes 0
COVID-19;HypertensioNumbers of COVID-19 patients enrolled thatYes 0
Severe Cor Drug: CD24Improvement of COVID-19 disease status Yes 0
COVID-19 Drug: Tocil One-month mortality rate Yes 0
CoronavirusOther: ObsCharacterize Patients With SARS-Cov-2 Infec Yes 0

Infection V Other: pre Maternal and perinatal outcomes Yes 0
Pregnancy;Other: Pre Clinical presentation;Disease prognosis o Yes 0
COVID-19;PBehavioral Change in Short-Form-36 (SF-36) Health Su Yes 0
CoronaviruBiological RNA in SARS-CoV-2;ICU Admissions;Hospital YMes 0
CoronaviruDrug: Hydr Number of death from any cause, or the need

Yes 0
COVID-19 Drug: Toci Clinical response;Biochemical response Yes 0
Infection V Other: biol COVID-19 desease description;COVID-19 desYes 0

CoronaviruDrug: Angi ventilator free days Yes 0
COVID-19 Drug: Defe Mortality rate Yes 0
COVID-19 Other: sur Number of physicians affected by social medYes 0
SARS-COV2;Device: CT Predictive association between CT-V, PBM s Yes 0
CoronaviruBehavioral Rate of COVID-19 infection Yes 0
CoronaviruDiagnostic Biomarkers expression;Liver Biomarkers exp Yes 0

COVID-19 Drug: Toci Clinical Status Assessed Using a 7-Category Yes True child
SARS-CoV IDrug: Hydr In-hospital mortality Yes 0
CoronaviruOther: ObseDefine Natural Symptom Course Yes 0
COVID-19 Drug: LopinClinical status of subject at day 15 (on a 7 poYes 0
Acute DiseaDiagnostic SAMBA COVID-19 POC PCR Test Yes 0
CoronaviruDevice: bi Pulse oximetry level Yes 0

Corona Vir Drug: Colc CRP increase to 3 x upper limit of normal;C Yes True parent
CoronaviruDrug: BCG COVID-19 disease incidence;Severe COVID-19Yes 0
COVID 19 Drug: Low- Symptomatic COVID-19;Peak severity of COVYes 0
HIV/AIDS; Other: No Mortality Yes 0
COVID-19 Drug: Hydr Hospitalization within 14 days of enrollment Yes 0
CoronaviruDrug: Ibup Disease progression;Time to mechanical ventYes 0
Corona ViruDrug: ColchNumber of participants who die or require h Yes 0

CoronaviruBiological Cumulative incidence of composite outcomeYes 0
Early CPAP Ventilatio Death or need of intubation Yes 0
Pneumonia, Viral;Hyperate of recovery Yes 0
Corona Vir Drug: RoAcTime to independence from supplementary Yes 0
SARS-CoV- Biological Treatment success Yes 0
Corona Virus InfectionSurvival;WHO progression scale COVID 19 Yes True parent
Corona ViruDrug: Sari Phase 2: Time to resolution of fever for at l Yes 0

Acute LungDrug: HypePO2/FiO2 (Safety);PO2/FiO2 (Efficacy);Early Yes 0
COVID-19;PBehavioral:Evaluation of covid-19 knowledge level of tu Yes 0
COVID-19 Drug: BCG Health Care Workers absenteeism Yes 0
Covid19;P Procedure:Number of antibiotic free days Yes 0
SARS-CoV- Drug: EicosEvaluation of EPA-FFA efficacy compared to Yes 0
SARS-CoV-2Drug: Toci Number of patients with ICU admission;Numb

Yes 0
Acute RespDrug: Dex 60-day mortality Yes 0
SARS (SeveOther: HumPresence of specific anti-SARS-CoV-2 antibodYes 0
Prone Posi Device: higTreatment failure;Intubation rate Yes 0
Pulmonary Procedure:
A Incidence of Treatment-Emergent Adverse EYes 0
Corona ViruDrug: Sari Survival without needs of ventilator utiliza Yes 0
Angina PecOther: Tel Providing a special electronic platform (e-h Yes 0
CPAP VentiDevice: CP Death or need of intubation Yes 0

Disease, In Device: Ins COVID-19 disease diagnosis Yes 0
COVID-19;CDrug: Hydr COVID-19-free survival Yes 0
SARS-CoV-2Other: NA (Immunogenicity primary outcome: Geometric

Yesm 0
COVID-19 Drug: Hydr Evolution of acute respiratory syndrome, ox Yes 0
Cancer;COVID-19 Number of participants who fill out the surv Yes 0
SclerodermOther: SPI Anxiety: Patient-Reported Outcomes MeasurYes 0

Coronavirus Infectio Hospital mortality Yes 0
Congenital Heart Dise Population characteristics Yes 0
COVID-19 Device: CapPercent of patient echos that are not interp Yes 0
PneumonitiDrug: Plaq Protection against COVID-19 Yes 0
Infection Viral;Coron Correlation between nasal and deep PCR posiYes 0
CoronavirusBiological Mortality changes in day 10;Mortality changeYes 0

COVID-19 FLUS findings and respiratory failure Yes 0
COVID-19 Other: Usu Time to Clinical Improvement Yes 0
Covid-19 InDrug: 2: U Time (in days) to clinical improvement withi Yes 0
COVID-19 Device: WeTo assess of the evolution of the number of Yes 0
CoronaviruDrug: TradiProportion of participants with normalizatio Yes 0
COVID-19 Drug: Sarg Improvement in oxygenation at a dose of 250Yes 0

CoronaviruDrug: Dex Ventilator-free days Yes 0
Covid-19;C Other: Sur International Physical Activity Questionnair Yes 0
COVID 19 Other: blo overactivity of the renin / aldosterone syst Yes 0
COVID-19 Drug: Mav Time to resolution of fever Yes 0
CoronaviruDevice: Se Deterioration resulting in healthcare review Yes 0
SARS-CoV-2Drug: lopinNational Institute of Allergy and Infectious Yes 0

CoronaviruProcedure:Evaluation of the extent of the virus transm Yes 0
CoronaviruOther: retr Time to negative conversion of severe acute Yes 0
Perceived Other: "Ca Perceived Stress Scale;Perceived Stress Scal Yes 0
COVID-19;ABiological Adverse reaction (AE) and severe adverse re Yes 0
CoronaviruDrug: Plas Change in Viral Load;Change in Immunoglob Yes 0
Pneumonia,Biological: reduction in oxygen and ventilation support Yes 0
Vascular S Procedure:30-days mortality Yes 0
COVID-19;RDiagnostic To perform a study in patients with clinica Yes 0

COVID-19 Drug: Hydr Median release from quarantine time;Rate ofYes 0
Contact Pe Drug: Hydr The rate of COVID-19 Yes 0
COVID-19 Drug: Cicl Rate of SARS-CoV-2 eradication at day 14 f Yes 0
CoronaviruDiagnostic Predictive performance No 0
Corona ViruDrug: NORSPrevention Study: Measure the effect of NORYes 0
COVID-19 Biological: CAP-1002 Allogeneic Cardiosphere-Derived CNo 0
COVID19 Biological: COVID-19 convalescent plasma No 0
COVID 19 Other: QuePrevalence of symptoms;Prevalence of positiv

Yes 0
TelerehabilOther: TelePhysical Activity Scale for the Elderly;Nottin Yes 0
Sars-CoV2 Drug: BLD- Antiviral Activity;Improvement of oxygenati Yes 0
COVID-19;CDrug: Hydr Total Hospitalization;Total Mechanical Venti Yes 0
COVID-19;Liver CirrhosAll-cause mortality of COVID-19 patients withYes 0
COVID-19 Drug: Silt Proportion of patients requiring ICU admissi Yes 0
Hypertens Drug: ThiazNumber of Covid-19 positive participants who

Yes 0
COVID-19 Other: No Physical health symptoms;Lack of physical Yes 0
COVID-19 Drug: Chlo COVID-19-related hospitalization or all-caus Yes 0
Corona ViruDrug: Toci Survival without needs of ventilator utiliza Yes 0
COVID-19 Drug: Hydr Confirmed cases of a COVID-19 Yes 0
COVID-19 Incidence of suspected, probable or confir Yes 0
COVID-19 Drug: Leva Clear chest CT-scan;PCR test Yes 0

COVID-19; Drug: RuxolProportion of patients with COVID-19 pneumo
Yes 0
COVID-19;CoronavirusNatural history of COVID-19: Characteristics Yes 0
COVID-19 Diagnostic Accuracy of the diagnosis of interstitial syn Yes 0
COVID-19;NDrug: Nint Changes in forced vital capacity (FVC) Yes 0
Covid19 Drug: Atov Virology Cure Rate Yes 0
COVID-19 Biological The immune function (TNF-a ?IL-1ÃŸ?IL-6?T Yes 0
2019-nCoVOther: Pul Association of pulmonary lesions on ultrasouYes 0

COVID-19 Drug: Hydr Prevention of COVID-19 measured by negative
Yes 0
Patients WDrug: Defibto able to reduce the progression of acute reYes 0
Social Isol Other: Vid World Health Organization Quality of Life QuYes 0
COVID-19 Drug: Pegi Duration of Viral shedding of SARS-CoV-2 b Yes 0
COVID-19 Drug: Toci In-hospital mortality;Need for mechanical ven

Yes 0
COVID-19; Drug: Azit Hospitalization Yes 0
COVID-19 Device: hy Mortality Yes 0

CoronaviruDrug: Plas Change in Viral Load;Change in ImmunoglobuYes 0
COVID-19 Pneumonia Percentage of patients with complete recoveYes 0
COVID-19 Biological Side effects Yes 0
HydroxychlDrug: Hydr Polymerase chain reaction assay (PCR) negatiYes 0
COVID-19 Drug: Hydr Difference in time to resolution of clinical Yes 0
COVID-19; Other: this Clinical course of COVID-19;Analysis of deve Yes 0
COVID-19 Biological Occurrence of adverse reactions;Anti SARS- Yes 0

CoronaviruOther: NonPrevalence;Incidence Yes 0
SARS-CoV- CombinatioChanges in patients viral load;Second evaluatYes 0
COVID-19 Other: QuesMeasure frequency of people suffered from Yes 0
COVID-19 Other: hospPercentage of children with severe or critica Yes 0
Covid19;SAProcedure:Comparison of the percentage of clinically Yes 0
RespiratoryDrug: StemChanges in clinical critical treatment index Yes 0
COVID19;SADrug: Sari Need for ventilation (including invasive and Yes 0

CoronaviruDrug: Hydr COVID Ordinal Outcomes Scale on Day 15 Yes 0
COVID-19 Drug: Hydr Rate of COVID-19 positive conversion Yes 0
COVID-19 Drug: Aspi All-cause mortality at 30 days after admissio Yes 0
Stress, Psy Other: que quantify and qualify distress over a large po Yes 0
COVID;AcutBiological: ACE2 level change over time Yes 0
COVID-19 Other: SurgReduction in COVID-19 infection frequency Yes 0

COVID-19 Diagnostic Positive or negative character of the three teYes 0
COVID-19;CDrug: Picl Duration of viral shedding in days;Time to c Yes 0
COVID-19 Drug: FavipViral nucleic acid test negative conversion r Yes 0
Patients I Dietary Su Composite of cumulative death (i.e. mortalityYes 0
COVID-19 Drug: Hydr Number of participants testing positive for Yes 0
COVID-19 Dietary Su Rates of hospitalization for a COVID-19 rela Yes 0
Follow-up;COVID-19;Indays to cure;Days of turning negative on RT- Yes 0

COVID;CoroDietary Su Symptom Reduction Yes 0
COVID19- IDrug: Nivo Time to clinical improvement Yes 0
COVID19 Drug: Nitr Rates of return visits to the ED Yes 0
COVID Behavioral Measure of the impact of COVID Emergency Yes

on 0
Coronavirus;CoronavirSuitable for discharge Yes 0
COVID-19 COVID-19 positive case Yes 0
COVID-19 Biological: Frequency of Adverse Events Yes 0

COVID 19 Device: Bi Stop home isolation;NEWS score Yes 0
COVID-19 Drug: Losa Number of participants with treatment-relatYes 0
COVID Other: ProsChest x-ray;Chest CT;Supportive care - ICU;S Yes 0
SARS-CoV- Other: obs symptoms of COVID-19 in older patients Yes 0
COVID19 Device: BI Time to diagnosis of COVID-19 by RT-PCR in Yes 0
Anxiety;DeThere are tAnxiety and depression represent a compositYes 0

COVID-19 Drug: Best Change in PaO2/FiO2 Yes 0
COVID-19 Drug: chlo change in virus duration (viral shedding);c Yes 0
CoronaviruDrug: Hydr Change from baseline to Day 3 in nasopharynge

Yes 0
Coronavirus Preferred means of communication for elderly

Yes 0
COVID-19;Re
The primaryIntegration to community as measured on the
Yes 0
COVID-19 (According Extravascular lung wa ### No 0
COVID;DrugOther: Sim To determine the Medication Risk Score of deYes 0
COVID-19;RDrug: Azit Proportion of alive patients free off mechaniYes True parent
CoronaviruBiological Feasibility of performing study pathway con Yes 0

Pneumonia,Other: No Mortality at day 28 Yes 0
COVID-19;PDrug: Toci Percentage of patients with normalization Yes 0
Cardiovasc Diagnostic Prevalence of cardiomyopathy, myocardial infa

Yes 0
RheumatoidOther: COVDisease activity Yes 0
Pediatric Respiratory Risk Factors;Immunulogical mechanisms;Lo Yes 0

COVID-19 ( 1. ### No 0
COVID-19 ( Incidence of pandemic ### No 0
CoronaviruDrug: INO- Percentage of Participants with Adverse EvenYes 0
CoronaviruDiagnostic Prevalence of positivity of COVID-19 virus Yes 0

MAGEC Ro Device: MATitanium level Yes 0
Covid19;N Other: newEvaluation of apgar status of newborns fromYes 0
SARS-CoV-2 Fraction of healthcare workers infected wit Yes 0
COVID-19;SDrug: RuxolRecovery of Pneumonia Yes 0
COVID-19 Drug: Anlu Changes in high-resolution computer tomogrYes 0
COVID 19 CombinatioDeath Yes 0
CoronaviruDrug: TJ00 Proportion (%) of subjects experiencing deteYes 0

Suspicion Diagnostic The positivity (Yes/No) of the serological testYes 0
COVID-19;CDrug: HydroReduction in the number of COVID-19 infectiYes 0
CoronaviruDrug: Nita Mechanical ventilation requirement Yes 0

Autism SpeExperimentPsycho Educational Profile,PEP;Self-Rated A No 0
Novel CoroCase seriesFever; No 0
COVID-19 Health Outcomes Yes 0
CoronaviruDevice: Tr Body temperature;Blood pressure;Pulse (heaYes 0
COVID-19 Drug: TraneHospitalization Yes 0

COVID;CoroProcedure:Risk of unfavourable outcome at D14 Yes 0
COVID-19 Drug: Hydr Successful treatment as determined by NegaYes 0
CoronaviruDrug: Emtr Number of confirmed symptomatic infectionYes 0
COVID-19 Drug: RhACCause of death or invasive mechanical ventilYes 0
COVID;Acute CoronaryDetermine the incidence of cardiomyopath Yes 0
Novel Corosurvival g survival; No 0
Novel CoroCase groupColour Sonography;electrocardiogram;PulmoNo 0
Corona ViruDrug: AnakSurvival without needs of ventilator utiliza Yes 0

COVID-19 Drug: Siro Progression to advanced respiratory supportYes 0
Pneumonia,Other: No sCharacteristics of pulmonary ultrasound for Yes 0
Infection Viral;Coron Rate of secondary aggravation Yes 0
COVID-19;Deep Vein Tto investigate the prevalence and identify poYes 0
Covid-19 Drug: Ruxooverall response rate in reversal of hyperin Yes 0
COVID;Tra Diagnostic Correlation of FAST+ pulmonary findings wit Yes 0
Cardiovasc Biological T-cell immunophenotype Yes 0

Novel CoroPatient:Su Environment viral load; No 0
sleep disor For the mi PSQI; No 0
Respirator Drug: Valsafirst occurrence of intensive care unit admis Yes 0
COVID-19 Biological: TTCI Yes 0
COVID-19 Device: ox Recovery time Yes 0
Liver Dise Diagnostic Breath volatile organic compound profiles;UtiNo 0
GynecologiDrug: Che SARS-CoV-2 infection Yes 0
Intraoral V Drug: Gar Intraoral viral load Yes 0
Dysfunctio Behavioral:The self-rated Generalized Anxiety Disorder Yes 0

Novel CoroExperimentLung CT Score; No 0
Novel Corocommon typ

Shorten the duration of the disease;AntipyreNo 0
COVID-19 Drug: FavipTime from randomization to clinical recover Yes 0
Endometriosis;Covid1 Covid 19 Anxiety levels in Endometriosis Pat Yes 0
Severe/VerDrug: Ruxolitinib Yes 0
CoronaviruOther: tele Impact of Gerontological telemonitoring on Yes 0
RespiratoryOther: MoniHACOR score efficacy;HACOR score addapta Yes 0

COVID-19, Drug: Hydr Effect of HCQ on in vivo viral clearance Yes 0
COVID-19 Other: PracEffect of GI societies recommendations on Yes 0
COVID 19;CDrug: Fluv Time to clinical worsening Yes 0
Musculoskeletal Pain The Rapid Office Strain Assessment (ROSA) Yes 0
COVID-19;SDrug: Chlo Proportion of patients with onset of severe Yes 0
Coronavirus;COVID Seroprevalence of SARS-CoV-2 infection in t Yes 0

Covid-19 Drug: AspirDeath Yes 0
COVID-19 All treatm -Composite endpoint with disease progressioYes 0

COVID-19 NA Number of people that download the app and No 0
COVID-19 Other: Dis Hierarchical composite endpoint Yes 0
EmergencyOther: COVRates of emergency visits needing surgical c Yes 0

COVID 19 Drug: Hydr Laboratory Result;Clinical Outcome Yes 0
COVID Drug: CamoNot hospitalized Yes 0
COVID-19; Drug: LY31 Number of Ventilator Free Days Yes 0
Addiction, Substance Evolution of consumption;Evolution of con Yes 0
Respiratory Distress Retrospective description of COVID-19 pati Yes 0
Mental Stress;Mental Depression;Anxiety symptoms;Stress relate Yes 0

Patients el Trade Main Objective: To determine the prevalenceYes True parent
COVID-19 pa
 Trade Main Objective: Study if blockade of IL-6 +/ No 0
COVID-19 Biological For patients hospitalized for COVID-19 but Yes 0
COVID-19 (kExposure toDescribe the clinical features of COVID-19.< Yes 0

COVID 19 Drug: Iver Number of cured patients Yes 0
COVID-19 Device: Hy Decrease incidence of intubation by 30% or Yes 0
CoronaviruDrug: Plac Clinical Improvement as assessed by change Yes 0
COVID-19 Drug: chlo negative testing of covid19 Yes 0
CharacterisOther: Fol Demographics of Coronavirus Disease 2019 (C

Yes 0
Healthy Volunteer;Moo
NIMH COVID Study survey - adult responses Yes 0
CoronaviruDiagnostic POCUS Score - Lungs;POCUS Score - Heart Yes 0
Cancer Other: Sur Distress at baseline measured by the COVID-1

Yes 0
Organ
dysfuncti
on by the
novel
SARS-
Cov-2
virus
 Med
DRA
version:
20.0
Level: LLT
Classifica
tion code
10035738
Term:
Pneumoni
a viral
NOS
System
Organ
Class:
10000000
4862
;
Therapeu
tic area:
Diseases
[C] - Virus
Diseases
[C02] Trade Main Objective: Our aim is to conduct one t Yes True parent
COVID-19; <Based on pDose adjustment required to attain a steady No 0
Severe Acu Number of hospitalise ### No 0
COVID-19 Drug: HydroTime to clinical improvement Yes 0
inflammator Expressive/Distress measured on Kessler Psychological DYes 0

Individual COVID-19 Anxiety (ada 1/1/2021 Yes 0
Aspergillos 1. I 8/5/2021 Yes 0
COVID-19 Drug: BaricPhase 2: Cumulative incidence of Grade 3 anYes 0
COVID-19 Device: Lo PaCO2;Driving Pressure;Tidal volume Yes 0
Solid Organ Transplan Assessing the utility of AlloSure dd-cfDNA t Yes 0

ARDS, HumProcedure:28 day all cause mortality Yes 0
COVID-19 (SInterventi Proportion of participants alive and not hav Yes 0
COVID-19 Po
InterventioImpact of Nasodine on the reduction in virusYes 0
Respirator Composite outcome comp

5/5/2021 Yes 0
COVID-19 ( All-cause mortality, s ### Yes 0
COVID-19 Device: No ECG changes associated with COVID-19 Yes 0
Corona ViruBehavioral PTSD Family members sup 22 Yes 0
Efficacy, S Other: Sati Efficiency of the telephone consultation Yes 0

CoronaviruDrug: LinagChanges in Glucose Llevels Yes 0
Novel Corointerventiocardiopulmonary function;motor function; Yes 0
Novel CoroExperimentTotal distances of 6 minutes walk test; Yes 0

Novel CoroCase seriesclinical characteristics and risk factors of d No 0
Novel CoroCase serie attitudes toward COVID-19;Consciousness No 0
Novel CoroNK cell gro Monitoring of adverse events within 24 hoursNo 0

Cesarean Case seriesPerioperative fever;Perioperative cough;Ou Yes 0
CoronaviruDrug: Hydr positive serology or reverse transcriptase ( Yes 0
CoronavirusDrug: Hydr Duration of viral shedding Yes 0
COVID-19 Biological Overall mortality until discharge from the h Yes 0

COVID-19;CProcedure:Number of antibodies against coronaviruses Yes 0
Novel CoroCase seriesRate of composite advers outcomes: SpO2, PNo 0
renal injuri Case seriesNGAL;MAU;cystatin C;Beta 2-MG; No 0
Lung CT after 3 days;Lung CT after 7 days;O Yes 0
COVID-19 mortality and end of mechanical respiratory No 0
Health Care Worker Number and percent of participants who enrol

Yes 0
COVID-19;ViDrug: Nita Symptomatic laboratory-confirmed COVID-1Yes 0

SARS-CoV-2Biological Mortality;Viral Load;Serum Antibody Titers Yes 0
COVID-19 Drug: Hydr Incidence Yes 0
Novel CoroNovel coro mortality; No 0
COVID-19 Case series:NA; No 0

Rheumatoid arthritis, pOur primary study parameter is the percentag
Yes 0
SARS-CoV2Lung Ultra Patients will receive regular care as indica No 0
Lower respiDuring rout28-day mortality Yes 0
SARS-CoV- InfotainmenElevation of proper hygiene behaviour (behaNo 0
COVID-19 Behavioral Change in stress level as measured by surve Yes 0
CoronaviruOther: No 14-Day Mortality Yes 0
COVID-19;APatients w Mortality[During Intensive care unit stay < Yes 0

Adult patie PharmaMain Objective: To compare the effect of disYes 0
Pregnancy;All women Maternal mortality from COVID-19[During pre Yes 0
COVID-19; <Oral adminEfficacy of Hydroxychloroquine in the comm Yes 0

Covid19 poImatinib o time to liberation from ventilation and sup Yes 0
Patients
with
SARS-
CoV-2
infection
and:
1. age =
18 years
and = 75
years
2.
SARS-
CoV-2
infection
confirme
d by PCR
(BAL,
sputum,
nasal
and/or
pharynge
al
swap)
3.
severe
disease
defined
by at
least one
of the
following:
a.
respir Trade Main Objective: To improve survival <brYes 0
severe acut Trade Main Objective: The main objective of this t Yes 0
Acute Respi Trade Main Objective: Assess, in patients with A Yes 0

COVID-19 inCOVID-19 syIn non-ventilated patients- Mean change in th
Yes 0
Acute inso Insomnia severity mea 4/6/2022 No 0
COVID-19;Th
 ProducMain Objective: The aim of this core protocolYes 0
COVID-19;T Trade Main Objective: To determine the efficacy ofNo 0

COVID-19 ( Hospital admission for ### Yes 0
COVID-19 (S The need for hospital ### Yes True parent
SARS-
CoV-2
infection
 Med
DRA
version:
20.0
Level: PT
Classifica
tion code
10049924
Term:
Infection
prophylax
is
System
Organ
Class:
10042613
- Surgical
and
medical
procedur
es
;
Therapeu
tic area:
Health
Care [N] -
Environm
ent and
Public
Health
[N06] Trade Main Objective: To assess the efficacy of h No 0
COVID-19
infection
 Med
DRA
version:
20.0
Level: PT
Classifica
tion code
10070255
Term:
Coronavir
us test
positive
System
Organ
Class:
10022891
-
Investiga
tions
;
Therapeu
tic area:
Diseases
[C] - Virus
Diseases
[C02] Trade Main Objective: Demonstrate the therapeuticYes 0
Patients on Trade Main Objective: To evaluate the efficacy of Yes 0

COVID-19 in Trade Main Objective: To determine the protectiveNo 0
Novel Coromild, modepartial pressure of arterial oxygen; No 0
Novel CoroPatients w Incidence of SARS-CoV-2 infection (includi Yes 0
COVID-19;Th
 Trade Main Objective: To compare the efficacy of tNo 0
Novel Coro1:Middle d Adverse reactions 0-14 days post vaccinationNo 0

COVID-19 1:none; semen;feces;blood;urine; No 0
Novel CoroGold Standanew coronavirus nucleocapsid (N) antigen;S Yes 0

Novel CoroGold Standproteomics;metabonomics;S antibody IgG;S No 0
COVID-19, Not applic To assess achieved immunity against COVID-1Yes 0
COVID-19 dNone -To describe the clinical presentation (sym Yes 0
SARS-CoV2Lung Ultra Diagnostic accuracyof LUSand CT in COVID-1No 0
COVID-19 wPatients in 30-day mortality (from randomization) Yes 0
COVID-19 In PharmaMain Objective: To demonstrate the superiorYes 0
Severe
pneumon
ia in
context of
COVID-19
 Med
DRA
version:
21.1
Level: PT
Classifica
tion code
10035737
Term:
Pneumoni
a viral
System
Organ
Class:
10021881
-
Infections
and
infestatio
ns
;
Therapeu
tic area:
Diseases
[C] -
Respirato
ry Tract
Diseases
[C08] ProducMain Objective: The primary objective of PhaYes 0
Healthcar
e workers
 Med
DRA
version:
21.1
Level: LLT
Classifica
tion code
10008434
Term:
Chemopr
ophylaxis
NOS
System
Organ
Class:
10000000
4865
 Med
DRA
version:
20.0
Level: LLT
Classifica
tion code
10061986
Term:
SARS
System
Organ
Class:
10000000
4862
; Trade Secondary Objective: 1. To evaluate the occuYes True parent
Patients wi ProducMain Objective: The main objective is to comYes True parent
acute hypox Trade Main Objective: The main objective is to ass Yes 0

Hospitaliz
ed
patients
with
severe
pneumon
ia
secondar
y to
COVID-
19.
 Med
DRA
version:
20.0
Level: LLT
Classifica
tion code
10051905
Term:
Coronavir
us
infection
System
Organ
Class:
10000000
4862
 Med
DRA
version:
20.0
Level: PT
Classifica
tion code
10070 ProducMain Objective: Main objective: - To stuNo True parent
COVID19;The
 Trade Main Objective: To evaluate in-hospital mortNo 0
COVID-19
 Med
DRA
version:
20.0
Level: LLT
Classifica
tion code
10051905
Term:
Coronavir
us
infection
System
Organ
Class:
10000000
4862
;
Therapeu
tic area:
Diseases
[C] - Virus
Diseases
[C02] Trade Main Objective: To assess the efficacy of a No 0
Coronavir
us
infection
 Med
DRA
version:
20.1
Level: PT
Classifica
tion code
10053983
Term:
Corona
virus
infection
System
Organ
Class:
10021881
-
Infections
and
infestatio
ns
;
Therapeu
tic area:
Diseases
[C] - Virus
Diseases
[C02] Trade Main Objective: Evaluate the effect of hydro Yes True parent
Adult respi Trade Name:

Main Objective:
Solu-ModerÃ
To evaluate
n 1 g polvo
theyefficacy
disolvente
of para
No soluciÃ³n inyectable Pharmaceutical
0 Form: Powde
results yes no

Covid 19 Trials

Uploaded by

Copyright:

Available Formats

Covid 19 Trials

Uploaded by

Document Information

Original Description:

Original Title

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

Covid 19 Trials

Uploaded by

Copyright:

Available Formats

TrialID Last Refre Public title Scientific tiAcronym Primary sp Date registDate regist Export dat Source Reg

ChiCTR200 17-Feb-20 Constructi Construction and Analysis

ChiCTR200 17-Feb-20 A Single-a A Single-arm Clinical Trial

NCT04246 3-Feb-20 A Randomize

ChiCTR200 17-Feb-20 A Medical A Medical Records Based

ChiCTR200 17-Feb-20 Study on c Effecacy and safty of conv

ChiCTR200 17-Feb-20 A RandomizA Randomized Controlled

ChiCTR200 17-Feb-20 Evaluate t Evaluate the effectiveness

ChiCTR200 17-Feb-20 Clinical S Clinical Study for Anti-agi

ChiCTR200 17-Feb-20 Clinical st Development and applicatio

NCT04252 17-Feb-20 The Efficac A Randomize

ChiCTR200 17-Feb-20 A comparatA comparative study on

ChiCTR200 17-Feb-20 Analysis of Optimization of treatment

ChiCTR200 17-Feb-20 Clinical S Clinical Study for Traditio

ChiCTR200 17-Feb-20 A multicentA multicenter, randomiz

ChiCTR200 17-Feb-20 The efficac The efficacy and safetyBeijing

ChiCTR200 17-Feb-20 A multicentA multicenter, randomize

ChiCTR200 17-Feb-20 A randomize

NCT04261 17-Feb-20 The Effica A Randomized, Open-la

NCT04261 17-Feb-20 Evaluating A Randomized, Open-la

ChiCTR200 17-Feb-20 Imaging Fe Imaging Features and Mechanis

ChiCTR200 17-Feb-20 A randomizA randomized controlled

ChiCTR200 17-Feb-20 A Single-b A Single-blind, Randomized

ChiCTR200 17-Feb-20 A randomize A randomized controlled

ChiCTR200 17-Feb-20 A medical Co-infection of novel corona

ChiCTR200 17-Feb-20 Early Dete Early Detection of Novel

ChiCTR200 17-Feb-20 A randomize

ChiCTR200 17-Feb-20 PsychologicPsychological survey ofGuangdong

ChiCTR200 17-Feb-20 A randomize

ChiCTR200 17-Feb-20 Efficacy of Efficacy of ChloroquineThe

ChiCTR200 17-Feb-20 A randomize

ChiCTR200 17-Feb-20 Immunomodu

ChiCTR200 17-Feb-20 Clinical st Clinical study for the inte

ChiCTR200 17-Feb-20 Immune Rep

ChiCTR200 17-Feb-20 A real wor A real world study for tradit

ChiCTR200 17-Feb-20 Traditiona Traditional Chinese medicin

ChiCTR200 17-Feb-20 A multicentA multicenter, randomized

ChiCTR200 17-Feb-20 An observaAn observational studyGuangdong

ChiCTR200 17-Feb-20 Efficacy an Efficacy and safety of aeros

ChiCTR200 17-Feb-20 A randomize

ChiCTR200 17-Feb-20 An observaAn observational studyNingbo

ChiCTR200 17-Feb-20 The efficac Study on Prevention and

ChiCTR200 17-Feb-20 CommunityCommunity based prevention

ChiCTR200 17-Feb-20 An open, prAn open, prospective, Beijing

ChiCTR200 17-Feb-20 Based on DBased on Delphi Method

ChiCTR200 17-Feb-20 Ba-Bao-DanStudy for the pharmacodyn

ChiCTR200 17-Feb-20 Study for t A prospective cohort study

ChiCTR200 17-Feb-20 A randomize

ChiCTR200 17-Feb-20 Chinese meA prospective randomized

ChiCTR200 17-Feb-20 Chinese meChinese medicine prevention

ChiCTR200 17-Feb-20 Clinical Ap Optimization of treatment

ChiCTR200 17-Feb-20 Clinical st Clinical study of nebulized

ChiCTR200 17-Feb-20 Traditiona Traditional Chinese Medic

ChiCTR200 17-Feb-20 Traditiona Traditional Chinese Medi

ChiCTR200 17-Feb-20 A randomize

ChiCTR200 17-Feb-20 Study for Effect of Novel Coronavirus

ChiCTR200 17-Feb-20 Study for c Study for clinical characteri

ChiCTR200 17-Feb-20 A Real WorA Real World Study ForThe